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Abstract 
Background: Aortic stiffness as measured by pulse wave velocity (PWV) is a predictor of 
cardiovascular disease and other outcomes in different diseased and healthy populations, 
independent of traditional risk factors. The relationships between PWV measurement, global 
functional outcome and injury to the brain, kidney, and heart have never been examined in 
cardiac surgery patients.  
 
Objective: The objective of this project was to assess the relationship between aortic stiffness 
and health related quality of life (QoL), cognitive function, acute kidney injury (AKI), and 
cardiac function in patients undergoing aortic valve replacement (AVR).  
 
Methods: Aortic PWV, QoL, cognitive function, left ventricular (LV) function and NYHA 
class were assessed pre- and post-operatively (409 ± 159 days). The brain injury biomarker, 
N-methyl-D-aspartate receptor antibody (NR2Ab), was measured pre-operatively only. The 
biomarker of myocardial strain, B-type natriuretic peptide (BNP), and the novel AKI 
biomarker, neutrophil gelatinase-associated lipocalin (NGAL), were measured pre-
operatively, and at 3 h and 18-24 h post-CPB.  
 
Results: Fifty-six patients (16 females; mean age, 71 ± 8.4 years) were included in this study, 
of which 50 (89%) patients attended the follow-up visit. No relationship was found between 
the degree of aortic stenosis (AS) and PWV, and AVR had no effect on aortic stiffness post-
operatively. QoL and NYHA class significantly improved, while cognitive function did not 
deteriorate after AVR. High PWV is independently related to poorer QoL, cognitive function 
levels and NYHA class both pre- and post-operatively. PWV was not related to LV function, 
BNP or NGAL levels, but it was independently related to the level of NR2Ab. PWV did not 
correlate with AKI which was developed in 30% of the cases. Early post-operative plasma 
level of NGAL is the earliest predictive marker of post-operative AKI and the need for early 
medical renal intervention. Pre-operative BNP level was significantly and negatively 
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correlated with pre-operative LV function, AS (valve area), and NYHA class in the post-
operative follow-up period. 
 
Conclusion: In AVR patients, PWV is independently related to global functional status, 
cognitive function and brain injury biomarkers, but is not related to AKI or myocardial strain. 
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1 Chapter 1 
Introduction and background to aortic stiffness, aortic valve 
stenosis, and a literature review of their relationship  
 
The main aim of this thesis is to investigate the relationship between aortic stiffness and 
aortic valve stenosis and the effect of aortic stiffness on perioperative quality of life (QoL), 
cognitive function, and post-operative recovery following aortic valve surgery. This chapter 
provides a background on aortic stiffness, indices, and modalities of measuring aortic 
stiffness and an overview of what is known so far about the predictive value of aortic stiffness 
in different pathological conditions. This chapter also includes a review of the literature with 
respect to aortic stiffness in aortic valve stenosis.  
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1.1 Arterial stiffness  
1.1.1 Pathophysiology 
The arterial system has two main functions: a) to act as a conduit to deliver blood supply from 
the heart to the rest of the body tissues; b) to act as a cushion, dampening the forceful 
pulsatile cardiac output pressure and flow. Recoil elasticity enables the aorta to maintain 
sufficient pressure during diastole in order for tissues to be adequately perfused following the 
closure of the aortic valve. In a normal, healthy, elastic aorta, radial expansion during systole 
acts as a volume (approximately 40% of the stroke volume) [1] and pressure reservoir 
(“cushioning effect”). This smoothens the pulsatile pressure and flow of cardiac ejection, 
providing nearly steady perfusion at the periphery [2]. This is possible because, 
histologically, the aorta, particularly at the proximal location, is richer in elastin than the rest 
of the arterial tree [3]. This is of special importance for coronary arteries; as a result of this 
recoil elastic property – the “aortic cushion” – the aorta is able to maintain sufficient pressure 
during diastole to adequately perfuse tissue, in particular the coronaries, after aortic valve 
closure when there is no more in-flow.  
 
Coronary arteries receive only a quarter of their blood flow during systole, with the 
remainder coming during diastole. Traditionally, it has been accepted that arterial waves 
return to the heart during diastole due to the elastic recoil property. This reflection augments 
pressure during diastole and maximizes coronary blood flow, which occurs mainly during 
diastole. 
 
Cardiovascular (CV) risk factors, including age, hypertension, diabetes, 
hypercholestroleamia, and smoking, generate structural damage in the arterial wall. After 
such damage, the functional and elastic properties of blood vessels become abnormal, 
consequently affecting blood flow patterns (Figure 1.1). CV disease prevention and treatment 
has traditionally targeted modifiable risk factors in order to reduce their effects on vascular 
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wall integrity. Recently, clinicians have begun to focus on the assessment and significance of 
arterial wall damage (arterial stiffness) in CV risk stratification. Arterial wall structural 
changes caused by CV risk factors include degeneration and fragmentation of elastin and an 
increase in collagen; such changes alter the elasticity of the arterial system, resulting in a 
gradual stiffening of the arterial wall and an increase in pulse wave velocity (PWV). When 
the elastic properties diminish, the aorta becomes stiffer, and the change in aortic diameter 
during systole and diastole is reduced. The rigidity of the aorta increases pulse wave speed, 
causing the reflected pressure wave towards the heart to occur at the beginning of systole, 
rather than during diastole. Consequently, an augmentation of systolic blood pressure (SBP) 
and elevation in cardiac afterload results in left ventricular (LV) hypertrophy (Figure 1.1). 
Additionally, the absence of diastolic augmentation reduces coronary flow during diastole and 
widens the pulse pressure (PP) (Figure 1.1) [4-6]. Recent studies [7] indicate that the 
contributions of wave reflection and systolic augmentation to PP have been overestimated, 
and that the magnitude of the PP is dependent upon the “cushioning effect” of the aorta. In 
conclusion, aortic stiffness is an unhealthy condition that increases the speed of the pulse 
wave, SBP, and cardiac afterload, all of which lead to microvascular damage of different 
tissues, including the heart, kidneys, and brain [5, 8-10], which may reduce the functional 
status and QoL of affected individuals.  
 
 32 
 
Figure 1. 1 Pathophysiology of arterial stiffness. 
 
1.1.2 How arterial stiffness is measured 
The importance of assessing arterial pulse for clinical examination was recognized early in 
history. In 1831, Julius Hèrisson developed an instrument to display the pulse beat visually 
for the first time in history and in 1854 the German physiologist Karl Vierordt created a 
device to record the movement of the pulse waveform on paper [11]. In 1863, the French 
physiologist Étienne-Jules Marey improved the aforementioned device by making a portable 
sphygmograph (Figure 1.2) [11]. Since this time, scientists have continued to develop and 
refine pulse waveform recording and interpretation. However, clinical interest in arterial 
waveforms diminished when the sphygmomanometer was developed as it enabled clinicians 
to measure systolic and diastolic blood pressure (DBP). For decades, clinicians and 
researchers focused on blood pressure (BP) measurements as a marker of arterial system 
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function and health rather than the shape of the waveform. In the last 10–15 years, however, 
scientists and clinicians have re-focused their interest on the significance of the arterial 
waveform and arterial stiffness as a direct measure of arterial wall health status [12].  
 
Stiffening of the arteries with the ageing process was recognized as early as the 1880 
by C.S. Roy [13]. The term ‘arterial stiffness’ is generic and refers to both the stiffness and 
rigidity of the arterial tree. Stiffness is the rigidity or resistance of an elastic tissue to 
distortion, and arterial stiffness can be expressed in terms of indices that are correlated to the 
biophysical properties of an arterial wall; arterial compliance, elasticity (or elastic modulus), 
distensibility, augmentation index, and vascular impedance are examples of such indices. 
Vascular impedance, for example, describes the relationship between pulsatile pressure and 
flow in an artery. Therefore, in order to calculate impedance, pressure and flow need to be 
measured simultaneously at one specific point in an artery, which is considered a limitation. 
Elastic (Young’s) modulus is the ratio of stress to strain (stress/strain). Stress is the force per 
unit area (force/area), while strain represents the deformation due to the force; it is the 
percentage of change in length caused by the applied force. Arterial compliance is the 
absolute change in area or in diameter of a vessel for a given pressure step, while 
distensibility is the relative change in diameter or in area per given change in pressure; 
therefore, it is the inverse of the elastic modulus. Many indices are dependent on blood 
pressure (BP), which is variable according to physiological status thus rendering such indices 
less reliable. In this respect, pulse wave velocity (PWV) is more valuable because it is 
independent of BP. A summary of these indices and methods of measurement is shown in 
Table 1.1 [12]. 
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Figure 1. 2 Sphygmograph by Etienne Jules Marey, courtesy to Wellcome library, London. 
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Table 1. 1 Indices and methods of measurement of arterial stiffness [12].  
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There are many different methods for assessing and measuring arterial stiffness. To 
follow, in descending order based on most frequently used, are descriptions of some of these 
methods. 
1.1.2.1 Pulse wave velocity 
PWV has been described as the gold standard parameter of arterial stiffness as it is the most 
accepted, valid, reproducible, and widely used as a direct measurement of arterial stiffness 
and damage [14] [15, 16]. It is also the method recommended by the European Network for 
Non-invasive Investigation of Large Arteries as a direct measure of arterial stiffness [14]. The 
travelling velocity of a pressure wave is influenced by the elastic properties of the containing 
vessel, with a stiffer wall producing a higher velocity [17]. Bramwell et al. in 1922 described 
PWV as the speed of travel of a pressure wave within the vascular tree [18]. It is calculated 
first by measuring the time taken for the waveform to travel between two sites along an 
arterial tree, then the distance between both sites is measured and divided by this timeframe. 
As such, PWV is inversely related to vascular compliance; therefore, a stiffer artery will have 
a higher PWV than a more elastic and distensible one. PWV does not measure the speed of 
travel of the same waveform, but, rather, involves recording waveforms from both sites and 
measuring the time delay between the reference points on two recorded waveforms. Readings 
from the two sites can be taken simultaneously or consecutively by gating separate recordings 
to a fixed point in the cardiac cycle using an electrocardiogram (ECG). The accuracy of PWV 
measurements is reduced if the recording sites are close to each other, thus the technique is 
usually reserved for large arteries. PWV is commonly used to assess central arterial stiffness 
(aortic PWV) rather than peripheral arterial stiffness, which is more relevant to CV disease 
risk assessment [19]. PWV can also be measured using various invasive and non-invasive 
methods, and can be applied to either flow, pressure, or distension waves as long as the 
reference point on the waveforms is fixed [14]. Frequently, applanation tonometry foot-to-
foot methodology is employed to avoid the confounding influence of wave reflection. A 
simpler method of measuring PWV has also been developed by measuring brachial-ankle (ba) 
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PWV using a volume-plethysmographic sensor connected to a BP cuff to create pulse volume 
waveforms, which are then used to calculate baPWV [20, 21]. This method correlates well 
with aortic PWV and exhibits excellent reproducibility; furthermore, it is simpler, less 
operator dependent, and more practical for screening vascular damages in large scale studies 
relative to more conventional PWV measurements [20, 21]. However, but this method has not 
been used and validated as widely like as has the classical applanation tonometry. 
 
Unlike other methods that use vascular imaging, such as magnetic resonance imaging 
(MRI) or using an intravascular catheter, PWV has an essential limitation of the imprecise 
measurement of the travelled distance between the two arterial sites because it is acquired 
from body surface using a tape measure or a rigid measure. PWV measurement is also limited 
to use on larger arteries because PWV becomes less accurate if the two arterial sites are very 
close together. Also, PWV assesses the stiffness of the local vessel being studied, rather than 
systemic arterial stiffness.  
 
1.1.2.2 Pulse waveform analysis and augmentation index 
As we mentioned previously, CV risk factors cause gradual stiffening of the arterial wall and 
an increase in PWV. When the aorta stiffens, its elastic properties diminish and the change in 
the aortic diameter between systole and diastole is reduced. The rigidity of the aorta increases 
the pulse wave speed, causing the reflected pressure wave towards the heart to occur at the 
beginning of systole, rather than during diastole [14]. Consequently, augmentation of SBP 
and elevation in cardiac afterload results in LV hypertrophy. The augmentation index (AIx) is 
the difference between the second and first systolic peaks (P2−P1) expressed as a percentage 
of the PP; it is a measure of the augmentation of central aortic pressure by a reflected pulse 
wave from the previous pulse [22].  
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AIx can be calculated from the pulse wave analysis (PWA) using applanation 
tonometry to record pressure waveform from superficial arteries, commonly from the radial 
artery (using a validated generalized transfer factor) or from the common carotid waveform 
[14, 23], Figure 1.3. AIx estimated form the carotid waveform seems to be more reliable and 
validated than AIx estimated from the radial waveform [24-26], but the radial artery is more 
popular because it is technically simpler and more practical. Augmentation index can also be 
used to estimate central BP, which is another arterial stiffness marker, that which is seems to 
be a superior predictor of CV risk than brachial pressure [24, 25]. 
 
Because the AIx measurement is dependent on applanation of superficial arteries, 
other devices using different technology and formulas, such as automated tonometry or 
plethysmography, have been developed to measure AIx in more practical ways and to make it 
less operator dependent [27].  In plethysmography device, beat-to-beat changes in finger 
arterial pulsatile volume are recorded with modified plethysmographic bio-sensors, and AIx is 
calculated as: (the reflected wave’s peak – the systolic peak) / the systolic peak. Though 
absolute AIx values obtained from each technique were different due to different arterial 
locations and different techniques and transformations, the correlations were high and 
significant [27]. Digital artery pulse waveform analysis has also been implemented using a 
servocontrolled pressure cuff [28]. Another method of assessing AIx is by using 
photoplethysmography, a technique that is similar to pulse oximetry. Photoplethysmography 
produces a digital volume waveform by detecting changes in the flow of the digital artery by 
measuring infrared light transmission through the finger [28-30]. However, the latter 
techniques involving digital arteries and distal circulation are not without major concerns: 1) 
the recorded waveform may be significantly damped making any calculation of central 
pressure less accurate; and 2) peripheral small artery circulation is more affected by 
temperature. Therefore, these methods are less acceptable and popular and need to be 
validated in large-scale studies.  
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Tonometry carotid artery AIx is an independent predictor of all-cause and CV 
mortality in end stage renal disease (ESRD) [31, 32], and a determinant of myocardial 
ischemic threshold in patients with moderate coronary arteries disease (CAD) [33]. AIx is 
also correlated with CV risk in patients with CV disease and in apparently healthy subjects 
[34]. Hashimoto et al. found that among estimated aortic BP, PWV measured between the 
carotid and femoral arteries, aortic AIx, aortic augmented pressure, and radial augmentation 
index, aortic AIx was the strongest determinant of treatment-induced LV mass reduction, 
independent of brachial BP [35]. In 297 males with established CAD followed-up for mean 
period of 1186 ± 424 days, Chirinos et al. investigated whether invasive aortic AIx can 
predict the risk of major adverse CV events (MACE): unstable angina, acute myocardial 
infarction, coronary revascularization, stroke, or death. They found that AIx is a significant 
predictor of MACE; the hazard ratio (HR) for each 10% increase in AIx was 1.28 (95% 
confidence interval [CI], 1.11–1.48; P = 0.004). After adjusting for other univariate 
predictors, AIx remained a significant predictor of MACE (adjusted HR, 1.28; 95%CI, 1.09–
1.50; P = 0.003) [36].  
 
Using patients with antineutrophil cytoplasmic antibody–associated systemic 
vasculitis as a model of systemic inflammation, Booth et al. investigated the relationship 
between inflammation and arterial stiffness. In this study, they found that C-reactive protein 
(CRP; an indicator of active inflammation) was independently related to PWV and was 
associated with AIx [37]. The relationship between systemic inflammation and aortic stiffness 
was also confirmed by Mahmud et al. in essential hypertension patients who showed that 
High-sensitivity CRP is independently related to aortic PWV and AIx (estimated from the 
radial artery) [38]  
 
Furthermore, a recent meta-analysis showed that AIx is an independent predictor of 
future CV events and all-cause mortality, and it predicts CV events independently of 
peripheral pressure [39]. Relative risk for an absolute increase of central AIx by 10% of total 
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CV events and total mortality was 1.318 (95%CI 1.093–1.588) and 1.384 (95%CI 1.192–
1.606), respectively [39]. 
 
 
 
 
 
Figure 1. 3 Carotid pressure waveform as recorded by applanation tonometry [14]. 
The height of the late systolic peak (P1) above the inflection (P2) defines the augmentation pressure, and the ratio 
of augmentation pressure to PP defines the AIx (in percent). 
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1.1.2.3 Pulse pressure 
The difference between SBP and DBP creates a pulse, and thus is called the PP. It is known 
that SBP and DBP increase markedly with age until the age of 50 to 60 years where the 
increase in DBP ceases and may even begin to decrease with age. Therefore, PP widens more 
markedly with age than does mean arterial pressure [40]. PP depends on cardiac output (rate, 
duration, and pattern of ventricular ejection), arterial stiffness, and wave reflection (amplitude 
and point of reflection) [12, 41]. PP can also be easily measured with a standard 
sphygmomanometer, but likely not with an oscillometric BP device, because it overestimates 
SBP and DBP readings in subjects with stiff arteries [42]. In a large prospective study of 
19,083 men with mean a follow-up period of nearly 20 years, wide PP was found to be an 
independent predictor of all-cause, CV, and coronary mortality, in addition, mortality rates 
were constantly higher as PP increased [43]. In one of the Framingham heart studies, 1,924 
middle-aged and elderly population-based cohorts with no history of coronary heart disease or 
antihypertensive medication were followed for more than 20 years. In this study, neither SBP 
nor DBP were superior to PP for predicting coronary heart disease risk [44]. Similarly, 
Palmieri et al. from the Strong Heart Study investigated 2,946 adults with no history of 
coronary heart disease for a mean follow-up period of approximately 7 years [45]. This study 
revealed that wider PP predicts CV mortality independently of traditional risk factors, 
including LV hypertrophy (LVH) and reduced EF. Finally, it was determined that carotid PP 
is a strong independent predictor of all-cause and CV mortality in patients with ESRD [32].  
 
Central PP appears to be a better predictor of CV disease than peripheral PP. 
Theoretically, central aortic pressure and stiffness is more related to CV target organ damage 
and CV events than brachial pressures because it more accurate reflects the loading 
conditions on the LV, coronary artery, and cerebral vasculature [46]. Carotid PP (but not 
brachial PP) is a strong independent predictor of all-cause and CV mortality [32]. In the 
Strong Heart Study, a large population-based study, data from 3,520 subjects showed that 
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central PP was more strongly related to carotid artery intimal-medial thickness (IMT), extent 
of atherosclerosis (plaque score), and incident of fatal and nonfatal CV events than was 
brachial PP [46]. In Marfan syndrome, carotid PP is closely related to ascending aorta 
diameter, while brachial PP, SBP, and mean BP were not when introduced into the statistical 
model instead of carotid PP [47]. One of the limitations of PP in assessing arterial stiffness is 
the amplification of the pressure wave as it travels from the aorta to the periphery. This makes 
the reflection, or its representation via peripheral PP measurement, such as in the upper arm, 
of the actual central PP inaccurate but still capable of positively identifying stiffer aortic areas 
[48, 49].  
 
1.1.3 Modalities of measuring arterial stiffness 
1.1.3.1 Applanation tonometry 
Applanation tonometry is the most common modality for assessing arterial stiffness. This 
procedure requires an applanation tonometer (connected to a computer or a device with 
specially designed software), ECG leads (for some models with one tonometer), and BP data 
(measured using a typical sphygmomanometer). The software interprets the arterial pressure 
wave and the ECG waveforms in order to calculate the PWV between the two arterial sites. 
The applanation tonometry procedure is easy to learn and can be performed in an office 
setting while the patient is in supine position. ECG leads (if needed) must be well fixed to 
obtain a clear and stable signal. Some systems use two tonometers to record the pressure 
wave simultaneously at sites A and B (with no need for ECG), while others use one 
tonometer to record the signal at site A first and then at site B (calculating the time with 
reference to the ECG signal). Most commonly, PWV is measured between the carotid and 
femoral arteries. The distance between the two sites is measured in millimetres, and 
calculated by subtracting the distance between the carotid site (A) and suprasternal notch 
from the distance between the suprasternal notch and femoral artery site (B). The software 
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calculates the PWV in m/s (PWV = Distance / ∆ Time) from these records as shown in Figure 
1.4 (quoted for the manual of the SphygmoCor Vx System, AtCor Medical, Australia).  
 
Aortic tonometry PWV is the most valid, reproducible, and commonly used method 
in assessing arterial stiffness in healthy volunteers and patients, and in disease-specific and 
population-based studies (see section 1.2 & 1.3).  
 
 
Figure 1. 4 Illustration of PWV measurement. 
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1.1.3.2 Magnetic resonance imaging  
MRI has also been used to assess arterial stiffness by measuring distensibility [50-53], or by 
measuring compliance [54] or PWV [55, 56]. MRI provides high quality 3D images of the 
blood vessel segment under study, including a cross sectional view of the vessel at any 
location and at any stage of the cardiac cycle using ECG gated acquisition. This easily allows 
the measurement of the vessel diameter or cross sectional area at diastole and systole to 
calculate distensibility. Therefore, MRI allows better regional assessment of arterial stiffness, 
which has been used to demonstrate age-related, regional increases in PWV [55]. In addition, 
MRI provides a very precise measure of the distance between two arterial sites making it 
superior to applanation tonometry PWV in this respect. Velocity-encoded MRI even measures 
blood flow velocity and wave propagation at two arterial locations. MRI has been accepted as 
a reliable, reproducible, and validated non-invasive method of assessing aortic PWV [55, 57, 
58] and aortic distensibility [50].  
 
Aortic stiffness assessed by MRI has good to excellent correlation or agreement with 
other methods, such as between MRI PWV and tonometry PWV [59, 60], MRI distensibility 
and tonometry carotid augmentation index [59], MRI PWV and invasive PWV [57] [58] and 
between MRI distensibility and tonometry PWV [50, 60].  
MRI aortic distensibility is inversely related to essential hypertension [53]. In diabetic 
patients, MRI aortic PWV seems to be affected by the associated hypertension more than 
diabetes mellitus (DM) itself [61]. Furthermore, MRI aortic distensibility is reduced in ESRD 
compared to healthy controls [62]. Although MRI may be more accurate for assessing arterial 
stiffness and provides more visual information from deep arteries, it is expensive and time-
consuming, requires expert operators, and is not available in every clinic. Therefore, it is not 
the best practical and cost-effective modality for routine clinical assessment, though it 
remains useful in research.  
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1.1.3.3 Ultrasound and echocardiography 
Ultrasound and echocardiography can be used to assess arterial stiffness by measuring 
distensibility or compliance. For both of these methods, several images of the artery are taken 
at different points of the cardiac cycle, then the maximum and minimum cross sectional areas 
or diameter of the vessel are calculated with computer software; distensibility and compliance 
can then be calculated using different formulas [63-70]. In diabetic and/ or CAD patients, 
aortic distensibility was reduced compared to normal controls, and it is negatively correlated 
with the duration of diabetes [71-73]. Furthermore, aortic distensibility and PWV were 
studied in 110 hypertensive patients and compared to 80 healthy controls; both parameters 
were significantly associated with hypertension [74]. Echocardiography can also be employed 
to assess PWV using pulse wave Doppler technology by measuring the transit time between 
Doppler velocity signals between the two arterial locations [75, 76], this method correlates 
well with applanation tonometry, though it is not commonly studied [77].  
 
Vascular ultrasound can also be used to measure IMT, commonly of the carotid, 
which is a structural surrogate marker and predictor of CV disease [78]. In older healthy 
adults (>46 years) PWV and IMT are directly and independently associated with each other (β 
= 1.233, P = 0.019), while PWV is inversely related with carotid artery distensibility [79]. 
Aortic distensibility is decreased in patients with hypertension, diabetes, or both when 
compared to healthy controls [80]. In patients with CAD, ascending aorta distensibility is 
independently related to age (β = –0.104, P = 0.019), hypertension (β = –0.202, P < 0.001), 
and atherosclerosis score (β = –0.457, P < 0.001) [81], and it is a risk factor for recurrent 
acute coronary events [82]. Coronary flow reserve seems negatively affected by increased 
aorta distensibility compared to normal aortic distensibility [83]. In addition, aortic 
distensibility is reduced in patients with CAD compared to normal controls independent of 
the number of affected vessels [84], while ascending aorta distensibility is not related to the 
development of coronary collateral circulation in patients with CAD [85].  
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The limitations of the modalities mentioned in this subsection include: 1) they are 
operator dependent techniques; 2) they are only applicable to larger and accessible arteries, 
such as the abdominal aorta, and the femoral and carotid arteries; 3) the quality of the image 
obtained may limit the detection of small changes in artery diameter; 4) BP measured in an 
arterial segment is different from the one being studied; 5) the assessment of the stiffness is 
based on the site being studied (which may have a local pathology), rather than on the long 
segment of that artery; 6) the machinery required is relatively expensive [12, 86]. All the 
above limitations, plus the availability of other more practical and valid methods, have 
limited the use of ultrasound and echocardiogram for measuring arterial stiffness [14].  
 
1.1.4 Rationale for using pulse wave velocity in this study 
In summary, the physical and mathematical principles of these different indices are confusing 
and not easily understood, and though they are all related to arterial stiffness, they are not 
interchangeable. The Satellite of the 1994 International Society of Hypertension (ISH) 
Meeting in Sydney highlighted issues regarding measurement and interpretation of these 
indices, making reservations against the use of many of them [87]. One issue is that BP 
measured in an arterial segment is often different from the one that is being studied. 
Additionally, the need for a simultaneous measurement of pressure and flow at the same point 
presents some practical issues; therefore, it is difficult to conclude which method is best. In 
addition, AIx and central PP depend on cardiac output (rate, duration, and pattern of 
ventricular ejection), arterial stiffness, and wave reflection (amplitude and point of reflection) 
[12, 41], making PWV more stable and constant in relation to physiological changes, such as 
heart rate. Also, in healthy, normotensive populations, the effect of age is more prominent on 
the AI x than aortic PWV until the age of 50, after which PWV becomes a better marker of 
arterial stiffness [88].  
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In general, PWV is the most valid and widely used method for assessing arterial 
stiffness [12, 14, 87, 89]. PWV is also the most practical, simple, non-invasive, and clinically 
validated technique used in extensive studies involving different diseased and healthy 
populations. Furthermore, PWV has a strong association with markers of atherosclerosis and 
coronary artery calcification and has good repeatability [90]. Aortic PWV measurements have 
the largest collection of evidence establishing its relationship with incident CV disease 
independently of traditional risk factors and in different diseased and healthy populations 
[89]. Based on all of the above reasons and background, and on the recommendations from 
the European Network for Non-invasive Investigation of Large Arteries – “Carotid-femoral 
PWV is the ‘gold standard’ for arterial stiffness, has the largest amount of epidemiological 
evidence for its predictive value for CV events” [14], we decided to use this method in the 
present study. The procedure is relatively simple and easy to learn, and the device is small, 
portable, and not very expensive. Furthermore, extensive data have shown that aortic PWV is 
an independent predictor of CV risk and different outcomes in healthy and patient populations 
(see section 1.2 & 1.3). All the above make aortic PWV the most valid, predictive, practical, 
and cost-effective for routine research and clinical setting use; therefore, we have employed 
this method in our study.  
 
1.2 Aortic stiffness in different pathological conditions 
1.2.1 Aortic stiffness in coronary diseases and atherosclerosis  
Aortic stiffness is associated with the presence of CV risk factors and atherosclerotic changes 
[14]. Atherosclerosis processes involve structural damage to the arterial wall and 
inflammatory responses that stiffen the arterial wall. Impaired aortic distensibility index 
measured by computed tomographic angiography was found to be associated with the severity 
of coronary atherosclerosis; the ability of the area under the receiver operating characteristic-
curve to predict significant coronary diseases was 0.75 [91]. In patients with established 
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coronary artery disease, central augmented pressure and AIx both predict the risk of future 
MACE [36].  
 
Aortic PWV is associated with fatal and nonfatal coronary heart disease in the 
general population [92]. In the Strong Heart Study (a large population-based study) data from 
3,520 subjects showed that aortic stiffness assessed by measuring estimated central PP was 
related to atherosclerosis (carotid artery IMT and plaque score) [46]. van Popele et al. 
investigated in an elderly population-based study the relationship between arterial stiffness 
and atherosclerosis, which was assessed by carotid artery IMT, the presence of plaque in the 
carotid artery and in the aorta, and the presence of peripheral arterial disease, and found that 
aortic PWV and carotid distensibility were both strongly associated with atherosclerosis at 
different arterial locations [93]. The same group of authors in another population-based 
cohort (1,757 elderly participants from the Rotterdam Study), found that aortic PWV was 
strongly and independently associated with the severity of coronary atherosclerosis [94]. In 
patients with a prior history of stroke, a significant positive correlation between the stiffness 
index measured by echocardiography and atherosclerotic risk factor score (r = 0.51, P = 
0.000) was identified [95]. 
 
1.2.2 Aortic stiffness in kidney disease 
Aortic stiffness is significantly increased in patients with chronic kidney disease (CKD) [96, 
97]. In 2,564 patients with CKD not on dialysis treatment, estimated glomerular filtration rate 
(eGFR) independently was significantly associated with aortic PWV, and each unadjusted 
decrement in eGFR of 10 ml/min/1.73m2 was associated with an average increase of 0.4 
m/sec in aortic PWV [97]. Patients with ESRD have reduced aortic distensibility, increased 
aortic PWV, increased LV mass index, advanced LV diastolic dysfunction, and reduced 
coronary perfusion compared to healthy controls [62, 98]. Furthermore, aortic distensibility is 
negatively correlated with extracellular water volume in ESRD [99]; carotid PP is a strong 
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independent predictor of all-cause and CV mortality in patients with ESRD [32]; and aortic 
PWV and AIx indices are strong independent predictors of all-cause and CV mortality in 
patients with end-stage renal failure.  
 
In 180 ESRD patients monitored for 52 ± 36 months, London et al. found that both 
aortic PWV and carotid AIx predicted all-cause and CV mortality, and that after adjusting for 
all confounding factors, for each 10% increase in AIx, the risk ratio was 1.51 (95%CI, 1.23–
1.86; P < 0.0001) for all-cause mortality and 1.48 (95%CI, 1.16– 1.90; P < 0.0001) for CV 
mortality [31]. In the calcification outcome in renal disease (CORD) study, 1,084 dialysis 
patients from 47 European dialysis centers were followed up for a mean period of 2 years. In 
this study, aortic PWV and abdominal aortic calcification score were independent predictors 
of mortality and nonfatal CV events, with each 1 m/s increase in PWV associated with a 15% 
higher risk of an event [100]. In renal transplants, donor aortic PWV is an independent 
predictor of recipient composite CV outcome (myocardial infarction, stroke, CV death, and 
doubling of serum creatinine or development of ESRD) [101]. In addition, the donor age 
seemed to have a major effect on the recipient aortic stiffness, the association between 
recipient aortic PWV and donor age was independent of recipient characteristics, such as age, 
gender, mean BP, pre-transplantation dialysis duration, conventional CV risk factors, and 
GFR [102]. The impact of renal function on arterial function seems not limited to adults only, 
as chronic renal failure (CRF) in children is significantly associated with abnormal aortic 
stiffness [103, 104].  
 
1.2.3 Aortic stiffness in diabetes mellitus 
Structural and functional changes in the arterial vessel caused by DM leads to progressive 
stiffening of the arterial system [105, 106]. In type II diabetic patients, increased carotid IMT 
or extracranial carotid artery plaque scores is associated with increased aortic stiffness [107]. 
Furthermore, aortic stiffness assessed by PWV is an independent predictor of all-cause and 
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CV mortality in type II diabetes and glucose-tolerance-tested participants in multi-ethnic 
population [108]. Compared to controls, using MRI technology, DM patients have been 
shown to have lower aortic distensibility and higher PWV [109, 110], and there is an inverse 
relationship between eGFR and aortic PWV not only in type I DM, but also in the control 
group [111]. Bouchi et al. studied 461 type II DM patients with a median follow-up period of 
5.9 years, and they found that aortic PWV was significantly associated with incident 
albuminuria (HR 1.23, 95%CI 1.13–1.33; P < 0.001), and with annual change in eGFR [112]. 
Brandts et al. suggested that hypertension has a predominant contributive effect on aortic 
stiffness (assessed by aortic PWV MRI) in type I DM patients more than DM itself [61]. On 
the other hand, Bruno et al. suggested that in hypertensive patients, type II DM might worsen 
arterial compliance by endothelium-related mechanisms, such as endothelium-dependent 
flow-mediated dilation [113]. However, Cardoso et al. suggested that high levels of physical 
fitness might moderate the negative effect of type II DM on aortic stiffness [114]. PWV, 
however, is positively correlated with diabetic control (HbA1c) and duration in patients with 
type II diabetes and hypertension, suggesting that early glycemic control may halt arterial 
stiffness [115]. 
 
1.2.4 Aortic stiffness in hypertension 
Though hypertension and aortic stiffness are associated and both are CV risk factors, they are 
not interchangeable and the exact mechanism behind their relationship is not fully understood 
[116, 117]. Aortic stiffness as a marker of sub-clinical vascular damage that can be assessed 
earlier than other clinical manifestations of vascular damage, such as hypertension and CV 
events, making it a superior predictor to other classical risk factors [118]. In addition, it has 
been shown that aortic stiffness has superior predictive value than the classical risk factors, 
such as age, gender, BP, diabetes hypercholesterolemia, and smoking [39, 118, 119]. Higher 
aortic stiffness is associated with a higher risk of incident hypertension, while baseline BP is 
not independently associated with the risk of progressive aortic stiffening [117].  
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In a study of 2,512 normotensive participants who were followed for 4 years, it was 
discovered that aortic stiffness was significantly associated with the development of 
hypertension after adjustment for classical risk factors [120]. Among hypertensive patients, 
aortic stiffness can also predict CV outcome. For example, in a longitudinal study of 1,045 
hypertensive patients (mean follow up period of 5.7 years), aortic PWV was an independent 
predictor of primary coronary events [121]. Also, hypertensive patients with high PWV have 
impaired systolic and diastolic regional myocardium function [122], and is associated with 
other target organ damage markers, such as albuminuria and LV mass index [123].  
 
PWV was recently found to be an independent predictor of microalbuminuria (a 
marker of microvascular damage) in patients with newly diagnosed type II diabetes or 
essential hypertension [124]. In patients with essential hypertension, human cartilage 
glycoprotein 39 (a proposed marker of inflammation and endothelial dysfunction) is 
independently associated with aortic PWV suggesting progressive vascular complications in 
essential hypertension [125].  
 
Aortic PWV is a risk factor for stroke in hypertensive patients. A prospective study of 
1,133 hypertensive patients with a mean age of 51.05 ± 12.64 years found PWV to be an 
independent predictor of stroke (HR = 1.40, 95%CI: 1.13–1.73; P < 0.001), indicating a 40% 
increase in the risk of stroke for each 1 m/s increase in PWV [126]. In patients with resistant 
hypertension, catheter-based renal sympathetic denervation significantly improves peripheral 
BP, central hemodynamics, and aortic stiffness [127]. However, treating hypertension does 
not necessary improve aortic stiffness; while some studies found a positive improvement 
relationship between hypertension treatment and aortic stiffness, other studies suggest that 
different antihypertensive drugs that produce similar effects on BP can have different effects 
on aortic stiffness [116, 128, 129]. Statin medications, however, seem to have a beneficial 
effect on both aortic stiffness and central aortic pressures [130]. As in normotensive 
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individuals, habitual physical activity is associated with reduced aortic stiffness among adults 
with newly diagnosed essential hypertension [131]. 
 
1.2.5 Aortic stiffness in brain stroke 
As expected, there is strong relationship between aortic stiffness and stroke [132, 133]; in 
multivariate analyses, hypertension and high PWV were independently related to 
intracerebral hemorrhage, while smoking and high PWV were found to be independent risk 
factors for cerebral infarction [133]. Patients with acute ischemic stroke have higher aortic 
PWV (11.8 ± 3.3 m/s versus [vs.] 10.02 ± 2.29 m/s, respectively) and AIx 103 ± 3.5 mmHg 
vs. 99 ± 4.6 mmHg, respectively) compared to matched subjects who have not undergone an 
acute ischemic stroke [132]. In the general population, after controlling other CV risk factors, 
high PWV was associated with an increased incidence of stroke [134, 135]. In patients with a 
prior history of stroke, there is a significant positive correlation between stiffness index and 
atherosclerotic risk factors score (r = 0.51, P = 0.000) [95]. In hypertensive patients, aortic 
stiffness is a risk factor for stroke, with a 40% increase in risk for each 1 m/s increase in PWV 
[126]. In addition, baPWV is associated with the presence of atherosclerosis (≥50% stenosis) 
in the intracranial cerebral artery of patients with acute ischemic stroke (n = 801 patients) 
[136]. With respect to ischemic stroke and transient ischemic attack (TIA), patients with 
ischemic stroke have a significantly higher aortic stiffness index and significantly thicker 
carotid and aortic intima-media [137].  
 
The relationship between aortic stiffness and cerebral microvessels was demonstrated 
using retinal vessels and advanced brain imaging [138] [139]. In ischemic stroke patients, 
aortic stiffening assessed by PWV is associated with retinal arteriolar luminal narrowing and 
features of retinal arteriolosclerosis, which is reflective of the changes in cerebral 
microvessels [138]. Furthermore, baPWV is independently and significantly associated with 
cerebral microbleeds in patients with strokes [139].  
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Aortic stiffness is also a predictor of post-stroke outcome. For instance, low aortic 
PWV measured 1-week after acute ischemic stroke onset is associated with early favorable 
outcome at hospital discharge, independent of other known prognostic factors [140]. In 
addition, aortic PWV improves the prediction of ≥50% asymptomatic CAD beyond classical 
risk factors in patients with non-disabling, non-cardioembolic ischemic stroke, or TIA, and no 
prior history of CAD [141]. Finally, aortic stiffness (distensibility and aortic strain) predicts 
all-cause mortality in patients within 1-year of first-ever acute ischemic stroke [142].  
 
1.2.6 Aortic stiffness in bicuspid aortic valves 
In comparison to 114 controls, Nistri et al. studied 127 bicuspid aortic valves (BAVs) with no 
or mild aortic valve impairment and found BAV patients have lower aortic root distensibility 
and greater stiffness index than controls [143]; similar findings were confirmed in another 
study using MRI technology [144]. In addition, the reduction of aortic elasticity in 
nonstenotic BAV patients is associated with the severity of aortic valve regurgitation and LV 
hypertrophy [144]. In children, the story is not different: in comparison to healthy controls 
with tricuspid aortic valves (TAVs), children with BAVs without significant valve 
dysfunction have lower aortic distensibility (8.51 ± 3.90 vs. 14.37 ± 4.20 10− 6 cm2 dyn− 1, 
respectively; P = 0.001) and higher aortic stiffness index (7.19 ± 4.45 vs. 4.05 ± 2.33, 
respectively; P = 0.04) [145]. This difference in the elastic properties of the aorta in BAV is 
also expressed by the difference in the size of the aortic root [143]. Compared to normal 
controls, BAV patients had larger aortic root annulus (2.2 ± 0.2 cm vs. 2.4 ± 0.2 cm, 
respectively; P < 0.001), sinus of Valsalva (2.6 ± 0.3 cm vs. 3.3 ± 0.4 cm, respectively; P < 
0.001), sinotubular junction (2.5 ± 0.2 cm vs. 2.9 ± 0.3 cm, respectively; P < 0.001), and 
proximal ascending aorta (2.5 ± 0.2 cm vs. 2.8 ± 0.3 cm, respectively; P < 0.001) [146]. 
However, not all patients with BAV have aortic root dilation, and it seems that only those 
with a dilated root have higher PWV, while non-dilated BAVs have a PWV similar to normal 
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TAVs [147, 148]. Another study comparing stenotic BAVs to matched controls without 
stenosis found patients had larger aortic roots, and only the stiffness index was significantly 
higher in patients compared to controls, while aortic root distensibility and strain were similar 
in both groups; no correlations were found between stenosis severity and indices of aortic 
elasticity or aortic dimensions [149].  
 
1.2.7 Aortic stiffness in aortic and mitral valve regurgitation 
Compared to healthy controls, patients with asymptomatic severe aortic regurgitation (AR) 
and good LV function have greater arterial compliance and distensibility as assessed by high-
resolution ultrasonography of the common carotid artery [150]. This could represent a 
compensatory mechanism to lessen the impact of high systolic volume ejected into conduit 
arteries [150]. On the other hand, an association between PWV and AR was reported using 
flow-sensitive 4D MRI, and the presence of aortic valve insufficiency suggested an average 
increase of 1.42 m/s in PWV [151]. AR patients, compared to aortic stenosis (AS) patients, 
exhibited significantly higher circumferential strain and distensibility and lower aortic 
stiffness as assessed by M-mode form echocardiography [152]. In repaired tetralogy of Fallot 
(TOF) patients, the degree of AR fraction seems to be associated with aortic root dilatation 
and reduced aortic elasticity as assessed by MRI [153]. The effect of aortic stiffness seems to 
extend beyond the aortic valve, reaching the mitral valve. Rossie et al. studied 175 patients 
(age 61 ± 13; 85% male) with functional mitral regurgitation and LV systolic dysfunction due 
to dilated cardiomyopathy with normal aortic valve. They found that PWV was significantly 
associated with mitral effective regurgitant orifice (r = 0.35; P < 0.0001), regurgitated volume 
(r = 0.36; P < 0.0001), and regurgitation fraction (r = 0.41; P < 0.0001), indicating that aortic 
stiffness is an important determinant of the severity of functional mitral regurgitation [154]. 
The exact mechanism of the relationship between aortic stiffness and valvular regurgitation is 
not fully understood, but increased cardiac or ventricular afterload because of high aortic 
stiffness may contribute to the development of the regurgitation [154]. 
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1.2.8 Aortic stiffness in Marfan syndrome 
Patients with Marfan syndrome have faster PWV, decreased aortic distensibility, and 
increased aortic stiffness index in the ascending and the abdominal aorta [155, 156], with an 
inverse correlation between aortic diameter and aortic distensibility [156]. In a prospective 
study with a mean follow up period of 29 ± 11 months, stiffness index was one of the 
significant predictors of aortic dilation and dissection in patients with Marfan syndrome 
[156]. Even in children, although the diameter of the abdominal aorta was not statistically 
different between children with Marfan syndrome and normal control group, the aortic 
stiffness index of the abdominal aorta was higher in children with Marfan syndrome [157]. A 
recent study suggests that aortic stiffness (including PWV) in Marfan patients is greater than 
in healthy controls in subjects aged ≤40 years, but not in those aged >40 years where aortic 
stiffness did not differ from controls [158]. 
1.2.9 Aortic stiffness in cardiomyopathies 
It is not surprising that aortic stiffness is associated with cardiomyopathies, where diseased 
myocardium faces increased afterload because of a stiffer aortic wall. PWV measured by 
velocity-encoded MRI was significantly higher in hypertrophic cardiomyopathy (HCM) 
patients (n = 100) compared to control subjects (n = 35; 8.72 ± 5.83 m/s vs. 3.74 ± 0.86 m/s, 
respectively; P < 0.0001), and it is more prominent in HCM patients with myocardial fibrosis 
than in those without (9.66 ± 6.43 m/s vs. 6.51 ± 3.25 m/s, respectively; P = 0.005) [159]. 
PWV is a predictor of exercise capacity (peak oxygen consumption [pVO2]) in patients with 
HCM independent of LV thickness, LV LVOT, gradient and diastolic indices, signifying the 
potential use of aortic stiffness in the evaluation of HCM symptoms [160]. In patients with 
non-ischemic dilated cardiomyopathy, PWV assessed by echo application was increased and 
it was correlated with LV shape and function, including neurohumoral activation [161, 162]. 
Compared to normal controls (n = 30), aortic strain and aortic distensibility were significantly 
decreased in idiopathic dilated cardiomyopathy patients (n = 37) and negatively correlated 
with high-sensitivity CRP [163].  
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1.3 The predictive value of aortic stiffness 
In summary, arterial stiffness affects the aorta and large elastic arteries more than peripheral 
blood vessels, and aortic stiffness is associated with the presence of CV risk factors and 
atherosclerotic changes [14, 93, 94]. In addition, aortic stiffness increases with age [164], and 
is associated with higher CV mortality and CAD in the general population [92] and with 
stroke in general healthy older adults [135]. Furthermore, it can predict MACE risk in males 
with established coronary artery disease [36]. The relationship between systemic 
inflammation and aortic stiffness was confirmed in essential hypertension patients [38], stroke 
[165 ], and in antineutrophil cytoplasmic antibody–associated systemic vasculitis [37].  
 
Aortic PWV is specifically associated with increased risk for a first major CV event in 
the general population [166]. A meta-analysis of 17 longitudinal studies including 15,877 
participants revealed that aortic PWV is a strong predictor of future CV events and all-cause 
mortality. Furthermore, an increase of aortic PWV of 1 m/s increases total CV events, CV 
mortality, and all-cause mortality by 14%, 15%, and 15%, respectively [39].  
 
Aortic PWV in the general healthy population is an independent predictor of coronary 
heart disease and stroke [134], and it is associated with fatal coronary heart disease [92]. 
Aortic PWV is also an independent predictor of all-cause and CV mortality in hypertensive 
patients [167, 168], DM [108], ESRD [169-171] and elderly above 70 years old of age [172]. 
Recently, aortic PWV was found to be significantly associated with cerebral small-vessel 
disease in hypertensive patients [173, 174], and with future CV events and CAD in patients 
with chest pain [175]. Furthermore, aortic PWV is an independent predictor of future 
increases in SBP and the development of hypertension in healthy volunteers [176]; an 
independent predictor of fatal stroke in patients with essential hypertension [126, 177]; and a 
determinant of myocardial ischemic threshold in patients with moderate CAD [33].  
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Further evidence of the value of aortic PWV is derived from the fact that it is 
independently and significantly associated with eGFR in chronic kidney disease [97] is a 
strong independent predictor of all-cause and CV mortality in patients with ESRD [31]; and 
was significantly associated with incident albuminuria and with annual change in eGFR in 
type II DM patients [112]. High PWV is also independently related to intracerebral 
hemorrhage and cerebral infarction [133]. In addition, aortic PWV is a predictor of post-
stroke outcome, including early favorable outcome at hospital discharge, [140] and prediction 
of ≥50% asymptomatic CAD [141]. PWV is also an independent predictor of exercise 
capacity in patients with hypertrophic cardiomyopathy [160], and aortic stiffness can be used 
as a marker of sub-clinical organ damage, which can predict CV mortality independently of 
classical risk stratification scoring systems that incorporate traditional CV risk factors [118]. 
Finally, aortic compliance measurements, such as PWV, can be useful for the early detection 
of aortic wall abnormalities in asymptomatic patients suspected of inherited aortic disease 
with normal aortic diameter [178].  
 
1.4 PWV reference values 
Despite the strong association between PWV and CV diseases, as shown in the many 
aforementioned studies, to date there is no real widespread use of PWV in clinical practice. 
This anomaly is mainly due to the absence of reference values. In 2010, however, the 
Reference Values for Arterial Stiffness’ Collaboration published reference and normal values 
for PWV based on a population of 16,867 subjects from eight European countries [89]. 
“Normal” values were derived from a population with no CV risk factor (apart from age and 
sex), while “reference” values were derived from a population with various risk factors, 
according to age and BP categories. The availability of such normal and reference values for 
PWV per age group makes identifying individuals with abnormal PWV possible and practical 
without the need for recruiting matched control groups as long as the methodology of 
measuring aortic PWV is the same. With these normal and reference values, we believe that 
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aortic stiffness will soon be widely used in the clinical setting, not only for risk factor 
assessment, but possibly for pre-operative risk stratification and monitoring the effectiveness 
of anti-risk factor therapies [179, 180]. 
 
1.5 Literature review of aortic stiffness and aortic valve stenosis 
1.5.1 Aortic stenosis (AS) 
1.5.1.1 Incidence and natural history 
The incidence of calcific aortic valve disease approaches 25% in all adults aged >65 years, 
but most of these patients are asymptomatic with normal valve function because the disease 
manifests as only mild focal valve thickening or aortic valve sclerosis [181]. In a longitudinal 
study, up to 44% of subjects with normal aortic valves progressed to aortic sclerosis over a 5-
year follow-up period, while 9% of patients with aortic sclerosis progressed to some degree of 
AS over the same period [182]. Advanced age (odds ratio [OR] 1.13, 95%CI 1.09–1.16) and 
male gender (OR 3.05, 95% CI 1.76–5.27) are independent predictors of progression to AS 
from normal valve or AS at baseline [182]. Thus, it is expected to observe increasing numbers 
of AS cases over the next few decades because of the worldwide increase in life span. AS is 
the most common valvular disease in Europe and North America; about 2% to 7% of all older 
adults (>65 years) have significant AS with obstruction to LV outflow [181, 183]. AS 
progress can take decades because of the prolonged latent period in which patients remain 
mostly asymptomatic with very low morbidity with a mortality rate similar to age-matched 
normal adults [183, 184]. Though it is very difficult to anticipate stenosis progression in 
individual patients, once moderate stenosis occurs, progression rapidly increases with 
approximately a 0.3 m/s per year increase in jet velocity, 7 mmHg per year increase aortic 
valve mean gradient (AVMG), and 0.1 cm2 per year decrease in valve area [184]. Once a 
patient starts to exhibit symptoms, such as exertional shortness of breath, dizziness, syncope, 
or angina, the prognosis (without intervention) becomes very poor with mean survival of 2–3 
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years (survival rates of 15–50% at 5 years), and they are at a high risk of sudden death [181, 
183, 184]. It is for these reasons that, fundamentally, the development of symptoms signifies 
the end of the latent period and starts the countdown toward surgical correction of AS, largely 
by aortic valve replacement surgery (AVR) [183, 185, 186].  
 
1.5.1.2 Pathophysiology and severity of the stenosis 
AS is associated with other CV risk factors, such as age, sex, hypertension, smoking, and 
DM, and it also associated with approximately a 50% increased risk of myocardial infarction 
and CV death compared to subjects with a normal aortic valve [184]. However, the exact 
nature of these associations is not clear.  
 
Pathologically, aortic-valve diseases involve inflammatory, atheromatous, and 
calcification processes sharing histopathological changes similar to those seen in coronary 
atherosclerosis [181, 187]. As aortic valves become narrower, the systolic pressure overload 
on the LV increases, leading to increased myocardial cell mass and LV wall hypertrophy and 
thickening. This process occurs to compensate for increased wall stress (Laplace's law), to 
overcome the outflow obstruction, and to maintain normal ejection fraction (EF) and normal 
cardiac output [181, 183, 184, 188]. If the LV wall hypertrophy and thickness is inadequate to 
maintain normal wall stress, the increased afterload causes a reduction in the EF [183, 184]. 
Increased wall thickness and reduced compliance causes increased LV end-diastolic pressure. 
In the advanced stages of chronic pressure overload, in combination with LV hypertrophy, 
limited coronary vasodilator reserve, and reduced EF, coronary blood flow reduces, 
particularly in the subendocardium, and LV systolic and diastolic functions gradually worsen 
[181, 183, 184, 188]. In end-stage disease, low EF or cardiac output occurs, usually preceded 
by clinical symptoms [181, 188].  
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The severity of AS is graded based mainly on three hemodynamic parameters 
measured by Doppler echocardiography: 1) aortic valve area (AVA); 2) mean aortic valve 
pressure gradient (AVMG); and 3) aortic jet velocity [184]. Mild AS manifests as an AVA 
more than 1.5 cm2, AVMG <25 mmHg, or jet velocity <3.0 m/s; moderate AS includes an 
AVA of 1.0 to 1.5 cm2, AVMG 25 to 40 mmHg, or jet velocity 3.0 to 4.0 m/s; and severe AS 
includes an AVA of <1.0 cm2 (or <0.6cm2 indexed to BSA), AVMG >40 mmHg, or jet 
velocity greater than 4.0 m/s [183, 184]. Surgical therapeutic decision-making processes 
depend on echocardiography assessment and also on the presence of symptoms (exertional 
shortness of breath, dizziness, syncope, or angina), as hemodynamic parameters alone are not 
the determinant for AVR [183, 184].  
 
1.5.1.3 Management and outcome 
Currently, echocardiography is the main tool for the diagnosis and assessment of AS, while 
the decision for surgery is based on the development of symptoms and echocardiography 
findings. This situation has not changed for decades; therefore, adding more 
pathophysiological markers, such as the recently added natriuretic peptides (a potential 
predictor of symptom free survival and outcome in severe AS) [183] and our proposal of 
adding aortic stiffness to this equation, may improve outcome predictions and enhance the 
decision-making process.  
 
There is no effective medical prophylaxis for preventing AS or halting its progress 
upon diagnosis [183, 184]. To date, there is no effective medical treatment for severe 
symptomatic AS other than AVR surgery [183, 184]. Although transcatheter aortic valve 
implantation (TAVI) is sometimes considered, it is a limited option reserved for patients 
considered (by the heart team) as unsuitable for conventional surgery because of severe 
comorbidities [183]. Compared to standard therapy, including percutaneous aortic balloon 
valvuloplasty, TAVI significantly improved mortality rate at 1 year (30.7% vs. 50.7%, 
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respectively) and at 2 years (43.3% vs. 68.0%, respectively), but this improvement comes 
with a significantly higher stroke rate (5.5% vs. 13.8%, respectively) [189, 190]. 
 
Conventional AVR improves patient symptoms, QoL, and survival, which may reach 
that of age-matched general populations of older patients [181, 184, 191]. Operative mortality 
rates have improved dramatically during the past two decades, ranging from 2.9% to 3.6%, 
while the risk of permanent stroke is about 1.5% to 1.8% in the USA [181, 184, 191]. Main 
operative complications also include acute kidney injury (AKI) and arrhythmias. Post-cardiac 
surgery AKI may occur in up to 30% of adult patients depending on the specific definition of 
AKI [192]. In a study that investigated 5,068 cardiac surgery patients, the incidence of acute 
renal failure after valve surgery was 4%, only 2.5% of them required renal replacement 
therapy [193]. Post-valvular surgery arrhythmia is a very common occurrence, with about 
3.2% to 8.5% of patients requiring permanent pacemaker implantation after AVR with or 
without other procedures, and about 3.4% in isolated AVR for severe symptomatic AS 
required permanent pacemaker, and it is higher in TAVI (7.3%) [194]. Other late adverse 
outcomes are procedure-specific, such as paravalvular leak or prosthesis-related 
complications, such as bleeding, clot formation, endocarditis, and suboptimal hemodynamic 
performance. In addition to classical risk factors, such as age, gender, and comorbidities, 
AVR outcome depends on pre-operative LV function. Those with LV dysfunction not due to 
excessive afterload (such as cardiomyopathy), AVR improves survival but does not 
necessarily improve symptoms; thus, it is recommended to perform AVR on symptomatic 
patients with normal LV function before the LV deteriorates  [183, 184].  
 
Any other factor that increases pressure overload on the LV, such as systemic 
hypertension, and we suggest aortic stiffness, may have a negative impact on the regression of 
LV hypertrophy and patient survival in AS patients [195]. 
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Management of asymptomatic severe AS is still controversial with conflicting results 
from different studies; it is evident, however, that these patients will develop symptoms 
within 5 years during which sudden death occurs at a rate of about 1% per year. Therefore, 
careful weighing of the benefits and risks from surgical treatment should be considered on an 
individual basis [181, 183, 184, 196]. 
 
Sixth National Adult Cardiac Surgical Database Report 2008 
According to the Sixth National Adult Cardiac Surgical Database Report 2008 of the Society 
for Cardiothoracic Surgery in Great Britain & Ireland and its online resources 
(http://bluebook.scts.org/#ActivityRates), the risk of developing AS is related to older age due 
to the degeneration and calcification of aortic valve leaflets; however, sometimes the stenosis 
is due to a congenital valve disease, as in BAV. In general, AVR is an elective surgery (75% 
of the time), while only 2% are performed on an emergency basis. More than 50,000 AV 
surgery cases with or without coronary artery bypass grafting (CABG) were performed in the 
UK between 1999 and 2008, with about 7,500 cases in 2011. The crude overall perioperative 
mortality is 3.8% (2004–2008); 2.8% for AV surgery and 5.3% for AV + CABG surgery. 
Perioperative risk factors include: 1) age (the average age of isolated AVR surgery is 68 
years, while combined AVR & CABG surgery is 73 years); 2) gender (mortality rates are 
higher in women than men; 3) priority (elective surgery is associated with the lowest 
mortality rate); 4) LV ejection fraction (good LV function is associated with the lowest 
mortality rate); and 5) other risk factors (such as left main stem artery disease, DM, 
hypertension, and renal diseases).  
 
A biological prosthetic valve is the dominant choice in AVR (about 65%, 2004–
2008), reflecting the increased age of this patient population and a change in practice toward 
biological valves in younger patients based on data that show better longevity for the modern 
generation biological valves. In patients less than 61 years of age, survival is better with 
mechanical prostheses, while in those over the age of 70 years survival is better with 
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biological valves; between the ages of 61 and 70 years, there is no difference between the two 
valves with respect to survival. The overall rate of post-operative stroke in isolated AVR is 
1.9% (2004–2008), which is higher than for isolated CABG (1–1.5%). The overall incident of 
new heart failure (HF)/ dialysis was 3.0% (2004–2008) following isolated AVR, which is also 
higher than following CABG surgery.  
 
1.5.2 Association between aortic valve disease and aortic wall disease 
To date, it is not clear whether there are associated changes between aortic valve diseases and 
histopathological aortic wall changes. Even when there is an associated change, the 
mechanism of development of such an association is not clear [197]. On one hand, the 
turbulent blood flow from a diseased valve may cause hemodynamic events leading to injury 
and repair processes within the aortic wall [198-200]. On the other hand, this association 
could be due to intrinsic histological factors that affect the tissues in both the valve and the 
aortic wall [201, 202]. The relationship between aortic valve morphology (such as BAV and 
TAV) and aortic wall mechanical and elastic properties is also controversial [197, 200, 202, 
203]. 
 
Benedik et al. studied the mechanical (mechanical stress test) and histological 
properties of the aortic wall in surgical AS (n = 135) and AR (n = 94) patients [197]. They 
found that, in AR patients, the incidence of aortic aneurysm (≥50 mm) was significantly 
higher and the quality (tendency for aortic media disruption and degeneration) of the 
ascending aorta wall was poorer despite a superior thickness compared to patients with AS. 
Combining both AS and AR patients, the cohesion of the aortic wall was poorer in patients 
with a slightly dilated aorta (40–49 mm) than those with normal aortic dimensions [197]. 
 
One of the reported late adverse aortic outcomes after AVR surgery is aortic 
dissection, which occurs in up to 3.5% of all cases independent of the morphology of the 
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native valve, making AVR a risk factor for future acute type A aortic dissection [204, 205]. 
Previous AVR, however, is an independent predictor of in-hospital mortality for type A aortic 
dissection repair surgery (OR, 4.54; 95%CI 1.10–18.73; P = 0.036) [205]. Histological 
examination may be the gold standard for evaluating the aortic wall, but requires extensive 
time and cannot be done intraoperatively to modify the surgery. Furthermore, in aortic 
dissection patients these histological changes could be due to the normal aging process rather 
than structural specific alterations responsible for the development of the dissection [197, 
199]. Currently, simple aortic size measurements are the standard practice to identify patients 
at risk for dissection [197, 206]. However, Pape et al. reviewed 591 type A dissection cases 
from the International Registry of Acute Aortic Dissection and found that 59% of patients had 
aortic diameters <5.5 cm and 40% patients had aortic diameters <5.0 cm and thus do not fall 
within current guidelines for elective ascending aortic surgery [207]. Therefore, it is apparent 
that risk stratification and surgical decision processes need more predictors than just simple 
aortic size measurement [197, 206]. To our knowledge, there is no method or test to assess 
the quality of aorta non-invasively in radiologically normal aorta; however, we propose that 
aortic PWV might be the solution to fill this gap. This necessitates more research into 
assessing the predictive value of aortic PWV in the surgical cardiac population.  
 
1.5.3 Literature review 
1.5.3.1 Search details 
In order to summarise what is known thus far about the relationship between aortic stiffness 
and aortic valve stenosis, a literature review was performed. A proper literature search using 
the PubMed search engine and the Web of Knowledge “All Databases” search engine, which 
includes MEDLINE (1950–current date) database, was performed on the October 11, 2013, 
using the following word combination as they were considered the most suitable, reliable, and 
practical combinations: 
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Web of Knowledge search terms 
• Title=(pulse wave velocity) OR  
• Title=(aortic stiffness) OR  
• Title=(arterial stiffness) OR 
• Title=(elastic properties)  
• AND 
• Topic=(aortic valve) 
Limits 
• English language 
• 1990–current date 
Result = 104 titles 
 
PubMed search terms 
• Title/Abstract=(pulse wave velocity) OR  
• Title/Abstract=(aortic stiffness) OR  
• Title/Abstract=(arterial stiffness) OR 
• Title/Abstract=(elastic properties) 
• AND 
• Title/Abstract=(aortic valve) 
Limits 
• English language 
• 1990–current date 
• Humans  
Search text: (((elastic properties[Title/Abstract] OR pulse wave velocity[Title/Abstract]) OR 
aortic stiffness[Title/Abstract]) OR arterial stiffness[Title/Abstract]) AND aortic 
valve[Title/Abstract] AND (("1990/01/01"[PDAT] : "2013/12/31"[PDAT]) AND 
"humans"[MeSH Terms] AND English[lang]) 
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Result = 76 titles 
In addition, references of the relevant, selected studies were also examined, including 
their references. Studies related to children, pure bicuspid aortic valve with no stenosis, and 
hereditary arteriopathies were excluded.  
 
1.5.3.2 Results 
No study that specifically reported the relationship between non-invasive aortic PWV and AS 
or any type of aortic valve surgery was found. Similarly, no study assessing the relationship 
between any aortic stiffness indices and post aortic valve surgery outcome, such as QoL and 
cognitive function, was found. However, a limited number of studies investigating the 
relationship between aortic stiffness and aortic valve disease were identified (10 studies). A 
summary of all the relevant studies included (n = 10) is presented in Table 1.2. 
 
1.5.3.2.1 Aortic stiffness indices (other than PWV) and AS 
Three studies [149, 152, 208] investigated the relationship between aortic stiffness indices 
(other than PWV) and AS. Petrini et al. assessed the difference in descending aorta strain, 
distensibility, and stiffness between AS patients (n = 54) and AR patients (n = 29) and found 
that AR patients exhibited significantly higher circumferential strain and distensibility, and 
lower aortic stiffness compared to AS patients [152]. Rosca et al. found that independent of 
the stenotic valvular load, high aortic rigidity is correlated with reduced LV longitudinal 
function, increased LV filling pressures, and B-type natriuretic peptides (BNP) levels in 
patients with severe AS and preserved LV EF (n = 48) [208]. The third study focussed on 
aortic stiffness index, aortic root distensibility, and strain in stenotic bicuspid aortic valves (n 
= 32) compared to matched controls (n = 32) [149]. This study revealed that only the stiffness 
index was significantly higher in patients compared to controls, while aortic root distensibility 
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and strain were similar in both groups. Furthermore, no correlations were found between 
stenosis severity and aortic elasticity or aortic dimensions, but there was a relationship 
between aortic dimensions and aortic stiffness (increased aortic dimension was associated 
with a stiffer aorta) [149].  
 
1.5.3.2.2 PWV and aortic valve disease 
Regarding the specific relationship between PWV and aortic valve disease, the number of 
studies is very limited, and they do not include any post-operative data [85, 209]. One study 
from Taiwan [209] showed invasive PWV (pigtail catheter and double-channel recording) in 
a degenerative AS group (n = 30) was higher than in matched control patients (15.5 ± 3.8 vs. 
8.0 ± 2.7 m/s, respectively; P = 0.001) and that PWV was strongly correlated with AS after 
adjustment for age, sex, mean BP, and LV function (R = 0.706, P < 0.0001). In contrast, 
another study from Turkey [85] showed that there was no significant difference between 
aortic valve sclerosis (defined as thickening and calcification of the trileaflet aortic valve, and 
not stenosis; n = 62) and the matched control patient group (n = 62) in aortic PWV (11.7 ± 3.3 
vs. 11.8 ± 3.7, respectively; P = 0.85) and augmentation index (28.0 ± 9.4 vs. 25.0 ± 8.6, 
respectively; P = 0.17). There was also a lack of association between aortic PWV and aortic 
valve sclerosis [85]. Another study from the same group of authors [85], used a more generic 
arterial stiffness index called the cardio-ankle vascular index (CAVI), which incorporates 
plethysmographic baPWV in its calculation equation [210]; they found that CAVI was 
significantly higher in patients (n = 80) with aortic valve sclerosis (not stenosis) compared to 
the control subjects (n = 80) and that CAVI was an independent determinant of aortic valve 
sclerosis [210]. 
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1.5.3.2.3 Aortic stiffness and AVR surgery 
The number of studies on the relationship between aortic stiffness and AVR surgery is again 
very limited [211, 212]. Two studies investigated the impact of AVR for sever AS on aortic 
stiffness assessed by echocardiography; however, neither PWV nor outcome were studied. 
One study (n = 31 patients) showed that aortic root distensibility and aortic root stiffness 
index improved 6-months post-operatively to values similar to pre-operative after transit 
deterioration [211]. The second study (n = 12 patients) demonstrated that pre-operative 
ascending aorta stiffness index in patients was significantly higher than in matched controls, 
but progressively improved to levels comparable to those of matched controls at the 1-year 
post-operative assessment [212].  
 
1.5.3.2.4 Aortic stiffness and other aortic valve or root surgeries 
Another two studies investigated the relationship between aortic stiffness and aortic valve 
(rather than AVR) or root surgery. One compared native ascending aorta stiffness index pre- 
and post-aortic root replacement (n = 13) to matched controls (n = 13) and found, in spite of 
progressive improvement in aortic stiffness index, that it remained higher in the former at the 
2-year assessment [213]. The final study found no significant change in the distensibility or 
stiffness index of the distal segment of the aortic root in 30 patients with severe AS before 
and 1-week post TAVI [214]. 
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1.6 Chapter summary 
• Aortic PWV measurement has a large collection of evidence establishing its 
relationship with incident CV disease independently of traditional risk factors in 
different diseased and healthy populations, and it is an emerging strong predictor of 
different outcomes.  
• Recently, the normal and reference values for PWV per age group became available, 
making identifying individuals with abnormal PWV possible and practical and 
without the need for recruiting matched control groups. 
• Currently, echocardiography is the main tool for the diagnosis and assessment of AS, 
while the decision for surgery is based on the development of symptoms; therefore, 
adding more pathophysiological markers, such as aortic PWV to this equation may 
improve outcome prediction and enhance the decision-making process.  
• Operative mortality rate for AVR has improved dramatically during the past two 
decades; therefore, more attention has been paid to improving other outcomes, such 
as QoL and cognitive function. Any factor that increases the pressure overload on the 
LV, such as aortic stiffness, may have a negative impact on LV regression and patient 
QoL.  
• While histological examination may be the gold standard for evaluating the aortic 
wall, to our knowledge, aortic stiffness may be the only method or test to non-
invasively assess the quality of radiologically normal aorta. 
• The number of studies investigating the relationship between aortic stiffness and 
aortic valve disease is very limited.  
 None of the published studies were from the UK. 
 There are only three studies using PWV as an aortic or arterial stiffness index, 
and only one of them was in an AS population, though the authors did not use 
applanation tonometry PWV, which is the gold standard index of aortic stiffness.  
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 There are only four studies investigating the relationship between aortic stiffness 
and aortic valve replacement or root surgery; none of them used PWV.  
 No study specifically investigating the relationship between aortic PWV and AS 
or any type of aortic valve surgery was found.  
 No study assessing the relationship between any aortic stiffness index and post-
aortic valve surgery outcome, such as QoL and cognitive function, was found. 
 Compared to matched controls, patients with aortic valve disease seem to have 
stiffer aorta. 
 The correlation between the severity of AS and indices of aortic elasticity is 
controversial and requires more data.  
 The correlation between aortic size and indices of aortic elasticity is 
controversial and requires more data.  
 Whether there is a difference in aortic elasticity between AS and AR patients is 
still controversial and requires more data.  
Though the perioperative mortality rate has improved, AVR is still associated with 
about 3% perioperative mortality and significant morbidity. It is important to identify patients 
that are at a high risk of developing complications in order to optimize management and 
facilitate informed consent. Exploring factors that may contribute to these risks, such as aortic 
stiffness (PWV), could potentially allow us to reduce surgical risks.  
Conflicting preliminary data has led to controversy surrounding the presence and 
significance of abnormal PWV in AS disease patients and whether histological changes in 
AV are linked to changes in aortic wall structure. This, together with the ability of PWV to 
predict poor outcomes in other patient populations, motivated us to conduct this study.
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Reference 
and Country 
n= Patients Indices Modality  Operation Findings Comments 
Relationship between aortic stiffness indices (other than PWV) and AS 
Petrini et al, 
2010[152] 
 
Sweden 
54 
 
29 
AS 
 
AR 
Descending 
aorta strain, 
distensibility
, and 
stiffness 
Transoesophageal 
echocardiography  
No operation AR patients compared to AS patients exhibited 
significantly higher circumferential strain and 
distensibility, and lower aortic stiffness  
 
Rosca et al, 
2011[208] 
 
Romania 
48 Severe AS with 
preserved LV 
ejection fraction 
(≥50%) 
Ascending 
aorta 
stiffness 
index  
Echocardiography 
 
No operation Severe AS with preserved LV ejection fraction, 
independently of the valvular load, and an 
increase in aortic rigidity is independently 
correlated with reduced LV longitudinal function, 
increased LV filling pressures, and BNP levels 
 
Yap et al, 
2008[149] 
 
Netherlands 
32 
 
 
 
32 
Congenital AS 
(bicuspid aortic 
valve) 
 
Matched controls 
Aortic 
stiffness 
index, aortic 
root 
distensibility 
and strain 
Echocardiography 
 
No operation  Patients had larger aortic roots. Only the stiffness 
index was significantly higher in patients 
compared to controls, while aortic root 
distensibility and strain were similar in both 
groups. No correlations were found between 
stenosis severity and indices of aortic elasticity or 
aortic dimensions. There seems to be a 
relationship between aortic dimensions and aortic 
stiffness (increased aortic dimension is associated 
with a stiffer aorta) 
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Relationship between specifically PWV and aortic valve disease 
Liu PY et al, 
2004[209] 
 
Taiwan 
30 
 
 
30 
Degenerative AS 
 
 
Matched control 
patients 
Invasive 
PWV 
Pigtail catheter and 
double-channel 
recording 
No operation Invasive PWV in patients was higher than 
matched controls (15.5 ± 3.8 vs. 8.0 ± 2.7 m/s, 
respectively; P = 0.001) and PWV was strongly 
correlated with AS after adjustment for age, sex, 
mean blood pressure, and left ventricular function 
(R = 0.706, P < 0.0001) 
 
Celik et al, 
2008[85] 
 
Turkey 
62 
 
 
62 
Aortic valve 
sclerosis 
 
Matched control 
patients 
Aortic PWV 
and 
augmentation 
index 
Applanation 
tonometry 
No operation There was no significant difference between the 
patients group (thickening and calcification of the 
trileaflet aortic valve) and matched control on 
aortic PWV and augmentation index (11.7 ± 3.3 
vs. 11.8 ± 3.7; P = 0.85; 28.0 ± 9.4 vs. 25.0 ± 8.6; 
P = 0.17, respectively). There was also a lack of 
association between aortic PWV and aortic valve 
sclerosis 
 
Korkmaz et 
al, 
2013[210] 
 
Turkey 
80 
 
 
80 
Aortic valve 
sclerosis 
 
Matched control 
patients 
Cardio-ankle 
vascular 
index (CAVI) 
Plethysmographic 
brachial–ankle 
PWV  
No operation CAVI was significantly higher in patients 
compared to the control subjects. Multivariate 
analysis demonstrated CAVI as an independent 
determinant of AVS 
Same authors 
group for 
reference [85], 
mostly same 
but slightly 
bigger data  
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Relationship between aortic stiffness and AVR surgery 
Barbetseas 
et al, 
2006[211]  
 
Greece 
31 Severe AS Aortic root 
distensibility 
and stiffness 
index 
Echocardiography AVR Aortic root distensibility and aortic root 
stiffness index improved 6-months post-
operatively to values similar to the pre-
operative values after transit deterioration 
 
Nemes et al, 
2007[212]  
 
Netherlands 
12 
 
12 
Severe AS 
 
Matched controls  
Ascending 
aorta 
stiffness 
index 
Echocardiography AVR Pre-operative ascending aorta stiffness index 
for patients was significantly higher than 
matched controls, but progressively 
improved to levels comparable with those of 
matched controls at the 1-year post-operative 
assessment 
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Table 1. 2 Summary of the references investigating the relationship between aortic stiffness and aortic valve stenosis.  
Relationship between aortic stiffness and other aortic valve or root surgeries 
Nemes et al, 
2009[213]  
 
Netherlands 
13 
 
 
 
 
 
 
 
13 
Acute aortic 
regurgitation due to 
endocarditis (n = 6) 
and aortic valve 
stenosis with or 
without 
regurgitation (n = 
7) 
 
Matched control 
patients  
Aortic 
stiffness 
index of the 
native 
ascending 
aorta 
Echocardiography 
 
Aortic root 
replacement 
After a transient short-term deterioration, a 
significant and progressive improvement was 
found in aortic stiffness index post-
operatively. Despite this progressive 
improvement, the aortic stiffness index 
remained increased compared to matched 
controls at the 2-year assessment. No 
significant differences in stiffness indices 
were observed between aortic stenosis and 
regurgitation patients 
Same authors 
group for 
reference 
[212] and 
[149] 
Vavuranakis
, et al, 
2012[214] 
 
Greece 
30 Sever AS 
 
vs. 
1-week post-
procedure 
Distal 
segment of 
the aortic 
root 
distensibility 
and stiffness 
index 
Echocardiography 
 
Transcatheter 
aortic valve 
implantation 
(TAVI) 
Distensibility did not change significantly 1-
week after TAVI and stiffness index also 
remained unchanged  
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2 Chapter 2  
A systematic review of the quality of life following cardiac 
valve surgery  
 
 
One of the main objectives of this thesis is to investigate the relationship between aortic stiffness and 
QoL pre- and post-aortic valve replacement (AVR), and whether aortic stiffness is a predictor of QoL. 
However, it is important to review in detail the nature of the relationship between QoL and cardiac 
valve surgery prior to establishing potential relationships. Therefore, this chapter delivers a systematic 
review of the published literature related QoL outcomes for patients of all ages who have undergone 
cardiac valve surgery. 
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2.1 Abstract 
 
Aim: Cardiac valve surgery outcomes have traditionally been measured by survival and surgical 
complications. However, there is an increasing appreciation for improvement in health-related quality 
of life (QoL) as a having a greater prognostic benefit over just increasing long-term survival. This 
systematic review aims to examine existing evidence related to cardiac valve surgery and 
consequential QoL.  
 
Methods: In total, 29 studies including a total of 3942 patients with an age range of 9.7 to 94 years 
who had undergone different types of isolated cardiac valve surgery and assessed for QoL after a 
follow-up period ranging from 1 month to 30 years were investigated. The quality of each study was 
scored using predefined criteria. 
 
Results: Nineteen of the studies (66%) were of high quality, while the remaining ten were of 
moderate quality. Twenty-six studies investigated improvements on follow-up QoL assessment by 
comparing to baseline or published norms. Overall, 24 of these showed that cardiac valve surgery led 
to an improvement in QoL.  
 
Conclusion: In general, all types of cardiac valve surgery in adult and elderly patients led to QoL 
improvements. Female gender, pre-existing PVD, less experienced operator, or moderate to severe 
mitral regurgitation (MR) seem to reduce the magnitude of this improvement following certain types 
of surgery or procedures. Despite the heterogeneity in QoL instrument used, type of valve, and type of 
procedure, the results were consistent, thus rendering the conclusion more reliable. QoL is a new 
parameter that needs to be added to the decision-making process regarding the timing and type of 
procedure to be performed. Future studies should overcome the discussed limitations and also focus 
more on identifying predictors of post-operative QoL improvement. 
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2.2 Introduction 
 
Health related quality of life (QoL) is a highly significant and effective Patient-Reported Outcomes 
(PROs) tool. Interest in PRO, and in particular QoL, has increased greatly over the last decade among 
healthcare providers and beneficiaries. Cardiac valve surgery outcome, however, is traditionally 
evaluated in terms of operative morbidity, mortality, and valve related complications, such as 
thromboembolism, anticoagulant-related hemorrhage, endocarditis, prosthesis failure, hemodynamic 
properties, and reoperation. Low rates of these adverse clinical outcomes are associated with 
favorable gains in patient wellbeing and functioning. However, in recent years, there has been 
growing recognition that morbidity and mortality data alone are incomplete measures of outcome 
following surgery. As with all surgeries, there are risks and potential negative consequences, some of 
which may impact more heavily on aspects of patients’ lives and, hence, impact their QoL more 
severely. Therefore, a patient’s perception of their health are increasingly recognized as important 
considerations in the assessment of health outcomes [215, 216]. Thus, improvement of a patient’s 
emotional state, performance of social roles, general satisfaction, and return to work with the ability to 
live independently following surgery, medication, or intervention, are all recognized as being equally 
important as survival [215, 216]. QoL questionnaires address most of the above questions and issues, 
and both generic and disease-specific questionnaires have been developed. Numerous methods exist 
for evaluating QoL of patients and these various tools can be implemented by various means, such as 
interview, questionnaire, and self-report [217].  
 
Total valve replacement for cardiac valve disease is commonly required and has traditionally 
been seen as a high risk procedure; however, subsequent survival from this procedure provides a high 
expectation with respect to QoL [183, 184, 218]. Aortic stenosis, the most common valve disease 
[219, 220], has a deteriorative effect on the life of a patient, not only when considering lifetime 
duration but also QoL [221].  
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More recently, newer surgical methods have come to the fore, and are implemented 
depending on the severity of valve disease. For example, in addition to traditional repair alternatives 
and various types of valve replacement that are available, less invasive procedures, such as 
transcatheter and percutaneous implantation, are becoming more commonplace [183, 221]. 
Consequently, with advancements in modern technology, surgical techniques, and anesthesia, 
morbidity and mortality rates following valvular heart surgery have significantly declined, which has 
made QoL a more central component of outcome. Hence, over recent years, there is an increasing 
interest in assessing QoL, which can be defined as a multi-dimensional assessment of an individual’s 
perception of the physical, psychological, and social aspects of life that can be affected by a disease 
process and its treatment [222]. In patients of an advanced age, cardiac valve surgery goals may be 
emphasized with a particular focus QoL improvement, or at least preservation, rather than on simply 
increasing lifespan [223-226]. This same principle has been applied to other interventions for other 
kinds of cardiac disease, such as congestive heart failure in which the main therapeutic goal is 
symptoms improvement, in which QoL improvement, rather than just survival, is considered [227].  
 
Cost containment and allocation are additional issues that need to be taken into consideration 
when deciding on patient intervention. There are several opinions on whether intervention to achieve 
significant QoL improvement in the elderly population is cost-effective compared to the same 
approach in younger patients [228, 229]. While acknowledging that these issues exist, the purpose of 
this review is not to take them into consideration, but rather to explore the published evidence 
detailing factors that can impact the strength of the link between QoL and cardiac valve surgeries.  
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2.3 Aims of the systematic review  
 
The aims of this study are to systematically review the published literature related to QoL outcomes 
for patients of all ages who have undergone cardiac valve surgery. Firstly, we assess the quality of 
studies within the literature, highlighting the important information and findings of the studies and the 
different tools used to assess QoL. Secondly, we perform comparative therapy assessment in terms of 
QoL, identifying predictors of QoL, and uncovering limitations of the current literature. Finally, we 
summarize the conclusions and recommendations for future work in this area.  
 
2.4 Methods 
2.4.1 Literature search  
This study was performed in accordance with guidelines for the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses (PRISMA) [230]. 
 
A systematic search was carried out using MEDLINE (from 1950 to date), EMBASE (from 
1980 to date), and PsycINFO (from 1966 to date) databases using the following MeSH terms: [cardiac 
valve surgery OR cardiac surgery] AND [health related quality of life] OR [quality of life]. The last 
search date was 31st March 2013.  
 
2.4.2 Eligibility criteria 
Articles relating to QoL outcomes in all patients who had previously undergone only cardiac valve 
surgery were included. Exclusion criteria were: (a) articles written in a language other than English; 
(b) QoL outcomes were reported in patients undergoing valve surgery and concomitant coronary 
artery bypass graft surgery (CABG) or other surgery; and (c) pure endocarditis population. 
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2.4.3 Study selection and data collection process 
Three reviewers independently identified potentially relevant articles. The full text of the article was 
obtained and further screened for inclusion to determine if they addressed QoL outcomes in patients 
after cardiac valve surgery. Conflicts between reviewers were subsequently discussed until 100% 
agreement was achieved on the final studies to be included in the review.  
 
The following information was extracted from each study: first author, year of publication, 
type of valve procedure, study type, number of patients and age, duration of follow-up, QoL 
instrument used, rate of follow-up completion, and overall conclusions. The quality score for each 
study was also calculated as explained in the following section. The ratio of males/females in some of 
the studies were calculated using the percentages reported when the actual numbers were not 
available, and when the percentage was not give we considered a 50% gender distribution as in 
Maliwa et al. [231]. When there were different responses rates for each instrument at same time point 
we reported the lowest rate.  
  
2.4.4 Quality scoring 
The quality of included studies was assessed using the criteria for assessing the methodological 
quality of studies in QoL, as previously described by Baig et al. [232], which was modified from Mols 
et al.’s list [233] (Figure 2.1). Briefly, there are 10 pre-defined criteria used in this modified scoring 
system; one point is assigned for each criterion if adequately covered, while zero is given where a 
criterion is described inadequately or not at all, generating an overall score range from 0–10. A score 
>8 was considered high-quality, a score between 5 and 8 was considered moderate quality, and <5 
poor quality.  
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Figure 2. 1 Scoring criteria for the methodological quality of the included papers. Adapted from Baig et al. [232], 
which was modified from Mols et al. [233]. 
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2.5 Results 
2.5.1 Study selection 
The initial search resulted in 1,024 citations of potentially relevant articles. Initial scan of these 
articles reduced this to 214 citations, 105 of which were excluded based on the information in the 
abstract. The 109 remaining articles were then assessed in depth, after which a further 90 articles were 
excluded and 19 were included. Twenty-three additional articles were found form the references of 
the included articles of which 13 were subsequently excluded. In total, 29 articles were deemed 
suitable for inclusion in the systematic review (Figure 2.2). Table 2.1 shows the summary of the data 
extracted from all the included articles, while Table 2.2 is a consolidated table of the included articles.  
 
2.5.2 Quality of included studies 
The quality of each study was individually scored as described above using the criteria outlined in 
Figure 2.1. Generally, the quality was fairly high with scores ranging between 5 and 10 (Figure 2.3). 
Nineteen of the studies (66%) were deemed of high quality, while the remaining 10 were of moderate 
quality. 
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Figure 2. 2 Flow chart of articles selection process. 
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2.5.3 Study design and population 
This review included 29 studies incorporating a total patient population of 3,942 (53% male) who 
were initially recruited (if prospective) or included (if retrospective), with a sample size ranging from 
26–628 patients (Table 2.2). Patient age varied from 9.7 to 94 years. Of these included patients, 2,580 
responded to a QoL questionnaire at the final follow up time-point, and the sample size of these final 
responses ranged from 3–340. The procedures involved one or more of: open aortic valve (AV) 
repair, replacement and catheter-based implantation, or open mitral valve (MV) repair, replacement, 
or catheter-based MV repair. The studies comprised of 27 cohort studies and two randomized control 
trials. Nine were carried out retrospectively, while 20 (70%) were prospective studies, and all studies 
took place in North America or Europe, including six multi-centered across both continents. 
 
One study measured the post-procedural QoL of very young patients with a median average 
age of 14.4 years [234], seven studies consisted of older patients with a mean age of less than 65 years 
of age [231, 235-240], while the remaining 21 studies looked at a patient population with a mean age 
greater than 65 years (Table 2.2) [241-261].  
 
2.5.4 Quality of life instruments 
A total of six different questionnaire instruments/tools were used across the 29 studies to measure 
QoL outcomes. Of the 29 studies, one study used three QoL tools [250], seven studies used two tools 
[231, 234, 243, 244, 249, 251, 256] and 21 studies used a single tool [235-242, 245-248, 252-255, 
257-261]. Quality Metric’s Short Form health survey (SF-36®, versions 1 and 2) was the most 
popular questionnaire and it was used in 19 (65%) of the total studies (Table 2.2). 
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Author, 
year 
 
  
Type of 
cardiac valve 
procedure 
Study type Patient 
population 
No. of 
patients 
at 
baseline 
Age of patients Follow-up 
duration 
(mean) 
QoL 
Instruments 
Conclusion Physical 
component 
improved 
Quality 
score 
Baseline QoL 
obtained  
Follow-up 
completion 
rate (no. 
patients) 
Mental component 
improved 
Aboud, 
2009 [241] 
AVR: 
Mechanical (n 
= 83)  
vs.  
 
Biological (n 
= 53) 
Retrospective 
cohort 
Department of 
Cardiothoracic 
Surgery, Herz- 
und 
Diabeteszentrum 
NRW, Bad 
Oeynhausen, 
Germany 
136 
Mean 64 years 
Range 44–81 
(mechanical) 
 
Mean 74 years 
Range 52–87 
(bioprosthesis) 
 
 
 
21.4 months 
SF-36 
 
The quality of life in patients with 
mechanical and biological valves was 
similar at 2 years postoperatively 
N/A-No comparison 
with pre or norms 
7 
No 100%  (136) 
N/A-No comparison 
with pre or norms 
 
 
Aicher, 
2011 [236] 
AV: 
Reconstructio
n  
vs.  
mechanical 
replacement 
vs.  
pulmonary 
autograft 
replacement 
Retrospective 
cross-
sectional 
Department of 
Thoracic and 
Cardiovascular 
Surgery, 
University 
Hospital of 
Saarland, 
Homburg/Saar, 
Germany 
166 
 
Mean 38 years 
(repair) 
 
Mean 40 years 
(mechanical) 
 
Mean 40 years 
(autograft) 
 
Range 18–45 
years (all) 
2.46 years 
(repair) 
 
6.48 years 
(mechanical) 
 
6.07 years 
(autograft) 
SF-36 
 
Compared to mechanical AVR, aortic 
valve reconstruction and pulmonary 
autograft replacement led to less 
long-term variation in quality of life 
from normal values 
 
All three surgical methods led to 
excellent quality of life and limited 
changes in anxiety and depression 
relative to healthy control subjects 
 
Yes-Comparable to 
age-matched 
population norms 
9 
100%  
(166) 
Yes-Comparable to 
age-matched 
population norms No 
Casali, 2008 
[255] 
AVR: 
Mechanical  
Prospective 
cohort 
Department of 
Cardiology and 
Cardiovascular 
Surgery, S. 
Camillo-Forlanini 
Hospital, Rome, 
Italy 
36 
Mean 66.9 years 
 
Range 31–83 
years 
4.4 years 
SF-36 
Implantation of the prosthesis 
improved the perceived quality of life 
Yes-Improved  
Yes 89%  (32) Yes-Improved  
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Detter, 2002 
[237] 
AVR: 
Minimally 
invasive (n = 
70)  
vs. 
conventional 
replacement 
(n = 70) 
Retrospective 
cohort 
Department of 
Cardiac Surgery, 
Klinikum 
Großhadern, 
Ludwig 
Maximilians 
University, 
Munich, Germany 
140 
Mean 64.3 years 
 
Range 34–83 
years 
34 months 
(minimally 
invasive) 
 
33.1 months 
(conventional) 
SF-36 
No significant differences in QoL 
between the groups at the end of the 
follow-up 
N/A-No comparison 
with pre or norms 
 
9 
No 90%  (126) 
N/A-No comparison 
with pre or norms 
 
Fairbairn, 
2012 [243] TAVI 
Prospective 
cohort Department of 
Cardiology, Leeds 
General 
Infirmary, Leeds, 
United Kingdom 
 
 
99 Mean 80 years 
 
1, 6, & 12 
months 
SF-12v2 
EQ-5D 
 
Quality of life is significantly 
improved early after TAVI and 
maintained to 1 year 
Yes-Improved and 
comparable to age-
matched population 
norms 
9 
Yes 
91% 1 month 
71% 6 months 
66% 12 
months  
(65) 
No-Not improved, 
but comparable to 
age-matched 
population norms 
Georgiadou, 
2011 [244] TAVI 
Prospective 
cohort 
Onassis Cardiac 
Surgery Denter, 
Athens, Greece 
36 Mean 80.5 years 11.3 months 
SF-36 
SF-12v2 
Marked 1-year clinical benefit in 
functional status and physical and 
mental health in patients who 
underwent TAVI 
Yes-Improved and 
comparable to age-
matched population 
norms 
9 
Yes 78%  (28) 
Yes-Improved and 
comparable to age-
matched population 
norms 
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Goldsmith, 
2001 [235] 
MV:  
Repair (n = 
40)  
vs.  
Mechanical 
bileaflet 
replacement 
(n = 21) 
Prospective 
cohort 
Walsgrave 
Hospital, 
Coventry, United 
Kingdom 
61 
Mean 64 years 
 
Range 20–85 
years 
3 months 
SF-36 
Significant improvement in quality of 
life at 3 months follow-up following 
mitral valve surgery, especially in 
those patients requiring mitral valve 
repair 
 
Patients with impaired left ventricle 
function or MR with end-systolic 
dimensions more than 45 mm were 
unlikely to demonstrate a significant 
improvement in QoL 
 
Yes-Improved 
9 
Yes 88%  (54) Yes-Improved 
Goncalves, 
2013[245] TAVI 
Prospective 
cohort Hospital Clinico 
San Carlos, 
Universidad 
Complutense, 
Madrid, Spain 
74 Mean 81.6 years 6.5 months 
MLHFQ 
TAVI significantly improves 
symptoms and quality of life in 
patients with severe AS  
 
Patients with PVD might be expected 
to have a less impressive 
improvement in quality of life after 
TAVI 
 
Yes-Improved 
8 
Yes 72%  (53) Yes-Improved 
Gotzmann, 
2011[246] TAVI 
Prospective 
cohort BG University-
Hospital 
Bergmannsheil, 
Bochum, 
Germany 
70 Mean 78 years 1 & 12 months 
MLHFQ 
TAVI leads to lasting enhancement of 
quality of life in patients with 
symptomatic and severe aortic 
stenosis 1 year after intervention 
 
 
 
 
Yes-Improved 
6 
Yes 72%  (51) Yes-Improved 
Grady, 
2011[238] 
AV repair or 
replacement 
(n = 96)  
vs. 
MV repair or 
replacement 
(n = 92) 
Retrospective 
cohort 
Northwestern 
Memorial 
Hospital, 
Chicago, Illinois 
188 
Mean  
62.1 years (AV) 
 
56.3 years (MV) 
3, 6, 12, 24, & 
36 months 
SF-36 
Physical and mental components of 
the SF-36 improved from baseline to 
within 3 to 6 months postoperatively 
and remained stable through 3 years 
for all groups 
Yes-Improved and 
comparable to age-
matched population 
norms 
7 
Yes 13%  (25) 
Yes- Improved and 
comparable to age-
matched population 
norms 
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Krane, 
2010[247] TAVI 
Prospective 
cohort 
German Heart 
Center Munich, 
Technische 
Universität 
München, 
Munich, Germany 
99 
Mean 82 years 
 
Range 57–94 
years 
3 months 
SF-36 
TAVI leads to a considerable quality 
of life improvement within 3 months 
after valve implantation 
Yes-Improved 
8 
Yes 69%  (68) No-Not improved 
Krane 
2012[248] TAVI 
Prospective 
cohort German Heart 
Center Munich, 
Technische 
Universität 
München, 
Munich, Germany 
186 Mean 80.8 years 3 & 12 months 
SF-36 
TAVI can improve the quality of life 
status of high-surgical risk patients 
with severe aortic valve stenosis that 
can be maintained for up to 1 year 
postoperatively 
 
Although the mental subscales 
improved slightly, it failed to reach 
statistical significance 
 
 
 
Yes-Improved and 
comparable to age-
matched population 
norms 
8 
Yes 57%  (106) 
Yes-Improved, but 
not significantly 
MacHaalan
y, 
2013[256] 
MV Repair 
Prospective 
cohort Multicenter: 14 
centers across 5 
countries in North 
America & 
Europe 
26 
Mean 71.6 years 
 
Range 46–89 
years 
1, 3, 6, & 12 
months 
MLHFQ 
EQ-5D 
Mild impact on QoL with suboptimal 
risk/benefit ratio during follow-up 
 
Implantation of the second-generation 
permanent Viacor PTMA device was 
feasible in 70% of the cases but 
remained associated with suboptimal 
safety and efficacy results 
No-Not improved 
5 
Yes 
77% 1 month 
38% 3 months 
35% 6 months 
11% 12 
months  
(3) 
No-Not improved 
Maliwa, 
2003[231] 
AVR: 
Mechanical  
Retrospective 
cohort St Antonius 
Hospital, 
Nieuwegein, The 
Netherlands 
78 
Mean 36 years 
 
Range 17–64 
years 
30 years 
SF-36 
EQ-5D 
At long term follow-up, quality of life 
of mechanical aortic valve 
replacement patients is relatively high 
and comparable to other studies with 
short term follow-up. 
Yes-Comparable to 
age-matched 
population norms 
7 
No 94%  (69) 
Yes-Comparable to 
age-matched 
population norms 
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Markou, 
2011[257] AVR 
Retrospective 
cohort 
Nijmegen 
Medical Center, 
Department of 
Cardiothoracic 
Surgery, The 
Netherlands 
200 
Mean 71.1 years 
 
Range 55–88 
years 
1 year 
EQ-5D At 1 year post-operatively, all patients 
experience significantly better QoL; 
however, patients undergoing 
combined CABG and AVR 
experienced more benefit from their 
operation compared to solely AVR 
Yes-Improved 
7 
Yes 36%  (72) Yes-Improved 
Nötzold, 
2001[239] 
AVR: 
Pulmonary 
autograft (n = 
40)  
vs.  
mechanical (n 
= 40) 
Retrospective 
cohort 
Departments of 
Cardiac Surgery 
& 
Anaesthesiology, 
Medical 
University of 
Lübeck, Lübeck, 
Germany 
80 
Mean 
57.6y  
(autograft) 
 
 
59.2y 
(mechanical) 
 
 
2.21 years 
(autograft) 
 
1.86 years 
(mechanical) 
SF-36 
Patients with pulmonary autografts 
tend to have greater benefit in terms 
of QoL compared to recipients of 
mechanical valve recipients 
N/A-No comparison 
with pre or norms 
 
9 
No 100%  (80) 
N/A-No comparison 
with pre or norms 
 
Reynolds, 
2011[249] TAVI 
Randomized 
clinical trial 
Multicenter: 21 
centers across 
North America & 
Europe 
(PARTNER trial) 
179 Mean 83 years 1, 6 & 12 months 
KCCQ 
SF-12 
Among inoperable patients with 
severe aortic stenosis, compared with 
standard care, TAVR results in 
significant improvements in health-
related quality of life that is 
maintained for at least 1 year 
Yes-Improved 
9 
Yes 
82 % 1month 
 
67 % 6 month 
 
61 % 12 
months  
 
(110) 
 
 
 
Yes-Improved 
90 
 
Reynolds, 
2012[250] 
 
AV:  
 
AVR (n = 
300)  
vs. 
TA-TAVI (n 
= 98)  
vs. 
TF-TAVI (n = 
230) 
Randomized 
clinical trial 
Multicenter: 25 
centers across 
North America & 
Europe 
(PARTNER trial) 
628 
Mean  
83.8 years 
(TAVI/TF) 
 
84.6 years 
(AVR/TF) 
 
82.6 years  
(TAVI /TA) 
 
83.2 years 
(AVR/TA) 
1, 6, & 12 
months 
KCCQ 
SF-12 
EQ-5D 
Substantial improvement 1 year after 
either TAVI or AVR. TAVI via 
transfemoral (not transapical) route is 
associated with a short-term 
advantage compared with surgery 
Yes-Improved 8 
Yes 
Mean across 3 
61% 1 month  
59% 6 months 
54% 12 
months  
(340) 
Yes-Improved  
Stortecky, 
2012 [258] TAVI 
Prospective 
cohort 
Department of 
Cardiology, Swiss 
Cardiovascular 
Center Bern, Bern 
University 
Hospital, Bern, 
Switzerland 
62 Mean 83 years 9 months 
SF-36 
TAVI leads to rapid and sustained 
restoration of all aspects of mental 
and physical health 
Yes-Improved 
8 
Yes 90% (56) Yes-Improved 
Taramasso, 
2012[251] TAVI 
Prospective 
cohort 
Cardiothoracic 
Department, San 
Raffaele 
Scientific 
Institute, Milan, 
Italy 
100 Mean 79.6 years 1 & 2 years 
SF-36v2 
 
MLHFQ 
TAVI in high-risk surgical candidates 
is associated with favorable short and 
long-term survival with improvement 
of quality of life up to 2 years after 
the procedure 
 
 
Yes-Improved 
8 
Yes 
83% 1 year  
73% 2 years  
(73) 
Yes-Improved 
Tseng, 
1997[252] AVR 
Retrospective 
cohort John Hopkins 
Hospital, 
Baltimore, 
Maryland 
247 
Mean 76.2 years 
 
Range 70-89 
years 
4.1 years 
SF-36 
AVR can be performed in patients 
older than 70 years of age with 
acceptably low mortality, good long-
term results, and excellent quality of 
life 
 
 
Yes-Comparable to 
age-matched 
population norms 
7 
No 28%  (70) 
No-lower than age-
matched population 
norms 
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Ussia, 
2009[253] TAVI 
Prospective 
cohort Ferrarotto Hospital, 
University of 
Catania, Catania, 
Italy 
39 Mean 81.7 years 5 months 
SF-12v2 
Mean pre-operative SF-12v2 scores 
showed a severe impairment of 
perceived quality of life compared 
with the general Italian population 
 
After 5 months, a striking 
improvement in both (physical and 
mental) scores was observed 
Yes-Improved and 
comparable to age-
matched population 
norms 10 
Yes 77%  (30) 
Yes-Improved and 
comparable to age-
matched population 
norms 
Ussia, 
2011[254] TAVI 
Prospective 
cohort Ferrarotto 
Hospital, 
University of 
Catania, Catania, 
Italy 
143 Mean 81.0 years 5 & 12 months  
SF-12v2 
Both high-surgical risk and elderly 
patients affected by severe 
symptomatic AS experience an 
improvement in quality of life after 
TAVI, with the procedure able to 
preserve a high degree of 
independence at 1-year follow-up 
 
Both the physical and mental score 
summaries at follow-up were not 
significantly different from the 
anticipated thresholds of the general 
Italian population 
Yes-Improved and 
comparable to age-
matched population 
norms 
9 
Yes 
85% 5 months 
82% 12 
months  
(117) 
Yes-Improved and 
comparable to age-
matched population 
norms 
Ussia, 2012 
[259] 
MV: 
Catheter-
based mitral 
valve repair 
Prospective 
cohort Ferrarotto Hospital, 
University of 
Catania, Catania, 
Italy 
49 Mean 72 years 6 months 
SF-12v2 
This novel procedure leads to 
significant short-term improvement in 
quality of life 
 
Remarkably, at six months, 
improvement in physical and mental 
status was higher in the group of 
patients with functional MR 
compared to degenerative MR 
Yes-Improved 
8 
Yes 79%  (39) Yes-Improved 
Van Doorn, 
2000[234] 
MVR: 
Mechanical 
Retrospective 
cross-
sectional Great Ormond 
Street Hospital for 
Children, London, 
United Kingdom 
30 
Median 14.4 
years 
 
Median range 
9.7–25.4 years 
6.2 years 
(CQOL) 
 
7.6 years (SF-
36) 
CQOL 
(9–15 years) 
 
SF-36 
(16 years & 
over) 
The effect of mitral valve 
replacement on quality of life appears 
to be age specific, with more 
impairment in younger children and 
near normal quality of life in 
adolescents and young adults 
Yes-Comparable to 
normal adolescents 
and young adults 
No-in younger 
children 
7 
No 63%  (19) 
No-lower than age-
matched population 
norms 
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Van 
Geldorp, 
2013[242] 
AVR 
Prospective 
cohort 
Catharina 
Hospital, 
Eindhoven, The 
Netherlands 
70 Mean 67.8 years  11 months 
SF-36v2 
Aortic valve replacement improves 
physical quality of life, general 
health, and vitality in patients with 
symptomatic severe aortic stenosis 
 
Mental Health did not improve after 
AVR, and remains much lower than 
in the age-matched general population 
Yes-Improved, but 
lower than age-
matched population 
norms 
8 
Yes 84%  (59) No-Not improved 
Vicchio, 
2012 [260] 
AVR: 
Mechanical  
Retrospective 
cohort 
Multicenter: two 
centers in Italy 406 Mean 74.3 years 
4.2 years 
 
Range 6 
months–17.7 
years 
SF-36 
There was no statistical difference in 
the scores obtained in the two groups 
of the study population 
 
The two groups of the study 
population significantly reached 
higher scores in all domains when 
compared with the general Italian 
population 
Yes-Comparable to 
age-matched 
population norms 
7 
No 77%  (312) 
Yes-Comparable to 
age-matched 
population norms 
Whitlow, 
2012[261] 
 
MV: 
Catheter-
based mitral 
valve leaflet 
repair 
Prospective 
cohort 
Multicenter: 12 
centers across 
USA (EVEREST 
II High Risk 
Study) 
47 Mean 76.7 years 1 & 12 months 
SF-36 The MitraClip device results in 12 
month improvement in quality of life 
scores with better improvement in 
physical scores compared to mental 
scores 
Yes-Improved 
8 
Yes 100%  (47) No-Not improved 
Zhao, 2007 
[240] 
MV: 
Repair or 
replacement 
Prospective 
cohort 
Multicenters: 4 
centers across 
North America 
276 
Mean 
59.4 years 
(mitral repair) 
 
63.0 years 
(mitral 
replacement) 
1, 3, & 12 
months 
SF-36 For both treatment groups, scores were worse than baseline at 1 month; 
however, at 3 and 12 months there 
were dramatic improvements in most 
of the domains, especially in patients 
undergoing mitral valve repair 
 
Yes-Improved 
9 
Yes 64%  (171) Yes-Improved 
 
Table 2. 1 Summary of the findings of the reviewed studies. 
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Characteristics  Result 
Patients initially included (n) 3942 
Male / female 2093/1849 
Mean age (range) 9.7–94 years 
Patients responded to the last follow up (n) 2580 (65.4% overall response rate) 
Mean follow up duration (range)  1 month to 30 years 
Retrospective studies (n) 9 
Prospective studies (n) 20 
Studies with mean age <15 (n) 1 
Studies with mean age 15–65 (n) 7 
Studies with mean age >65 (n) 21 
QoL instrument used (frequency, eg, number of studies)  
Short Form 36 (SF-36) 19 
Short Form 12 (SF-12) 7 
European Quality of life five-dimension (EQ-5D)  5 
Minnesota Living with Heart Failure Questionnaire (MLHFQ) 4 
Kansas City Cardiomyopathy Questionnaire (KCCQ) 2 
Child Quality of Life Questionnaire (CQOL) 1 
Studies with baseline QoL assessment  21 
Studies investigated improvement by comparing against baseline or 
published norms (n) 
26 
Studies found improvement in QoL after valve procedure (%)  
Improvement in physical health domains 92% 
Improvement in mental health domains 73% 
Table 2. 2 Consolidation table of the reviewed articles.!
94 
 
 
Figure 2. 3 Quality score for each included study 
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2.5.5 Timing of QoL scoring 
Twenty-one studies assessed baseline QoL scoring pre-procedure, and all 29 studies had post-
procedure follow-up QoL assessment (Table 2.1). Follow-up duration between baseline and follow-up 
assessment or between procedure date and QoL assessment date (for the retrospective studies with no 
baseline assessment) ranged from 1 month to 30 years (Figure 2.4).  
 
2.5.6 Follow-up completion rate 
The follow-up completion rate of the included studies varied between 11% and 100%, depending on 
the follow-up duration. Fifteen studies described  follow-up of ≥75% [231, 235-237, 239, 241, 242, 
244, 253-255, 258-261]. The other 14 studies had <75% follow-up completion rate at the last 
assessment [234, 238, 240, 243, 245-252, 256, 257]. All 29 studies contained information regarding 
patients lost to follow-up. 
 
2.5.7 Study conclusions 
Twenty-six studies compared post-procedure QoL score with pre-procedure or with age-matched 
population norms, and all but two (92% of the studies) found significant improvement in physical 
health domains. In the mental health domain, the situation is little different: seven studies found no 
significant improvement; ie, 73% of the studies found improvement in mental health domains.  
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Figure 2. 4 Mean follow-up time of each study 
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2.6 Comments 
Cardiac valve surgery, as with many types of surgery, has advanced over the years with 
respect to application and, consequently, safety and survival has increased, particularly in the 
elderly [262, 263]. Despite these advancements, long-term survival from an intervention 
standpoint is not always the desired primary objective from the patient’s perspective, 
especially for the elderly. With a need for a matched/improved QoL for their remaining years, 
many elderly patients would prioritize a high QoL above all else, and namely above a slightly 
increased quantity of life [264]. Our review has attempted to aid this cause by analyzing 
studies to present adequate relevant data in order to provide as much information as possible 
regarding cardiac valve surgery outcomes. We performed this study so that health 
professionals can be confident in providing accurate and thorough counseling to patients who 
can then make more informed decisions regarding their individual needs and intervention. 
Our review, however, has attempted to be inclusive of patients of all age groups and of all 
current isolated cardiac valve procedures and, as a result, we have some interesting findings 
to add to the general conclusion that cardiac valve surgery results in an improved QoL. 
 
2.6.1 Age groups  
Twenty-four of the 29 studies concluded that, in general, cardiac valve surgery results in an 
improved QoL compared to baseline pre-procedure score or to age-matched population 
norms. However, one study contrasted this view and reported an ensuing impairment in QoL 
of younger patients, with a greater degree of impairment in young children compared to 
adolescents and young adults [234].  
 
Conventionally, “elderly” is defined as patients above the age of 65 [265]. Therefore, 
more specifically, the patient population in our 29 studies can be divided into younger [234], 
middle-aged [231, 235-240] and elderly patients [241-261]. Cardiac valve surgery is a more 
common procedure in the elderly group as cardiac valve disease, such as aortic stenosis, is 
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common consequence of ageing [266]. Thus, there is a greater wealth of evidence available in 
this age group. 
 
Though our review only included one study assessing QoL in very young patients, it 
was retrospective with no pre-operative QoL assessment, consisted of a small sample size (n 
= 30), and the quality score was 7. In addition, the instrument used to measure QoL in this 
very young age group was a child-specific tool, and was not used in any of the other studies. 
It is therefore biased and inappropriate to directly compare the post-procedure QoL between 
very young and older patients, thus rendering such a comparison inconclusive. However, 
impairment of QoL in younger patients may be explained by the fact they are very young and 
it is expected to have a life full of energy and activities that are not limited by health problem. 
In addition, surgical treatment in such a group may be indicated earlier before symptoms 
arise, while post-operative life is affected by sternotomy incision, change in life style, and 
regular follow-up, which affect not only physical capacity but also mental status. It is, 
however, evident that this is an age group that requires greater depth of data from which more 
reliable conclusions may be drawn, while in adult and elderly patients the evidence of 
significant improvement is a straightforward conclusion. 
 
2.6.2 Type of cardiac valve procedure 
The majority of the articles focus on AV and only 20% focus on MV, while all presented data 
pertaining to mechanical and biological replacement, open repair, and transcatheter 
implantation. Nevertheless, there are common findings regarding the procedures on each 
valve that are of interest and do not require comparisons between the different valves 
themselves. 
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2.6.2.1 Mitral valve: catheter-based vs. open surgery 
Six studies solely involved the MV [234, 235, 240, 256, 259, 261]; three of these MV articles 
were prospective studies about catheter-based MV repair, of which two showed improvement 
in post-procedure QoL [259, 261], while the third showed mild impact on QoL [256]. 
However, the third one that was in contrast to the other two was a Phase 1 trial of the second-
generation permanent Viacor percutaneous transvenous mitral annuloplasty, the trial and the 
development of the device were prematurely stopped because of discouraging early results 
[256]. Furthermore, this study included the least number of patients (n = 26) and had low 
follow up rates of 38% at 3 months, 35% at 6 months, and 11% at 12 months. Therefore, it 
may be reasonable and advisable to disregard the results of this study.  
 
The other three articles on open MV repair or replacement also confirmed the 
improvement in post-operative QoL, with the exception of the one that investigated the 
younger age group mentioned earlier [234].  
 
2.6.2.2 Mitral valve: repair vs. replacement 
As described above, both repair and replacement led to significant improvement in post-
operative QoL. However, two of the articles emphasize an even greater improvement in QoL 
outcome in MV repair compared to replacement up to 1-year after surgery [240] [235]. The 
exact reasons for the differences between repair and replacement are not yet known, but may 
be due to better left ventricular remodeling and cardiac hemodynamics in the former. This 
finding may support the choice of MV repair over replacement in the complex decision-
making process [240]. However, the insufficient number of studies, small number of patients 
reported, and heterogeneity in the clinical characteristics of the patients, including left 
ventricle (LV) function, atrial fibrillation, and anticoagulant therapy, are all limitations of this 
conclusion.  
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2.6.2.3 Aortic valve 
With 22 articles investigating QoL related to AV surgery, the overwhelming majority of data 
from this review noticeably focuses on procedures involving this valve [237] [239] [255, 257, 
258] [260] [231, 235, 236, 241-254]. Among the 23 articles that included the AV, 20 studies 
compared the follow up QoL to baseline values or to the age-matched population norms, and 
they all show that every included intervention had a positive benefit on QoL.  
 
2.6.2.4 Aortic valve replacement 
Six articles focused exclusively on AVR [231, 242, 252, 255, 257, 260]. Compared to 
baseline pre-operative score or to published noms, they all revealed either improvement or 
comaprable results to age-matched population norms, and this hold true whether the mean 
follow-up was 11 months or 30 years, whether the mean age was 36 or 76 years, or whether 
the prosthetic valve size was small as in Casali et al.’s study [255]. Even when there is 
concomitant CABG with the AVR, which nearly doubles the operative mortality rate, the 
survivors show no difference in QoL improvement after a mean follow-up period of 4.2 years 
[260]. In fact, Markou et al. found that the scale of benefit in QoL score was slightly higher in 
patients with concomitent CABG, which may be due to greater symptomatic relief in this 
group [257]. This post-operative improvement can be easy to understood considering the 
effects of replacing a diseased, stenosed AV that burdens heart function and reduces tissue 
blood supply particularly during exersion with an affective prosthetic valve that allows 
reasonable restoration of cardiac hemodynamic fuction [255].   
 
2.6.2.5 Aortic valve: mechanical vs. biological prostheses  
Three retrospective studies directly compared two types of valve replacement, namely 
mechanical with either biological or pulmonary autograft replacement [236, 239, 241]. 
Although the post-operative QoL was comparable to published norms [236], the difference in 
magnitude of benefit was found to be greater in autograft over in mechanical replacement 
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(mean follow-up period range 1.8–6.4 years) [236, 239]. The age groups of these two studies 
fall within the middle-aged bracket of 18 to 59 years.  
 
The ongoing follow-up and requirement for anti-coagulation treatment with 
mechanical valve replacement, as well as the risk of developing a thromboembolism, may 
account for the aforementioned difference [267]. Along with anti-coagulation treatment 
comes the increased risk of hemorrhage and post-operative complications [268, 269], and 
such risks may adversely affect the psychological aspect of QoL by inducing fear in the 
patient [236]. That is not to say that biological or autograft valve replacements do not also 
carry risks, namely rejection, valve degeneration, or short term survival of the valve [270]; 
however, it seems that the absence of post-procedural day-to-day anti-coagulation 
maintenance [239] and even the disturbance caused by the clicking noise of a mechanical 
valve render it slightly less favorable in terms of QoL than autograft replacement and, 
similarly, valve repair [236]. When considering mechanical and biological AVR for older 
patients, there was no significant difference in QoL between the groups with mean follow up 
period of 21.4 months [241].  
 
2.6.2.6 Aortic valve: ministernotomy vs. full-length sternotomy 
We found only one study that specifically investigated the effect of sternotomy type on post-
AVR QoL [237]. In this retrospective study, 70 patients who underwent L-shaped 
ministernotomy were compared to matched 70 conventional sternotomy patients after a mean 
period of 33–34 months post-AVR. The authors found no significant difference in post-
operative QoL between the two groups; unfortunately, however, there was no pre-operative 
data to compare these results to. The absence of a difference between these two groups may 
be explained by the follow-up duration which was nearly 3 years. The results and conclusions 
might look different if the comparison was done during the first 6 months where the pain, 
discomfort, and physical functioning is more likely to be affected by the size of incision.   
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2.6.2.7 Transcatheter aortic valve implantation 
 
Another distinction made in the studies regarding the procedure involved was the use of 
minimally invasive catheter-based AV implantation. Transcatheter AV implantation (TAVI) 
or tanscatheter AV replacement (TAVR), or the less commonly used term percutaneous AV 
implantation (PAVI), is normally reserved for patients with severe aortic stenosis who are 
deemed unsuitable for traditional AVR [221], especially elderly who have a higher likelihood 
of comorbidities and a shorter life expectancy. As the incidence of aortic stenosis is 
increasing with the ageing population [219], the role of TAVI is becoming more prominent. 
Its link with QoL is therefore very relevant, as QoL has a greater importance in an elderly 
population than absolute survival benefit [243]. The popularity of TAVI is somewhat 
prevalent as about 40% (n = 12) of the studies explored the effect of these techniques on QoL 
[243-251, 253, 254, 258]. 
 
The included studies included patients with mean age of approximately 80 years, and 
a mean follow up duration ranging from 1 month to a maximum of 2 years, and explored 
different entry routes (transfemoral, transapical, transaxillary, and transsubclavian). All these 
studies were prospective in design and had baseline pre-procedure QoL assessment, and they 
all demonstrated significant improvement in follow up QoL compared to baseline or to 
published age-matched population norms.  
 
While TAVI is a less invasive procedure deemed suitable for high surgical risk 
patients and thus considered as a safer alternative to conventional surgical methods [271-
273], it has been shown to cause cerebrovascular complications [190]. Nevertheless, our 
review has found TAVI to be just as effective in improving QoL, with results showing a post-
procedure increase and maintenance of QoL levels up to, at most, 2 years [251]. However, as 
previously mentioned, the criteria for TAVI includes those patients who are in a more severe 
state of cardiac valve disease [274]. Therefore, due to the subjective nature of QoL 
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assessment, which will be discussed in greater detail later, these patients may rate a smaller 
improvement in absolute health as approximately equal to a larger absolute improvement in a 
healthier patient undergoing a more invasive procedure, despite gaining a stable health state 
following surgery [247]. 
 
All of the above findings may signify that when AVR replacement is indicated, 
regardless of age, comorbidities, and procedure type, the QoL in those who survive will 
improve post-procedure. This post-procedure QoL improvement may be explained by the 
subsequent improvement in cardiac hemodynamic parameters, coronary circulation, and 
symptoms relief, which is evident by the associated regression in New York Heart 
Association (NYHA) class post-procedure [247, 254].  
 
2.6.2.8 TAVI access route 
The approach to gain access to the affected AV via less invasive access sites is what makes 
TAVI less invasive than AVR. The routes most commonly utilized are the transfemoral [275] 
and the transapical arteries [276]. Among the 12 articles that included TAVI, only one study 
detailed differences in the results depending on the specific TAVI approach, rather than 
pooling all the approaches into one group [250]. In the biggest study in our review, Reynolds 
et al. prospectively compared QoL pre- and post-procedure between three groups: AVR, 
transapical TAVI, and transfemoral TAVI. They found that, when compared to each other and 
alongside traditional AV replacement surgery, TAVI via the transfemoral route was 
associated with a short-term advantage in QoL; however, there was no mid-term benefit 
found during the 1-year follow-up period [250].  
 
Again, this  may indicate that the QoL in AV disease is affected mainly by the 
diseased valve more than any other patient-related or procedure-related factor or comorbidity, 
which is evident from the post-procedure QoL improvement even in high-risk patients. It is, 
nonetheless, a surgical technique that presents an opportunity for large scope future 
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exploration with the aim to develop and revolutionize our practices to inclusively advance 
patient QoL. 
 
2.6.2.9 Mitral valve vs. aortic valve 
Though the comparison between mitral and AV surgery and QoL is not valid for decision-
making, it is still interesting for knowledge and counseling points. Only one study 
investigated both mitral and AV procedures (repair and replacement), with direct comparisons 
between the two valves [238]. At baseline, MV patients have better QoL score than AV 
patients, MV score was similar to age-matched population norms. At all follow-up time-
points, MV patients had better QoL scores than AV patients, though the magnitude of 
improvement was slightly higher in the latter. This favorable difference in QoL for MV 
patients might be attributed to the fact that MV patients are generally younger, asymptomatic, 
and have less comorbidity. It is worth noting that QoL in MV surgery habitually, yet non-
significantly, declined in the immediate post-operative period (1–3 months), before moving 
toward a significant improvement from baseline [238, 240]. 
 
2.6.2.10 Additional procedures 
While this review only includes data from isolated cardiac valve procedures, a small number 
of papers include this data alongside comparable data involving coronary artery bypass 
grafting (CABG). Two studies compared isolated AV replacement to replacement with 
concomitant CABG, with one concluding improved QoL in the combined procedure [257] 
and the other finding no difference [260]. An additional study directly compared MV 
replacement, AV replacement, and CABG, and found no significant differences in resulting 
QoL between all three groups of these isolated cardiac procedures [238]. Further data directly 
comparing combined with isolated procedures would be of considerable use when deciding 
on cardiac valve surgery in those patients who require more than one procedure. 
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2.6.3 QoL improvement: physical vs. mental components 
The correlation between post-procedure improvement in QoL with respect to physical and 
mental components was not consistent across the literature reviewed. In contrary to the stable 
and consistent results regarding the physical component of the QoL, seven studies reported no 
improvement or non-comparable QoL scores to age-matched population norms with respect 
to the mental component of the follow-up assessment [234, 242, 243, 247, 252, 256, 261]. 
These seven studies included AVR, TAVI, MV replacement, and catheter-based MV repair; 
therefore, it is difficult to establish a link between the mental component and procedure or 
valve type. With the exception of one study [234], the mean age in these studies were not 
distinctively different from other studies that report significant improvement in mental 
component of the QoL. Nevertheless, in the QoL field it is known that the physical 
component is more objective and reflective of symptomatic status. In addition, about 70% of 
the reviewed articles found significant improvement in the mental component of QoL 
following cardiac valve surgery or procedure.    
 
2.6.4 Duration of QoL improvement 
The ultimate aim beyond improving or restoring QoL is to maintain this result, rather than to 
improve QoL only to have it subsequently deteriorate. Therefore, an intervention enabling not 
only short-term but also long-term QoL improvement is ideal for cardiac valve disease 
sufferers, as well sufferers of any chronic disease. 
 
The studies in our review collectively had a follow-up period ranging from 1 month 
to 30 years. All 29 studies described an overall improvement in QoL post-procedurally up to 
their respective time points, thus suggesting that cardiac valve surgery not only improves QoL 
in the months following the procedure, but also maintains these results for a long-term period. 
However, differences in QoL did arise with respect to certain components at specific post-
procedure time-points. 
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2.6.5 Predictors of quality of life 
Twenty-one of the total studies recorded patient pre- and post-procedural health 
characteristics. This allowed observation of pre-existing health trends that may influence the 
degree of QoL outcome. While most studies found improvement in QoL, only eight articles 
investigated whether there is any predictor of QoL; examples of these that contributed to a 
lesser QoL improvement are discussed below. It is worth mentioning that age was not found 
to be a limiting factor for QoL improvement [223, 251].  
 
2.6.5.1 Gender 
In TAVI patients, female gender was predictive of lower QoL improvements but only for the 
first 3 months, as after 12 months only a statistical trend could be recognized [248]. Similarly, 
in open MV repair or replacement, female gender was an independent predictor of patients 
who were unlikely to observe improvement in their general health 3 months post MV surgery 
[235]. On the other hand, male gender was an independent predictor of greater improvement 
in QoL at 1-year post TAVI [243]. 
 
2.6.5.2 Mitral regurgitation 
In TAVI, greater than mild pre-procedural mitral regurgitation (MR) was found to be 
predictive of lower post-TAVI QoL improvement; however, this only reached statistical 
significance up to 3 months, and this trend, while present, was not significant at the 12 month 
follow-up [248]. Furthermore, MR with end-systolic dimensions of more than 45 mm was 
associated with non-significant improvement in QoL 3 months post-open MV repair or 
replacement [235]. The etiology of MR seems to also play a role in QoL as, like in catheter-
based MV repair, post-procedure QoL improvement was higher in patients with functional 
MR compared to degenerative MR [259]. 
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2.6.5.3 Coronary artery disease 
In the early post-operative period following an isolated cardiac surgery, prior myocardial 
infarction was predictive of faster QoL physical component improvement [238], while CABG 
was an independent predictor of greater improvement in the physical component of QoL at 1-
year post-TAVI [243]. History of coronary artery disease, acute myocardial infarction, and 
previous PCI and CABG were associated with non-significant improvement in mental QoL 
following the TAVI procedure [251].  
 
2.6.5.4 Left ventricular function and NYAH class 
In open MV repair or replacement, patients with impaired LV function (ejection fraction 
between 30% and 50%) showed no significant improvement in QoL; higher NYHA 
functional class independently predicted patients who were unlikely to observe improvement 
in their general health 3 months post MV surgery [235]. In contrast, post-AVR QoL 
components were not significantly correlated with pressure gradients, ejection fraction, or 
NYHA functional class [239]  
 
2.6.5.5 Peripheral vascular disease 
Patients with peripheral vascular disease (PVD) were found to have a lower improvement in 
QoL following TAVI than patients without PVD [246]. 
 
2.6.5.6 Other factors 
In TAVI patients, the level of improvement in post-operative physical QoL seems to be 
negatively affected by obesity and the presence of pre-operative chronic renal failure [238, 
251], while operator experience (more than 50 cases) was an independent predictor of greater 
improvement in post TAVI QoL at 1-year [243]. 
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2.6.6 Difficulties using QoL tools 
While many instruments exist for assessing QoL, the fact remains that there is currently no 
standardized universal tool in place for this purpose; the different instruments have been 
designed and validated for more specific uses in certain patient and disease populations. In 
this review, for instance, six different assessment tools were used in the 29 included articles. 
However, different instruments have previously demonstrated virtually identical results when 
applied to the same study [231], suggesting that their co-existence does not affect reliability. 
Without an elusive, all-encompassing QoL instrument, the use of more than one instrument 
within a study can only help to yield more valid data, particularly in the absence of cardiac 
surgery-specific questionnaires and in the presence of the extensively validated generic 
questionnaires, such as SF-36, SF-12, and EQ-5D. For instance, Fairbairn et al. demonstrated 
complimentary use of EQ-5D and SF-12 instruments [243]. EQ-5D is a preference-based 
measure and is more suitable for assessing QoL in patients with a very poor state of health, 
whereas SF-12 is a generic measure that may actually underestimate the severity of ill health 
in such groups [277]. Therefore, the use of both enables a more accurate representation of the 
QoL data obtained by each tool minimizing any negative effect that the other tool may have 
had on the overall data. 
 
This discrimination between instruments and varying usage between different studies 
may make it difficult to achieve a gold standard instrument encompassing data for the same 
procedure across different populations and demographics. However, as we have discovered, 
inter-population differences can give rise to the acquisition of more valid QoL data from 
different populations.  
 
There is some controversy over using certain QoL instruments for different age 
groups. The SF-36 has been argued as not being sensitive enough when used to assess a 
child’s QoL following MV replacement, especially compared to the CCQOL tool [234]. 
However, validation studies support its use to detect ill health even to low levels in such an 
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age group [277, 278]. In contrast, several studies in octogenarians have shown that despite 
naturally occurring lower physical and mental baselines, AVR resulted in an improvement in 
QoL outcomes comparable to younger patients [223, 279, 280]. 
 
Deciding which QoL instruments to use can be quite a difficult task. One factor in 
this decision may be the time required to complete the questionnaire and the burden that this 
may have on each patient. Obtaining as much data as possible requires efficient patient 
participation and is often difficult, which is why the shorter SF-12 was developed from the 
SF-36 [281]. While using this shorter tool lessens patient burden and ensures improved 
response rates, shorter instruments are not as extensive and may overlook which aspects of 
the QoL require more focused attention in current practice. 
 
The practical application of instruments is another difficulty of note. There is a need 
for the same interviewer or observer to administer the questionnaire in order to minimize the 
introduction of human error and to maintain accuracy in recording data between patients. An 
ongoing assessment of QoL may also be beneficial, which is the current assessment method, 
but even when carried out at many time points, assessment is still essentially a matter of recall 
for the patient during a few minutes of questioning and answering. Ongoing assessment on a 
weekly or monthly basis may nullify any bias introduced, however this extreme approach 
would likely result in increased patient burden and declined response rates.  
 
Language and culture are a significant consideration in QoL instrument application, 
especially when utilized in large multi-centered studies. Culturally and linguistically validated 
studies are of prime importance in maintaining accuracy of data across diverse populations 
[249], but cultural bias and interpretation can still creep in if careful application is not 
performed. 
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Pain is a factor in QoL scoring and is understandably poorly scored post-procedure. 
Often after cardiac valve surgery, the pain is not only pain immediately on or around the 
wound or incision points but includes a longer, delayed spreading effect sometimes 
accompanied by painful respiratory movement, especially following thoracotomy and median 
sternotomy [282, 283]. Despite not significantly diminishing QoL improvement, pain still 
makes a contribution, suggesting that QoL could be further improved by mitigating the effects 
of post-procedural pain via careful attention and application of epidural anesthesia as well as 
other pain control measures [250]. In fact, post-operative pain is one of the factors that make 
early post-operative QoL assessment less reliable and conclusive, while longer follow-up 
timing allows more time for pain to subside, wounds to heal, and temporary post-operative 
issue, such as atrial fibrillation to settle, thereby reducing or eliminating this confounding 
variable.   
 
Pre-procedural assessment of QoL is vital to guarantee a baseline for comparison. 
However, problems can still arise when assessing baseline values to use to compare to post-
procedural values; for instance, higher pre-procedural mental component scores can result in 
limited sensitivity of the same measurement post-procedure [248]. Similarly, very low 
baseline mental component scores can lead to an underestimation of improvement post-
procedurally, especially among the young who are mentally more concerned and anxious 
about their current health, results of surgery, and future health. Degree of social networking is 
taken into consideration within this score, which is quite commonly poor amongst elderly 
patients with considerable comorbidities. Rebuilding these networks post-procedurally may 
take many months or even years to score relatively highly on QoL assessment [248]. A 
method to counteract this effect may be to apply pre- and post-procedure psychological 
investigation to enable any severe pre-procedure psychosocial disturbance to be identified and 
its effect on the data excluded [241]. 
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The importance of baseline measurements extends beyond the purpose of data 
comparison. An early assessment of QoL may also allow a more optimal choice of whether to 
implement surgical intervention or not. The pre-procedural decision between surgical and 
conservative treatment could be greatly assisted by the use of early baseline QoL assessment 
[242]. 
 
2.6.7 Limitations  
Despite the methodical process of our systematic review and the high scoring nature of the 
articles included, our review is not without limitations. For instance, the small sample sizes of 
the studies reviewed are very diverse and only six of the studies were multi-centered [240, 
249, 250, 256, 260, 261], which may raise concerns regarding the acceptability of our 
generalizations; however, having consistent, stable results from all the included studies 
renders this issue less concerning.  
 
Focusing on very poor health at baseline, these patients are in need of a greater 
absolute increase of QoL but are simultaneously the most likely to not complete QoL 
questionnaires due to adverse health or mortality [250]. This is likely to result in the majority 
of follow-up data being obtained from the patients who are in a relatively good state of health, 
which can subsequent skew QoL data to overestimate the effect of cardiac valve surgery on 
QoL. In addition, those patients with mental health diseases, such as dementia, were ruled out 
of the studies. These patients may have differing levels of QoL changes post-procedure than 
those patients included in the study. However, there are extreme difficulties in applying 
questionnaires or interviews to this group of patients, as well as ethical issues when obtaining 
fully informed consent to participate. 
 
Other influences on post-procedure QoL are post-procedure complications. Most 
cardiac valve procedures are uncomplicated and result in a post-procedure hospital stay of 
less than 48 h in cardiothoracic intensive care unit (ICU). However, it is the small proportion 
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of patients requiring prolonged intensive care following procedure complications that may 
have a greater influence on overall post-procedure QoL. This group will have increased 
morbidity and mortality both in hospital and after discharge [284-286]. Due to their condition, 
these patients may not contribute to QoL data post-procedure and, hence, the overall result 
may be an overestimation of post-procedural QoL for the whole cohort of patients 
investigated. However, this group of patients is usually covered with a different type of 
clinical studies where operative mortality and morbidity are assessed, and when their QoL is 
studied, they usually fall within another patient population group; eg, intensive care patients.  
 
The studies we reviewed were individually scored for quality. However, this standard 
of scoring may not be as good a reflection as first thought when carrying out this review. For 
instance, one of the studies scored very highly at 9 out of 10, yet it carries a number of 
limitations of its own that could result in biased data, most notably the lack of baseline QoL 
measurements and its retrospective nature [236]. 
 
As mentioned, not all studies included baseline measurements of QoL, nor a control 
group to compare data to. This reduces the validity of QoL data for determining how it is 
affected by cardiac valve surgery. The absence of pre-operative score makes it difficult to 
assess whether the follow-up scores represent an improvement or a decline from the pre-
operative surgery or whether pre-operative score was comparable to the age-matched 
population norm [252].  
 
The follow-up completion rate is not only affected by patient preference and ability to 
be contacted, but also by the mortality rate at the time of follow-up which can reach up to 
30%, particularly in TAVI patients [249]. The range of follow-up in the articles reviewed 
spans a large period of time consisting of almost 30 years (Figure 2.4); however, excluding 
the study involving the greatest mean follow-up period by Maliwa et al. [231], the range is 
considerably less at only 7.9 years. In fact, the majority of studies had a follow-up of 1 year 
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or less. While this provides a good wealth of data for the short-term effects on QoL, it does 
not allow us to thoroughly explore the long-term QoL effects and maintenance. This may not 
be as important in elderly patients compared with younger patients, and with the majority of 
the studies focusing on the elderly group it is evident why the follow-up periods reviewed are 
more concerned with short-term effect.  
 
As discussed previously, the lack of a standardized QoL measurement may somewhat 
limit the inter-study comparison of the data used in our review. The possibility of merging 
and validating the different instruments used, or at least incorporating a standard set of 
combinations, may help to realize this more standardized ideal. However, this would be very 
time consuming and could lead to logistical issues in implementation. There is also the issue 
of applying the instruments to different age groups. It is clear, as has already been discussed, 
that the requirements for fulfillment of QoL are very different between age groups. In the 
elderly age group, the ability for independent living pre- and post-procedure was not always 
assessed. This may be a more important QoL factor to those elderly patients without family or 
a support network, yet such a question was included in only three studies [245, 247, 248]. 
Considering this factor alongside the standardized QoL assessment would answer a very 
important question that may well be a fundamental aspect of a patient decision when 
undergoing cardiac valve surgery.  
 
In young children, Van Doorn et al. [234] were unable to identify a satisfactory 
validated questionnaire to apply to children under 9 years of age for obvious comprehension 
issues. Therefore, our review did not examine data for children younger than this age. This 
could be offset by a third-party parental rating of QoL, as in most cases examined there is 
agreement between individual parental and child QoL assessment in children older than nine 
[234, 241].  
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Finally, all of the above limitations are article or topic related, and thus another 
limitation in this was study is related to the unavailability of the full text of some of the 
relevant titles we identified during the search process. However, the large number of articles 
included and the consistent results across them makes this issue less pertinent.   
 
2.6.8 Summary of findings 
•  While in adult and elderly populations the significant improvement following any 
mitral or AV procedure or surgery is evident, the data in very young patients is 
extremely limited and insufficient to draw any conclusion.  
• For all types of prostheses and all types of surgical approaches for different operative 
risk groups, including high-risk patients, AV replacement lead to improvement in 
QoL; however, the scale of improvement seems to be greater in surgeries using 
pulmonary autografts than mechanical prostheses.  
• Open MV repair seems to generate a greater improvement in QoL than valve 
replacement.  
• Ministernotomy does not offer additional benefits over conventional sternotomy in 
terms of QoL.  
• TAVI via the transfemoral route is associated with a short-term advantage in QoL 
compared to transapical and conventional AVR. 
• The improvement in the physical component of the follow-up QoL assessment is 
more remarkable and consistent than the mental component. 
• Female gender, PVD, less experienced operator (less than 50 cases), and moderate to 
severe MR are predictors of lower QoL improvements in post-TAVI patients. 
• Concomitant CABG procedure does not reduce the magnitude of QoL improvement. 
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2.7 Clinical application 
Though the benefit of surgery over conservative treatment for cardiac valve surgery is 
unquestionable based on survival and symptomatic gain, the improvement in QoL findings 
following valve procedure or surgery add more supportive data for the current surgical and 
clinical practice and add another aspect that needs to be evaluated when other treatment 
options become available.  
 
Timing of intervention, type of valve, and type of procedure in cardiac valve diseases 
are crucial issues undergoing ongoing debate and evolution. Currently, the decision-making 
process is mainly based on symptomatic and cardiac hemodynamic assessment. Symptoms 
can sometimes be subjective and underestimated by patients and/or clinicians with a 
subsequent delay in the timing of intervention. Therefore, qualitative and quantitative 
assessment of symptoms by using a QoL questionnaire in routine pre-operative assessment 
may add decisive information to the decision-making process. This concept was also 
conveyed by the European Association of Cardio-Thoracic Surgery and the European Society 
of Cardiology in their position statement about the transcatheter valve implantation for 
patients with aortic stenosis [183, 221]. 
2.8 Conclusions 
Cardiac valve surgery or procedure improves QoL in adult and elderly patients affected by 
cardiac valve disease, and this improvement is more notable in the physical component than 
in the mental component. The improvement is still present, although less substantial, in 
females, patients with pre-existing PVD, procedures performed by less experience operators, 
or patients with moderate to severe MR. Furthermore, the improvement in QoL following 
cardiac valve surgery has been shown to last for up to 30 years post-procedurally, but the vast 
majority of data currently strongly supports a more substantial short-term improvement 
within the first year post-procedure. It would be of benefit to patients and healthcare 
professionals alike to obtain more data regarding the predictors of QoL outcome to advance 
the factors already discussed. This would aid in making the most appropriate management 
 116 
choice for cardiac valve disease sufferers by allowing even greater insight into the effect of 
surgical intervention. Additionally, more data investigating long term follow-up periods is 
needed to determine the sustainability of QoL improvement. 
 
There may also be a need for age-specific validated questionnaires for younger 
patients, and a standardized, universal instrument of QoL assessment to standardize data and 
allow comparisons of outcomes across different groups.  
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3 Chapter 3  
Hypotheses, objectives, and general methodology  
Following the comprehensive introduction and literature review in the previous chapter, this 
chapter explains the hypotheses of this project, the objectives we aim to achieve, and the 
methodology used to conduct this study.  
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3.1 Hypotheses 
The core hypothesis of this study is that aortic stiffness is related to global functional outcome 
and organ injury or strain (brain, kidney, and heart). Therefore, aortic stiffness might be a 
predictor of health related quality of life (QoL), cognitive function, brain injury biomarker, 
acute kidney injury (AKI), and cardiac function in aortic valve replacement (AVR) patients.  
 
As explained in detail in the introduction, a stiff aorta causes aggressive unsteady 
blood flow that can cause end-organ microvascular changes and tissue hypoperfusion, which 
in turn can affect organ function and post-operative recovery. Carotid-femoral pulse wave 
velocity (cfPWV) is the gold standard method for measuring aortic stiffness. A large body of 
evidence confirms the association between PWV and cardiovascular (CV) disease, 
independent of traditional risk factors in different healthy and diseased populations; however, 
the predictive value of PWV in AVR patients has not yet been studied. Therefore, we 
hypothesize that in patients who need AVR, high (abnormal) pre-operative PWV is: 
1) related to global functional outcome assessed by QoL; 
2) related to cognitive function and brain injury assessed by a biomarker; 
3) related to kidney function and injury assessed by AKI and a biomarker; 
4) and related to cardiac function and myocardial strain assessed by a biomarker. 
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3.2 Measurable objectives 
To test the above hypotheses, the following objectives have been identified: 
A) asses aortic stiffness by measuring PWV in AVR patients pre-operatively and 
compare with published European norms; 
B) measure QoL pre- and post-AVR and assess its relationship with pre-operative PWV; 
C) measure cognitive function pre- and post-AVR and assess its relationship with pre-
operative PWV; 
D) measure the novel brain injury biomarker N-methyl-d-aspartate (NMDA) receptor 
antibodies (NR2Ab) pre-operatively and assess its relationship with pre-operative 
PWV; 
E) assess renal function pre-operatively and identify post-AVR AKI cases and assess the 
relationship between renal function, AKI and pre-operative PWV. For this endpoint, 
we are also assessing the predictive value of the novel kidney injury biomarker 
neutrophil gelatinase-associated lipocalin (NGAL) for early detection of AKI and we 
compare it to the standard biomarker (creatinine); 
F) and asses the relationship between pre-operative PWV and: a) cardiac function (pre- 
and post-operatively); and b) myocardial strain assessed by myocardial strain 
biomarker B-type natriuretic peptides (BNP) pre-operatively and immediately post-
operatively, need for post-operative inotropes, and the development of post-operative 
arrhythmia. 
 
 
3.3 Statement of originality 
To our knowledge, when this project was registered for a PhD degree (2009) or when this 
thesis was written (2013 yearend), there is no published study that has assessed any of the 
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above objectives, particularly with respect to aortic stenosis or using any cardiac surgery 
patient cohort. This is an original work that does not overlap with any other previous 
departmental or institutional work or with any ongoing study, either scientifically or 
financially. 
 
3.4 Research governance and regulatory approval 
All the necessary regulatory body approvals were successfully obtained before 
commencement of the study. 
 
3.4.1 Sponsor 
Imperial College London acted as the main sponsor for this study.  
 
3.4.2 Ethics Approval 
 The Chief Investigator obtained the first ethics approval from East London & The 
City REC Alpha on 01/07/2009, Ref. 09/H0704/41. 
 Institutional and Trust R&D approval was obtained on 25/09/2009, Ref. 09/DC/002. 
 The second ethics approval was obtained from North London REC 3 on 15/03/2011, 
Ref. 11/H0709/3.   
 Institutional and Trust R&D approval was obtained from the AHSC Joint Research 
Office, Imperial College London on 10/05/2011, Ref. JROSM0182. 
 
3.4.3 Research governance audit  
The Research Governance Manager subjected this study to routine inspection and audit from 
the Joint Research Compliance Office, Imperial College London (Reference; JROSM0182 
CRO1449) on Monday April 30th, 2012. The outcome of the audit was very satisfactory with 
no concerns or issues to follow.   
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3.5 General methodology 
This section explains the methodology we followed in conducting this project and provides an 
overview of the protocols undertaken. For ease of reading and understanding, certain chapter-
specific methodology is comprehensively described in their respective chapters and omitted 
from this section. 
 
3.5.1 Patient populations 
Patients referred for surgical AVR were eligible to be included in this study. Most of the 
patients were referred to our surgical team from the cardiology clinic or from the joint 
cardiology cardiac surgery (JCC) meeting for AVR surgery. Participants were initially 
approached at the pre-assessment clinic (PAC), which usually occurs about 2–6 weeks before 
surgery, giving patients plenty of time to read the information sheet, think about the project, 
and sign the consent form willingly.   
 
3.5.2 Patient groups 
PWV was analyzed using traditional methods as a continuous variable to verify our 
hypotheses. In addition, we decided to use a novel approach that was not previously used or 
considered at the time of this project proposal: analyzing PWV as a dichotomous variable 
(PWV-norm group vs. PWV-high group). 
 
Based on patients’ pre-operative PWV measurements and the published European 
normal values of PWV for the matched age group (subtracted method, Figure 3.1)[89], 
patients were divided into two groups:  
 
A- PWV-norm group: PWV equal or below normal reference values for their age group. 
B- PWV-high group: PWV above the normal reference values for their age group.  
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This approach not only offers additional statistical analysis to verify our hypotheses 
and to strengthen the objectives measured, but may also provide preliminary data to assess the 
practical usability of the published reference values in identifying patients at risk.  
 Furthermore, when necessary, we grouped patients according to the endpoint studied 
in certain chapters; for example, the brain injury biomarker (NR2Ab-low vs. NR2Ab-high) or 
the development of AKI (AKI-Yes vs. AKI-No). 
 
 
 
Figure 3. 1 The published mean of normal PWV values per age group (direct and subtracted methods) used 
to measure the distance between the two arterial sites [89] 
Abbreviations: pc, percentage; SD, standard deviation. 
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3.5.3 Pre-registration evaluation 
Referring letter, JCC meeting forms, and patient medical notes were used for pre-registration 
evaluation. 
 
3.5.4 Recruitment and consent 
Involvement of participants in our study was voluntary. Participants were approached by the 
PhD student (EK) and proper explanation of the study and a Patient Information Sheet were 
provided. Informed consent was obtained voluntarily prior to participant enrolment. 
 
3.5.5 Exclusion criteria 
The majority of these criteria were implemented to reduce the confounding effect of specific 
variables on the selected endpoints:  
a) Emergency cases: lack of sufficient time to obtain consent and take pre-operative 
measurements. 
b) Chronic kidney disease: aortic stiffness is related to chronic kidney disease. 
c) Previous cardiac or vascular intervention or surgery: post-operative morbidities, PWV, 
and health related QoL might be more related to the repeat operation or to the previous 
vascular intervention. 
d) Thoracic aorta (more than just the root) or abdominal aortic aneurysm (aorta dilated at 
least 1.5 times that of adjacent healthy aorta; the diameter is at least 50% greater than the 
normal size): aortic stiffness is related to aneurysmal aorta. 
e) Associated congenital vascular disease including Marfan’s syndrome: aortic stiffness is 
related to congenital vascular disease. 
f) Aortic dissection: the aortic wall is structurally distorted.  
g) Moderate to severe chronic obstructive pulmonary disorder (COPD): post-operative 
morbidities and health related QoL is likely to be more related to co-existing COPD. 
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h) Any psychiatric or significant neurological condition or patient taking any regular 
medication for mental illness, including antidepressants: these factors have negative 
impact on cognitive function.  
i) Mini mental state examination score below 25 points: to exclude patients with dementia. 
 
3.5.6  Withdrawal criteria 
Participants had the right to withdraw from the study at any stage as they so desired. The 
patients had no obligation to attend follow-up visits, nor were incentives provided for 
participation. 
 
3.5.7 Study site 
Patients were recruited at the Cardiac Surgery Unit at Hammersmith Hospital, Imperial 
College of London, NHS Trust.  
 
3.5.8 Sample storage 
Blood samples were initially stored in a freezer inside a locked research lab in the Imperial 
Centre for Translational and Experimental Medicine, Hammersmith Campus. They were 
subsequently moved to the research lab in the Department of Surgery and Cancer, St. Mary’s 
Campus, Imperial College, London for analysis.  
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3.5.9 Data collection 
A Patient Data Sheet designed specifically for this project by the PhD student (EK) was used 
to collect the required data, which included: 
1. Demographic and anthropometric data: age, sex, race, height, weight, body mass index 
(BMI), body surface area, and postcode. 
2. Clinical data: history of present illness, New York Heart Association classification 
(NYHA), Canadian Cardiovascular Society (CCS) angina classification, hypertension, 
diabetes mellitus, dyslipidaemia, syncope, palpitation, arrhythmias, smoking, past 
medical history (PMH), past surgical history (PSH), alcohol history, and drug history. 
3. Physical examination: pulse rate (PR), brachial blood pressure (BP), and leg edema. 
4. Electrocardiography (ECG). 
5. Routine baseline blood test: full blood count (FBC), lipid profile, renal function tests 
(RFT), coagulation profile, and liver function test.  
6. Echocardiographic data: aortic valve area, peak and mean transvalvar gradient in stenosis, 
left cardiac chambers dimensions (LVEDV, LVESV), and ejection fraction (EF). 
7. PWV: cfPWV was measured using one of the commercially available applanation 
tonometry devices pre-operatively and at the follow-up visit post-operatively.  
8. Health related (QoL) data: using known and validated questionnaires (SF-36 and EQ-5D), 
the data were collected pre-operatively and at the follow-up visit post-operatively. 
9. Cognitive function test data: using a computer-based battery, the test was performed pre-
operatively and at the follow-up visit post-operatively.  
10. Intra-operative data: size of valve, any concomitant coronary artery bypass graft (CABG), 
cardio-pulmonary bypass time, and cross clamp time. 
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11. AKI data: pre-operative RFT and plasma NGAL; post-operative RFT and plasma NGAL 
(at 3 h post-CPB and 18–24 h post-CPB); post-operative fluid balance and urine output 
was also checked from the Cardiac Recovery Unit (RCU) and High Dependency Unit 
charts.   
12. Post-operative course data: inotropes, blood product transfusion, extubation time, 
arrhythmias, neurocognitive event, any significant event, length of stay, and medication 
prescribed on discharge.  
13. Biological samples: pre-operative plasma and serum samples, 3 hour post-CPB plasma, 
and 18–24 hour post-CPB plasma; plasma samples for the NGAL and BNP, and serum 
samples for the NR2Ab test. 
 
3.5.10 Operative techniques 
Operating surgeons and anesthetists were blinded to recruited patients. The surgical approach 
was through median sternotomy. Following full anticoagulation with a routine dose of 
heparin (300 IU/kg) to maintain an activated clotting time of 400–600 seconds, 
cardiopulmonary bypass (CPB) was instituted using ascending aortic cannulation and right 
atrial venous cannulation. Cardiotomy suction was used and myocardial protection was 
achieved with intermittent antegrade cold crystalloid cardioplegia. All procedures were 
carried out using standard cardiopulmonary bypass and moderate hypothermia (32–34°C). 
Through transverse aortotomy, the diseased valve was excised and the prosthetic valve 
inserted. The type of prosthesis and suturing technique were decided according to the 
surgeons’ personal preference. The need for intra or post-operative inotropes was decided by 
the anesthetist or the clinical team based on routine clinical practice. 
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3.5.11 Study protocol  
Figure 3.2 summarizes the protocol in flowchart form, and Table 3.1 shows a summary of the 
endpoint protocol.  
The following is the protocol summary in chronological order (different time stages) 
with descriptions of the data collected at each stage:  
 
1. At the PAC: Eligibility criteria, exclusion criteria, and initiation of the consent process 
with verbal explanations and the Patient Information Sheet.  
 
2. On admission: Informed consent, baseline demographic, clinical, physical, and ECG 
data; PWV, health related QoL questionnaires, and cognitive test; routine blood tests, 
plasma sample for NGAL and BNP, and serum sample for NR2Ab. 
 
3. AVR: Patients underwent AVR; intra-operative data. 
 
4. 3 h post-CPB: At the intensive care unit (ICU), routine blood tests, including RFT test, 
and plasma samples for NGAL and BNP samples. 
 
5. 18–24 h post-CPB: At the ICU, routine blood tests, including RFT test, and plasma 
samples for NGAL and BNP samples. 
 
6. During hospital stay: Daily RFT and assessment for any neurocognitive events; post-
operative course data. 
 
7. At the follow up visit (409 ± 159 days) post-operation: Repeated PWV, health related 
QoL questionnaires, cognitive test, and physical measurements data. 
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Figure 3. 2 Protocol summary. 
Abbreviations: PWV, pulse wave velocity; HRQoL, health related quality of life; NMDA, N-methyl-D-aspartate; 
NGAL, neutrophil gelatinase-associated lipocalin; BNP, B-type Natriuretic peptide; CPB, cardiopulmonary bypass. 
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Endpoint Tool Pre-op 3 h post-
CPB 
18 h post-
CPB 
Follow-
up visit 
Aortic stiffness cfPWV +   + 
Quality of life SF36 & EQ-5D 
questionnaires 
+   + 
Cognitive 
function 
CANTAB cognitive test +   + 
Brain injury 
novel biomarker 
Serum NMDA receptors 
antibodies (NR2Ab) 
+    
Acute kidney 
injury novel 
biomarker 
Plasma NGAL + + +  
Cardiac function 
and strain 
 
Echocardiography +    
NYHA  +   + 
Plasma BNP + + +  
Need for inotropes  + +  
Arrhythmias   + + + 
Table 3. 1 Summary of the endpoint protocol. 
Abbreviations: CPB, cardiopulmonary bypass; PWV, pulse wave velocity; SF36, short form 36; EQ-5D, European 
quality of life 5 dimensions; NGAL, neutrophil gelatinase-associated lipocalin; NMDA, N-methyl-D-aspartate; 
NYHA, New York Heart Association; BNP, B-type Natriuretic peptide. 
  
 130 
 
3.5.12 Endpoint measurements 
To follow are descriptions of the common (cross-chapter) measurements, such as PWV, while 
other chapter-specific measurements, such as; QoL, cognitive function and NGAL are 
described in their respective chapters for ease of reading and understanding.  
 
3.5.12.1 Aortic stiffness assessment by measuring PWV  
At least 2 h of abstinence from tobacco, alcohol, and tea or coffee was required prior to 
measurement. Patients were asked to rest for at least 10 minutes in a quiet, temperature- 
controlled room (22–25°C) before baseline hemodynamic measurements were obtained. 
Brachial BP and heart rate (HR) were measured with an automated digital 
sphygmomanometer (Model 506N3; Criticare Systems Inc, Waukesha, WI, USA). Two 
readings separated by the PWV measurements were taken and the mean was used for the 
analysis. The mean arterial pressure (MAP) was calculated as follow:  
MAP = diastolic BP + (pulse pressure/3)  
Aortic PWV (cfPWV) was obtained with an automatic applanation tonometry system 
(SphygmoCor® Vx system, AtCor Medical, Sydney, Australia). Briefly, while the patient 
was resting in a supine position, ECG-gated pulse waveforms were obtained sequentially 
from the common carotid and then femoral arteries by application of applanation tonometry. 
Propagation time of the pulse wave was measured from the foot of the carotid waveform to 
that of the femoral waveform referenced to the R-wave on the recorded ECG. The transit 
distance was measured in millimeters over the surface of the body by subtracting the distance 
between the supra-sternal notch and carotid site from the distance between the supra-sternal 
notch and femoral site. The system software of the Sphygmocor® device calculated PWV 
automatically in meters per second (m/s) by dividing the travelled distance by the propagation 
time. Three to five PWV readings were obtained per patient, and the PWV was determined by 
averaging the measurements that met the quality control (QC) parameters, as set by 
SphygmoCor® Clinical User Manual.  
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Quality control 
Quality control of the consecutive PWV measurements was met if: 
 The tonometry waveforms was clear and smooth and the foot of the waveform was 
easily identified. 
 The R-wave on the ECG was the tallest part of the ECG trace and the green dots were 
located at the top of the R-wave and not on any other part of the ECG trace. 
 The standard deviation (SD; in m/s) in the statistical table was below 6% of the mean 
time. 
 The PWV value had a SD ≤10%; if the SD between 10% and 15% and thus 
considered borderline, waveforms were carefully examined before making a decision 
as to whether to repeat the reading; for a SD above 20%, a repeat reading was done. 
 The signal strength of the recoded waves is more than 350. 
 The mean pulse-waveform height is above 120 mV. 
 
The aforementioned parameters are available on the measurement and report screens 
(Figure 3.3). All PWV and hemodynamic measurements were performed by a single operator 
(EK) using the same machine. 
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Figure 3. 3 Measurement and report screens of the PWV machine (SphygmoCor® Vx system; AtCor 
Medical). 
Abbreviations: ECG, electrocardiogram; PWV, pulse wave form.  
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Reproducibility 
The reproducibility of PWV using the SphygmoCor® machine has been proven in a wide 
range of studies [287-289]. This holds true even if the operator is newly trained [290] and 
when compared to other devices [291]. In fact, SphygmoCor® is currently recommended by 
the ARTERY Society as “the reference device” for the validation of any new device 
measuring cfPWV [292]. Therefore, most recently published studies have not checked the 
reproducibility of these values [293, 294]; including the European reference values studies 
[89, 295, 296]. Reproducibility of PWV measurements depends on the quality of 
measurement; therefore, all the aforementioned quality control parameters were used when 
taking readings. Any reading that did not meet these parameters was repeated. Additionally, 
before starting the study, the operator (EK) received proper training from an expert, and then 
measured the PWV of 10 volunteers as part of training. The raw data of these measurements 
were examined by an international expert in arterial stiffness at Cambridge University (Dr 
Carmel McEniery), who confirmed good quality of signal acquisition and PWV 
measurements.   
 
3.5.12.2 Echocardiography assessment 
Experienced echocardiographers performed a standard pre-operative transthoracic 
echocardiography, in accordance with guidelines from the American Society of 
Echocardiography [297]. All the relevant data for this study were obtained, including peak 
aortic velocity (cm/s), and peak and mean transvalvular gradient (mmHg). Effective aortic 
valve area was measured by means of the continuity equation. Wave Doppler and color flow 
Doppler were used to quantify aortic regurgitation (AR) and mitral regurgitation (MR). 
Regurgitation was graded as mild, moderate, or severe. M-mode was used to measure left 
ventricular end-diastolic and end-systolic diameter, as well as septal wall thickness. Left 
ventricular ejection fraction was also measured. The same echocardiographic assessment was 
done at the follow-up visit after surgery.  
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3.5.12.3 Health related quality of life  
This is covered in detail within the relevant chapter. The most popular and validated health 
related QOL questionnaires (SF-36 and EQ-5Q) were used to measure QoL. 
 
3.5.12.4 Cognitive function test 
This is covered in detail within the relevant chapter. Highly sophisticated computer-based 
system Cambridge neuropsychological automated battery (CANTAB) was used (for the first 
time in cardiac surgery) to assess cognitive function. 
 
3.5.12.5 Novel brain injury biomarker  
This is covered in detail within the relevant chapter. NR2Ab was measured for this endpoint. 
 
3.5.12.6 Acute kidney injury  
This is covered in detail within the relevant chapter. Standard definitions of AKI and the 
novel biomarker NGAL were used for this endpoint.   
 
3.5.12.7 Cardiac function and myocardial strain 
This is covered in detail within the relevant chapter. Echocardiography, NYHA class, need 
for inotropes, development of post-operative arrhythmias, and BNP were used for this 
endpoint. 
3.5.13 Sample size calculation 
It was not reasonable to calculate the exact sample size for our multiple end-points project 
because there was no data available in the literature concerning our hypotheses. Therefore it 
is an explorative study to test novel hypotheses and provide preliminary data for future 
studies. However, the sample size for this thesis was calculated by the supervising professor 
surgeon and statistician, and was aided by the published literature. The primary outcome 
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parameter (QoL) was used for the sample-size calculation, and a standard significance level 
of 0.05 was chosen [298]. In order to detect statistically significant differences in QoL (SF-
36) between the two groups of PWV with 1 SD (9.2 points) [299] and a power of 80%, we 
required 18 subjects in each group. Using a correlation coefficient between PWV and QoL 
(PCS) of 0.91 [300] to calculate the sample size for an α-level of 0.01 and β-level of 0.01, we 
required 14 subjects. However, we aimed for a minimum of 20 participants per group to 
compensate for common problems, including potential withdrawal at follow-up, and problems 
with sample and data processing. 
 
3.5.14 Statistics and data analysis 
This is covered in detail within the relevant chapter. In general, statistical analysis was 
conducted using SPSS version 18–20 software package (IBM Corporation, Armonk, NY, 
USA).  Patient characteristics and results are expressed as means ± SD or as medians and 
ranges when suitable for continuous variable and as frequencies for categorical variables; P-
values < 0.05 were considered statistically significant. Test for normality was carried out on 
all variables studied, and for the purpose of regression analysis, non-normally distributed data 
was transformed accordingly.  
PWV was analyzed as a continuous variable to verify the hypotheses. In addition, 
PWV was also analyzed as dichotomous variable (PWV-norm group vs. PWV-high group). 
Comparative analysis between any two groups was carried out using an independent samples 
t-test or non-parametric equivalent (Mann–Whitney U test) for continuous variables, and 
Pearson Chi-Square or Fisher’s exact tests for categorical variables. Correlation analysis 
between variables was conducted using Spearman’s rank-order correlation and point biserial 
correlation (for dichotomous variables), while the Phi test was used to compare two 
dichotomous variables (2 x 2). Simple regression (linear or logistic) between endpoints and 
other variables was used to identify potential predictors. All variables with significant simple 
regression or correlation, in addition to age and gender, were then included in the multiple 
regression (linear or logistic) (Enter method) analysis.   
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4 Chapter 4  
The relationship between aortic stiffness, aortic valve 
stenosis and quality of life  
 
This chapter addresses whether there is any relationship between aortic valve stenosis (AS) 
and aortic stiffness, and whether there is a relationship between aortic stiffness and health 
related quality of life (QoL) pre- and post-aortic valve replacement (AVR).  
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4.1 Abstract  
Background: Aortic stiffness is an emerging risk factor for cardiovascular disease. The 
predictive value of aortic pulse wave velocity (PWV) for quality of life (QoL) and severity of 
surgical aortic valve stenosis (AS) has not previously been examined. 
 
Objective: The objectives of this study are to assess the relationship between PWV and: a) 
AS; and b) QoL pre- and post-aortic valve replacement (AVR).  
 
Methods: Patients scheduled for AVR were eligible for this study. Aortic stiffness was 
assessed by measuring aortic PWV with applanation tonometry pre-operatively and at the 
follow-up visit post-operatively; similarly, QoL was assessed using SF-36 and EQ-5D 
questionnaires pre-operatively and at the follow-up visit post-operatively. PWV was analyzed 
as: a) a continuous variable using the actual value; and b) as a dichotomous variable (PWV-
norm and PWV-high groups) according to published normal reference values. A comparative 
analysis of QoL (inter-group and intra-group) was also performed.  
 
Results: Fifty six patients (16 females), mean age of 71 ± 8.4 years were included in this 
study, 50 (89%) patients completed the follow-up (409 ± 159 days post-operation), and no 
mortality or cerebrovascular event was recorded at follow-up. The overall mean PWV (m/s) 
value was 9.3 ± 2.2 and there was a significant difference between different age groups (P = 
0.001; analysis of variance), but not between males and females (P = 0.34). Mean PWV for 
the PWV-norm group (n = 35) was 8.1 ± 1.5, while mean PWV for PWV-high group (n = 21) 
was 11.3 ± 1.6 (P < 0.001). There was no significant difference between the two groups with 
respect to age, gender, or any classical hemodynamic measurement. There was no significant 
relationship between aortic stenosis (mean gradient or valve area) and PWV.  PWV-norm 
group scored significantly better than the PWV-high in the EQ-5D visual analogue scale and 
the EQ-5D index pre-operatively (p<0.001 and p=0.03, respectively) and post-operatively 
(p<0.001 for both). In SF-36, PWV-norm group scored better than PWV-high group in the 
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physical health domains at pre-operative stage and in all health domains at post-operative 
stage. Spearman’s correlation was significant between pre-operative PWV and QoL 
component summaries pre- and post-operatively. Among PWV, age, and gender, multiple 
regression analysis demonstrated that pre-operative PWV was an independent predictor of 
QoL outcomes pre- and post-operatively (P-values between <0.01 and <0.05). Furthermore, 
AVR had no significant effect on post-operative PWV value compared to baseline pre-
operative PWV measurement. Similar to the pre-operative finding, post-operative PWV was 
significantly correlated to, and independently predictive of post-operative QoL outcome. 
 
Conclusion: PWV does not correlate with AS severity, but is a predictor of QoL before and 
after AVR. The published European PWV reference values can be used to categorize pre-
operative AS patients for QoL risk stratification. 
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4.2 Introduction 
4.2.1 Aortic stiffness, PWV, and aortic valve disease 
 
Recoil elasticity enables the aorta to maintain sufficient pressure during diastole in order for 
tissues to be adequately perfused following the closure of the aortic valve. When the aorta 
becomes stiffer, this elastic capacity diminishes and the aortic diameter does not vary as much 
between systole and diastole. Aortic rigidity increases the speed of the pulse wave, systolic 
blood pressure (SBP), and cardiac afterload leading to microvascular damage of different 
tissues, which may reduce the functional status and QoL of affected individuals. PWV is the 
most validated and widely used method to assess arterial stiffness, and it has been described 
as the gold standard parameter of arterial stiffness [12, 14, 87, 89]. In 2010, the Reference 
Values for Arterial Stiffness’ Collaboration published a set of normal and reference values for 
PWV based on a population of 16,867 subjects from eight European countries [89]. The 
availability of these reference values can facilitate the assessment of PWV in different patient 
populations compared to normal values without the need to recruit a normal control group. 
 
Our literature search could not identify any study specifically investigating the 
relationship between applanation tonometry determined aortic PWV and AS or any type of 
aortic valve surgery. For more background on aortic stiffness, PWV, and AS see Chapter 1. 
 
4.2.2 Health related quality of life  
QoL is a highly significant and effective patient-reported outcomes measures (PROMs) tool. 
The interest in PROMs, and more specifically in QoL, has increased greatly over the last 
decade among healthcare providers and beneficiaries. This tool measures health outcomes and 
well-being from the patients’ point of view, rather than using the classical mortality measure. 
Advances in surgery, medicine, anesthesia, and intensive care have considerably reduced 
mortality, thus healthcare providers are using additional parameters beyond mortality to direct 
 140 
further developments and advances in healthcare. Following surgery, medication or 
intervention, relevant questions include: has the general health of the patient improved? Is 
patient health status improving or declining? Are other health aspects that are not directly 
related to the primary condition significantly (e.g. mental health) affected? What is the health 
status of the studied population compared to the general healthy population?’’ The answering 
of such questions by patients themselves can aid clinicians in improving the healthcare 
system and optimizing treatment options for the right patients at the right time.  
 
QoL questionnaires address most of the above questions, and both generic and 
disease-specific questionnaires have been developed. We are not aware of any disease-
specific QoL questionnaire for cardiac or valve surgery patients. Therefore, we have used the 
Quality Metric's SF-36v2® Health Survey and the European QoL 5-dimensions (EQ-5D™) as 
PROM tools, as they are the most validated and powerful generic questionnaires that have 
been used extensively in cardiac surgery populations (see Chapter 2). 
 
Many studies have been conducted addressing changes in QoL following the 
diagnosis/occurrence of heart conditions, such as ischemic heart disease (whether treated 
medically, surgically, or interventionally) [301-304], heart failure [305, 306], heart 
transplantation [307], and changes after cardiac rehabilitation [308]. Improvement in QoL 
after heart valve surgery has previously been demonstrated [241, 309-311]. Furthermore, QoL 
after aortic valve surgery has been studied extensively [312, 313], and improvement 
following surgery in adults was indicated across most domains of different QoL instruments 
used, though more prominent in the elderly [313]. It appears that QoL improvement is not 
limited by age and, in addition, some studies have recorded an improvement level greater in 
these patients than the age-matched general population [223, 312-314]. Interestingly, 
concomitant coronary artery bypass surgery does not affect this QoL improvement [260, 313], 
and improvement in QoL is comparable between patients receiving bioprostheses and 
mechanical aortic valve prostheses and age-matched general population [299, 315]. Pre-
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operative factors that can impact post-operative QoL include: combination regurgitation and 
stenosis, diabetes mellitus, chronic obstructive pulmonary disease, and depression [312, 313].  
As evidence of improvement in QoL after cardiac surgery has been clearly established, and 
based on the fact the QoL level correlates well with long-term survival [316], some clinicians 
and researchers have investigated the relationship between said improvement and other pre-
operative factors in order to assess their predictive value. For example, the effect of gender or 
operative risk score (EuroScore) on QoL improvement after cardiac surgery has been 
explored [317, 318]. However, QoL assessment is time-consuming, can be complicated, and 
requires time-point measurements and follow-up visits, which can be difficult to routinely 
perform in a clinical setting. Therefore, identifying a clinical, physiological, or biochemical 
predictor for QoL has significant clinical value.  
 
To date, no study has investigated the relationship between aortic stiffness and post 
aortic valve surgery outcome measures such as QoL. This lack of preliminary data pertaining 
to the presence and significance of abnormal PWV in AS disease patients and whether PWV 
can predict poor outcomes after AVR was the impetus behind this study. Because aortic 
stiffness reflects the health status of the vascular system, which delivers blood to body tissues, 
we hypothesize that aortic stiffness may have an effect on patient QoL and that a simple pre-
operative PWV measurement can predict pre- and post-operative QoL.    
 
4.3 Objectives 
The objectives of this study are: 1) to investigate the relationship between aortic stiffness 
(PWV) and surgical AS; 2) to assess the clinical utility of PWV for predicting QoL outcome 
measures in surgical AS patients before and following AVR; and 3) to test the validity of the 
recently published PWV reference values for identifying patients at higher risk of poorer QoL 
outcome [89]. 
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4.4 Materials and methods 
4.4.1 Patient population and overview 
After obtaining ethical approval and informed consent, patients with moderate to severe AS 
who were to undergo AVR at Hammersmith Hospital, London, UK were recruited for this 
study between June 2010 and August 2012. Eligibility/exclusion criteria were applied. All 
included patients underwent aortic stiffness assessment by measuring carotid-femoral PWV 
and QoL assessment using SF-36 and EQ-5D questionnaires pre-operatively and at the 
follow-up visit post-operatively. Pre-operative responses were considered the baseline QoL 
measurement, which was used for analysis and comparison with the normal population and 
the second, post-operative response. All demographic, clinical, and disease-relevant data were 
prospectively collected pre-, intra-, and post-operatively. Based on patients’ pre-operative 
PWV measurement and the published European normal values of PWV for the age-matched 
group (subtracted method, Figure 3.1) [89], patients were divided into two groups:  
A- PWV-norm group: PWV equal or below normal reference values for the age group. 
B- PWV-high group: PWV above the normal reference values for the age group.  
 
4.4.2 PWV measurement protocol 
This has been covered comprehensively in the methodology section of the previous chapter. 
 
4.4.3 QoL assessment 
Self-administrated QoL questionnaires (SF-36 and EQ-5D) were used to assess QoL. A single 
investigator (EK) met the included and consenting patients in person and thoroughly 
explained the purpose of these questionnaires and how to answer them. After adequate 
response time was given, both questionnaires were collected and answers were entered into 
the research database and to questionnaire-specific software to calculate individual QoL 
scores. The guidelines on how to respond to these questionnaires as described in the manuals 
were followed.  
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4.4.3.1 Quality Metric's Short Form health survey (SF-36v2®) 
SF-36v2 is the most reliable and validated generic health questionnaire available for 
measuring patient-reported outcomes, with more than 13,000 and 235 previously published 
articles using SF-36 and SF-36v2, respectively. This questionnaire can be self-administrated 
(on paper or online) or interview-administered (in person or by phone). SF-36v2 consists of 
36 questions relating to functional health and well-being, assessing both physical and mental 
health components. These questions represent eight domains (Figure 4.1) [319]: (1) physical 
functioning (PF), ranging from self-care daily activities to vigorous activities such as walking, 
bathing, dressing, bending, cleaning, moving table, lifting heavy objects, and strenuous 
sports, capturing and scoring both the presence and the extent of any physical limitation; (2) 
role physical (RP), representing the degree of physical role limitations for a patient’s specific 
age and social responsibility, with low scores signifying problems with work and other 
activities; (3) bodily pain (BP), signifying both the intensity of bodily pain and the degree of 
interference with daily activities, including work outside home; (4) general health (GH), 
reflecting a self-rating of general health and also the patient’s opinion, attitude, and 
expectations toward their health status; (5) vitality (VT), assessing energy levels and 
tiredness; (6) social functioning (SF), assessing the impact of physical or emotional problems 
on social activities and relationships (including family, friends, and neighbors); (7) role 
emotional (RE), assessing the effect of emotional problems and personal feelings on work 
performance or other daily activities; and (8) mental health (MH), evaluating the patient’s 
mental health by focusing on the major mental health dimensions, such as anxiety, 
depression, emotional control, and psychological well-being.  
 
SF-36v2 can give scores for each of the eight domains, the physical component 
summary (PCS), and the mental component summary (MCS). SF-36v2 is a multi-item, multi-
domain health survey, with a measurement model that has three levels: items, domains, and 
component summary. Each domain is an aggregation of specific items, and all domains 
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contribute to the scoring of the component summary, but with a different strength of 
correlation. PF, RP, and BP scales contribute most to PCS scoring, while MH, RE, and SF 
scales contribute most to MCS scoring (Figure 4.2) [319].    
 
 Interpretation of SF-36v2 results is simplified using norm-based scoring (NBS). In 
this system, each scale is scored after calibrating to the normal general population using the 
same mean (50) and same standard deviation (SD; 10 points). This has the advantage of 
determining the status of the health domain or component summary in relation to the mean 
without referring to tables of norms. Thus, individual scores below 45 or groups with mean 
scores below 47 can be interpreted as below average for the general population. Full set of the 
SF-36v2 questionnaire can be found using this link 
(http://www.qualitymetric.com/demos/TP_Launch.aspx?SID=100). Permission to reproduce 
and to use the SF-36v2 Health Survey for both scholarly and commercial purpose can be 
obtained completing a Survey Information Request Form at; http://www. Qualitymetric.com/ 
or contacting OptumInsight Life Science. Inc. at1-800-572-9394..  
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Figure 4. 1 Health domains of the SF-36v2 QoL questionnaire [319]. 
SF-36v2 is a registered trademark of the Medical Outcomes Trust and is used under license. The SF-
36v2 Health Survey is copyright 1992, 1996, 200, by Medical Outcomes Trust and QualityMetric 
Incorporation.  
 
 146 
 
 
 
Figure 4. 2 SF-36v2 measurement model (item, domain, and summary) [319]. 
Each item contributes to the scoring of a single domain, and all domains contribute to the scoring of the both 
physical and mental component summary. Strong contribution is indicated by solid line connection (____), while 
lesser degree of contribution is indicated by dotted line connection (…..).. 
 
SF-36v2 is a registered trademark of the Medical Outcomes Trust and is used under license. The SF-
36v2 Health Survey is copyright 1992, 1996, 200, by Medical Outcomes Trust and QualityMetric 
Incorporation.  
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4.4.3.2 EQ-5D health questionnaire 
EQ-5D™ is a trademark of the European Quality Of Life Group, a group that was established 
in 1987 by a network of international, multilingual, multidisciplinary researchers from 
Europe. Their aim was to generate a simple, standardized, non-disease specific instrument for 
describing and valuing health-related QoL [320]. The EQ-5D questionnaire is both easy to 
understand and answer. It can be self-administrated or interview-administered, producing a 
descriptive profile and single index value, which can be used for clinical and economic 
studies. The questionnaire consists of two parts: 1) The Descriptive System, consisting of five 
questions reflecting five dimensions: mobility, self-care, usual activity, pain or discomfort, 
and anxiety or depression. Participants respond to these questions by ticking one of the three 
possible levels (no problems, some problems, or extreme problems) that they feel best 
correlates to their health. The answer results in a one-digit number (from 1 to 3) for each 
dimension. The EQ-5D score is calculated by combining scores from the five dimensions to 
form a five-digit number describing the respondent’s health state; 2) The Visual Analogue 
Scale (EQ-VAS), a 20-cm vertical graph of analogue scale ranging from 0 (the worst 
imaginable health status) to 100 (the best imaginable health status) is presented. Participants 
are asked to rate their health state by drawing a line from the box marked “Your health state 
today” to the appropriate point on the scale. The result represents a visual overall self-rating 
health status. EQ-5D has been validated in hundreds of economic and clinical studies on a 
wide range of health conditions all over the world, particularly in Europe [320].  
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4.4.4 Statistical analysis 
IBM SPSS Statistics 18.0 software package and Microsoft Office Excel 2010 were used for 
all statistical analyses (IBM Corporation, Armonk, NY, USA). All continuous variables were 
initially tested for normality with the Shapiro-Wilk test; non-normally distributed variables 
were transformed for the purpose of regression analysis. The population characteristics were 
expressed as the means$±$SD (for continuous variables) and as frequencies (for categorical 
variables). P-values <0.05 were considered statistically significant. One-way analysis of 
variance (ANOVA) was employed to compare PWV values between different age groups.  
 
PWV was analyzed as a continuous variable to verify our hypothesis. In addition, 
comparative analysis between the two PWV groups (PWV-norm and PWV-high) was carried 
out using independent-samples t-tests or non-parametric equivalent (Mann–Whitney U test) 
for continuous variables, and Pearson chi-square or Fisher’s exact test for categorical 
variables. Changes in health status scores between the baseline pre-operative score and post-
operative follow-up visits within each group were calculated with a paired samples t-test or 
non-parametric equivalent (Wilcoxon test). We also conducted a further analysis of the five 
EQ-5D dimensions by grouping levels 2 and 3 of the responses (patients with any reported 
problem) and comparing them between the PWV-norm and PWV-high groups using binary 
logistic regression analysis. To test the strength of a linear association between QoL 
components and PWV in patients with AS, we pooled all QoL and PWV data from both 
groups into a bivariate correlation analysis of Spearman’s rank-order correlation and point 
biserial correlation (for the dichotomous variables) for both pre- and post-operative stages. In 
addition, PWV, age, and gender were incorporated in a multiple linear regression model to 
identify the independent predictors of QoL outcomes. The differences in QoL outcomes 
measures between PWV-norm and PWV-high groups were tested with analysis of covariance 
(ANCOVAs) using the baseline QoL scores as linear covariates. The variance due to the 
different on PWV was measured by Partial Eta Squared (ƞp2).  
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4.5 Results 
4.5.1 Descriptive results 
From June 2010 to August 2012, 56 patients (16 females) with a mean ± SD age of 71 ± 8.4 
years were included in this study. Fifty (89%) patients were able to attend the follow-up visit 
and six patients refused to return after their initial enrollment at the pre-operative stage; no 
mortality or cerebrovascular event was recorded at the follow-up time (409 ± 159 days). 
Thirty-five (62.5%) patients had PWV measurements that were equal or below the reference 
value for their age group (PWV-norm group) and 21 patients (37.5%) had PWV 
measurements above the reference value for their age group (PWV-high group). Table 4.1 
summarizes the demographic and clinical characteristics of the patients that participated in 
this study. There was no significant difference between the PWV-norm and PWV-high 
groups in terms of age, gender, classical hemodynamic measurements, or other clinical 
characteristics assessed.  
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Parameter Total 
n = 56 
PWV-norm 
n = 35 
PWV-high 
n = 21 
P-value 
Male 40 (71.4%) 27 (77.1%) 13 (61.9%) 0.36 
Age (years) 
Age range (years) 
71 ± 8.4 
53 - 90 
70.2 ± 9 
53 - 90 
72 ± 8 
56 - 85 
0.43 
White Caucasian [n (%)] 55 (98%) 35 (100%) 20 (95%) 0.37 
DM [n (%)] 8 (14.3%) 4 (11.4%) 4 (19.1%) 0.43 
Smoking [n (%)] 2 (3.6%) 2 (5.7%) 0 (0 %) 0.21 
BMI (kg/m2) 27.2 (4.2) 26.5 (4.3) 28.1 (4.1) 0.18 
SBP (mmHg) 136 ± 24 132 ± 27 142 ± 18 0.14 
DBP (mmHg) 76 ± 11 75 ± 12 77 ± 11 0.58 
PP (mmHg) 62 ± 15 61 ± 14 65 ± 16 0.32 
MAP (mmHg) 97 ± 12 96 ± 13 98 ± 11 0.56 
Cholesterol (mmol/l) 4.5 ± 1.2 4.6 ± 1.3 4.4 ± 0.8 0.60 
Hypertension [n (%)] 38 (67.9%) 22 (62.9%) 16 (76.2%) 0.38 
Statin treatment [n (%)] 38 (67.9%) 22 (62.9%) 16 (76.2%) 0.38 
Bicuspid aortic valve [n (%)] 8 (14.3%) 6 (17.1%) 2 (9.5%) 0.69 
PVD [n (%)] 2 (3.6%) 0 (0%) 2 (9.5%) 0.13 
EuroSCORE (Logistic) 5.5 ± 4.3 5.1 ± 4 6.1 ± 4.7 0.23 
Aortic valve area (cm2) 0.73 ± 0.2 0.74 ± 0.2 0.71 ± 0.2 0.67 
AVMG  48 ± 13 50 ± 13 46 ± 11 0.27 
AVPG 82 ± 24 86 ± 27 76 ± 19 0.13 
Ejection fraction  59 ± 15 58 ± 15 61 ± 16 0.56 
Concomitant CABG 15 (26.8%) 10 (28.5%) 5 (23.8%) 0.76 
CPB time (minutes) 87 ± 23 87 ± 20 87 ± 27 0.95 
Hospital stay (days)  6.7 ± 1.7 6.6 ± 1.6 6.7 ± 1.8 0.84 
PWV 9.3 ± 2.2 8.1 ± 1.5 11.3 ± 1.6 <0.001 
Table 4. 1 Demographic and clinical characteristics. 
Values are shown as n (%) for categorical variables and the mean ± standard deviation for continuous 
variables. Abbreviations: DM: diabetes mellitus; BMI: body mass index; SBP: systolic blood pressure; DBP: 
diastolic blood pressure; PP: pulse pressure; MAP: mean arterial blood pressure; PVD: peripheral vascular 
disease; AVMG: aortic valve mean gradient; AVPG: aortic valve peak gradient; CABG: coronary artery 
bypass graft surgery; CPB: cardiopulmonary bypass; PWV: pulse wave velocity.  
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4.5.2 PWV in patients with aortic valve stenosis 
The overall mean PWV (m/s) value was 9.3 ± 2.2; however, it is known that PWV increases 
with age and our results confirmed that a significant difference existed between different age 
groups (P = 0.001; ANOVA; Figure 4.3), but not between males and females (P = 0.34). The 
correlation coefficient between age and PWV was 0.5 (P < 0.001), and the Beta coefficient of 
their linear regression was 0.49 (P < 001). Interestingly, the mean PWV value for each age 
group was not consistently higher than the reference value derived from the normal European 
population, as shown in Figure 3.1 [89]. However, 21 patients (37.5%) had PWV values that 
were higher than the reported reference value, which represents the group of interest (PWV-
high group). There was no significant difference between the PWV-norm and PWV-high 
groups with respect to AS severity, as assessed by the aortic valve mean gradient (AVMG), 
aortic valve peak gradient (AVPG), and aortic valve area (Table 4.1). Spearman’s correlation 
analysis using PWV as a continuous variable confirmed the absence of any relationship 
between AS parameters and PWV (P-values: 0.69 for AVMG, 0.10 for AVPG, 0.69 for aortic 
valve area). Concomitant coronary artery bypass graft surgery procedure (CABG) was not 
associated or related to PWV value (correlation coefficient: 0.18, P = 0.17; P-value of the 
binary logistic regression: 0.13).  
 
 
Figure 4. 3 Difference in mean PWV between different age groups.  
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4.5.3 The relationship between pre-operative PWV and QoL outcomes 
With the EQ-5D questionnaire, the PWV-norm group had significantly better QoL scores 
than the PWV-high group in terms of the EQ-5D VAS (P < 0.001) and the EQ-5D index (P = 
0.03) at the baseline pre-operative assessment (Figure 4.4). The average scores of both groups 
on the EQ-5D VAS were markedly improved after surgery from 77 ± 10 to 88 ± 7 (P < 0.001) 
in the PWV-norm group and from 62 ± 10 to 75 ± 12 (P < 0.001) in the PWV-high group. In 
the EQ-5D index, the scores improved from 0.79 ± 0.12 to 0.97 ± 0.06 (P < 0.001) in the 
PWV-norm group and from 0.71 ± 0.18 to 0.78 ± 0.17 (P = 0.19) for the PWV-high group. 
The post-operative scores for the PWV-norm group continued to be significantly better than 
those of the PWV-high group (Figure 4.4).  
 
 
 
 
 
Figure 4. 4 Differences in the EQ-5D VAS and EQ-5D index scores between the PWV-norm and PWV-high 
groups pre- and post-operatively. 
Abbreviations: PWV: pulse wave velocity.  
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To identify which dimensions of the EQ-5D contributed most to this difference, 
binary logistic analysis was performed between patients who reported any problem in the five 
dimensions of the EQ-5D and those who did not in both groups. Binary logistic analysis 
revealed that only mobility (P = 0.02) and activity (P = 0.05) were significantly better in the 
PWV-norm group than the PWV-high group pre-operatively, which then changed to activity 
(P < 0.01) and pain or discomfort (P < 0.001), post-operatively (Table 4.2).  
 
In the SF-36 questionnaire, using the metric score, the PWV-norm group scored 
better than the PWV-high group in the physical health domains pre-operatively and in all 
health domains post-operatively (Table 4.3). Post-operatively, the PWV-norm group had 
improved in all SF-36 health domains either significantly or clinically, and similar findings 
were found in the PWV-high group with the exception of the GH and RE domains (Table 
4.3). Table 4.3 shows that there was a significant correlation between the pre- and post-
operative scores for the PF, RP, and VT domains. 
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Variables Pre-operative Post-operative 
 Total 
n = 56 
PWV-norm 
n = 35 
PWV-high 
n = 21 
P-value Total 
n = 50 
PWV-norm 
n = 30 
PWV-high 
n = 20 
P-value 
Mean ± standard deviation of 
different domains 
        
Mobility  1.41 ± 0.49 1.29 ± 0.45 1.62 ± 0.49 0.01 1.14 ± 0.35 1.0 ± 0.0 1.35 ± 0.48 <0.001 
Self-care 1.04 ± 0.18 1.0 ± 0.0 1.10 ± 0.30 0.06 1.04 ± 0.19 1.0 ± 0.0 1.10 ± 0.30 0.08 
Usual activity 1.45 ± 0.50 1.34 ± 0.48 1.62 ± 0.49 0.04 1.22 ± 0.46 1.03 ± 0.18 1.50 ± 0.60 <0.001 
Pain or discomfort 1.59 ± 0.53 1.54 ± 0.50 1.67 ± 0.57 0.40 1.32 ± 0.47 1.10 ± 0.30 1.65 ± 0.48 <0.001 
Anxiety or depression 1.41 ± 0.53 1.34 ± 0.53 1.52 ± 0.51 0.22 1.08 ± 0.27 1.03 ± 0.18 1.15 ± 0.36 0.14 
Patient distribution at 
different levels for each 
domain, n (%) 
        
Mobility    0.02    0.99 
No problem 33 (58.9) 25 (71.4) 8 (38.1)  43 (86) 30 (100) 13 (65)  
Any problem 23 (41.1) 10 (28.6) 13 (61.9)  7 (14) 0 (0.0) 7 (35)  
Self-care    0.13    0.99 
No problem 54 (96.4) 35 (100) 19 (90.5)  48 (96) 30 (100) 18 (90)  
Any problem 2 (3.6) 0 (0.0) 2 (9.5)  2 (4) 0 (0.0) 2 (10)  
Usual activity    0.05    <0.01 
No problem 31 (55.4) 23 (65.7) 8 (38.1)  40 (80) 29 (96.7) 11 (55)  
Any problem 25 (44.6) 12 (34.3) 13 (61.9)  10 (20) 1 (3.3) 9 (45)  
Pain or discomfort    0.57    <0.001 
No problem 24 (42.9) 16 (45.7) 8 (38.1)  34 (68) 27 (90) 7 (35)  
Any problem 32 (57.1) 19 (54.3) 13 (61.9)  16 (32) 3 (10) 13 (65)  
Anxiety or depression    0.12    0.17 
No problem 34 (60.7) 24 (68.6) 10 (47.6)  46 (92) 29 (96.7) 17 (85)  
Any problem 22 (39.3) 11 (31.4) 11 (52.4)  4 (8) 1 (3.3) 3 (15)  
Table 4. 2 The mean scores and patient distributions at different levels for each domain of the EQ-5D at pre- and post-operative stages. 
Bold values indicate statistical significance. Abbreviations: PWV: pulse wave velocity.  
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SF–36 Domains  Pre–operative Postoperative Mean 
difference 
Correlation Significance of 
correlation 
P–value** 
(improvement) 
Physical 
functioning 
PWV–norm 70 ± 16 85 ± 11 –15 ± 12 0.651 <0.001 <0.001 
PWV–high 54 ± 23 65 ± 23 –11 ± 17 0.731 <0.001 <0.01 
P–value* <0.01 <0.001     
Role–physical PWV–norm 68 ± 21 85 ± 15 –17 ± 18 0.497 <0.01 <0.001 
PWV–high 56 ± 19 68 ± 25 –12 ± 23 0.466 0.03 0.03 
P–value* 0.04 <0.01     
Bodily pain PWV–norm 81 ± 16 87 ± 15 –6 ± 20 0.179 0.34 0.09 
PWV–high 63 ± 21 73 ± 17 –10 ± 23 0.316 0.17 0.07 
P–value* <0.001 <0.01     
General health PWV–norm 70 ± 15 84 ± 13 –14 ± 12 0.603 <0.001 <0.001 
PWV–high 59 ± 15 64 ± 17 –5 ± 21 0.152 0.52 0.27 
P–value* 0.02 <0.001     
Vitality PWV–norm 58 ± 17 76 ± 14 –18 ± 17 0.394 0.03 <0.001 
PWV–high 51 ± 15 62 ± 13 –11 ± 14 0.497 0.02 <0.01 
P–value* 0.09 <0.01     
Social 
functioning 
PWV–norm 77 ± 23 95 ± 8 –18 ± 24 0.135 0.47 <0.01 
PWV–high 73 ± 22 85 ± 17 –12 ± 25 0.266 0.25 0.04 
P–value* 0.57 0.01     
Role–emotional PWV–norm 81 ± 21 94 ± 8 –13 ± 20 0.263 0.16 <0.01 
PWV–high 68 ± 29 77 ± 21 –9 ± 35 0.103 0.66 0.28 
P–value* 0.07 <0.001     
Mental health PWV–norm 77 ± 18 88 ± 8 –11 ± 17 0.287 0.12 <0.01 
PWV–high 72 ± 16 81 ± 11 –9 ± 17 0.287 0.22 0.03 
P–value* 0.53 <0.01     
Table 4. 3 The mean differences between pre- and post-operative SF-36 scores for PWV-norm and PWV-high groups. 
Bold values indicate statistical significance; *P-value is for the PWV-norm vs. PWV-high groups (independent-samples analysis); **P-value is for the pre-op vs. post-op groups (paired-samples 
analysis). Abbreviations: PWV: pulse wave velocity. 
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Further analysis using the NBS system (Figure 4.5) reveals that the pre-operative 
scores of the PWV-high group were below the average range for the general population 
(mean <47) in all domains except mental health, while only the PF, RP, and SF scores of the 
PWV-norm group were below the average range for the general population. Post-operatively, 
the QoL scores for both groups improved; however, the scores of the PWV-norm group were 
significantly better in all health domains (Figure 4.5).  
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Figure 4. 5 Changes in the pre- and post-operative score for each SF-36 domain (norm-based scores) for 
both the PWV-norm and PWV-high groups. 
Lateral P-value is for the PWV-norm vs. PWV-high groups (independent-samples analysis); central P-value is for 
the pre-op vs. post-op groups (paired-samples analysis). Abbreviations: PWV: pulse wave velocity; SD: standard 
deviation. 
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The association between the actual PWV measurements and the QoL component 
summaries was tested using Spearman’s correlation. Significant correlations were found 
between PWV and the EQ-5D index, EQ-5D VAS, and PCS scores at both the pre- and post-
operative stages (Table 4.4). These associations (point biserial correlation) became stronger if 
the PWV were categorized according to normal PWV reference values (PWV cut-off), 
particularly at the post-operative stage (Table 4.4).  
 
 
Variables EQ–5D 
index 
EQ–5D    
VAS 
SF–36 
PCS 
SF–36 
MCS 
PWV PWV 
cut–off  
 Pre–operative  
EQ–5D index 1      
EQ–5D VAS 0.329* 1     
SF–36 PCS 0.41** 0.52** 1    
SF–36 MCS 0.20 0.13 –0.10 1   
PWV –0.28* –0.34** –0.41** 0.04 1  
PWV cut–off –0.30* –0.55** –0.38** –0.08 0.71** 1 
       
 Post–operative 
EQ–5D index 1      
EQ–5D VAS 0.591** 1     
SF–36 PCS 0.70** 0.71** 1    
SF–36 MCS 0.40** 0.37** 0.30* 1   
PWV –0.57** –0.32* –0.41** –0.22 1  
PWV cut–off –0.61** –0.58** –0.49** –0.43** 0.71** 1 
Table 4. 4 Bivariate correlation matrix, Spearman’s rank-order correlation for the EQ-5D index, EQ-5D 
VAS, PCS (SF-36 physical component summary), MCS (SF-36 mental component summary), PWV, and the 
point biserial correlation for the PWV cut-off (PWV-norm vs. PWV-high). 
*Correlation is significant at the 0.05 level (2-tailed); **correlation is significant at the 0.01 level (2-tailed). 
Abbreviations: PWV: pulse wave velocity. 
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To identify any potential predictor to be entered into the multiple regression analysis, 
bivariate correlation was run between the following variables: SBP, diastolic blood pressure 
(DBP), mean arterial blood pressure (MAP), pulse pressure (PP), body mass index (BMI), 
diabetes mellitus (DM), hypertension, AVPG, AVMG, aortic valve area, ejection fraction, 
cholesterol level, triglyceride level, concomitant CABG, and the QoL components 
summaries. Significant correlation was only found between pre-operative EQ-5D VAS and 
aortic valve area, and between post-operative SF-36 PCS and cholesterol level. Therefore, the 
multiple regression analysis was conducting using only the classical variables of age and 
gender in additional to the PWV as predictors for the main components summaries of QoL 
outcomes.  
 
Multiple regression analysis (enter method) using PWV value as a continuous 
variable, and age and gender as predictors, revealed that PWV was an independent predictor 
of pre-operative PCS (P = 0.02) and EQ-5D VAS scores (P = 0.02), and post-operative PCS 
(P = 0.02), EQ-5D index (P < 0.01), and EQ-5D VAS scores (P = 0.05; Table 4.5). 
Furthermore, the same multiple regression analysis was repeated using PWV cut-off 
(dichotomous), age, and gender as predictors (Table 4.5); PWV (dichotomous) is the only 
independent predictor for QoL outcomes at both pre- and post-operative stages (with the 
exception of pre-operative MCS). ANCOVA analysis revealed that after adjustment for pre-
operative QoL score, there was a statistically significant difference in post-operative QoL 
score between the two PWV groups (Table 4.6). 
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Analysis Variable 
Pre–operative Post–operative 
EQ–5D 
index 
 
EQ–5D 
VAS 
 
PCS 
 
MCS A 
 
EQ–5D 
index 
 
EQ–5D 
VAS A 
 
PCS B 
 
MCS A 
 
Regression 
(beta) 
(Model 1) 
PWV –0.21 –0.35* –0.36* –0.02 –0.59** –0.30* –0.32* –0.17 
Age –0.05 0.15 –0.09* –0.06 0.16 0.10 0.07 0.10 
Gender 0.06 0.16 0.04 –0.15 0.03 0.23 0.23 0.26 
          
Regression 
(beta) 
(Model 2) 
PWV 
cut-off 
–0.27* –0.54** –0.35** –0.11 –0.68** –0.53** –
0.44** 
–0.37** 
Age –0.13 0.04 –0.24 0.09 –0.08 –0.02 –0.06 0.03 
Gender 0.05 0.11 0.03 0.13 0.004 0.18 0.21 0.21 
Table 4. 5 Standardized beta coefficients from the multiple regression analysis using PWV, age, and gender 
as predictors of QoL outcomes. 
*P < 0.05, **P < 0.01; only significant variables from the bivariate correlation, in addition to age and gender, were 
included in this multiple regression (enter method) analysis. Model 1 includes PWV value as a continuous 
predictor; Model 2 includes PWV cut-off as a dichotomous predictor; Asquare root transformation; Blog 
transformation. Abbreviations: PWV: pulse wave velocity; VAS: visual analogue scale; PCS: physical component 
summary; MCS: mental component summary. 
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Dependent 
variables 
 Independent variables 
 
QoL Domains  PWV cut–off Age Gender 
 
EQ–5D index 
[beta (95% CI)] 
Pre–op. –0.27 (–0.13/0.00) * –0.13(–0.005/0.002) 0.05 (–0.05/0.08) 
Post–op. –0.68 (–0.22/–0.11) 
** 
–0.08 (–0.004/0.002) 0.004 (–0.05/0.06) 
ANCOVA F 23.73
** 1.79 0 
ƞp2 0.75 0.85 0 
     
 
EQ–5D VAS 
(beta [95%CI]) 
Pre–op. –0.54 (–19.84/–7.85) 
** 
0.04 (–0.28/0.39) 0.11 (–3.19/9.58) 
Post–op. A –0.53 (–0.81/–2.22) 
** 
–0.02 (0.37/–0.04) 0.18 (1.34/–0.20) 
ANCOVA 
F 24.63** 6.97** 7.7* 
ƞp2 0.75 0.95 0.49 
     
 
PCS 
(beta 95%CI]) 
Pre–op. –0.35 (–10.72/–1.70) 
** 
–0.24 (–0.50/–0.01) 0.03 (–4.20/5.39) 
Post–op. B –0.44 (–0.10/–0.41) 
** 
–0.06 (0.007/–0.011) 0.21 (0.29/–0.04) 
ANCOVA 
F 16.14** 2.85 1.46 
ƞp2 0.67 0.89 0.15 
     
 
MCS 
(beta [95%CI]) 
Pre–op. A –0.11 (0.46/–1.03) 0.09 (0.05/–0.03) 0.13 (1.16/–0.41) 
Post–op. A –0.37 (–0.18/–1.15) 
** 
0.03 (0.03/–0.02) 0.21 (0.95/–0.11) 
ANCOVA F 0.76 2.45 0.59 ƞp2 0.08 0.88 0.06 
Table 4. 6 Standardized beta coefficients from the multiple regression analysis using PWV cut-off, age, and 
gender as predictors for QoL outcomes, in addition to the results of the ANCOVA analysis. 
*P < 0.05, **P < 0.01. ANCOVA analysis was used to test the predictors of the post-operative QoL scores after 
adjustment to the baseline pre-operative scores as a covariate; Asquare root transformation; Blog transformation.  
Abbreviations: QoL: quality of life; CI: confidence interval; ANCOVA: analysis of covariance; VAS: visual 
analogue scale; PCS: physical component score; MCS: mental component score.  
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4.5.4 Post-operative PWV and its relationship with post-operative QoL 
The effect of AVR on PWV was also examined by assessing the change in PWV at the 
follow-up visit. Over the follow-up period there was slight increase in PWV measurement, 
which was not significant (mean PWV was 9.3 ± 2.2 vs. 9.6 ± 1.9 m/s, P = 0.275). Only three 
patients (14.3%) from the PWV-high group showed a change in their category to PWV-norm 
and three patients (8.5%) from the PWV-norm group changed to the PWV-high group. In 
order to rule out post-operative medications having an effect on the difference in QoL 
between the two PWV groups, medication history was recorded at the follow-up visit. There 
was no significant difference between the PWV-norm and PWV-high groups (Pearson chi-
square) with respect to the use of aspirin (P = 0.53), warfarin (P = 0.48), statins (P = 0.22), 
beta blockers (P = 0.34), or angiotensin converting enzyme (ACE) inhibitors (P = 0.07), 
Table 4.7. In addition, there was no significant difference in the main cardiac characteristics 
(AVPG and left ventricle function) between the two groups (Table 4.7). Unlike pre-
operatively, two hemodynamic indices (SBP and PP) were significantly different between the 
PWV-norm and PWV-high groups (P = 0.03 and < 0.01, respectively; Table 4.7).  
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Parameter Total 
n = 50 
PWV-norm 
n = 30 
PWV-high 
n = 20 
P-value 
Male 36 (72%) 24 (80%) 12 (60%) 0.12 
Age (years) 
 
71 ± 8 71 ± 8 71 ± 8 0.64 
BMI (kg/m2) 27.3 ± 4.2 27.1 ± 4.3 27.7 ± 4.1 0.62 
SBP (mmHg) 134 ± 14 130 ± 14 140 ± 13 0.03 
DBP (mmHg) 75 ± 9 75 ± 10 75 ± 9 0.61 
PP (mmHg) 60 ± 12 55 ± 10 66 ± 13 <0.01 
MAP (mmHg) 95 ± 9 94 ± 10 96 ± 8 0.36 
Aspirin [n (%)] 35 (70%) 20 (66.7%) 15 (75%) 0.53 
Warfarin [n (%)] 12 (24%) 6 (20%) 6 (30 %) 0.48 
Beta blockers [n (%)] 31 (62%) 17 (56.7%) 14 (70%) 0.34 
Statin treatment [n (%)] 38 (76%) 21 (70%) 17 (85%) 0.22 
ACE inhibitor [n (%)] 20 (40%) 9 (30%) 11 (55%) 0.07 
AVPG  24 ± 8 24 ± 8 24 ± 8 0.77 
LV function (good)  38 (88%) 22 (58%) 16 (42%) 0.63 
PWV 9.6 ± 1.9 8.8 ± 1.5 10.9 ± 1.8 <0.001 
Table 4. 7 Post-operative clinical characteristics.  
Values are shown as n (%) for categorical variables and the mean ± standard deviation for continuous 
variables. Abbreviations: BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood 
pressure; PP: pulse pressure; MAP: mean arterial blood pressure; ACE: angiotensin converting enzyme; 
AVMG: aortic valve peak gradient; PWV: pulse wave velocity; LV: left ventricle.  
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To examine if these hemodynamic measures are associated with post-operative QoL, a 
bivariate correlation of the post-operative QoL component summaries, PWV, and PWV cut-
off and these significant hemodynamic measurements were performed (Table 4.8). While 
significant correlations were found between PWV value and all QoL component summaries, 
which is even stronger if the PWVs were categorized into PWV-norm vs. PWV-high (PWV 
cut-off), SBP and PP were not significantly correlated with the QoL component summaries 
(Table 4.8). 
 
Post–operative 
Variables 
EQ–5D 
index 
EQ–5D    
VAS 
SF–36 
PCS 
SF–36 
MCS 
PWV PWV 
cut–
off  
SBP PP 
EQ–5D index 1        
EQ–5D VAS 0.59** 1       
SF–36 PCS 0.71** 0.71** 1      
SF–36 MCS 0.39** 0.37** 0.31* 1     
PWV –0.35* –0.35* –0.42** –0.35* 1    
PWV cut–off –0.43** –0.44** –0.40** –0.48** 0.67** 1   
SBP –0.18 –0.23 –0.18 –0.21 0.43** 0.32* 1  
PP –0.36* –0.27 –0.28 –0.08 0.49** 0.36* 0.77** 1 
Table 4. 8 Bivariate correlation matrix for the post-operative QoL component summaries, PWV, PWV cut-
off, and the significant hemodynamic measurements. 
*Correlation is significant at the 0.05 level (2-tailed); **correlation is significant at the 0.01 level (2-tailed). 
Abbreviations: VAS: visual analogue scale; PCS: physical component summary; MCS: mental component 
summary; PWV: pulse wave velocity; SBP: systolic blood pressure; PP: pulse pressure. 
 
 
To confirm which of the post-operative hemodynamic measurements (PWV value, 
PWV cut-off, SBP, and PP) is significantly related to (and therefore predictive of) post-
operative QoL component summaries, multiple regression analysis was conducted (stepwise 
method). In the first multiple regression analysis using PWV value (continuous variable), PP 
(as it is a better blood pressure index than SBP from the correlation analysis), age, and gender 
as predictors, PWV was an independent predictor of the EQ-5D VAS scores and PCS, while 
PP and gender were independent predictors for the EQ-5D index and MCS, respectively 
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(Table 4.9). Furthermore, the same multiple regression analysis was repeated using PWV cut-
off (dichotomous), PP, age, and gender as predictors (Table 4.9), which revealed that PWV 
cut-off was an independent predictor for all QoL outcomes, while PP was an independent 
predictor for EQ-5D index only (Table 4.9). 
 
Dependent 
variables 
 Independent variables 
(Post–operative) 
Post–operative 
QoL Domains 
PWV PP Age Gender 
 
EQ–5D index 
(beta [95%CI]) 
NS –0.43 
(–0.007/–0.002) ** 
NS NS 
EQ–5D VAS A 
(beta [95%CI]) 
–0.32 
(–0.027/–0.44) * 
NS NS NS 
PCS B 
(beta [95%CI]) 
–0.38 
(–0.015/–0.099) ** 
NS NS NS 
MCS A 
(beta [95%CI]) 
NS NS NS 0.29 
(1.13/0.01) * 
     
QoL Domains PWV cut–off PP Age Gender 
 
EQ–5D index 
(beta [95%CI]) 
–0.35 
(–0.15/–0.20) * 
–0.31 
(–0.006/0.00) * 
NS NS 
EQ–5D VAS A 
(beta [95%CI]) 
–0.45 
(–0.51/–2.06) ** 
NS NS NS 
PCS B 
(beta [95%CI]) 
–0.37 
(–0.05/–0.38) * 
NS NS NS 
MCS A 
(beta [95%CI]) 
–0.45 
(–0.319/–1.288) ** 
NS NS NS 
Table 4. 9 Multiple regression analysis using post-operative PWV, PP, age, and gender as predictors for 
post-operative QoL outcomes. 
*P < 0.05, **P < 0.01; Asquare root transformation; Blog transformation. Abbreivations: PWV: pulse wave 
velocity; PP: pulse pressure; CI: confidence interval; VAS: visual analogue scale; NS: not significant; QoL: 
quality of life. 
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4.6 Discussion 
Our data has confirmed what has been previously published: there is a significant relationship 
between aortic stiffness and age. Interestingly, before patients were divided into two groups, 
the mean aortic PWV for each age group was not higher than their respective European 
reference value; however, 21 (37.5%) of the 56 patients had abnormal PWV according to the 
same reference values [89], which represented the group of interest in this study. The number 
of studies investigating the relationship between PWV and aortic valve disease is very limited 
[85, 209], and include no post-operative data and provide inconsistent findings, and none are 
from Europe. Our study found no significant relationship between aortic PWV and surgical 
AS in terms of AVMG, AVPG, or aortic valve area (Table 4.1), which supports the 
hypothesis that AS is an isolated pathology that is not directly associated with aortic wall 
changes, unlike the relationship between aortic stiffness and coronary arteries disease [90]. 
The absence of any association between PWV and the degree of stenosis in this particular 
study makes the findings between PWV and QoL more reliable; if this were not the case, any 
difference in QoL between the PWV-norm and PWV-high groups pre-operatively might have 
been attributed to the degree of valve stenosis.  
 
Of note, there was no significant difference between the PWV-norm and PWV-high 
groups in terms of routine standard non-invasive hemodynamic measurements (SBP, DBP, 
MAP, and PP). This highlights the fact that such classical CV assessment tools are not the 
best parameters to reflect actual vascular wall status [176]. Certain risk factors such as 
bicuspid aortic valve, diabetic and hypertension correlate with aortic stiffness (Chapter 1), 
however, the aim of this study was to explore the relationship between aortic stiffness and 
QoL regardless the aetiology of this high PWV. Though our sample size was not large enough 
to assess the effect of classical risk factors on the relationship between PWV and QoL. 
Nevertheless, the lack of significant differences in clinical characteristics, including bicuspid 
valve and standard risk factors such as diabetes and hypertension was beneficial in our study, 
and may add to previously published evidence that PWV measurements constitute a superior 
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method of assessing the CV system than clinical risk factors or functional hemodynamic 
measurements.       
 
Only two studies from the UK and the Netherlands have investigated the relationship 
between PWV and QoL or functional status [300, 321], and their findings were contradictory. 
Our study represents the first data regarding this specific relationship in AS.  Pre-operatively, 
there was a significant relationship between higher PWV values and poorer QoL scores in 
terms of mobility, activity, and EQ-5D VAS and EQ-5D index of the EQ-5D health 
questionnaire, and in the PF, RP, BP, GH, and PCS components of the SF-36. In fact, the 
mean PCS of the PWV-high group was approximately one SD below the mean of the general 
population (Figure 4.6). These findings are similar to the aforementioned UK study 
performed in the generally healthy population [300]. Post-operatively, as anticipated, both 
groups improved either significantly or clinically in almost all health domains compared to 
baseline pre-operative scores. However, the mean degree of improvement for the QoL 
measurements was higher for the PWV-norm group in all QoL domains, with the exception of 
the EQ-5D VAS and BP domains. This means that the differences in the QoL scores between 
the two groups were even larger post-operatively in favor of the PWV-norm group. This 
difference in QoL outcomes according to the PWV value was supported by the results of the 
bivariate correlation analysis, which revealed a significant association between PWV values 
as a measure of aortic stiffness and the main components summaries of EQ-5D index, EQ-5D 
VAS, and PCS component, which were stronger post-operatively (Table 4.4).  
 
Finally, to test whether aortic stiffness as assessed by PWV could predict QoL 
outcomes pre- and post-AVR, multiple regression analysis revealed that aortic stiffness was 
related to the main physical indices both pre- and post-operatively (Table 4.6).  Though our 
sample size was enough to produce significant statistical difference and larger than some 
other relevant studies [209, 211, 212], it was not large enough for multiple regression models 
that include more than 4-5 independent variables, however, in our sample, we did not need 
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more than such number of variables to be included based on correlation analysis. In a further 
multiple regression analysis, we added the aortic valve mean gradient to this model as an 
index of AS severity, this did not change the result significantly (data not shown). After the 
multiple regression analysis proved the relationship between PWV and QoL, ANCOVA 
analysis was performed to test this relationship after the post-operative QoL score was 
adjusted to the baseline pre-operative score (Table 4.6). This confirmed the significant 
relationship between pre-operative PWV and post-operative QoL, which indicated that 
individuals with a normal PWV are expected to have a greater improvement in their QoL 
after AVR relative to patients with high PWV values. 
 
 In case the relationship between pre-operative PWV and QoL (pre- and post-
operatively) is affected by AVR and other post-operative factors, statistical analysis was 
carried out on the relationship between pots-operative QoL and post-operative PWV. The pre-
operative absence of association between AS and aortic wall stiffness was confirmed by the 
absence of effect of AVR on aortic stiffness (post-operative PWV). Over the follow up period 
there was slight increase in PWV measurement, which was not significant (mean PWV was 
9.3± 2.2 vs. 9.6 ± 1.9 m/s, P = 0.275); this may be due to slow, progressive aortic wall 
stiffening over more than a 1-year period. We also assessed if the difference in post-operative 
QoL between the two PWV groups was due to the differences in medications taken, and we 
found no significant difference between the two groups in this regard. Interestingly, and 
unlike the pre-operative situation, two post-operative hemodynamic indices (SBP and PP) 
were significantly different between PWV-norm and PWV-high groups, and were 
significantly correlated with PWV. However, these BP indices did not correlate well with 
QoL outcome, while post-operative PWV (particularly the PWV cut-off) independently 
predicted QoL outcome. This may be of special significance in the sense that even when 
classical hemodynamic indices are strongly correlated with aortic stiffness, PWV is a superior 
predictor of QoL outcome. The significance and predictive value of PP has been reviewed in 
detail in Chapter 1 (section 1.1.2.3). A possible explanation for why BP indices did not 
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correlate pre-operatively but correlated post-operatively with PWV is the presence of aortic 
stenosis, which could have attenuated classical BP parameters. 
 
Strengths 
This study was conducted using PWV measurements, which is the gold standard method for 
assessment of aortic stiffness. To the best of our knowledge, this is the first study to 
investigate the relationship between PWV as a measure of aortic stiffness and QoL outcomes 
in AVR, particularly in a European population. PWV has the advantage of comprehensive 
follow-up data that enables the analysis of QoL changes over time in relation to independent 
predictors. Additionally, it increases the data that correlates aortic stiffness and QoL, but in a 
disease-specific population. Although these findings may not change clinical practice at 
present, they provide strong preliminary data for future investigations that will test the use of 
PWV as a pre-operative predictor of post-operative outcomes. 
 
Limitations 
Some may argue about the very specific disease population that was studied, and that it would 
be better if we had involved coronary bypass surgery patients to explore the study objectives 
in this important surgical group. Unfortunately, the resources available to study the 
relationship between PWV and QoL were limited to the number of patients enlisted, and we 
decided to include AS patients alone for two main reasons: 1) to assess whether aortic valve 
pathology was related to aortic wall pathology; and 2) to reduce the number of confounding 
factors that affect QoL, such as myocardial pain and left ventricular function. We were unable 
to identify any demographic or clinical variable that could explain the difference in PWV 
values that existed between the two groups. However, this may have been a consequence of 
the relatively small number of patients studied or of certain biological factors that we did not 
investigate. Therefore, future studies investigating the role of such factors, including tumor 
necrosis factor alpha, high sensitivity C-reactive protein, plasminogen activator inhibitor-1, 
and elastin-derived peptide, are needed [322, 323]. 
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4.7 Conclusion and potential future implications 
This study suggests that there is no relationship between AS and aortic wall stiffness, and that 
AVR has no effect on aortic stiffness post-operatively. This study confirms the improvement 
in QoL following AVR for AS, and that such improvement might be predicted by aortic 
stiffness status. Patients with surgical AS and high PWV values are associated with poorer 
QoL scores both pre- and post-AVR. This study also demonstrates that the recently published 
European PWV reference values can be used to identify the group of patients with abnormal 
PWV. This is the first study to demonstrate a significant relationship between aortic stiffness 
and patient-reported functional status in AVR both pre- and post-operatively, and thus adds 
new predictive and clinical applications to PWV measurement. Aortic PWV is a predictor of 
cardiovascular disease and outcomes in different diseased and healthy populations, adding 
more dependent variables (such as functional outcome) that can be predicted by or associated 
with PWV can increase the clinical applications of such measurement.  Further research into 
the relationship between PWV and post-operative outcomes particularly the functional 
outcome in larger sample and in other disease-specific populations is now required to 
evaluate its potential use as a marker for post-operative outcome and its inclusion in operative 
risk stratification systems. 
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5 Chapter 5 
The relationship between aortic pulse wave velocity and 
cognitive function in aortic valve replacement 
 
This chapter investigates the question of whether there is a relationship between aortic 
stiffness and cognitive function pre- and post-aortic valve replacement (AVR). 
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5.1 Abstract 
Background: Previous studies have linked cardiac surgery to post-operative cognitive 
dysfunction (POCD), which seems to occur more commonly after valve surgery. Cognitive 
function is related to vascular health status; however, the relationship between pre-existent 
arterial stiffness and perioperative cognitive dysfunction has yet to be defined. 
 
Objectives: We hypothesized that aortic stiffness is related to pre-operative cognitive 
function in aortic valve replacement (AVR) patients and may predict post-operative cognitive 
dysfunction. 
 
Methods: Between June 2010 and August 2012, patients undergoing aortic valve replacement 
(AVR) were selected for inclusion. Aortic pulse wave velocity (PWV) was used as a measure 
of aortic stiffness, and cognitive function was assessed using the computerized Cambridge 
Neuropsychological Test Automated Battery (CANTAB) pre-operatively and post-AVR (409 
± 159 days). We analyzed PWV using two methods: 1) as a continuous variable (PWV) using 
the actual value; and 2) as a dichotomous variable (PWV-norm and PWV-high groups) based 
on the published normal reference values per age group. 
 
Results: Fifty-six patients (16 females, mean age of 71 ± 8.4 years) were recruited and 50/56 
(89%) patients completed the post-operative follow-up. Demographic details were similar 
between PWV-norm (n = 21) and PWV-high (n = 35) groups, with no significant relationship 
between PWV and degree of AS. Pre- and post-operatively, the performance of the PWV-
norm group was significantly better with respect to delayed memory, sustained visual 
attention, and executive function components, while immediate memory and decision-making 
components of the cognitive battery showed no significant differences. Interestingly, there 
was no deterioration in cognitive function after AVR; in fact, there was greater improvement 
(both non-significant and significant) in most of the components of the cognitive function test 
in the PWV-high group than in the PWV-norm group. Significant bivariate correlations were 
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found between PWV (continuous) or PWV cut-off (dichotomous) and all the main 
components of cognitive function at both the pre- and post-operative stages. 
 
In two multiple regression analysis models, PWV as a continuous variable was an 
independent predictor of all pre-operative cognitive components and post-operative executive 
function component, while PWV cut-off was an independent predictor of pre- and post-
operative cognitive function. 
 
Conclusion: AS patients with higher pre-operative aortic stiffness have significantly 
worse pre- and post-surgical cognitive function. Furthermore, valve replacement surgery may 
not be associated with a decline in cognitive function and patients with higher aortic stiffness 
may achieve a greater functional cognitive benefit from surgical intervention. 
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5.2 Introduction 
5.2.1 Cerebral injury in cardiac surgery 
The etiology of post-cardiac cerebral injury is multifactorial and may be related to both pre-
operative risk factors as well as to one or more operative factors [324, 325], such as: 
 
5.2.1.1 Systemic inflammatory response syndrome 
Cardiac surgery is associated with a significant risk of systemic inflammatory response 
syndrome (SIRS) particularly if cardiopulmonary bypass (CPB) is used. Contact of blood 
components with the artificial surfaces of the bypass circuit, cardiac arrest, and the 
reperfusion process are considered the main causes of this inflammatory response [326, 327]. 
These factors stimulate the inflammatory system to produce vasoactive and cytotoxic 
substances, which results in increased capillary permeability, interstitial fluid, and 
inflammatory cell infiltration into different organs, including the brain. 
 
5.2.1.2 Macro- and microembolization 
Generally, emboli can be categorized as macroemboli and microemboli. Macroemboli 
occlude arteries larger than 200 µm in diameter, whereas microemboli occlude smaller 
arteries, arterioles, and capillaries [328]. Emboli include gaseous and particulates, such as 
lipid or clotting particulates, which result from the complex surgical techniques that involve 
CPB, including manipulating atherosclerotic or calcified aorta, activating the coagulation 
system, production of surgical debris, and post-operative atrial fibrillation. The clinical 
impact and outcome of these emboli depend on their number, size, and nature. While 
macroemboli may cause apparent clinical presentation, such as stroke or peripheral ischaemia, 
microemboli usually manifest as end-organ injury or dysfunction, such as renal injury or 
neuropsychological impairment. 
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5.2.1.3 Hypoperfusion 
Periods of low mean perfusion pressure during cardiac surgery can contribute to the 
development of cerebral injury. Older patients with associated risk factors like diabetes and 
hypertension are at higher risk of hypoperfusion injury because of impaired cerebral vascular 
autoregulation. This might be why higher perfusion pressures during coronary artery bypass 
(CABG) surgery have been associated with reduced neurological adverse outcomes in 
patients with severe aortic atherosclerosis [329]. 
 
All of the aforementioned mechanisms of cerebral injury are more prominent in older 
patients with cerebrovascular risk factors due to pre-existent cerebral and systemic vascular 
disease and weak vascular autoregulation responses [330-338]. However, randomized trials 
comparing post-operative cognitive dysfunction (POCD) between on-pump and off-pump 
CABG show conflicting results, which renders the effects of CPB on cognitive function 
controversial [335, 338-342]. 
 
5.2.2 Types of neurocognitive dysfunction 
Generally, neurocognitive complications after cardiac surgery can be classified into two 
categories [343, 344]: type I adverse outcomes, which include stroke, transient ischaemic 
attack (TIA), coma, and stupor; and type II adverse outcomes, which include any new 
deterioration in intellectual function, including confusion, agitation, disorientation, memory 
deficit, and neurocognitive dysfunction (NCD). Type I complications are caused by specific 
focal cerebral injury; therefore, diagnosis is achieved through routine clinical and 
radiographic examinations. Conversely, type II injuries are due to more diffuse or systemic 
insults and are much more common and transient than type I injuries. 
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5.2.2.1 Stroke and transient ischaemic attack 
Stroke is the sudden death of brain cells due to a lack of oxygen supply caused by blood flow 
impairment (due to either blockage or rupture of the feeding artery) resulting in a clinically 
apparent focal neurological deficit [345]. The neurological deficit depends on the site and 
severity of the stroke. This new deficit may be permanent or transient (as in TIA). Stroke is 
the most common outcome of type I neurocognitive injury with an estimated incidence after 
cardiac surgery of 1–5% [343, 346, 347]. The socioeconomic impact of stroke is significant: 
it is associated with a 10-fold increase in mortality and substantial increases in hospital stay 
and the use of intermediate- or long-term care facilities [343]. Embolization from the 
atheromatous aorta may be the most important causative factor for stroke in post-cardiac 
surgery patients [348]. This type of complication is clinically easy to diagnose and is 
confirmed by radiological tests. 
 
5.2.2.2 Cognitive dysfunction 
A simple description of cognition (or mental activity) is the acquisition, storage, 
transformation, and use of knowledge [349]. It is a complex process that involves interactions 
between different parts of the brain, particularly the hippocampus. The hippocampus is where 
the main fractions of memory are located, and it is considered to be a hypoxia-sensitive area 
[350]. Cognitive dysfunction can affect different cognitive domains, such as attention, 
memory, learning, executive function, and visual spatial, or it can be manifested as a 
behavioral change. In spite of the absence of a focal neurological deficit, cognitive 
dysfunction is associated with higher mortality and morbidity and has a significant impact on 
socioeconomic cost. It is associated with a 5-fold increase in mortality, prolonged intensive 
care and hospital stay, reduced quality of life (QoL) and employment, and a significant need 
for sociomedical care following discharge [343, 351]. 
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While post-operative stroke is a distinct clinical entity with clinical and radiological 
criteria, cognitive impairment is less definite and its detection is mainly dependent on detailed 
neurocognitive assessment. Cognitive assessment is currently regarded as the ‘gold standard’ 
for the investigation of post-operative cognitive impairment [352]. However, such 
assessments present some practical issues, including being time-consuming and laborious for 
the patient and examiner; therefore, identifying a clinical or biochemical measurement that 
can act as a marker for cognitive function would be clinically important and useful [330, 331]. 
In this study we employed the Cambridge Neuropsychological Test Automated Battery 
(CANTAB) to assess this endpoint. 
 
5.2.3 Cognitive dysfunction after cardiac surgery 
Over recent decades we have seen a significant decline in morbidity and mortality after 
cardiac surgery such that these outcomes are no longer always the optimal goals by which to 
measure operative success. Symptomatic and functional outcomes, including cognitive 
function, have therefore become of increasing importance. 
 
The majority of studies have reported deterioration in cognitive function after cardiac 
surgery [332, 337, 353-357]. In the UK, the incident of new stroke is about 1% in isolated 
CABG and 1.9% in isolated AVR as documented in the Sixth National Adult Cardiac 
Surgical Database Report 2008. Post-CPB neuropsychological/cognitive dysfunction is even 
higher, and include, for example, delirium (10% to 30%), short-term (33% to 83%), and long-
term cognitive changes (20% to 60%) [358]. The incidence of cognitive dysfunction is higher 
in valve surgery than in isolated CABG [358]. 
 
However, other recent studies demonstrated no decline or improvement in cognitive 
function post-operatively [340, 342, 359, 360]. Selnes et al. found, compared to the baseline, 
no significant difference in the cognitive function 72 months after CABG with or without 
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CPB, indicating that management strategy for CAD is not an important determinant of long-
term cognitive outcomes [340]. In fact, some pre-operative factors, such as anxiety, 
depression, and stress, that are related to cardiac symptoms and the planned major surgery 
[361, 362] may reduce pre-operative cognitive function, particularly memory; therefore, 
elimination of these factors should ideally improve post-operative cognitive function. 
 
Whether there is deterioration in cognitive function following cardiac surgery or not 
is a very difficult question with no definite answer. The long list of research studies on this 
topic likely adds more questions as opposed to answering them. The lack of a universal 
definition of POCD and a standardized test battery, the heterogeneity of patient and 
population characteristics, cognitive test timing, and bias in methodology toward preferred 
common answers have all led to different and conflicting findings. Therefore, we believe that 
more disease-specific populations, better homogeneous patient characteristics, robust 
cognitive test modalities, and longer follow-up re-assessment may significantly help answer 
the above question [340, 363] [342]. 
 
5.2.4 How to measure cognitive function 
Cognitive function can only be measured by neuropsychological tests. To date, there are no 
biomarkers or neuroimaging tests to measure cognitive function. Cognitive tests are sensitive 
and objective tools designed to quantify cognitive performance of the different cognitive 
domains, such as general intellectual function, memory, orientation, attention/concentration, 
decision-making, and executive function [363]. There is a long list of cognitive tests that have 
been developed by different groups for different purposes (e.g., general, disease-specific, and 
drug effect monitoring). Unfortunately, there are no agreed upon universal test batteries that 
should be used for the diagnosis of POCD. Different studies have used various 
neuropsychological tests, with each test reflecting different cognitive domain and brain 
location, and use different definitions for POCD, which makes pooling and meta-analysis of 
 179 
these data difficult [363]. The most commonly used and suggested neuropsychological tests 
are [363-366]: 
 
 Digit Span: a test of working memory. 
 Digit Symbol Substitution: a test of working memory and information processing 
speed. 
 Rey Auditory Verbal Learning: a test verbal learning, recall, and recognition. 
 Trial Making: a test of visual attention and task switching. 
 Grooved Peg Board: a test of manual dexterity and psychomotor coordination. 
 Letter-digit coding: speed of information processing test. 
 Boston Naming: a test of word finding ability. 
 Stroop-word Interference: a test of attention, concentration, and executive function. 
 
The definition of POCD is also an issue, as different definitions yield different results. 
The most popular definitions of POCD are [363, 367]: 
 
 The 20-20 rule: POCD is diagnosed when post-operative score is less than the 
baseline score by more than 20% of the baseline score in 20% of the 
neuropsychological tests (usually two or more tests). 
 The 1SD rule: POCD is diagnosed when post-operative performance declined greater 
than or equal to 1SD of the baseline performance for that group on that task (usually 
two or more tests). 
 The combined Z score: By calculating the combined Z score for all tests per patient 
divided by the SD of this summation in the control group. POCD is then defined as a 
combined Z score of less than 2, or two or more Z scores for single tests of less than 2. 
 
As before, there are pros and cons of each method; therefore, an alternative method of 
analyzing the results as continuous variables has been suggested [363]. 
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Classically, neuropsychological/cognitive tests are paper-based and are either written 
or orally administered to assess different aspects of an individual’s cognitive function. These 
paper-based tests require a trained administrator and language competency, and are prone to 
operator error and bias. In addition, subtle cognitive changes can easily be missed. Computer-
based tests eradicate all of these limitations with superior precision for measuring responses 
and reaction times [363, 368]. 
 
5.2.5 Cambridge Neuropsychological Test Automated Battery 
The Cambridge Neuropsychological Test Automated Battery (CANTAB) is a laptop-based, 
computerized, non-linguistic, and culturally independent cognitive test that was developed by 
an expert team at the University of Cambridge (http://www.cantab.com/) [369]. CANTAB is 
non-verbal; language competence is only required to understand the explanation of 
instructions prior to task launch. The CANTAB system has 22 tests, two of which are 
introductory warm-up tests that familiarize the participant with the operating system and 
method of response using a touch-sensitive screen (Figure 5.1). The remaining are 
neuropsychological tests that are categorized into: 1) visual memory; 2) executive function; 3) 
attention; 4) semantic/verbal memory; and 5) decision-making and response control. 
 
CANTAB can assess the cognitive functioning of specific areas in the brain 
depending on the test performed [370, 371]. It has been validated in imaging studies [372] 
and has been used in routine clinical setting in some centers for screening and follow-up of 
neuropsychological abnormalities [373]. In addition to its strong psychometric properties and 
non-verbal nature, CANTAB may have a greater detecting power for subtle or marginal 
cognitive deficits than classical clinical or paper-based measures because it is a computerized 
battery that automatically and accurately captures response times and errors. To our 
knowledge, none of the previous studies on cognitive dysfunction in cardiac patients were 
conducted using this highly sophisticated computer-based cognitive battery (CANTAB). 
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Figure 5. 1 Illustration of some of the CANTAB tests. 
 
5.2.6 Pulse wave velocity 
Pulse wave velocity (PWV) is a measure of the pattern of blood flow through a vessel; it 
reflects the functional elastic properties and structural integrity of the vessel wall, referred to 
as the ‘arterial stiffness’. Structural damage to the vessel wall results in an increase in vessel 
stiffness and PWV. Carotid-femoral PWV is the ‘gold standard’ measure of arterial stiffness 
and is the most validated and widely used method to assess the quality of the aorta [12, 14, 87, 
89]. 
  
The Reference Values for Arterial Stiffness’ Collaboration published in 2010 
provides reference and normal values for PWV based on more than 16,000 subjects from 
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eight European countries [89]. The availability of these reference values makes it conceivable 
to investigate the relationship between arterial stiffness and other end points in different 
disease-specific populations. Detailed background of aortic stiffness and PWV and their 
predictive value are discussed in Chapter 1. 
 
5.2.7 PWV and cognitive function 
High PWV is significantly associated with cerebral small-vessel disease and cognitive 
function impairment and decline in the elderly [374-376]. Furthermore, arterial stiffness has 
recently been linked to poorer cognitive function or cognitive decline in both the general 
population and hypertensive patients [377-381]. In 2011, the statement for healthcare 
professionals from the American Heart Association and American Stroke Association about 
the vascular contributions to cognitive impairment and dementia stated: “Carotid intimal-
medial thickness and arterial stiffness are emerging as markers of arterial aging and may 
serve as risk markers for VCI (vascular cognitive impairment)” [382]. However, to our 
knowledge, no study has been performed assessing the relationship between PWV and 
cognitive function in cardiac surgery patients or has utilized an accurate computer-based 
cognitive battery (CANTAB) for cognitive assessment. 
 
5.2.8 Objectives 
In summary, previous studies have linked cardiac surgery to POCD, and it seems to occur 
more commonly after valve surgery. At the same time, cognitive function is related to 
vascular health status. However, the question of how much pre-existent aortic stiffness can be 
attributed to perioperative cognitive dysfunction in cardiac patients has not previously been 
studied. Therefore, we hypothesize that aortic stiffness measured with PWV may be an 
indicator of pre-existing pre-operative cognitive dysfunction in AS patients and may predict 
cognitive function following AVR. 
 
 183 
5.3 Materials and methods 
5.3.1 Patient population and an overview 
Ethical approval and participant informed consent were obtained prior to study. Between June 
2010 and August 2012, patients who planned to undergo AVR were eligible. Patients with: 1) 
aortic dissection; 2) emergency cases; 3) thoracic aorta (more than just the root) or abdominal 
aortic aneurysm; 4) Marfan’s syndrome; 5) any psychiatric or significant neurological 
condition; 6) a history of taking any regular medication for mental illness including 
antidepressants; or 7) a Mini Mental State examination score below 25 points were excluded 
from this study. All included patients were mentally well enough to read and understand the 
invitation letter to attend the assessment clinic and were able to make their way to the correct 
place on the date and time specified for their visit. They were all also able to understand the 
study aims and protocol, and to give informed consent. 
 
Aortic stiffness was assessed by measuring carotid-femoral PWV and cognitive 
function was assessed using CANTAB. Based on patients’ pre-operative PWV measurement 
patients were grouped as described in Chapter 3 and 4.  
 
Both PWV and cognitive function tests were re-assessed at the follow-up visit (409 ± 
159 days) post-operatively. Relationships between PWV and cognitive function were 
examined in linear and in categorical statistical analyses. The pre-operative response was 
considered the baseline measure of cognitive function for analysis and was used to compare 
to the second post-operative response. 
 
5.3.2 PWV measurement protocol 
Detailed descriptions of measurement protocols, quality control, and reproducibility of PWV 
has been covered in the methodology section of Chapter 3. 
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5.3.3 Cognitive function assessment 
The methodology we followed for assessing cognitive function, including the assembling of 
the test battery, was based on: 
 recommendations from the “statement of consensus on assessment of 
neurobehavioral outcomes after cardiac surgery” [364]; 
 advice from our collaborating team of professor of Clinical Neuropsychology (B. 
Sahakian) and his team on the components of the testing battery; 
 convenience for the participants, particularly with respect to the total time needed to 
perform the test. 
 
Cognitive function was assessed using CANTAB. In this test, patients are exposed to 
different non-verbal geometrically designed tasks on a touch-sensitive screen. Participants 
respond by simply touching the screen with their fingers; neither writing nor drawing is 
required to take the test. The time required by patients to undertake this battery ranged from 
30 to 50 minutes depending on the cognitive performance. The battery was administrated by a 
single investigator (EK) to all participants. 
 
The components of the CANTAB battery used and the important measures are 
described in Table 5.1. 
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Test Tested 
function 
Description Parts/ levels Reference Important measures 
Pattern 
Recognition 
Memory (PRM) 
Memory A test of visual memory function that 
involves recalling 12 difficult visual 
patterns in the immediate memory 
part and different 12 difficult visual 
patterns in the delayed memory part.  
- Immediate memory (tested 
immediately) 
- Delayed memory (tested after 20 
minutes delay) 
Sahakian et 
al [383] 
 
 
Percentage of correct answers★ (up) 
Latency (time needed) of subject’s response 
(down) 
Rapid Visual 
Information 
Processing 
(RVP) 
Sustained 
attention 
A test of sustained attention 
involving detection of and 
responding to three sequences of 
numbers (3-digit each) among 
randomly changing digit from 2 to 9 
at the rate of 100 digits per minute. 
 Sahakian et 
al [384] 
 
Total missed targets★ (down) 
Latency of subject’s response★ (down) 
A’ measure of sensitivity to the target stimulus 
(range 0.00 to 1.00; bad to good)  
Probability of correct hit★ (up) 
Total correct rejections★ (up) 
Information 
Sampling Task 
(IST) 
Decision-
making 
and 
impulsivity 
 
A test of decision-making and 
impulsivity by playing a game for 
points by making a correct decision 
about which color of two is in the 
majority under 25 grey boxes after 
opening some or all of the grey boxes 
by the patient.  
-Decreasing-win condition: points a 
patient wins for a correct decision 
starts at 250 and decreases by 10 points 
for every box opened 
-Fixed-win condition: points patient 
wins for a correct decision is fixed (100 
points) regardless the number of boxes 
opened 
Clark L et al 
[385] 
 
 
Total correct trials★ (up) 
Mean number of boxes opened per trial★ 
(down) 
Latency of subject’s response★ (down) 
One Touch 
Stockings of 
Cambridge 
(OTS) 
Executive 
function 
A spatial planning test involving 
intellectual planning of a sequence of 
the minimum number of moves to 
make an arrangement of colored balls 
to achieve a goal arrangement 
without moving the balls on screen. 
1-level (most easy) 
2-level 
3-level 
4-level 
5-level (most difficult)  
Baker et al 
[386] 
 
Problems solved on first choice ★ (up) 
Mean choices to correct★ (down) 
Mean latency to correct★ (down) 
Table 5. 1 Description of the cognitive battery components used. 
★Measures used in this study analysis; (up), indicates higher, which is better; (down), indicates smaller, which is better. 
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As shown in Table 5.1, the CANTAB battery consists of four tests; the test 
explanations are quoted from the CANTAB manual. 
 
5.3.3.1 Pattern Recognition Memory 
Pattern Recognition Memory (PRM) is a test of visual memory function. The patient is 
presented with a series of 12 visual patterns, one at a time, in the center of the screen. These 
patterns are designed so that they cannot easily be given verbal labels. In the recognition 
phase, the patient is required to choose between two patterns, one pattern they have already 
seen and another novel pattern, as shown in Figure 5.2. In this phase, the test patterns are 
presented in the reverse order to the original order of presentation. This is then repeated with 
12 new patterns. The second recognition phase can be given either immediately or after a 20-
minute delay. This test’s outcome measures include the percentage of correct trials and 
latency (time subject needed to response). A higher percentage of correct responses and 
shorter latency is indicative of better memory. 
 
 
Figure 5. 2 Illustration of Pattern Recognition Memory (PRM) test. 
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5.3.3.2 Rapid Visual Information Processing 
Rapid Visual Information Processing (RVP) is a test of sustained attention and it has proven 
useful in many studies in which drugs are used to help develop a disease model. It is sensitive 
to dysfunction in the parietal and frontal lobe areas of the brain and is also a sensitive 
measure of general performance. A white box appears in the center of the black computer 
screen, inside which digits from 2 to 9 appear in a pseudo-random order at the rate of 100 
digits per minute. Patients are requested to detect target sequences of digits (for example, 2-4-
6, 3-5-7, and 4-6-8) and to register responses using the press pad (Figure 5.3). The RVP 
outcome measures cover latency, probabilities, and sensitivity (calculated using Signal 
Detection Theory), and hits, misses, false alarms, and rejections. 
 
 
 
Figure 5. 3 Illustration of the Rapid Visual Information Processing (RVP) test. 
 
5.3.3.3 Information Sampling Task 
In the Information Sampling Task (IST) test, the patient is presented with a 5 x 5 array of 
grey boxes on a black computer screen and two larger, colored panels below these boxes. 
The patients are instructed that they are playing a game for points, which they can win by 
making a correct decision about which color is in the majority under the grey boxes. They 
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must touch the grey boxes one at a time which opens up to reveal one of the two colors shown 
at the bottom of the screen. Once a box has been touched, it remains open. When the patient 
has made their decision about which color is in the majority, they must touch the panel 
corresponding to that color at the bottom of the screen to indicate their choice (Figure 5.4). 
After the patient has indicated their choice, all the remaining grey boxes on the screen reveal 
their colors and a message is displayed to inform the patient whether or not they were correct. 
The colors change from trial to trial. At the end of a trial, the grey boxes are displayed on the 
screen again at a speed that depends on how fast the trial was completed, so that there is 
always at least 30 seconds between trials. 
 
There are two conditions for this test: the fixed-win condition, in which the patient is 
awarded 100 points for a correct decision regardless of the number of boxes opened, and the 
decreasing-win condition, in which the number of points that can be won for a correct 
decision starts at 250 and decreases by 10 points for every box touched. In either condition, 
an incorrect decision costs 100 points. 
 
The IST outcome measures include latency, total correct trials, mean number of 
boxes opened per trial, and probability of the participant’s decision being correct based on the 
available evidence at the time of the decision. 
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Figure 5. 4 Illustration of the Information Sampling Task (IST) test. 
 
5.3.3.4 One Touch Stockings of Cambridge (OTS) 
One Touch Stockings of Cambridge (OTS) is a spatial planning test of executive function that 
gives a measure of frontal lobe function. OTS places greater demands on working memory as 
the patient has to visualize the solution. The patient is presented two displays containing three 
colored balls. The displays are presented in such a way that they can easily be perceived as 
stacks of colored balls held in stockings or socks suspended from a beam. This arrangement 
makes the 3-D concepts involved apparent to the patient, and fits with the verbal instructions. 
There is a row of numbered boxes along the bottom of the screen. The test administrator first 
demonstrates to the patient how to move the balls between stockings in the lower display to 
copy the pattern in the upper display, and completes one demonstration problem in which the 
solution requires one move. The patient must then complete three further problems, one each 
of two moves, three moves, and four moves. Next, the patient is shown further problems, and 
must work out in their head how many moves the solutions to these problems require, then 
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touch the appropriate numbered box at the bottom of the screen to indicate their response 
(Figure 5.5). If the response is wrong, the subject is asked to think again and respond again by 
selecting a different numbered box until problem solved. 
 
OTS outcome measures cover problems solved on first choice, mean choices to 
correct answer, and mean latency to correct answer. Each of these measures may be 
calculated for all problems, or for problems with a specified number of moves (one move to 
five or six moves). 
 
A higher number of problems solved on first choice, lower mean choices to the 
correct answer, and shorter mean latencies indicate better performance. 
 
 
 
Figure 5. 5 Illustration of the One Touch Stockings of Cambridge (OTS) test. 
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5.3.4 Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics software package version 18.0 
and Microsoft Office Excel 2010 (IBM Corporation, Armonk, NY, USA). Patient 
characteristics are expressed as means!±!standard deviation (for continuous variables) and as 
frequencies (for categorical variables). Statistical significance was considered where P < 0.05. 
The distribution of all outcome variables was first assessed for normality and all non-
normally distributed variables were transformed before inclusion in the regression analysis. 
PWV and cognitive function were examined using both linear and categorical approaches. 
 
PWV was analyzed as a continuous variable to verify our hypothesis. In addition, 
comparative analysis between the PWV-norm and PWV-high groups was carried out using an 
independent samples t-test or non-parametric equivalent (Mann–Whitney U test) for 
continuous variables, and Pearson Chi-square or Fisher’s exact tests for categorical variables. 
Differences between pre-operative and post-operative scores were analyzed using a paired 
samples t-test or non-parametric equivalent (Wilcoxon test). 
 
The strength of the linear association between cognitive function components, PWV, 
and patient characteristics was tested using bivariate correlation analysis (Spearman’s rank-
order correlation and Point/Rank biserial correlation in the case of dichotomous variables, 
such as PWV cut-off, for both pre- and post-operative stages). All variables with significant 
correlation, in addition to age and gender, were then included in two multiple regression 
models (enter method): 1) Model 1, using PWV as a continuous predictor; 2) Model 2, using 
PWV cut-off as a dichotomous predictor. Furthermore to the paired-sample t-test, additional 
repeated measure analysis was conducted using mixed ANOVA to check the main effect of 
time (follow up period) and of group (PWV groups) on the repeated measure. 
 
Additional analysis was performed to identify individual cases of POCD using the 
1SD rule. We calculated the mean difference between post and pre-operative score for each 
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test for each participant. A participant was classified as having POCD if there was a decline 
greater than or equal to 1SD from baseline performance for the whole group on two or more 
tasks. 
 
5.4 Results 
5.4.1 Descriptive results 
Fifty-six patients (16 females) with a mean age of 71 ± 8.4 years were included in this study. 
No emergency cases were recruited and none of the included patients developed shock or 
sepsis, or required intra-aortic balloon pump or intensive care admission, and only one patient 
required more than 24-hour intubation post-operatively. Thirty-five (62.5%) patients had 
PWV measurements equal or below the normal value for their age group (PWV-norm group) 
and 21 patients (37.5%) had PWV measurements above the normal value for their age group 
(PWV-high group). Fifty (89%) patients were able to attend the follow-up visit following the 
AVR and six patients refused to return after their initial enrollment at the pre-operative stage; 
none of the follow-up cases suffered major adverse events that warranted major hospital 
readmission. There was no significant difference between the two groups with respect to age, 
gender, classical hemodynamic measurements, estimated IQ level as measured by the 
National Adult Reading Test (NART) [387], operative characteristics, or other clinical 
characteristics (Table 5.2). 
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Parameter Total 
n = 56 
PWV-norm 
n = 35 
PWV-high 
n = 21 
P-value 
Male 40 (71.4%) 27 (77.1%) 13 (61.9%) 0.36 
Age (years) 
Age range (years) 
71 ± 8.4 
53–90 
70.2 ± 9 
53–90 
72 ± 8 
56– 85 
0.43 
White Caucasian [n (%)] 55 (98%) 35 (100%) 20 (95%) 0.37 
DM [n (%)] 8 (14.3%) 4 (11.4%) 4 (19.1%) 0.43 
Smoking [n (%)] 2 (3.6%) 2 (5.7%) 0 (0 %) 0.21 
BMI (kg/m2) 27.2 (4.2) 26.5 (4.3) 28.1 (4.1) 0.18 
SBP (mmHg) 136 ± 24 132 ± 27 142 ± 18 0.14 
DBP (mmHg) 76 ± 11 75 ± 12 77 ± 11 0.58 
PP (mmHg) 62 ± 15 61 ± 14 65 ± 16 0.32 
MAP (mmHg) 97 ± 12 96 ± 13 98 ± 11 0.56 
Cholesterol (mmol/L) 4.5 ± 1.2 4.6 ± 1.3 4.4 ± 0.8 0.60 
Hypertension [n (%)] 38 (67.9%) 22 (62.9%) 16 (76.2%) 0.38 
Statin treatment [n (%)] 38 (67.9%) 22 (62.9%) 16 (76.2%) 0.38 
Bicuspid aortic valve [n (%)] 8 (14.3%) 6 (17.1%) 2 (9.5%) 0.69 
PVD [n (%)] 2 (3.6%) 0 (0%) 2 (9.5%) 0.13 
EuroSCORE (Logistic) 5.5 ± 4.3 5.1 ± 4 6.1 ± 4.7 0.23 
AVA (cm2) 0.73 ± 0.2 0.74 ± 0.2 0.71 ± 0.2 0.67 
AVMG (mmHg) 48 ± 13 50 ± 13 46 ± 11 0.27 
AVPG (mmHg) 82 ± 24 86 ± 27 76 ± 19 0.13 
EF  59 ± 15 58 ± 15 61 ± 16 0.56 
CPB time (minutes) 87 ± 23 87 ± 20 87 ± 27 0.95 
Hospital stay (days)  6.7 ± 1.7 6.6 ± 1.6 6.7 ± 1.8 0.84 
PWV (m/second) 9.3 ± 2.2 8.1 ± 1.5 11.3 ± 1.6 <0.001 
Estimated IQ 111± 6 111± 6 112± 6 0.77 
Table 5. 2 Demographic and clinical characteristics of included patients. 
Values are shown as n (%) for categorical variables and the mean ± standard deviation for continuous variables. 
Abbreviations: AVA, aortic valve area; AVMG, aortic valve mean gradient; AVPG, aortic valve peak gradient; 
BMI, body mass index; CPB, cardiopulmonary bypass; DBP, diastolic blood pressure; DM, diabetes mellitus; EF, 
ejection fraction; MAP, mean arterial blood pressure; PP, pulse pressure; PVD, peripheral vascular disease; PWV, 
pulse wave velocity; SBP, systolic blood pressure. 
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5.4.2 Memory function 
No significant difference was seen in the immediate portion of the PRM between the two 
groups either pre- or post-operatively (Figure 5.6). Conversely, PWV-norm patients 
demonstrated a significantly better delayed PRM than PWV-high patients in that they 
remembered a greater percentage of patterns both pre- (P < 0.001) and post-operatively (P = 
0.01). Interestingly, no deterioration in memory function was seen after AVR and, in fact, 
there was non-significant overall improvement in memory function in both groups (Figure 
5.6). 
 
Figure 5. 6 Differences between PWV-norm and PWV-high groups in the Pattern Recognition Memory 
(PRM) test at pre- and post-operative stages. 
*P-value is for PWV-norm vs. PWV-high (independent samples analysis); **P-value is for pre-op vs. post-op 
value for same the group (paired samples analysis). Abbreviations: PWV, pulse wave velocity. 
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5.4.3 Sustained attention 
PWV-norm patients demonstrated a globally better performance in the RVP test than PWV-
high patients both pre- and post-operatively. PWV-norm patients recognized and hit more 
targets (missed less targets), responded faster (latency), and avoided responding to incorrect 
targets (correct rejections) more than the PWV-high group. Though not statistically 
significant, there was noticeable post-operative improvement in most of the components of 
this cognitive function, which was greater in the PWV-high group than in the PWV-norm 
group (Table 5.3). 
 
RVP measure   Pre-operative Post-
operative 
Mean 
Difference  
**P-value 
Total missed 
targets 
(Smaller is 
better)  
PWV-norm 11 ± 4 11 ± 5 0.3 ± 5.8 0.75 
PWV-high 18 ± 4 14 ± 6 4 ± 7 0.06 
*P-value <0.001 0.04     
Latency of 
subject response 
(ms) 
(Faster is better) 
PWV-norm 526 ± 162 511 ± 136 14 ± 182 0.70 
PWV-high 652 ± 144 598 ± 211 54 ± 260 0.44 
*P-value <0.01 0.11     
A’ (sensitivity 
to the target 
stimulus 
(Higher is 
better) 
PWV-norm 0.88 ±0.04 0.89 ± 0.05 –0.004 ± 0.05 0.67 
PWV-high 0.82 ± 0.04 0.84 ± 0.05 –0.02 ± 0.06 0.15 
*P-value <0.001 0.01     
Probability of 
correct hit 
(Higher is 
better)  
PWV-norm 0.56 ± 0.2 0.59 ± 0.2 –0.03 ± 0.25 0.59 
PWV-high 0.34 ± 0.13 0.43 ± 0.17 –0.09 ± 0.21 0.11 
*P-value <0.01 0.01     
Total correct 
rejections 
(Higher is 
better) 
PWV-norm 246 ± 12 234 ± 30 12 ± 33 0.29 
PWV-high 230 ± 10 221 ± 60 9 ± 58 0.56 
*P-value <0.001 0.42     
Table 5. 3 The mean differences between PWV-norm and PWV-high groups in Rapid Visual Processing 
(RVP) scores at pre- and post-operative stages. 
*P-value is for PWV-norm versus PWV-high (independent samples analysis); **P-value is for pre-op versus post-
op value for same the group (paired samples analysis). Abbreviations: PWV, pulse wave velocity. 
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5.4.4 Decision-making and impulsivity 
Decision-making and impulsivity was assessed using the IST test in which total correct trials, 
mean number of boxes opened per trial, and latency of the patient’s response were measured. 
The groups performed similarly in both decreasing-win (requiring judgment between risk of 
loss and benefit of win) and fixed-win conditions (where participants are not accountable for 
the number of tries [boxes opened] to make a decisions). P-values for pre-operative total 
correct trials, mean number of boxes opened per trial, and latency of the subject’s response 
were 0.207, 0.165, and 0.208, respectively, for the fixed-win condition, and 0.410, 0.949, and 
0.933, respectively, for the decreasing-win condition. Furthermore, no significant difference 
was seen between pre- and post-operative assessments for either group. 
 
The RVP A’ (sensitivity to the target stimulus) and the RVP probability of correct hit 
components can also be interpreted in the context of the decision-making process. Notably, 
PWV-norm patients performed significantly better than PWV-high patients in both 
components pre- (P < 0.001 and P < 0.01, respectively) and post-operatively (P = 0.01 for 
both). 
 
5.4.5 Executive cognitive function 
Executive cognitive function was assessed using the OTS test. PWV-norm patients solved 
significantly more problems on their first choice than PWV-high patients both pre- (16.6 ± 
1.9 vs. 14 ± 2.7, P < 0.001) and post-operatively (17.7 ± 1.3 vs. 14.1 ± 3.1, P < 0.001). For 
simple problems, both groups required a similar number of choices to reach the correct 
answer. However, in more complex problems requiring three, four, or five moves to solve the 
test, the relationship between PWV and the number of trials diverge significantly in favor of 
the PWV-norm group. In addition, patients with normal PWV required less time to solve 
problems at all difficulty levels (Figure 5.7). 
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Interestingly, there was no deterioration in problem solving function over time. In 
fact, the latency (time required to solve the problem) of the most difficult problems (level 
five) was significantly improved in both PWV-norm (P = 0.007) and PWV-high (P = 0.003) 
groups. 
 
5.4.6 Post-operative cognitive dysfunction 
Though it was not necessary because the improvement in post-operative cognitive function 
was obvious in both PWV groups, to confirm post-operative cognitive dysfunction 
improvement at the individual level, additional analysis was performed to identify individual 
cases of POCD using the 1SD rule. Only five cases had POCD, two from the PWV-high 
group and three from the PWV-norm group, therefore no further statistical analysis was 
conducted to compare between those who developed POCD and those who did not. 
 198 
 
Figure 5. 7 The executive function test (OTS) for PWV-norm and PWV-high groups showing mean latency and mean number of trials (choices) needed to solve the problems 
at different difficulty levels pre- and post-operatively. 
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5.4.7 Correlation and regression 
For the purposes of the regression analysis, the following main components of cognitive 
function were considered: (1) PRM test: delayed component; (2) RVP test: total missed and A’ 
components; and (3) OTS test: problems solved on first choice, mean choices, and mean 
latency to correct level five components. Bivariate correlation analysis was used to assess the 
linear association between the main cognitive function components, PWV, and patient 
characteristics. Bivariate correlation demonstrated significant correlation between PWV value 
and all the main components of cognitive function both pre- and post-operatively (Table 5.4). 
These associations remained significant when PWV was categorized according to normal 
PWV reference values (PWV cut-off; Table 5.4). Furthermore, age, gender, ejection fraction, 
and aortic valve area were significantly correlated with some but not all cognitive 
components as demonstrated in the correlation matrix in Table 5.4. The correlation between 
main intra- and post-operative factors and post-operative cognitive function was also assessed 
(Table 5.4). Post-operative cognitive function did not correlate with cardiopulmonary bypass 
time, while executive function and sustained attention were correlated to prosthetic valve size 
and post-operative inotropes (more than 6 h), respectively. Interestingly, four out of six post-
operative cognitive components were associated with the presence of post-operative atrial 
fibrillation (AF). 
 
All variables with significant correlation, along with age and gender, were included in 
two multiple linear regression models (enter method; Table 5.5). Model 1 (PWV as a 
continuous variable) revealed PWV to be an independent predictor of all pre-operative 
cognitive components and the post-operative executive function component of cognitive 
function. Model 2 (PWV as a dichotomous variable) demonstrated PWV to be an independent 
predictor of all pre- and post-operative main cognitive function components, with age 
becoming another prominent predictor of cognitive function. Post-operative AF was 
independently related to 50% of post-operative cognitive function in Model 1, then lost this 
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significant relationship in Model 2. Generally, PWV was independently related to pre- and 
post-operative cognitive function, and when other variables sharing this relationship in some 
of the cognitive components, PWV had higher regression coefficient. 
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Analysis Variables 
Pre-op Post-op 
PRM 
delayed, 
% of 
correct 
RVP 
total 
missed 
RVP A OTS 
Problems 
solved on 
1st choice 
OTS 
choices to 
correct    
(5-level) 
OTS 
latency to 
correct    
(5-level) 
PRM 
delayed, 
% of 
correct 
RVP 
total 
missed 
RVP A OTS 
Problems 
solved on 
1st choice 
OTS 
choices to 
correct    
(5-level) 
OTS 
latency to 
correct  
(5-level) 
Correlation 
coefficient 
PWV -0.513** 0.656** -0.646** -0.561** 0.560** 0.486** -0.337* 0.389* -0.465** -0.627** 0.506** 0.667** 
PWV cut-off (PWV-
high) 
-0.574** 0.660** -0.662** -0.596** 0.514** 0.467** -0.370* 0.314* -0.403* -0.564** 0.618** 0.618** 
 
Age  -0.256 0.499** -
0.501** 
-0.455** 0.508** 0.380** -0.223 0.376* -
0.434** 
-0.388* 0.349* 0.429** 
Gender (male) 0.157 -0.098 0.109 0.278* -0.222 -0.128 0.143 0.078 0.001 0.261 -0.354* -0.108 
MAP (mmHg) -0.077 0.078 -0.048 -0.084 0.075 -0.002 0.073 -0.076 0.165 -0.034 0.108 0.043 
BMI (kg/m2) -0.143 0.056 -0.088 -0.275 0.131 0.003 0.032 0.079 0.004 -0.052 -0.011 0.089 
Smoking -0.067 0.030 -0.012 -0.004 0.009 0.144 0.305 -0.024 0.107 0.048 -0.228 -0.148 
DM -0.232 0.108 -0.061 0.013 -0.166 -0.206 0.111 -0.157 0.217 0.317 -0.320 -0.236 
EF 0.091 -0.201 0.143 0.191 -0.209 -0.058 0.375* -0.159 0.187 -0.003 0.068 -0.082 
AVPG 0.055 -0.122 0.130 0.154 -0.098 0.025 0.127 0.033 -0.124 -0.152 0.028 0.000 
AVMG -0.007 -0.028 0.080 0.098 -0.063 0.080 0.135 0.049 -0.129 -0.175 -0.021 0.023 
AVA (cm2) 0.041 -0.146 0.101 0.034 -0.166 -0.250 0.416* -0.188 0.312 0.298 -0.500** -0.307 
Cholesterol (mmol/l) -0.031 -0.010 0.063 0.106 -0.064 0.179 0.109 -0.074 -0.044 -0.128 0.110 0.166 
CPB time (min.)       0.004 -0.044 0.065 0.159 -0.247 -0.060 
Prosthesis size       -0.034 -0.082 0.010 0.411** -0.299 -0.336* 
Inotropes       0.019 -0.313* 0.292 -0.219 0.173 0.293 
Blood products       0.002 0.000 -0.079 -0.252 0.163 0.183 
Follow-up AF        -0.145 0.181 -0.362* -0.327* 0.451** 0.33* 
Table 5. 4 Bivariate correlation identifying variables independently associated with cognitive function. 
*P < 0.05; **P < 0.01; Abbreviations: AF, atrial fibrillation; AVA, aortic valve area; AVMG, aortic valve mean gradient; AVPG, aortic valve peak gradient; BMI, body mass index; CPB, 
cardiopulmonary bypass; DM, diabetes mellitus; EF, ejection fraction; MAP, mean arterial blood pressure; PWV, pulse wave velocity. 
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Analysis Variables 
Pre-op Post-op 
PRM 
delayed, 
% of 
correct A 
RVP total 
missed 
RVP A B 
OTS 
Problems 
solved on 
1st choice 
B 
OTS 
choices to 
correct 
(5-level) C 
OTS 
latency to 
correct 
(5-level) B 
PRM 
delayed, 
% of 
correct A 
RVP total 
missed 
RVP A 
OTS 
Problems 
solved on 
1st choice 
B 
OTS 
choices to 
correct 
(5-level) C 
OTS 
latency to 
correct 
(5-level) B 
 
Regression 
(beta) 
 
(Model 1) 
PWV -0.411** 0.488** -0.469** -0.367** 0.317* 0.308* -0.321 0.390* -0.317 -0.38* 0.399* 0.478** 
Age -0.028 0.258* -0.267* -0.293* 0.364** 0.257 0.054 0.308* -0.166 -0.062 -0.001 0.019 
Gender 0.066 -0.037 0.051 0.170 -0.121 -0.034 -0.026 -0.005 -0.082 -0.040 -0.163 0.236 
EF       0.417*      
AVA (cm2)       0.235    -0.35*  
Prosthesis size          0.344  -0.383* 
Inotropes        -0.552**     
Follow-up AF         -0.317* -0.266 0.263* 0.309* 
 
Regression 
(beta) 
 
(Model 2) 
PWV cut-off -0.522** 0.614** -0.613** -0.479** 0.447** 0.434** -0.391* 0.36** -0.335* -0.442** 0.497** 0.520** 
Age -0.175 0.433** -0.433** -0.423** 0.473** 0.363* -0.073 0.452** -0.314* -0.279 0.185 0.25 
Gender 0.034 0.000 0.012 0.140 -0.089 -0.003 -0.033 0.013 -0.084 -0.026 -0.158 0.158 
EF       0.412*      
AVA (cm2)       0.187    -0.318*  
Prosthesis size          0.236  -0.258 
Inotropes        -0.512**     
Follow-up AF         -0.237 -0.133 0.158 0.151 
Table 5. 5 Multiple linear regression identifying variables independently related to cognitive function. 
*P < 0.05; **P < 0.01; only significant variables from the bivariate correlation, in addition to age and gender, were included in this multiple regression (Enter method) analysis. Model 1 includes 
PWV value as a continuous predictor; Model 2 includes PWV cut-off as a dichotomous predictor. Abbreviations: AF, atrial fibrillation; AVA, aortic valve area; EF, ejection fraction; PWV, 
pulse wave velocity. A square root transformation; B log transformation; C inverse transformation. 
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Mixed ANOVA was performed to check the main effect of time (follow up period) 
and of group (PWV groups) on the repeated measure (Table 5.6). The main effect of group 
(Between-Subjects effect) revealed a statistically significant difference in all cognitive 
components between PWV groups, F range was 11.38-22.14, partial eta squared (ƞp2) range 
was 0.23 – 0.37. The main effect of time (Within-Subjects effects) showed a statistically 
significant difference in memory and executive function only between different time points, F 
range was 4.86 – 15.65, partial eta squared (ƞp2) range was 0.11 – 0.29. There was no 
statistically significant interaction between the PWV groups and follow up period on any 
component of cognitive function.  
 
Cognitive 
Function 
Main effect Degrees 
of 
freedom 
Mean 
Square  
 
F-test P-value ƞp2 
PRM 
delayed, % of 
correct A 
Within-Subjects 
effects 
1 5.43 4.86 0.034 0.11 
Between-Subjects 
effect 
1 24.75 11.38 0.002 0.23 
RVP total 
missed 
Within-Subjects 
effects 
1 76.8 3.79 0.059 0.09 
Between-Subjects 
effect 
1 525.1 17.47 <0.001 0.31 
RVP A B Within-Subjects 
effects 
1 0.001 2.08 0.16 0.05 
Between-Subjects 
effect 
1 0.014 17.13 <0.001 0.32 
OTS Problems 
solved on 1st 
choice B 
Within-Subjects 
effects 
1 0.11 5.57 0.02 0.12 
Between-Subjects 
effect 
1 1.23 17.22 <0.001 0.31 
OTS choices to 
correct (5-
level) C 
Within-Subjects 
effects 
1 0.05 3.38 0.07 0.08 
Between-Subjects 
effect 
1 0.74 17.58 <0.001 0.32 
OTS latency to 
correct (5-
level) B 
Within-Subjects 
effects 
1 0.36 15.65 <0.001 0.29 
Between-Subjects 
effect 
1 1.54 22.14 <0.001 0.37 
Table 5. 6 Mixed ANOVA for the main cognitive function components.  
Main effects are: The effect of time, follow up period, (Within-Subjects effects); The effect of PWV group,  
(Between-Subjects effect). Abbreviations: Partial Eta Squared (ƞp2). A square root transformation; B log 
transformation; C inverse transformation. 
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5.5 Discussion 
The complexity of the etiology of post-operative cognitive dysfunction, including SIRS, 
hypoperfusion, and microembolization, associated with cardiac surgery is well established. 
While most of the causes of cognitive dysfunction are operative factors, in this study we have 
attempted to identify a simple and practically applicable pre-operative predictor of cognitive 
dysfunction occurrence or severity of damage. The findings of this study suggest that aortic 
stiffness as determined by PWV may predict cognitive outcome as determined by the 
CANTAB, which is more accurate and robust than the classical paper-based assessment 
because it is a computerized and automated system and, therefore, less operator dependent. 
This technique may hence play a vital role in the future perioperative evaluation of patients 
undergoing cardiac surgery. 
 
Our results demonstrate that low aortic compliance (high PWV) is associated with 
significantly poorer delayed memory performance, poorer attention, slower response, and 
worse problem solving both pre- and post-operatively in patients undergoing AVR. In the 
sustained attention test (RVP), which requires interactions between the parietal and frontal 
lobes of the brain, there was also a significant relationship between abnormal PWV and poor 
attention and response both pre- and post-operatively. The PWV-norm group significantly 
recognized and hit more targets, responded faster (latency), and they avoided responding to 
incorrect targets (correct rejections) more than the PWV-high group. 
 
In the decision-making cognitive function test (IST), there was no significant 
difference between the two groups in any of the components of the IST test pre- and post-
operatively. However, patients with low aortic compliance were found to be more impulsive 
and less accurate in detecting target sequences. The problem solving test (OTS) assesses the 
executive function of the frontal lobe, and PWV was found to be significantly associated with 
the number of problems solved on first choice. In addition, the PWV-high group needed 
significantly more time and trials (choices) to solve the problems pre- and post-operatively. 
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Interestingly, there was no deterioration in memory, sustained attention, or problem solving 
function between pre- and post-operative tests; in fact, some post-operative improvements 
were observed in cognitive function and time to solve more difficult problems, particularly in 
the high PWV group. 
 
Among PWV, age, gender, MAP, body mass index (BMI), smoking, DM, ejection 
fraction AVPG, AVMG, AVA, cholesterol level, triglyceride level, CPB time, prosthetic size, 
and post-operative inotropes, blood products and AF, only age and PWV were significantly 
correlated with cognitive function components in the bivariate correlation analysis pre- and 
post-operatively. While AF was another interesting correlated variable with post-operative 
cognitive function. In Model 1 multiple regression analysis, PWV was associated with all 
cognitive components pre-operatively and with three of six cognitive components post-
operatively, while age and post-operative AF were independently related to pre- and post-
operative cognitive function respectively. Model 2 demonstrated that PWV cut-off was a 
stronger predictor that PWV value, age continued to be independently related mainly to pre-
operative cognitive function. 
 
The findings in this study support several recent reports demonstrating an association 
between high PWV and poorer cognitive function or cognitive decline in both the general 
population and in hypertensive patients [377-380]. However, this is the first study of its kind 
to confirm this association after aortic valve surgery utilizing the CANTAB computer-based 
cognitive battery. 
 
While many studies have reported deterioration in cognitive function after cardiac 
surgery [332, 337, 353-357], our results are in concordance with other studies [340, 342, 359, 
360] that demonstrate no decline or an improvement in cognitive function post-operatively. 
Although one could argue the post-operative results are affected by practice effects. 
Considering the time interval between pre-operative and follow-up assessments, it is unlikely 
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that the results were disturbed by practice effects and most probably reflected true cognitive 
status after AVR. Furthermore, the design of the tests makes it nearly impossible to remember 
specific pattern (as they are designed so that they cannot be given verbal labels) or 
remembering number stimuli or problem solution (as the presentation order is fast and 
random). In addition, a most of previous studies have, however, focused on cognitive decline 
after CABG or included a mixed population of patients. The present study uniquely assessed 
primarily patients undergoing AVR for severe AS. As such, we believe that post-surgical 
improvements in systemic blood pressure, cerebral, and systemic circulation, in addition to 
the elimination of anxiety and stress related to the cardiac symptoms and the planned major 
surgery, may account for the improvement in many aspects of cognitive function. Indeed, 
relief of pre-syncope and syncope (which is a sign of low cerebral circulation) was a 
symptomatic indication for AVR in a large proportion of our patients. Furthermore, by 
extending follow-up to more than 1-year after surgery, unquantifiable factors, such as acute 
systemic inflammatory response, hypoperfusion, and microembolisation occurring in the 
early post-operative period may be given time to plateau, thus allowing for a more accurate 
estimate of the true long-term effect of AVR on cognitive function [330] [388]. The use of a 
computer-based battery rather than paper-based cognitive tests may also explain why this 
relationship between aortic stiffness and cognitive function after valve surgery has yet to be 
reported. Such novel techniques improve our ability to discriminate marginal differences in 
errors and timing, thus allowing us to detect previously unobserved and subtle changes in 
cognition. 
 
The majority of previous studies investigating the relationship between cardiac 
surgery and POCD analyzed pre-operative cardiac patients as one group to compare with the 
healthy population, or with other surgical or non-surgical groups [340, 356, 359, 389, 390]. In 
this study, we categorized the pre-operative cardiac population according to the proposed 
predictor (arterial stiffness) and proved that there is a difference in cognitive function 
between the two groups of the same population (AS). Many studies investigated pre-existing 
 207 
(pre-operative) cognitive dysfunction and identified factors such as age, multiple cerebral 
infarctions, cerebrovascular disease, baseline cognitive index, and metabolic syndrome as 
predictors of pre- and post-operative cognitive dysfunction [342, 357, 391-396] [389]. In the 
present study, we hypothesized that aortic stiffness may act as a practical surrogate marker of 
these baseline patient-related predictors. Indeed, patients with a higher arterial stiffness 
demonstrated poorer cognitive function before and after surgery, and seemed to attain a 
greater cognitive benefit from AVR than matched patients with normal arterial stiffness. 
 
The aforementioned findings represent preliminary data from a novel approach for 
assessing cognitive function in cardiac patients. Therefore, future larger studies assessing the 
relationship between cognitive function (using computer-based batteries) and aortic stiffness 
in CPB patients with more than 1-year follow-up period is recommended. If larger studies 
confirm these findings, then the informed consent process may change considerably by 
eliminating the potential effect of cardiac surgery on cognitive function. 
 
The absence of an association between PWV and degree of stenosis in this particular 
study suggests that the correlation between PWV and cognitive function is more reliable and 
stable; if this were not the case, cognitive function findings may have been attributed to the 
degree valve stenosis. The same rationale applies for clinical and operative characteristics. 
 
This study adds support to the progressively accumulating evidence regarding the 
importance and predictive value of aortic stiffness, aiming for routine measurement of PWV 
in clinical settings as a tool for functional and frailty status. 
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Strengths 
This study is the first of its kind to investigate the relationship between aortic stiffness and 
cognitive function in AS patients. The use of the ‘gold standard’ PWV as a measure of aortic 
stiffness and the CANTAB computer-based battery as a measure of cognitive function allows 
for an accurate and robust methodology that is automated and less operator dependent. None 
of the previous studies in cardiac patients was conducted using a computer-based cognitive 
battery like the one we used (CANTAB). Our disease-specific and matched patient groups 
also remove the potential for variations in cognitive function due to extraneous factors, such 
as hypertension, ischaemic heart disease, diabetes mellitus, and cerebrovascular disease. 
 
Limitations 
The main limitation to the present study is the absence of a brain imaging component, which 
would potentially provide a very interesting link between aortic stiffness and cognitive 
function. However, previous studies have identified the presence of pre-existing white matter 
lesions and cerebral infarctions in patients undergoing cardiac surgery [391, 397] and their 
association with cognitive dysfunction [391, 394]. Based on cost-efficiency, pre-operative 
cognitive tests (rather than brain imaging) have been proposed as tools for identifying high 
risk groups [330]. On the other hand, the severity of arterial diseases, such as the severity of 
coronary artery calcification, carotid artery lesions, and aortic calcification, were found to be 
associated with cerebral lesions [398-400]. We believe that PWV can collectively replace the 
presence of arterial diseases for describing the aforementioned relationship with the cerebral 
pathological changes, and will therefore be associated with subsequent cognitive dysfunction. 
Though our sample was homogenous and produced statistical significant results, the existing 
results should be treated as exploratory in nature giving preliminary data for interesting future 
studies.   
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5.6 Conclusions and potential future implications 
Arterial stiffness is an emerging predictor of post-surgical morbidity and mortality. The 
findings presented in this chapter suggest that patients with AS with higher pre-operative 
aortic stiffness have a significantly poorer pre- and post-surgical cognitive function. 
Furthermore, valve replacement surgery may not be associated with a decline in cognitive 
function. Bivariate correlations exhibited PWV to be significantly correlated with many 
components of cognitive function, and multiple regression confirmed PWV as an independent 
predictor of cognitive function both pre- and post-operatively. Thus PWV might be useful as 
an additional indicator for cognitive dysfunction before and after the surgical intervention for 
AS. Nevertheless, further larger studies must show whether PWV is really proficient of going 
beyond this to show effects of cardiac surgery on cognitive function. Application of PWV 
measures of aortic stiffness in the future may reform pre-operative assessment of cardiac 
surgical patients, allowing surgeons to better predict post-operative cognitive dysfunction and 
improve both pre-operative consent and risk stratification. 
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6 Chapter 6 
The relationship between aortic stiffness and ischemic brain 
injury biomarker N-methyl-D-aspartate receptor antibody 
levels in aortic valve replacement 
 
This chapter investigates the potential relationship between aortic stiffness and serum levels 
of the brain injury biomarker N-methyl-D-aspartate receptor antibody (NR2Ab) aortic valve 
replacement. 
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6.1 Abstract 
Background: Aortic stiffness changes the flow pattern of circulating blood causing 
microvascular damage to different end-organ tissues, such as brain cells. Such microvascular 
damage can be translated into ischemic cellular injury manifested by circulating biomarkers.   
 
Objectives: The objective of this study was to assess, for the first time, the relationship 
between aortic stiffness measured by pulse wave velocity (PWV) and serum ischemic brain 
injury biomarker N-methyl-D-aspartate receptor antibody (NR2Ab) levels in aortic valve 
replacement (AVR). 
 
Methods: Patients undergoing AVR had their PWV and NR2Ab serum levels measured pre-
operatively. We analyzed PWV and NR2Ab in two ways: 1) as continuous variables using the 
actual value; and 2) as dichotomous variables (PWV-norm and PWV-high groups) and 
(NR2Ab-low and NR2Ab-high groups). 
 
Results: Fifty-six patients (71 ± 8.4 years) were included in this study. The NR2Ab level 
(ng/ml) was significantly higher in the PWV-high group (n = 21) than in PWV-norm group (n 
= 35; median 1.8 ± 1.2 vs. 1.2 ± 0.7, respectively, P = 0.003), and PWV (m/s) was 
significantly higher in the NR2Ab-high group (n = 17) than in the NR2Ab-low group (n = 35; 
mean 10.9 ± 2.1 vs. 9.1 ± 2.2, respectively, P = 0.05). NR2Ab level was positively associated 
with PWV and negatively associated with male gender. Multiple regression analysis revealed 
that PWV cut-off was stronger than PWV value as an independent predictor of both NR2Ab 
level and the NR2Ab 1.8 ng/ml cut-off, and it was associated with a 7.23 times increase in the 
likelihood of having high NR2Ab (>1.8 ng/ml). 
 
Conclusion: Higher PWV in AVR patients is associated with higher levels of the ischemic 
brain biomarker NR2Ab. 
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6.2 Introduction 
6.2.1 Aortic stiffness measured by pulse wave velocity 
Detailed background on aortic stiffness and pulse wave velocity (PWV) and their predictive 
value is discussed in Chapter 1. 
 
6.2.2 Aortic stiffness and brain ischemia 
Vascular autoregulation maintains a relatively stable brain blood flow despite blood pressure 
changes. However, regional increases in brain activity causes regional surges in blood 
demand and influences regional increases in blood flow, a process known as functional 
hyperemia [401]. Efficient global brain circulation, autoregulation, and functional hyperemia 
depend not only on blood volume and blood pressure, but also critically rely on intact, healthy, 
and reactive cerebral blood vessels [401]. 
 
Aortic stiffness changes the flow pattern of circulating blood and makes it more 
aggressive and pulsatile, which leads to microvascular damage to different end-organ tissues, 
such as brain cells [9, 402]. Aortic stiffness assessed using transesophageal echocardiography 
was found to be independently associated with ischemic stroke compared to control subjects 
[403]. In a longitudinal study of 1,715 essential hypertensive patients with a mean follow-up 
of 7.9 years, PWV independently predicted fatal stroke after full adjustment for classic 
cardiovascular risk factors, including age, cholesterol, diabetes, smoking, mean blood 
pressure, and pulse pressure [177]. Furthermore, Okuyama et al. found that aortic stiffness is 
an independent predictor of stroke recurrence after a mean follow-up period of 459 days for 
201 stroke patients [404]. Furthermore, there is an association between aortic PWV and 
intracranial large artery disease in patients with history of ischemic stroke [405]. The 
mechanism of progressive neurological deficit in patients with acute deep subcortical 
infarction is unknown; however, Saji et al. has recently hypothesized that PWV may be part 
of such a mechanism, as they found that PWV was independently associated with progressive 
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neurological deficit in these patients [406]. As the relationship between aortic stiffness and 
cerebrovascular outcome becomes further established, additional studies on the mechanisms 
and mediators of this relationship using advanced imaging technology are becoming more 
prevalent. PWV is independently associated with the manifestations of cerebral small vessel 
disease, such as silent brain infarction and white matter disease, which are risk factors for 
stroke [173, 407, 408]. Thus, direct assessment of cerebral blood flow to assess the impact of 
aortic stiffness on brain tissue is an important concept that requires further proof. Using the 
advanced magnetic resonance imaging (MRI) arterial spin labeling (ASL) technique, Tarumi 
et al. found a significant inverse relationship between aortic stiffness and cerebral perfusion 
of frontal white matter [409] and the occipitoparietal region [410]. 
 
Together, the above findings suggest that aortic stiffness may be used as a prognostic 
tool for risk assessment of ischemic stroke, and it is associated with microvascular damage 
and dysfunction, which, in turn, causes brain cell injury [401]. 
 
The damaging effect of vascular risk factors, including central arterial stiffness, on 
brain tissue by different mechanisms, such as chronic hypoperfusion, has been investigated 
widely using imaging technologies that are expensive and have practical limitations [398, 
411]. Therefore, identifying a practical and more cost-efficient clinical or biochemical marker 
linking vascular pathology to brain injury would be of immense clinical value. 
 
6.2.3 Ischemic brain injury biomarkers 
Typical biomarkers of ischemic brain injury include proteins produced exclusively by brain 
cells during the brain injury process, such as the ischemic effect of small vessel disease, and 
that cross the blood-brain barrier so that they can be tested in peripheral blood samples with 
high sensitivity and specificity. Ischemic brain biomarkers have been studied for decades with 
the intention of identifying a reliable and practical biomarker equivalent to cardiac troponins. 
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Four recent scientific reviews thoroughly discussed biomarkers of ischemic stroke [412-415]. 
Overall, approximately 70 ischemic brain injury biomarkers have been studied over the last 
four decades, and most of these biomarkers were investigated in one study, while the others 
have been investigated more frequently [412-415]. Some of the identified biomarkers, such as 
S-100 and neurone specific enolase (NSE), are predictive not only of the presence of acute 
ischemic brain injury, but also the volume of ischemia and thus the outcome [416-418]. 
 
In general, these biomarkers can be categorized into four major groups according to 
their origin or role: 1) nervous system tissue injury biomarkers; e.g., N-methyl-D-aspartate 
(NMDA) receptors antibodies (NR2Ab), NSE, and S100B; 2) inflammatory biomarkers; e.g., 
C-reactive protein (CRP), interleukin (IL)-6, and tissue necrosis factor-alpha (TNF-α); 3) 
coagulation biomarkers; e.g., D-dimer and fibrinogen; and 4) other biomarkers; e.g., 
nucleotide diphosphate kinase A (NDKA) and B-type neurotrophic growth factor [413]. 
Despite the encouraging and promising results of many of these biomarkers, none of them are 
currently used in clinical practice for the diagnosis of acute brain ischemia, mostly because 
the necessary sensitivity and specificity have not been achieved or because they did not add 
significant predictive power to the validated clinical model [412, 413]. 
 
Some of these biomarkers have been identified as potential candidates for future 
studies involving ischemic injuries, including NR2Ab, S-100, tau protein, NSE, brain 
natriuretic peptide, and CRP    [412-414, 419-426]. Our literature search could not find any 
study investigating brain biomarkers of chronic cerebral ischemia. Therefore, the predictive 
value of such biomarkers and their association with other potential risk factors of chronic 
brain ischemia, such as aortic stiffness, is an area of research interest. 
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N-methyl-D-aspartate receptor antibodies 
NMDA brain cell receptors are voltage-dependent glutamate receptors, and activation of these 
receptors results in cation inflow. The NMDA receptor has two obligatory NR1 subunits and 
two regionally localized NR2 subunits that compile in the endoplasmic reticulum to form 
functional heteromultimers. These receptors are highly permeable to calcium; NR2 is co-
activated by glutamate while NR1 is co-activated by glycine. Different arrangements of these 
NR1 splice variants and NR2 subunits lead to the formation of NMDA receptor complexes 
with different functional properties [427]. Death or ischemia of neural cells causes 
degradation of NR2 subunits of the NMDA receptor, and the proteolytic fragments start to 
circulate in the bloodstream. This in turn stimulates the immune system to produce antibodies 
against these NR2 fragments (NR2Ab), which can be assayed in blood samples [428]. Adult 
patients with acute or recent ischemic stroke have elevated blood levels of NR2Ab that 
correlate with the amount of brain damage or the presence of recent stroke compared to 
controls. Test sensitivity and specificity for diagnosing ischemic stroke within 3 h of 
symptom onset was 100% and 89% for a cut-off of 1.8 ng/ml, and 97% and 98% for a cut-off 
point of 2.0ng/ml [429, 430]. Bokesch et al. found that pre-operative serum concentrations of 
NR2Ab are predictive of severe neurological adverse events after cardiac surgery in high-risk 
adults, and that patients with NR2Ab levels ≥2.0 ng/ml pre-operatively (selected based on the 
above study [429]) were nearly 18 times more likely to develop a neurological event post-
operatively than patients with NR2Ab <2.0 ng/ml [420]. However, elevated levels of these 
antibodies were also found to be associated with hypertension, systemic lupus erythematous, 
and encephalitis, indicating that certain risk factors may be a source of NR2Ab production. 
Physiologically, the production of these antibodies may take time and they last in the blood 
for many months after ischemia, making the clinical applications of this test not limited to the 
acute setting [413, 415, 431]. The above two factors support the hypothesis of investigating 
NR2Ab level in more chronic pathologies, such as arterial stiffness. NR2Ab is a promising 
brain injury biomarker, but its relationship with aortic stiffness has not previously been 
investigated. 
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6.2.4 Aortic stiffness and ischemic brain injury biomarkers 
A literature search did not reveal any study that investigated the relationship between 
ischemic brain biomarkers and aortic stiffness, or between ischemic brain biomarkers and any 
chronic vascular pathology, such as cranial or carotid arteries atherosclerosis, or even with 
traditional potential risk factors, such as diabetes. Since aortic stiffness is related to cerebral 
small vessel disease, we hypothesize that patients with higher PWV may have impaired or 
dysfunctional brain circulation assessed by measuring ischemic the brain injury biomarker 
NR2Ab. 
 
6.2.5 Objective 
The relationship between aortic stiffness and cardiovascular and cerebrovascular adverse 
outcome has been established. Therefore, identifying a practical biomarker (such as NR2AB) 
linking the vascular cause (such as aortic stiffness) to end-organ damage (such as the brain) is 
of clinical importance, particularly if this biomarker is proportional to the degree of the 
causative pathology. 
 
The objective of this study is to investigate the relationship between aortic stiffness 
(PWV) and the ischemic brain injury biomarker NR2Ab in AVR. 
 
6.3 Materials and methods 
6.3.1 Patient population and overview 
Ethical approval and participant informed consent were obtained prior to the study. From 
June 2010 to August 2012, patients planning to undergo AVR were eligible. Exclusion 
criteria included: 1) aortic dissection; 2) emergency cases; 3) thoracic aorta (more than just 
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the root) or abdominal aortic aneurysm; 4) Marfan’s syndrome; 5) a history of stroke in the 
last year. 
Carotid-femoral PWV was used to assess aortic stiffness. To measure NR2Ab, blood 
samples were collected from each patient pre-operatively [420, 429]. 
 
Based on patients’ pre-operative PWV measurement patients were grouped as 
described in Chapter 3 and 4.  
6.3.2 Pulse wave velocity measurement protocol 
Detailed descriptions of the measurement protocol, quality control, and reproducibility of 
PWV is covered in the methodology section of Chapter 3. 
 
6.3.3 NR2Ab biomarker 
Blood samples were collected 18–24 h prior to surgery from 52 of 56 patients who had their 
PWV measured. Blood samples were centrifuged immediately at 3000 rpm at 20°C for 10 
minutes, and then serum samples were separated and frozen at –80°C. Frozen samples were 
processed by enzyme-linked immunosorbent assay (ELISA) using Gold Dot NR2 Antibody 
Test (CIS Biotech Inc., Atlanta, GA, USA). This was done according to the manufacturer’s 
procedure and as previously published [430]. In brief, frozen samples were thawed at –8°C. 
Serum samples were diluted 1:50 (20 µL of serum sample + 980 µL of working buffer) into 3 
ml tubes. Microplates were washed with working buffer for 5 minutes at 37ºC on a shaker. 
We then added 100 µL of calibrators, negative controls, positive controls, and prepared 
diluted sera to microplates coated with NR2 peptide and incubated the plates for 30 minutes 
at 37ºC on a shaker. After incubation, the microplates were washed with buffer, and 100 µL 
(1:1000 dilution) of anti-human horseradish peroxidase (A-HRP) was added to the 
microplates and incubated for 30 minutes at 37ºC on a shaker to structure the 
immunocomplex. The microplates were then washed with working buffer and distilled water 
and 100 µL of tetramethylbenzidine (TMB) substrate was added and plates were incubated in 
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darkness at room temperature for 10 minutes to develop color. The color reaction was stopped 
by adding Stop Reagent (100 µL) and gentle shaking for 30 seconds. The optic density was 
measured within 10 minutes at 450 nm/630 nm using a dual wave microplate reader. The 
NR2A antibodies in serum were measured using a standard calibration curve of the 
absorbance obtained for each calibrator x-axis vs. the NR2 antibody concentration in ng/ml 
on the y-axis. 
 
6.3.4 Statistical analysis 
Statistical analysis was conducted using IBM SPSS 20.0 software package (IBM Corporation, 
Armonk, NY, USA). Patient characteristics and results are expressed as means ± standard 
deviation, except for NR2Ab, which is expressed as median$±$standard deviation, for 
continuous variable and as frequencies for categorical variables; P-values < 0.05 were 
considered statistically significant. Normality testing was carried out on all variables studied. 
For the purpose of the regression analysis, non-normally distributed NR2Ab levels were log-
transformed. 
 
PWV was analyzed as a continuous variable to verify our hypothesis. In addition, it 
was also analyzed as a dichotomous variable (PWV-norm group vs. PWV-high group). 
NR2Ab was analyzed as a continuous variable by using the actual serum level to verify our 
hypothesis. Additional analyses as a dichotomous variable was performed using the median 
value of the NR2Ab level of the PWV-high group (1.8 ng/ml) as a cut-off point to classify 
patients into NR2Ab-low (<1.8 ng/ml) and NR2Ab-high (≥1.8 ng/ml) groups; this cut-off was 
previously tested [429]. 
 
Comparative analysis between the two PWV groups (PWV-norm and PWV-high) and 
the two NR2Ab groups (NR2Ab-low and NR2Ab-high) was carried out using an independent 
samples t-test or non-parametric equivalent (Mann–Whitney U test) for continuous variables, 
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and Pearson Chi-square or Fisher’s exact tests for categorical variables. Correlation analysis 
between variables was conducted using Spearman’s rank-order correlation and point biserial 
correlation (for dichotomous variables), while Phi test was used between two dichotomous 
variables (2 x 2). Simple regression (linear or logistic) between end points and other variables 
were used to identify potential predictors. All variables significant by simple regression or 
correlation, in addition to age and gender, were then included in two models of multiple 
regression (linear or logistic; enter method) analysis: 1) Model 1, including PWV as a 
continuous predictor; and 2) Model 2, including PWV cut-off as a dichotomous predictor. 
 
6.4 Results 
6.4.1 Descriptive results 
Fifty-six patients (16 females) with a mean age of 71 ± 8.4 years were recruited for this study. 
No mortality or severe neurological event (stoke or TIA) was recorded after a mean follow-up 
period of 409 ± 159 days post-operatively (post-AVR). Table 6.1 summarizes the 
demographic and clinical data of the patients and the correlation of these variables with 
NR2Ab level and the NR2Ab 1.8 ng/ml cut-off. NR2Ab was significantly associated with 
aortic stiffness (PWV), while the NR2Ab 1.8 ng/ml cut-off, in addition to PWV, was 
negatively associated with male gender. 
  
 220 
 
Variables Total (n = 56) NR2Ab level a r NR2Ab 1.8 ng/ml 
cut-off a r 
PWV 9.3 ± 2.2 0.28* 0.27* 
PWV cut-off –– 0.42** 0.43** 
NR2Ab 1.8 ng/ml cut-off –– 0.74** 1.00 
Age (years) 71 ± 8.4 –0.08 0.01 
Gender (male) 40 (71.4%) –0.26 –0.32* 
DM [n [(%)] 8 (14.3%) 0.14 0.09 
Smoking [n (%)] 2 (3.6%) -–0.08 0.02 
BMI (kg/m2) 27.2 (4.2) –0.21 –0.23 
SBP (mmHg) 136 ± 24 –0.03 0.02 
DBP (mmHg) 76 ± 11 –0.22 –0.24 
PP (mmHg) 62 ± 15 0.11 0.21 
MAP (mmHg) 97 ± 12 –0.11 –0.15 
Cholesterol (mmol/L) 4.5 ± 1.2 0.23 0.22 
Hypertension [n (%)] 38 (67.9%) 0.18 0.14 
Statin treatment [n (%)] 38 (67.9%) 0.10 0.02 
PVD [n (%)] 2 (3.6%) 0.12 0.25 
EuroSCORE (logistic) 5.5 ± 4.3 0.04 0.18 
AVA (cm2) 0.73 ± 0.2 –0.09 –0.10 
AVMG (mmHg) 48 ± 13 0.00 –0.06 
AVPG (mmHg) 82 ± 24 0.14 0.01 
EF  59 ± 15 0.22 0.06 
Table 6. 1 Demographic and clinical characteristics and their correlation with NR2Ab level and NR2Ab 1.8 
ng/ml cut-off. 
*Correlation is significant at the 0.05 level (2-tailed); **correlation is significant at the 0.01 level (2-tailed). aThe 
correlation was tested with Spearman’s rank-order correlation between continuous variables, with point biserial 
correlation between continuous and dichotomous variables, and with Phi test between dichotomous variables. 
Abbreviations: AVA, aortic valve area; AVMG, aortic valve mean gradient; AVPG, aortic valve peak gradient; 
BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; EF, Ejection fraction; MAP, mean 
arterial blood pressure; NR2Ab, N-methyl-D-aspartate (NMDA) receptor antibodies; PP, pulse pressure; PVD, 
peripheral vascular disease; PWV, pulse wave velocity; SBP, systolic blood pressure. 
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6.4.2 NR2Ab and aortic stiffness 
The overall mean PWV value was 9.3 ± 2.2 m/s and, as expected, it was significantly related 
to different age groups (P = 0.001, analysis of variance [ANOVA]), but not gender (P = 0.34). 
Thirty-five (62.5%) patients were classified in the PWV-norm group and 21 patients (37.5%) 
were in the PWV-high group. There was no significant difference between the two groups of 
PWV with respect to age, gender, classical hemodynamic measurements, aortic valve mean 
gradient, aortic valve peak gradient and aortic valve area, estimated IQ, and other clinical 
characteristics (data are shown in previous chapters). 
 
The NR2Ab level (ng/ml) was significantly higher in the PWV-high group than in the 
PWV-norm group (median 1.8 ± 1.2 vs. 1.2 ± 0.7, respectively, P = 0.003), and PWV (m/s) 
was significantly higher in the NR2Ab-high group (n = 17) than in the NR2Ab-low group (n 
= 35; mean 10.9 ± 2.1 vs. 9.1 ± 2.2, P = 0.05). Table 6.1 demonstrates the significant 
correlations between NR2Ab and PWV value (r = 0.28, P = 0.05), NR2Ab and PWV cut-off 
(r = 0.42, P = 0.002), NR2Ab 1.8 ng/ml cut-off and PWV value (r = 0.27, P = 0.05), and 
NR2Ab 1.8 ng/ml cut-off and PWV cut-off (Phi = 0.43, P = 0.002). 
 
To confirm the findings of the correlation analysis, simple linear regression between 
NR2Ab and other variables (age, gender, mean arterial pressure, body mass index, smoking 
diabetes mellitus, ejection fraction, aortic valve peak gradient, aortic valve mean gradient, 
aortic valve area, cholesterol, triglycerides, and PWV) was preformed to identify potential 
predictors of NR2Ab (Table 6.2). In this simple linear regression analysis, the relationship 
between NR2Ab (log transformation) was significantly related only to PWV value 
(continuous), PWV cut-off (dichotomous), and gender (Table 6.2). All variables with 
significant linear regression or correlation, in addition to age and gender, were included in a 
multiple regression (enter method) analysis (Table 6.2). 
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Model 1 of the multiple linear regression (includes PWV, age, and gender) 
statistically significantly predicts NR2Ab (F = 3.33, P = 0.03), and 17.2 % of variance in 
NR2Ab can be explained by changes in these variables. PWV was the only independent 
predictor of NR2Ab level (Beta = 0.37; P = 0.022). Model 2 of the multiple linear regression 
(includes PWV cut-off, age, and gender) statistically significantly predicts NR2Ab level (F = 
4.13, P = 0.01), and 20.5% of variance in NR2Ab can be explained by changes in these 
variables. The PWV cut-off was the only independent predictor of NR2Ab level (Beta = 0.37; 
P = 0.008). 
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Simple linear regression 
Predictors NR2Ab level 
beta (P-value) 
PWV value 0.27 (0.05) 
PWV cut-off 0.39 (<0.01) 
Age –0.05 (0.71) 
Gender (male) –0.27 (0.05) 
DM 0.08 (0.57) 
Smoking –0.12 (0.38) 
BMI (kg/m2) –0.2 (0.15) 
MAP (mmHg) –0.16 (0.26) 
Cholesterol (mmol/L) 0.09 (0.67) 
EuroSCORE (logistic) 0.07 (0.49) 
AVA (cm2) –0.09 (0.55) 
AVMG (mmHg) –0.01 (0.92) 
AVPG (mmHg) –0.06 (0.66) 
EF 0.03 (0.83) 
 
Multiple linear regression (Model 1) 
PWV value 0.37 (0.02) 
Age –0.25 (0.12) 
Gender (male) –0.21 (0.12) 
 
Multiple linear regression (Model 2) 
PWV cut-off 0.37 (<0.01) 
Age –0.09 (0.46) 
Gender (male) –0.21 (0.11) 
Table 6. 2 Simple and multiple linear regression analysis to identify variables that independently predict 
NR2Ab level. 
Values are shown as standardized beta coefficient (P-value) and bold values indicate statistical significance. 
Abbreviations: AVA, aortic valve area; AVMG, aortic valve mean gradient; AVPG, aortic valve peak gradient; 
BMI, body mass index; DM, diabetes mellitus; EF, Ejection fraction; MAP, mean arterial blood pressure; NR2Ab, 
N-methyl-D-aspartate (NMDA) receptor antibodies; PWV, pulse wave velocity. 
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Additional analysis was performed to ascertain the effects of PWV on the likelihood 
of patients being in the NR2Ab-high group (≥1.8 ng/ml). First, simple logistic regression was 
conducted to confirm the findings from the correlation analysis; only PWV cut-off and gender 
were statistically significant, while the PWV value was clinically significant (Table 6.3). 
Therefore, only PWV (the predictor of interest), and age and gender (classical variables) were 
included in the multiple logistic models. 
 
In Model 1 of the multiple logistic regression (Table 6.3), though the entire model 
was statistically significant (P = 0.017) and explained 24.7% (Nagelkerke R2) of the NR2Ab 
variance, the PWV value itself was not a significant predictor; gender was the only significant 
predictor, of which male gender was protective (odds ratio [OR] below 1). 
 
Model 2, using PWV as a dichotomous variable (PWV-norm vs. PWV-high), was 
even more significant than Model 1. The logistic regression model was statistically significant 
(P = 0.002) and the Hosmer and Lemeshow goodness of fit test was not significant (P = 
0.12). The model explained 35.5% (Nagelkerke R2) of the variance in NR2Ab and correctly 
classified 73.1% of cases; the positive predictive value was 66.6% and the negative predictive 
value was 74.4%. In this model, PWV cut-off was statistically significant, as changing the 
status of PWV from normal to high was associated with a 7.23 times increased likelihood of 
having high NR2Ab (>1.8 ng/ml; Table 6.3). 
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Simple logistic regression 
Predictors NR2Ab 1.8 ng/ml cut-off 
OR (95%CI) P-value 
PWV value 1.29 (0.97–1.71) 0.08 
PWV cut-off 6.93 (1.91–25.17) <0.01 
Age 1.0 (0.93–1.01) 0.96 
Gender (male) 0.18 (0.05–0.67) 0.01 
DM 1.63 (0.33–8.01) 0.54 
Smoking 0.94 (0.33–2.65) 0.92 
BMI (kg/m2) 0.88 (0.79–1.02) 0.09 
MAP (mmHg) 0.97 (0.92–1.02) 0.31 
Cholesterol (mmol/L) 1.63 (0.84–3.19) 0.14 
EuroSCORE (Logistic) 1.09 (0.95–1.25) 0.21 
AVA (cm2) 0.35 (0.01–6.98) 0.49 
AVMG (mmHg) 0.99 (0.64–1.03) 0.69 
AVPG (mmHg) 1.0 (0.97–1.02) 0.96 
EF 1.0 (0.96–1.05) 0.72 
 
Multiple logistic regression (Model 1) 
PWV value 1.4 (0.94–2.06) 0.09 
Age 0.95 (0.86–1.05) 0.32 
Gender (male) 0.21 (0.05–0.79) 0.02 
 
Multiple logistic regression (Model 2) 
PWV cut-off 7.23 (1.74–30.1) <0.01 
Age 0.98 (0.91–1.06) 0.66 
Gender (male) 0.19 (0.04–0.8) 0.02 
Table 6. 3 Simple and multiple logistic regression analysis to identify variables that independently predict 
patients with high NR2Ab (NR2Ab 1.8 ng/ml cut-off).  
Values are shown as odd ratio (OR) and P-value; bold values indicate statistical significance. Abbreviations: AVA, 
aortic valve area; AVMG, aortic valve mean gradient; AVPG, aortic valve peak gradient; BMI, body mass index; 
DM, diabetes mellitus; EF, Ejection fraction; MAP, mean arterial blood pressure; NR2Ab, N-methyl-D-aspartate 
(NMDA) receptor antibodies; PWV, pulse wave velocity; OR, odds ratio; CI, confidence interval. 
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6.5 Discussion 
Most of the previous studies focused on the predictive value of the NR2Ab in acute ischemia 
(stoke and TIA) [429, 430]; however, scant research has explored the predictive value of this 
biomarker in more chronic cerebrovascular pathologies, such as arterial stiffness. In our 52 
patients, NR2Ab levels ranged from 0.33 to 4.73 ng/ml, and although the age range varied 
from 53 to 90 years, it was not related to age. Conversely, male gender was related with lower 
NR2Ab level. Furthermore, our results showed that only two variables, gender and PWV, 
were associated with NR2Ab level; male gender had a negative association, while PWV 
(aortic stiffness) had a positive association. To test the objective of whether PWV is related to 
NR2Ab biomarker level, correlation and multiple regression analyses were performed. These 
analyses revealed that PWV value was significantly related to and independently predicted 
NR2Ab, but not the NR2Ab 1.8 ng/ml cut-off. Grouping patients according to their PWV into 
PWV-norm and PWV-high (PWV cut-off) increased the significance of the relationship with 
NR2Ab; PWV cut-off was an independent predictor of NR2Ab level and it was associated 
with a 7.23 times increased likelihood of having high NR2Ab >1.8 ng/ml. 
 
It is known that high PWV is significantly associated with cerebral small vessel 
disease [374, 378, 379] and NR2Ab is a potential ischemic brain injury biomarker [428-430]. 
The positive relationship between NR2Ab and PWV may be explained by the hemodynamic 
ischemic effect of arterial stiffness on brain tissue and subsequent release of proteolytic 
fragments of NR2 subunits of the NMDA receptors and the formation of NR2Ab over time. 
This does not undermine the importance of NR2Ab in acute ischemia, particularly if serum 
levels are proportional to the size and severity of the ischemia. For example, it was previously 
reported that the mean NR2A/2B antibody level (ng/ml) in patients with ischemic stroke was 
5.01 ±1.23 (range, 3.24–7.21), in patients with TIA it was 4.02 ±2.04 (range, 2.71–7.23), 
and in patients with hypertension/atherosclerosis it was 1.72 ±0.23, while in controls it was 
only 1.49 ±0.22 (range, 1.02–1.98) [429]. Our results are similar to the values of the 
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atherosclerosis and controls groups (median 1.8 ± 1.2 vs. 1.2 ± 0.7 for the PWV-high vs. 
PWV-norm groups, respectively) as no patient developed stroke or had a TIA. 
 
There was no correlation between AS parameters, such as AVA, AVMG, or AVPG, 
and NR2Ab level (Table 6.1). The absence of such a relationship may indicate that AS has no 
chronic ischemic effect on brain tissue. However, this conclusion would be more concrete if 
we measured NR2Ab levels post-operatively to determine if replacing a stenotic valve (AVR) 
has any effect on NR2Ab levels. 
 
To the best of our knowledge, this is the first study to investigate and establish a 
relationship between aortic stiffness (PWV) and NR2Ab biomarker levels. 
 
Limitations 
NR2Ab level was only measured pre-operatively; it may be useful to measure sequential 
levels post-operatively to determine whether there is a change in NR2Ab level following 
AVR. The effect of potential confounders, such as diabetes, hypertension, and dyslipidemia, 
on the relationship between aortic stiffness and NR2Ab requires a much larger sample size to 
be adequately evaluated. However, the aim of this part of the current project was to provide 
explorative preliminary data that can be used to direct future studies. 
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6.6 Conclusions and future clinical prospects 
Higher PWV value in AVR patients is associated with higher levels of the ischemic brain 
biomarker NR2Ab. 
 
As for any predictor of disease condition, early identification of patients at risk will 
facilitate regular monitoring, risk stratification, and future planning and consideration of 
potential therapies, if available. PWV is a predictor of adverse cardiovascular and 
cerebrovascular outcomes, while NR2Ab is a potential pathophysiological predictor of 
adverse cerebrovascular outcomes. The association between two predictors of common or 
different outcomes, for example between diabetes and hypertension or in our case between 
PWV and NR2Ab, provides a better understanding of the disease development process, 
facilitates the development of future risk stratification models, and renders their clinical use, 
to some degree, interchangeable. 
 
This study offers a significant step forward in our knowledge pertaining to end-organ 
damage in the presence of increased aortic stiffness. Future cross-sectional studies with larger 
sample sizes to adjust for potential confounders, such as hypertension, diabetes, and 
dyslipidemia, are required to establish or reject this relationship. Establishing such a 
relationship in cross-sectional studies will warrant the need for longitudinal studies to assess 
the predictive value of NR2Ab level for clinical outcomes across different groups of PWV 
values. Ultimately, this will move us a step closer to discovering new clinical (PWV) and 
biochemical (NR2Ab) predictors of neurocognitive outcomes, in addition to the traditional 
risk factors currently in use. 
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7 Chapter 7  
The relationship between biomarker N-methyl-D-aspartate 
receptor antibody level and cognitive function and quality of 
life in aortic valve replacement 
 
This chapter investigates whether there is a relationship between serum brain injury 
biomarker N-methyl-D-aspartate receptor antibody (NR2Ab) levels, cognitive function, and 
quality of life (QoL) in aortic valve replacement.  
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7.1 Abstract 
Background: N-methyl-D-aspartate receptor antibody (NR2Ab) is a promising brain injury 
biomarker as it is predictive of severe neurological adverse events after cardiopulmonary 
bypass.  
Objectives: To investigate the relationship between NR2Ab biomarker and: 1) cognitive 
function; and 2) quality of life (QoL) in aortic valve replacement (AVR). 
 
Methods: NR2Ab serum levels were measured pre-operatively for patients planning to 
undergo AVR. Cognitive function was assessed using the Cambridge Neuropsychological 
Test Automated Battery (CANTAB) test, and QoL was scored using SF-36 and EQ-5D 
questionnaires. QoL and cognitive function were re-assessed 409 ± 159 days post-operatively. 
We analyzed NR2Ab levels in two ways: 1) as a continuous variable using the actual value; 
and 2) as a dichotomous variable (NR2Ab-low and NR2Ab-high groups) using 1.8 ng/ml as 
the cut-off value. 
 
Results: Fifty-six patients (16 females) with a mean age of 71 ± 8.4 years were recruited for 
this study, and 52 patients had their NR2Ab levels measured pre-operatively. Fifty (89%) 
patients were able to attend the follow-up visit (mean, 409 ± 159 days) post-operatively (post-
AVR). No mortality or severe neurological event (stoke or transient ischaemic attack [TIA]) 
was recorded. The association between NR2Ab and cognitive function was limited only to 
pre-operative memory function. The NR2Ab-low group had better QoL scores than the 
NR2Ab-high group at pre- and post-operative stages, particularly in the physical health 
domains, which suggests that patients with low NR2Ab levels benefit more from AVR. 
Multiple regression analyses revealed that NR2Ab level and the NR2Ab 1.8 ng/ml cut-off 
were independent predictors of QoL (pre- and post-operatively).  
 
Conclusion: In AVR patients, the NR2Ab biomarker is an independent predictor of QoL pre- 
and post-AVR, but not of cognitive function.  
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7.2 Introduction 
7.2.1 Cognitive function 
Cognitive function is a complex process that involves interactions between different parts of 
the brain, particularly the hypoxia-sensitive hippocampus where memories are primarily 
stored [350]. Post-operative cognitive dysfunction (POCD) can affect different cognitive 
domains, such as attention, memory, learning, executive function, and the visual spatial 
domain, or it can manifest as a behavioral change. Furthermore, cognitive dysfunction is 
associated with a 5-fold increase in mortality, prolonging hospital stay, reduced QoL and 
employment, and a significant need for sociomedical care following discharge [343, 351]. 
Detailed background of cognitive function, the definition of POCD, and how cognitive 
function is measured are discussed in Chapter 5. 
 
7.2.2 Quality of life in cardiac patients 
As discussed previously, health related QoL is a highly significant and effective patient-
reported outcomes (PROs) tool. Surgical outcome is traditionally evaluated in terms of 
operative mortality and morbidity, such as infection, stroke, need for intensive care, and acute 
renal injury, and low rates of these adverse clinical outcomes are associated with favourable 
gains in patient wellbeing and functioning. However, in recent years, there has been growing 
recognition that morbidity and mortality data alone are incomplete measures of outcome 
following surgery, and that a patient’s own perception of their health is an important aspect of 
health outcome assessment [215, 216]. Detailed background on QoL, instruments used to 
measure QoL, the significance of QoL in cardiac patients, and predictors of QoL are all 
thoroughly discussed in Chapter 2. 
 
 232 
7.2.3 N-methyl-D-aspartate receptor antibodies  
Neural cell death or ischaemia causes degradation of N-methyl-D-aspartate (NMDA) receptor 
subunits (NR2), which, in turn, releases proteolytic fragments into circulation. This process 
stimulates the immune system to produce antibodies against these NR2 fragments (NR2Ab), 
which can be assayed in blood samples [428]. Previous literature has linked serum NR2Ab 
level to acute or recent ischaemic stroke [429, 430], and these levels are predictive of severe 
adverse neurological events after cardiac surgery [429]. In Chapter 6 we revealed that serum 
NR2Ab levels are related to aortic stiffness measured by pulse wave velocity (PWV; Chapter 
6). Whether NR2Ab is predictive of other clinical end points is an interesting and important 
research question. Further detailed background on NR2Ab is discussed in Chapter 6. 
 
7.2.4 Objectives 
Cognitive function and QoL can only be measured by neuropsychological tests and QoL 
questionnaires, respectively, which are time consuming and laborious tasks for both the 
patient and administrator, and usually require repetition at different time-points. Therefore, 
identifying biomarkers that can predict cognitive function or QoL is clinically important, 
practical, and novel. To date, there is no biomarker to measure or predict cognitive function in 
any patient population or to predict QoL in cardiac surgery patients. 
 
It is well known that cognitive function and QoL are related to vascular health status, 
and in previous chapters we have demonstrated that aortic stiffness is uniquely related to the 
ischaemic brain biomarker NR2Ab, cognitive function, and QoL in our population. Therefore, 
we hypothesize that NR2Ab may be related to cognitive function and/or QoL aortic valve 
replacement. 
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7.3 Materials and methods 
7.3.1 Patient population and overview 
Ethical approval and participant informed consent were obtained prior to study 
commencement. From June 2010 to August 2012, patients planning to undergo AVR were 
eligible. Exclusion criteria included: 1) aortic dissection; 2) emergency cases; 3) thoracic 
aorta (more than just the root) or abdominal aortic aneurysm; 4) Marfan’s syndrome; 5) any 
psychiatric or significant neurological condition; 6) taking any regular medication for mental 
illness including antidepressants; and 7) a Mini Mental State examination score below 25 
points.  
 
Serum NR2Ab levels were measured pre-operatively, cognitive function was 
measured using the computer-based Cambridge Neuropsychological Test Automated Battery 
(CANTAB) system, and QoL was assessed using SF-36 and EQ-5D questionnaire pre- and 
post-operatively (409 ± 159 days post-AVR). 
 
7.3.2 N-methyl-D-aspartate receptor antibody biomarker assessment 
Blood samples were collected 18–24 h prior to surgery from 52 patients of 56 patients who 
had their QoL and cognitive function measured pre-operatively. A complete description of 
NR2Ab biomarker measurements are covered in Chapter 6.  
 
7.3.3 Cognitive function assessment 
A computer-based cognitive battery was used to eliminate most of the limitations of paper-
based batteries, as it offers superior precision in measuring responses and reaction time [363, 
368]. Cognitive function was assessed using the CANTAB test, which is a computerized, 
non-linguistic, and culturally independent cognitive test that was developed by a team of 
experts at the University of Cambridge (http://www.cantab.com/) [369]. Details of cognitive 
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function assessment, including the descriptions of the components of the battery used and the 
measured outcomes, are fully covered in Chapter 5. 
 
7.3.4 Quality of life assessment 
Self-administrated SF-36 and EQ-5D QoL questionnaires were used to assess QoL. Details of 
QoL assessment, including descriptions of the questionnaires used and the measured 
outcomes, are fully covered in Chapter 4. 
 
7.3.5 Statistical analysis 
Statistical analysis was conducted using the IBM SPSS 20.0 software package (IBM 
Corporation, Armonk, NY, USA). Patient characteristics and results are expressed as means ± 
standard deviation or as medians ±$standard deviation or ranges when suitable for continuous 
variables, and as frequencies for categorical variables; P-values < 0.05 were considered 
statistically significant. Tests for normality were carried out on all variables studied and, for 
the purpose of regression analysis, non-normally distributed variables were transformed when 
neccessary. 
  
NR2Ab was analyzed as a continuous variable by using the actual serum level to 
verify our hypothesis. Additional analysis as a dichotomous variable was performed using the 
median NR2Ab value of the PWV-high group (1.8 ng/ml) as a cut-off point to classify 
patients into NR2Ab-low (<1.8 ng/ml) and NR2Ab-high (≥ 1.8 ng/ml) groups; this cut-off 
was tested previously [429].  
 
Comparative analyses between the NR2Ab-low and NR2Ab-high groups were carried 
out using independent-samples t-tests or the non-parametric equivalent (Mann–Whitney U 
test) for continuous variables, and Pearson Chi-square or Fisher’s exact tests for categorical 
variables. Correlation analysis between variables was conducted using Spearman’s rank-order 
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correlation and point biserial correlation (for the dichotomous variables), while the Phi test 
was used between two dichotomous variables (2 x 2). Simple regression (linear or logistic) 
between end points and other variables was used to identify potential predictors. All variables 
with significant simple regression or correlation, in addition to age and gender, were then 
included in two models of multiple regression (linear or logistic; enter method) analysis: 1) 
Model 1, including NR2Ab as a continuous predictor; and 2) Model 2, including the NR2Ab 
1.8 ng/ml cut-off as a dichotomous predictor.  
 
7.4 Results  
7.4.1 Descriptive results 
Fifty-six patients (16 females) with a mean age of 71 ± 8.4 years were recruited for this study. 
Fifty (89%) patients were able to attend the follow-up visit (409 ± 159 days) post-operatively 
(post-AVR). No mortality or severe neurological event (stoke or transient ischaemic attack 
[TIA]) was recorded. Fifty-two of the 56 patients had their NR2Ab levels measured pre-
operatively. Table 7.1 summarizes patient demographic and clinical data, as well as NR2Ab-
high (n = 17) and NR2Ab-low group (n = 35) information stratified according to the 1.8 
ng/ml cut-off value. The only statistically significant difference between NR2Ab-high and 
NR2Ab-low groups was found in relation to gender (P < 0.01) and in NR2Ab level (2.8 ± 1.0 
vs. 1.1 ± 05, respectively; P <0.001).  
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Parameter Total     
(n = 52) 
NR2Ab-high 
(n = 17) 
NR2Ab-low  
(n = 35) 
P-value 
Male 37 (71.2%) 8 (47.1%) 29 (82.9%) <0.01 
Age (years) 
Age range (years) 
71 ± 8 
53–90 
71 ± 9 
54–83 
71 ± 8 
53–90 
0.78 
White Caucasian [n (%)] 51 (98%) 16 (94.1%) 35 (100%) 0.14 
DM [n (%)] 8 (16.3%) 3 (21.4%) 5 (14.3%) 0.54 
Smoking [n (%)] 2 (3.8%) 0 (0%) 2 (5.7 %) 0.44 
BMI (kg/m2) 27.5 ± 4.3 26.1 ± 4.4 28.2 ± 4.1 0.13 
SBP (mmHg) 139 ± 17 139 ± 22 139 ± 14 0.84 
DBP (mmHg) 76 ± 12 73 ± 12 79 ± 11 0.08 
PP (mmHg) 62 ± 15 66 ± 19 60 ± 12 0.32 
MAP (mmHg) 97 ± 12 95 ± 14 98 ± 11 0.37 
Cholesterol (mmol/L) 4.4 ± 0.9 4.1 ± 1.0 4.3 ± 0.9 0.14 
Hypertension [n (%)] 35 (67.3%) 13 (76.5%) 22 (62.9%) 0.32 
Statin treatment [n (%)] 36 (69.2%) 12 (70.6%) 24 (68.6%) 0.88 
PVD [n (%)] 2 (3.6%) 2 (11.8% 0 (0%) 0.10 
EuroSCORE (logistic) 5.3 ± 4.2 6.4 ± 5.3 4.8 ± 3.4 0.52 
Aortic valve area (cm2) 0.74 ± 0.2 0.71 ± 0.2 0.76 ± 0.2 0.58 
AVMG  48 ± 13 47 ± 13 48 ± 12 0.70 
AVPG 82 ± 24 82 ± 24 82 ± 25 0.52 
Ejection fraction  61 ± 15 62 ± 17 60 ± 15 0.35 
Concomitant CABG 14 (26.8%) 3 (17.6%) 11 (31.4%) 0.29 
CPB time (minutes) 89 ± 22 83 ± 26 92 ± 20 0.10 
NR2Ab (ng/ml) 1.6 ± 1.0 2.8 ± 1.0 1.1 ± 05 <0.001 
Table 7. 1 Patient demographic and clinical characteristics. 
Values are shown as n (%) for categorical variables and means ± standard deviation for continuous variables.  
Abbreviations: DM, diabetes mellitus; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; PP, pulse pressure; MAP, mean arterial blood pressure; PVD, peripheral vascular disease; 
AVMG, aortic valve mean gradient; AVPG, aortic valve peak gradient; CABG, coronary artery bypass graft 
surgery; CPB, cardiopulmonary bypass; NR2Ab, N-methyl-D-aspartate receptor antibody. 
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7.4.2 N-methyl-D-aspartate receptor antibody level and cognitive function 
A limited correlation was found between NR2Ab and the main components of cognitive 
function (Table 7.2). Pre-operatively, there was a significant correlation between delayed 
memory (pattern recognition memory [PRM]) and NR2Ab level, and NR2Ab cut-off, test (r = 
–0.29 and -0.32, respectively) indicating that higher levels of NR2Ab are associated with 
lower memory. Post-operatively, there was significant correlation between the problem 
solving test and NR2Ab level, and NR2Ab cut-off, (r values from 0.31 to 0.36); the NR2Ab-
high group was associated with a lesser number of problems solved on first trial and a higher 
number of trials needed to solve difficult problems (Table 7.2). Therefore, only these 
cognitive components were tested in the subsequent multiple regression analysis (data not 
shown).  
 
Model 1 multiple regression (enter method) included age, gender, and NR2Ab (log-
transformed) as a continuous predictor. This regression identified that NR2Ab independently 
predicted pre-operative delayed memory (PRM test; square root transformed; Beta = –0.31, P 
= 0.03), but not one touch stockings of Cambridge (OTS; problem solving) components 
(square root transformed). Conversely, age was a superior independent predictor of poorer 
PRM and OTS test results; P-values ranged from 0.03 to <0.01. 
 
Similarly, Model 2 multiple regression (enter method), which included age, gender 
and the NR2Ab 1.8 ng/ml cut-off as a dichotomous predictor, identified that the cut-off 
independently predicted delayed pre-operative PRM (Beta = –0.34, P = 0.02), but not OTS 
components. As in Model 1, age was an independent predictor of both PRM and OTS test 
scores; P-values ranged from 0.04 to <0.01. It is worth mentioning that the NR2Ab 1.8 ng/ml 
cut-off was a stronger predictor of pre-operative delayed memory (PRM) than age, but not 
problem solving (OTS) test results.  
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Parameter NR2Ab level a r NR2Ab 1.8 ng/ml cut-off a r 
Male –0.32* –0.37** 
Age (years) –0.09 0.01 
Pre-operative cognitive 
function 
  
PRM delayed, % of correct –0.29* –0.32* 
RVP total missed 0.22 0.23 
RVP A’ –0.25 –0.23 
OTS Problems solved on 
1st choice 
–0.15 –0.18 
OTS choices to correct   
(level five) 
0.20 0.28 
OTS latency to correct   
(level five) 
0.18 0.23 
Post-operative cognitive 
function 
  
PRM delayed, % of correct –0.09 –0.17 
RVP total missed –0.01 –0.01 
RVP A –0.04 –0.03 
OTS Problems solved on 
1st choice 
–0.25 –0.34* 
OTS choices to correct     
(level five) 
0.31* 0.36* 
OTS latency to correct     
(level five) 
0.16 0.15 
Table 7. 2 Bivariate correlation between NR2Ab level, NR2Ab 1.8 ng/ml cut-off, and the main components 
of cognitive function. 
r: correlation coefficient; *correlation is significant at the 0.05 level (2-tailed); **correlation is significant at the 
0.01 level (2-tailed). Abbreviations: PRM, pattern recognition memory; RVP, rapid visual information processing 
(A’ measure of sensitivity to the target stimulus); OTS, one touch stockings of Cambridge; NR2Ab, N-methyl-D-
aspartate receptor antibody.   
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7.4.3  N-methyl-D-aspartate receptor antibody level and quality of life  
Using the EQ-5D instrument, the NR2Ab-low group scored significantly better than the 
NR2Ab-high group in mobility, self-care, and usual activity both pre- and post-operatively 
(Table 7.3). Similarly, the NR2Ab-low group scored better on the self-rating visual analogue 
scale (EQ-5D VAS) and on the EQ-5D index, which is a summary score of all health 
domains, pre- and post-operatively. Over the follow-up period, the NR2Ab-low group had 
significantly improved in six of seven components of the EQ-5D (with the exception of self-
care), while the NR2Ab-high group significantly improved in only three of seven 
components: anxiety or depression, EQ-5D VAS, and EQ-5D index (Table 7.3). 
 
With respect to the SF-36 QoL instrument, using the metric score, the difference in 
pre-operative scores (higher scores indicate better QoL) between NR2Ab-low and NR2Ab-
high groups were significant only in the physical health domains in favour of the NR2Ab-low 
group (P-values between 0.05 and < 0.01; Table 7.4). Post-operatively, the QoL scores for 
both groups improved (significantly and non-significantly) in all domains; however, the 
NR2Ab-low group scores were significantly better in all physical and mental health domains 
than their NR2Ab-high counterpart (P-values between 0.04 and < 0.01; Table 7.4). Consistent 
with the EQ-5D findings, over the follow-up period, the NR2Ab-low group experienced 
significant improvement in all 10 components of the SF-36, while the NR2Ab-high group 
significantly improved in five of 10 components (Table 7.4). 
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EQ-5D 
domains 
 Pre-
operative 
Post-
operative 
Mean 
difference 
**P-value 
(improvement) 
Mobility NR2Ab-low 1.31 ± 0.47 1.0 ± 0.0 –0.31 ± 0.44 <0.01 
NR2Ab-
high 
1.65 ± 0.49 1.41 ± 0.51 –0.24 ± 0.66 0.15 
*P-value 0.02 <0.001   
Self-care NR2Ab-low 1.0 ± 0.0 1.0 ± 0.0 0.0 1.0 
NR2Ab-
high 
1.12 ± 0.33 1.12 ± 0.33 0.0 1.0 
*P-value 0.04 0.05   
Usual activity NR2Ab-low 1.31 ± 0.47 1.03 ± 0.18 –0.28 ± 0.50 0.02 
NR2Ab-
high 
1.65 ± 0.49 1.59 ± 0.62 –0.06 ± 0.56 0.65 
*P-value 0.02 <0.001   
Pain or 
discomfort 
NR2Ab-low 1.5 ± 0.52 1.23 ± 0.42 –0.27 ± 0.61 <0.01 
NR2Ab-
high 
1.71 ± 0.58 1.53 ± 0.51 –0.18 ± 0.64 0.25 
*P-value 0.46 0.03   
Anxiety or 
depression 
NR2Ab-low 1.40 ± 0.55 1.06 ± 0.25 –0.34 ± 0.59 0.01 
NR2Ab-
high 
1.51 ± 0.51 1.12 ± 0.33 –0.39 ± 0.47 0.02 
*P-value 0.84 0.52   
VAS (visual 
analogue 
scale) 
NR2Ab-low 74.7 ± 10.2 87.5 ± 7.2 12.8 ± 7.16 <0.001 
NR2Ab-
high 
63.5 ± 14.4 74.1 ± 13.1 10.6 ± 12.5 <0.01 
*P-value 0.01 <0.001   
Index NR2Ab-low 0.78 ± 0.11 0.94 ± 0.08 0.16 ± 0.14 <0.001 
NR2Ab-
high 
0.72 ± 0.12 0.82 ± 0.14 0.10 ± 0.14 0.01 
*P-value 0.04 <0.01   
Table 7. 3 Mean scores for each domain of the EQ-5D and for the component summaries (VAS and index) 
at pre- and post-operative stages. 
Values are shown as mean ± standard deviation. Bold values indicate statistical significance; *P-value is for the 
NR2Ab-low vs. NR2Ab-high groups (independent-samples analysis); **P-value is for the pre-op vs. post-op 
groups (paired samples analysis). Abbreviations: NR2Ab, N-methyl-D-aspartate receptor antibody.  
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SF-36 
domains 
 Pre-
operative 
Post-
operative 
Mean 
difference 
**P-value 
(improvement) 
Physical 
functioning 
NR2Ab-low 70 ± 15 85 ± 10 –14 ± 12 <0.001 
NR2Ab-high 52 ± 25 64 ± 25 –12 ± 17 0.01 
*P-value <0.01 <0.01   
Role-
physical 
NR2Ab-low 67 ± 21 85 ± 15 –18 ± 18 <0.001 
NR2Ab-high 56 ± 20 67 ± 27 –11 ± 25 0.14 
*P-value 0.03 0.02   
Bodily pain NR2Ab-low 79 ± 15 86 ± 14 –7 ± 18 0.04 
NR2Ab-high 63 ± 26 74 ± 20 –11 ± 26 0.09 
*P-value 0.03 0.04   
General 
health 
NR2Ab-low 68 ± 15 83 ± 11 –14 ± 14 <0.001 
NR2Ab-high 60 ± 16 63 ± 20 –3 ± 20 0.53 
*P-value 0.05 <0.001   
Vitality NR2Ab-low 58 ± 13 75 ± 11 –17 ±16 <0.001 
NR2Ab-high 49 ± 19 61 ± 17 –12 ± 17 0.02 
*P-value 0.06 <0.01   
Social 
functioning 
NR2Ab-low 80 ± 21 96 ± 7 –15 ± 23 <0.01 
NR2Ab-high 66 ± 27 82 ± 19 –16 ± 30 0.04 
*P-value 0.08 <0.01   
Role-
emotional 
NR2Ab-low 80 ± 20 94 ± 8 -13 ± 20 <0.01 
NR2Ab-high 68 ± 34 76 ± 23 –8 ± 38 0.34 
*P-value 0.28 0.02   
Mental 
health 
NR2Ab-low 77 ± 19 87 ± 10 –12 ± 20 <0.001 
NR2Ab-high 76 ±14 82 ± 11 –6 ± 12 0.06 
*P-value 0.65 0.04   
Physical 
component 
summary 
(PCS) 
NR2Ab-low 47 ± 8 52 ± 5 –5 ± 7 <0.001 
NR2Ab-high 40 ± 9 44 ± 9 –4 ± 8 0.04 
*P-value <0.01 <0.01   
Mental 
component 
Summary 
(MCS) 
NR2Ab-low 50 ±10 57 ± 4 –7 ± 10 <0.001 
NR2Ab-high 48 ± 10 52 ± 7 –5 ± 10 0.12 
*P-value 0.44 0.01   
Table 7. 4 Mean differences between pre- and post-operative SF-36 scores classified by NR2Ab-low and 
NR2Ab-high groups. 
Values are shown as mean ± standard deviation. Bold values indicate statistical significance; *P-value is for the 
NR2Ab-low vs. NR2Ab-high groups (independent-samples analysis); **P-value is for the pre-op vs. post-op 
groups (paired samples analysis). Abbreviations: NR2Ab, N-methyl-D-aspartate receptor antibody.  
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Further analysis using the norm-based scoring (NBS) system confirmed the above 
findings; Figure 7.1 is a visual presentation of these results in relation to general population 
scores (mean of 50). It is worth noting that the pre-operative score of the NR2Ab-high group 
was below the average range for the general population (mean <47) in seven of 10 
components; namely, physical functioning, role-physical, vitality, social functioning, role-
emotional, and physical component summary. Conversely, the NR2Ab-low group had lower 
scores than the general population only on the physical functioning and role-physical 
components (Figure 7.1) and SF-36 components (Figure 7.2). Interestingly, even with the 
improvement in QoL over the follow-up period, the NR2Ab-high group was still scoring 
below the general population on five components and were comparable to the general 
population in the other five components, while the NR2Ab-low group scores were 
comparable to the general population on four components and performed better on six 
components.   
 
Figure 7.2 shows the differences between the two NR2Ab groups and changes over 
the follow-up period for QoL component summaries of the SF-36 (PCS and MCS) and EQ-
5D (VAS and index). The NR2Ab-low group had significantly better scores than the NR2Ab-
high group in almost all of the components pre- and post-operatively (aside from pre-
operative mental component summary).  
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Figure 7. 1 Changes in the norm-based scores between pre- and post-operative score of each SF-36 domain 
for the NR2Ab-high and NR2Ab-low groups. 
Side P-values represent the significance of differences between the NR2Ab-low vs. NR2Ab-high groups 
(independent-samples); middle P-values represent the significance of differences (improvement) between the pre-
operative vs. post-operative scores (paired-samples). Abbreviations: NR2Ab, N-methyl-D-aspartate receptor 
antibody.  
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Figure 7. 2 Changes between the pre- and post-operative scores of the QoL component summaries (SF-36 
and EQ-5D) for the NR2Ab-high and NR2Ab-low groups. 
Side P-values represent the significance of differences between the NR2Ab-low vs. NR2Ab-high groups 
(independent-samples); middle P-values represent the significance of differences (improvement) between the pre-
operative vs. post-operative scores (paired samples). Abbreviations: NR2Ab, N-methyl-D-aspartate receptor 
antibody, VAS, visual acuity scale.  
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7.4.4 Quality of life correlation and regression analysis 
There were significant correlations between NR2Ab (level or cut-off) and most of the QoL 
component summaries pre- and post-operatively (Table 7.5).  
 
Variables EQ-5D 
index 
EQ-5D 
VAS 
PCS MCS NR2Ab 
level 
NR2Ab 1.8 
ng/ml cut-off 
Pre-operative 
EQ-5D index 1      
EQ-5D VAS 0.33* 1     
PCS 0.41** 0.52** 1    
MCS 0.20 0.13 -0.10 1   
NR2Ab level –0.11 –0.34* –0.37** 0.002 1  
NR2Ab 1.8 
ng/ml cut-off 
–0.28* –0.36* –0.39** –0.11 0.81** 1 
Post-operative 
EQ-5D index 1      
EQ-5D VAS 0.591** 1     
PCS 0.70** 0.71** 1    
MCS 0.40** 0.37** 0.30* 1   
NR2Ab level –0.48** –0.47** –0.45** –0.23   
NR2Ab 1.8 
ng/ml cut-off 
–0.41** –0.55** –0.41** –0.37*   
Table 7. 5 Bivariate correlation between NR2Ab level, NR2Ab 1.8 ng/ml cut-off, and main quality of life 
component summaries. 
*Correlation is significant at the 0.05 level (2-tailed); **correlation is significant at the 0.01 level (2-tailed). 
Abbreviations: EQ-5D VAS, EQ-5D visual analogue scale; MCS, mental component summary of the SF-36; PCS, 
physical component summary of the SF-36; PWV, pulse wave velocity; NR2Ab, N-methyl-D-aspartate receptor 
antibody.  
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Simple linear regression between the main QoL component summaries and other 
variables was used to identify potential QoL predictors (Table 7.6); gender was a potential 
predictor of post-operative QoL, and NR2Ab level and cut-off were potential predictors of 
pre- and post-operative QoL, while age, aortic valve area (AVA), and triglyceride levels were 
predictors of one component summary each (Table 7.6). 
 
 Only significant variables from the simple linear regression or correlation analysis, in 
addition to age and gender, were included in multiple regression (enter method) analysis. In 
the multiple regression analysis (Table 7.7), NR2Ab level (Model 1 analysis) was an 
independent predictor of QoL (except for the MCS and pre-operative EQ-5D index). 
Furthermore, the NR2Ab 1.8 ng/ml cut-off (Model 2 analysis) was also an independent 
predictor of QoL (except for pre-operative MCS and EQ-5D index). Age, AVA, and 
triglyceride levels were also independent predictors of one QoL component each.  
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Predictors Pre-operative 
beta (P-value) 
Post-operative 
beta (P-value) 
 EQ-5D 
Index 
EQ-5D 
VAS 
SF-36 
PCS 
SF-36 
MCS A 
EQ-5D 
Index 
EQ-5D 
VAS A 
SF-36 
PCS B 
SF-36 
MCS A 
Age 0.15 
(0.255) 
–0.21 
(0.879) 
–0.28 
(0.037) 
0.08 
(0.568) 
–0.09 
(0.515) 
–0.05 
(0.732) 
–0.09 
(0.521) 
–0.00 
(0.995) 
Gender 
(male) 
0.15 
(0.267) 
0.21 
(0.131) 
0.01 
(0.525) 
0.15 
(0.278) 
0.21 
(0.135) 
0.30 
(0.035) 
0.31 
(0.030) 
0.29 
(0.040) 
MAP 
(mmHg) 
–0.06 
(0.659) 
0.12 
(0.385) 
0.09 
(0.493) 
–0.11 
(0.434) 
0.04 
(0.761) 
0.01 
(0.928) 
0.12 
(0.376) 
–0.20 
(0.172) 
BMI (kg/m2) 0.00 
(0.997) 
0.04 
(0.734) 
–0.04 
(0.766) 
–0.09 
(0.487) 
–0.05 
(0.688) 
–0.12 
(0.386) 
–0.13 
(0.371) 
–0.23 
(0.105) 
Smoking 0.10 
(0.459) 
0.24 
(0.079) 
0.24 
(0.081) 
–0.02 
(0.850) 
–0.11 
(0.477) 
0.14 
(0.337) 
0.08 
(0.589) 
0.07 
(0.604) 
DM 0.01 
(0.953) 
–0.14 
(0.308) 
–0.121 
(0.395) 
0.06 
(0.639) 
0.05 
(0.711) 
–0.07 
(0.836) 
0.05 
(0.727) 
0.15 
(0.320) 
EF 0.04 
(0.809) 
0.22 
(0.168) 
0.05 
(0.755) 
–0.05 
(0.761) 
–0.13 
(0.434) 
0.15 
(0.397) 
0.13 
(0.461) 
0.07 
(0.691) 
AVPG 
(mmHg) 
–0.04 
(0.792) 
–0.10 
(0.475) 
–0.02 
(0.885) 
0.16 
(0.237) 
–0.08 
(0.568) 
0.11 
(0.434) 
0.06 
(0.662) 
–0.27 
(0.857) 
AVMG 
(mmHg) 
0.02 
(0.915) 
–0.002 
(0.988) 
–0.02 
(0.860) 
0.27 
(0.061) 
–0.09 
(0.557) 
0.11 
(0.488) 
0.09 
(0.528) 
0.15 
(0.320) 
AVA (cm2) 0.06 
(0.685) 
0.35 
(0.015) 
–0.02 
(0.889) 
0.21 
(0.157) 
0.06 
(0.682) 
0.12 
(0.425) 
–0.06 
(0.712) 
0.17 
(0.258) 
Cholesterol 
(mmol/L) 
–0.26 
(0.059) 
–0.071 
(0.623) 
–0.05 
(0.739) 
–0.06 
(0.655) 
–0.15 
(0.301) 
–0.15 
(0.312) 
–0.19 
(0.193) 
–0.18 
(0.226) 
Triglyceride 
(mmol/L) 
0.11 
(0.452) 
–0.17 
(0.227) 
–0.06 
(0.676) 
–0.06 
(0.657) 
–0.43 
(0.003) 
–0.18 
(0.233) 
–0.15 
(0.324) 
–0.24 
(0.104) 
NR2Ab 
level B 
–0.03 
(0.835) 
–0.36 
(0.009) 
–0.39 
(0.004) 
–0.09 
(0.493) 
–0.45 
(0.001) 
–0.36 
(0.011) 
–0.36 
(0.012) 
–0.20 
(0.164) 
NR2Ab 1.8 
ng/ml cut-
off 
–0.22 
(0.10) 
–0.41 
(0.002) 
–0.38 
(0.005) 
–0.10 
(0.473) 
–0.45 
(0.001) 
–0.52 
(<0.001) 
–0.40 
(0.005) 
–0.36 
(0.013) 
Table 7. 6 Simple linear regression analysis identifying potential predictors of main quality of life 
component summaries. 
Values are shown as beta (P-value), bold values indicate statistical significance. A square root transformation; B log 
transformation. Abbreviations: AVA, aortic valve area; AVMG, aortic valve mean gradient; AVPG, aortic valve 
peak gradient; BMI, body mass index; DM, diabetes mellitus; EF, Ejection fraction; EQ-5D VAS, EQ-5D visual 
analogue scale; MAP, mean arterial blood pressure; MCS, mental component summary; PCS, physical component 
summary; NR2Ab, N-methyl-D-aspartate receptor antibody.  
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Predictors Pre-operative 
beta (P-value) 
Post-operative 
beta (P-value) 
 EQ-5D 
Index 
EQ-5D 
VAS 
SF-36 
PCS 
SF-36 
MCS A 
EQ-5D 
Index 
EQ-5D 
VAS A 
SF-36 
PCS B 
SF-36 
MCS A 
Model 1 
NR2Ab level B –0.00 
(0.095) 
–0.33 
(0.02) 
–0.41 
(0.003) 
–0.14 
(0.337) 
–0.45 
(0.002) 
–0.31 
(0.033) 
–0.30 
(0.037) 
–0.15 
(0.308) 
Age –0.17 
(0.214) 
–0.08 
(0.514) 
–0.33 
(0.011) 
–0.03 
(0.842) 
–0.24 
(0.083) 
0.09 
(0.488) 
–0.09 
(0.510) 
0.00 
(0.987) 
Gender (male) 0.11 
(0.456) 
0.04 
(0.744) 
–0.13 
(0.904) 
–0.16 
(0.276) 
0.01 
(0.929) 
–0.22 
(0.120) 
0.24 
(0.09) 
0.19 
(0.205) 
AVA  0.31 
(0.030) 
      
Triglyceride     –0.35 
(0.011) 
   
Model 2 
NR2Ab 1.8 
ng/ml cut-off 
–0.21 
(0.159) 
–0.39 
(0.011) 
–0.40 
(0.005) 
–0.06 
(0.674) 
–0.48 
(0.003) 
–0.49 
(0.001) 
–0.33 
(0.032) 
–0.32 
(0.048) 
 
Age –0.17 
(0.214) 
–0.08 
(0.544) 
–0.30 
(0.019) 
–0.02 
(0.872) 
–0.23 
(0.093) 
0.11 
(0.370) 
–0.09 
(0.475) 
–0.01 
(0.923) 
Gender (male) 0.03 
(0.822) 
0.01 
(0.922) 
–0.05 
(0.696) 
–0.09 
(0.522) 
0.09 
(0.553) 
–0.09 
(0.534) 
0.17 
(0.252) 
0.09 
(0.550) 
AVA  0.32 
(0.023) 
      
Triglyceride     –0.30 
(0.018) 
   
Table 7. 7 Multiple linear regression analysis to identify predictors of main quality of life component 
summaries. 
Values are shown as beta (P-value), bold values indicate statistical significance. A Square root transformation; B 
Log transformation. Model 1 includes NR2Ab level as a continuous predictor; Model 2 includes NR2Ab 1.8 ng/ml 
cut-off as a dichotomous predictor. Abbreviations: AVA, aortic valve area; EQ-5D VAS, EQ-5D visual analogue 
scale; MCS, mental component summary; PCS, physical component summary; NR2Ab, N-methyl-D-aspartate 
receptor antibody.  
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7.5 Discussion  
In our 52 patients, NR2Ab levels ranged from 0.33 to 4.73 ng/ml, and since NR2Ab is a brain 
injury biomarker, one would theoretically expect high levels of NR2Ab to be related to poorer 
cognitive function. Therefore, it was surprising that we did not identify a meaningful 
relationship between NR2Ab and cognitive function. We did find a limited association 
between NR2Ab and cognitive function (NR2Ab was predictive of only pre-operative 
memory function), which makes the conclusion of the absence of a relationship between 
NR2Ab and cognitive function more certain; however, future reassessment and evaluation of 
the memory domain may be important as it is at the heart of cognitive function. An 
explanation for the lack of relationship between NR2Ab and cognitive function is rather 
difficult elucidate, particularly due to the absence of any previous studies on this topic. It may 
simply be that although brain cells are sensitive to central hemodynamic changes, such as 
aortic stiffness (see Chapter 6), overall cognitive function is preserved until late, advanced 
stages when a larger percentage of brain tissue is affected. It was previously reported that 
mean NR2A/2B antibodies levels (ng/ml) were 5.01 ±1.23 (range, 3.24–7.21) in patients 
with ischaemic stroke, 4.02 ±2.04 (range, 2.71–7.23) in patients with TIA, and 1.72 ±0.23 
in patients with hypertension/atherosclerosis, while in controls mean values were 1.49 ±0.22 
(range, 1.02–1.98) [429]. Taking into consideration that our population did not suffer from 
neurological events and their NR2Ab levels were not extremely high, it may be that NR2Ab 
levels need to be much higher to be associated with a change in cognitive function. Therefore, 
we suggest that future studies examining the relationship between NR2Ab and cognitive 
function be conducted on patient populations with a history of cerebrovascular events as 
NR2Ab levels are more likely to be higher in these cases and thus significantly related to 
cognitive function.  
  
Health related QoL tools measure health outcomes and wellbeing from the patient’s 
prospective, which is in contrast to mortality rates. Improvement in QoL after heart valve 
surgery has been studied previously [223], and it has been shown that QoL in this cohort may 
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reach even greater levels than the age-matched general population [314]. As we reviewed in 
Chapter 2, predictors of QoL improvement have been identified, but none of these are 
biomarkers. In our study, patients with low levels of NR2Ab had significantly better QoL 
scores than those with high levels at pre- and post-operative stages, particularly in the 
physical health domains and in more than one QoL instrument. Though both groups 
experienced improved scores after AVR, the amplitude (mean difference) and the significance 
of improvement in the NR2Ab-low group were higher than in the NR2Ab-high group (Tables 
7.3, 7.4). Furthermore, compared to general population SF-36 scores, both the NR2Ab-high 
and NR2Ab-low groups scored lower pre-operatively in seven and two health domains, 
respectively. Post-operatively, the NR2Ab-high group continued to score below the general 
population in five health domains, while the NR2Ab-low group scores were either 
comparable or exceeded those of the general population.  
 
To test whether the NR2Ab biomarker is related to QoL (pre- and post-AVR), 
correlation and multiple regression analyses were performed. These analyses revealed that 
NR2Ab level and the NR2Ab 1.8 ng/ml cut-off were significantly associated with QoL pre- 
and post-operatively, particularly with respect to the physical health domains. NR2Ab level 
was also an independent predictor of QoL pre- and post-operatively and the cut-off value of 
1.8 ng/ml was able to stratify patients into significantly different groups with respect to pre- 
and post-operative QoL.  
 
The aforementioned results indicate that pre-operative QoL in AS patients can be 
related to preexisting variables, such as NR2Ab, and that NR2Ab can predict the 
improvement in QoL post-AVR; therefore, we conclude that individuals with low NR2Ab 
levels are expected to have a greater QoL improvement after AVR compared to patients with 
high NR2Ab levels. Though this relationship is of particular interest to both patients and 
clinicians, the exact mechanism governing this relationship remains unknown and warrants 
further study. In Chapter 4 we demonstrated a relationship between aortic stiffness and QoL, 
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which is logical as aortic stiffness is a marker of blood circulation and tissue perfusion, and 
thus it can affect QoL. Therefore, we argue that although NR2Ab is a brain-specific marker, it 
may be used as a surrogate marker of overall body perfusion, particularly in the absence of 
significant focal neurological damage, similar to the relationship between biomarkers of 
clinically apparent diseases and QoL; for example, the associations between the N-terminal 
pro-brain natriuretic peptide (NT-proBNP) concentrations and QoL in heart failure patients 
[432], between glomerular filtration rate (GFR) or C-reactive protein (CRP) and QoL in 
chronic kidney disease [433], and the association between CRP or erythrocyte sedimentary 
rate (ESR) and QoL in rheumatoid arthritis [434]. The difference between our biomarker 
(NR2Ab) and the aforementioned biomarkers is that there was no apparent neurological or 
cognitive disease in our patient group. The notion of “using tissue or organ-specific 
biomarkers to predict QoL outcome” may open the door to more interesting research in this 
area, and we believe we are the first to describe this concept using such terminology. 
 
To the best of our knowledge, this is the first study investigating and establishing a 
relationship between the NR2Ab biomarker and QoL. Our study has the specific advantage of 
comprehensive QoL follow-up data. Furthermore, the findings of this study provide clinically 
significant preliminary data for future investigations that will test the use of the NR2Ab 
biomarker as a predictor of QoL outcomes in different patient populations and in larger 
sample sizes.  
 
Limitations 
In the present study, NR2Ab levels were only measured pre-operatively; post-operative 
NR2Ab levels would have been useful to determine any changes over the follow-up period 
and the relationship of such changes with QoL. Furthermore, it may be difficult to generalize 
the findings of this study because of the disease-specific population used. However, this study 
was not designed to change clinical practices or generalize findings; rather, it was designed to 
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explore original research questions and to create preliminary data in order to direct future 
studies. 
 
7.6 Conclusions and potential future implications 
This study demonstrates that in AVR patients, higher NR2Ab levels are associated with 
poorer QoL pre- and post-AVR, while its association with cognitive function was limited to 
pre-operative memory function. The NR2Ab biomarker is an independent predictor of QoL in 
surgical AS patients, and a cut-off point of 1.8 ng/ml might be a suitable value for such 
assessments. Future studies proving the proposed concept of “using tissue or organ-specific 
biomarkers to predict QoL outcome” may help identify biomarkers that are not only clinically 
useful, but also can replace existing QoL assessments, which have inherent practical 
limitations.  
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8 Chapter 8  
Pulse wave velocity and neutrophil gelatinase-associated 
lipocalin as predictors of acute kidney injury and the need 
for early medical renal intervention in aortic valve 
replacement  
 
This chapter investigates the potential relationship between aortic stiffness measured by pulse 
wave velocity (PWV) and the development of post-operative acute kidney injury (AKI) or the 
need for early medical intervention for renal causes. This chapter also assesses the value of 
the novel AKI biomarker neutrophil gelatinase-associated lipocalin (NGAL) for predicting 
AKI in aortic valve replacement.  
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8.1 Abstract  
Background: Accurate prediction and early detection and treatment of post-cardiac acute 
kidney injury (AKI) are essential for improving outcome in this group of patients. Adding an 
arterial wall marker to the current AKI pre-operative predictor list and a kidney tissue injury-
specific biomarker to existing post-operative diagnostic tools, such as aortic pulse wave 
velocity (PWV) and neutrophil gelatinase-associated lipocalin (NGAL), respectively, may 
enhance the ability to predict and diagnosis post-operative AKI.  
 
Objectives: To assess if aortic stiffness (PWV) and the novel AKI biomarker NGAL are 
predictors of AKI or the need for early medical renal intervention following aortic valve 
replacement (AVR). Furthermore, we evaluate whether PWV is related to NGAL in these 
patients. 
 
Methods: Patients undergoing AVR had their aortic PWV and plasma NGAL level assessed 
pre-operatively. Post-operatively, NGAL level was re-measured at 3 and 18–24 h post-
cardiopulmonary bypass (CPB). Any additional use of diuretics or dopamine infusion 
exclusively for renal causes were categorized as early medical renal intervention. Post-
operative AKI was defined using risk, injury, failure, loss, end-stage renal disease (RIFLE) 
criteria. Comparative analyses between patients with (AKI-Yes) and without (AKI-No) AKI 
and between patients with (Intervention-Yes) and without (Intervention-No) medical renal 
intervention were carried out. The diagnostic utility of NGAL measurements for predicting 
outcomes was assessed by conventional area under the receiver operating characteristic 
curves (AUC-ROC). The cut-off point of the 3 hour post-CPB NGAL was selected based on 
the best sensitivity and specificity values. 
 
Results: Fifty-three patients participated in this study, including 37 (70%) males with an 
overall mean age of 71 ± 9 years. In total, 16 patients (30%) developed AKI and 24 patients 
(45%) received early medical intervention (Intervention-Yes), indicated by low urine output 
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for less than 6 h. There was no significant difference between AKI-Yes and AKI-No or 
between Intervention-Yes and Intervention-No groups with respect to age, gender, 
hemodynamic parameters, or main clinical and operative characteristics. Approximately 89% 
of the total patients had normal to mildly impaired renal function (chronic kidney disease 
[CKD] stages 1 or 2), while 11% had stage 3 CKD. There was no correlation between PWV 
and baseline renal function, or between PWV and AKI (r = 0.12, P = 0.13) or early 
intervention (r = 0.18, P = 0.18). At the early post-operative stage (3 h post-CPB), among 
serum creatinine, glomerular filtration rate (GFR), and NGAL, only NGAL (ng/ml) was 
significantly different between the two groups for both outcomes. Early post-operatively (3 h 
post-CPB), the AUC-ROC of the NGAL measurement to predict AKI and early intervention 
was much higher than creatinine (0.83, 95% confidence interval [CI] 0.70–0.95 vs. 0.65, 
95%CI 0.47- 0.82; 0.84, 95%CI 0.72–0.96 vs. 0.56, 95%CI 0.38–0.73, respectively). Plasma 
NGAL (3 h post-CPB) ≥150 and ≥136 ng/ml were significantly associated with AKI (r = 
0.68, P < 0.001) and early intervention (r = 0.64, P < 0.001). Simple linear regression showed 
no relationship between PWV and any NGAL level.  
 
Conclusion: In AVR patients with normal to mildly impaired renal function, aortic PWV was 
not correlated with post-operative AKI or plasma NGAL levels in our sample. However, 
larger sample sizes that include patients with more diverse renal functioning will facilitate 
drawing better conclusion about this very interesting aorto-renal association. Early post-
operative plasma NGAL level is the earliest predictive marker of post-operative AKI or the 
need for early medical renal intervention.  
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8.2 Introduction 
8.2.1 Acute kidney injury in cardiac surgery 
Acute kidney injury (AKI) is a medical term that is currently used to cover a wide range of 
renal dysfunctions ranging from a minor change in serum creatinine to a transitory period of 
acute tubular necrosis requiring renal replacement therapy [435]. There are over 30 
definitions of AKI [436]; however, the most common three quantitative measures used to 
assess AKI are: serum creatinine, glomerular filtration rate (GFR), and urine output. AKI 
definitions include an increase in serum creatinine of 25% or greater within 48–72 h after 
operation, or a urine output of less than 0.5 ml/kg/hour for 6 h. Post-cardiac surgery AKI may 
occur in up to 30% of adult patients depending on the definition of AKI [192, 437]; however, 
the incidence of AKI requiring renal replacement therapy varies between 1% and 5% [438-
442]. AKI is a common and serious complication after cardiac surgery that is associated with 
high morbidity (up to 4-fold increase) and mortality [443, 444]. In fact, even minor increases 
in serum creatinine after cardiac surgery is associated with a 3-fold increased risk of 30-day 
mortality [444]. It is therefore apparent that patients with perioperative AKI are at higher risk 
of death, and AKI is a risk factor for a poor prognosis associated with prolonged hospital stay, 
need for hemofiltration, and increased hospital costs [438-444]. Therefore, clinicians and 
researchers continue to invest a great deal of effort in the prediction, early detection, and 
prevention of AKI after cardiac surgery.  
 
8.2.2 Etiology of acute kidney injury in cardiac surgery 
AKI following cardiac surgery is a complex and multifactorial pathogenic process that is not 
fully understood. Bellomo et al. suggests at least six major injury pathways: exogenous and 
endogenous toxins, metabolic factors, ischemia and reperfusion, neurohormonal activation, 
inflammation, and oxidative stress [445]. Predisposing arterial pathologies, poor cardiac 
function, periods of hypoperfusion, inflammatory response to CPB and surgical trauma, 
administration of nephrotoxic medications, fluctuations in fluid, electrolyte and acid-base 
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balance are all common injurious factors of AKI. The damaging effect of these factors on 
renal function occur at different time stages in different magnitudes [445].  
 
Risk factors for AKI in cardiac surgery have been studied extensively to improve risk 
management by early prevention or intervention, and studies on different cardiac populations 
have proposed different risk factors. Based on studies with large sample sizes, many operative 
risk stratification models have been developed to achieve better AKI prediction, prevention, 
and management [437]. In general, these factors can be categorized into pre-operative, intra-
operative, and post-operative. Pre-operative factors include: age, gender, body mass index 
(BMI), pulse pressure (PP), hypertension, diabetes mellitus (DM), chronic pulmonary disease, 
haemoglobin concentration, serum creatinine, previous cardiac surgery, ejection fraction 
(EF), and emergency operation [437, 446]; intra-operative factors include: CPB time, 
inotropic support, combined surgery, and red blood cell transfusion [437, 446]; and post-
operative factors include: central venous pressure >14 cm of water, and low cardiac output 
[437]. In cardiac surgery, a risk model that accurately calculates a patient’s risk for AKI can 
optimize perioperative treatment strategies to minimize the risk for AKI. The importance of 
this is clearly reflected by the large number of studies that have been conducted and the 
different risk models that have been developed. The lack of an agreed upon universal risk 
model is a sign of the ongoing evolution of this field, which implies that further studies are 
needed to assess new predictors, such as aortic stiffness and novel biomarkers.  
 
8.2.3 Aortic stiffness and acute kidney injury 
A long list of predictors/risk factors have been identified for the development of post-CPB 
AKI [437, 446, 447]. In addition to these predictors, we believe that abnormal blood flow 
patterns can affect renal perfusion and function, and that increased aortic stiffness may be 
associated with higher incidence of AKI in cardiac patients. The relationship between aortic 
stiffness and chronic kidney disease (CKD) was well established many years ago [97, 448, 
449]; however, although it is known that structural wall damage associated with metabolic 
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changes in CKD is of critical importance, the exact underlying mechanisms of this 
relationship are not completely understood [97, 448]. Though an inverse relationship was 
found between GFR and aortic stiffness in hypertensive patients with normal renal function 
[450], the number of studies linking aortic stiffness to renal function decline in non-kidney 
disease patients is limited [451-453]. However, preliminary data from these studies suggests 
that elevated arterial stiffness is a risk factor for the decline in renal function in the general 
population [451, 452]. Aortic stiffness as a predictor of post-CPB AKI or the need for early 
preventive medical renal intervention has never previously been investigated.  
 
8.2.4 Neutrophil gelatinase-associated lipocalin 
Serum creatinine is the gold standard biomarker that is currently used to assess and monitor 
renal function, but it is insensitive due to the delay in serum level elevation (12–48 h) after 
AKI onset. Therefore, in the last decade much research attention was focused on identifying 
novel kidney injury troponin-like biomarkers [454]. Unfortunately, only a few biomarkers 
that have been discovered have shown any promise, including cystatin C, interleukins (IL), 
kidney injury molecule 1 (KIM 1), C-reactive protein (CRP), and neutrophil gelatinase-
associated lipocalin (NGAL).  
 
NGAL is a novel biomarker for AKI [452, 455-457]. It is a 25 kDa lipocalin that was 
first identified as a protein stored in specific granules of human neutrophils, and it is a natural 
protein expressed in very low levels in several other human tissues, such as the kidneys, 
trachea, lungs, and colon [458, 459]. The LCN2 gene encodes the NGAL protein, which is 
involved in innate immunity and acts by sequestrating iron to restrict bacterial growth [460]. 
NGAL concentration in renal proximal tubules increases rapidly after renal ischemia–
reperfusion injury. In addition, NGAL concentrations begin to increase in serum and urine 
after 2 h in children [461] and 1 hour in adults following CPB [462]. Haase-Fielitz et al. [463] 
measured plasma NGAL levels using the Triage Meter upon intensive care unit (ICU) arrival 
and set a threshold value of >150 ng/ml for predicting AKI; the AUC-ROC was 0.80 and the 
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sensitivity and specificity were 0.76 and 0.91, respectively. Plasma NGAL levels in cardiac 
surgery patients have also been investigated in a limited number of studies [454], mostly in 
coronary artery bypass graft surgery (CABG) patients, but none have investigated NGAL in 
relation to aortic stiffness or have evaluated its predictive value for requiring early preventive 
medical intervention for AKI [454]. In addition, the results of these studies are not consistent, 
but it is believed that NGAL levels will eventually be used in clinical practice; however, more 
studies need to be performed with better sample collection timing, more homogenous 
populations, and with consideration for subclinical AKI [435, 454]. The above data, and 
additional information from different patient populations, have encouraged us to measure this 
new AKI biomarker to assess its ability for early AKI detection in cardiac surgery.  
 
8.2.5 Hypothesis and objectives 
The relationship between renal function decline and atypical hemodynamic parameters has 
been previously established. Therefore, we hypothesize that abnormal blood flow patterns 
related to increased aortic stiffness may be associated with a higher incidence of AKI and/or 
the need for early medical renal intervention in cardiac surgery patients. 
 
The objectives of this study are to assess: a) if aortic stiffness (measured by PWV) is a 
predictor of post- aortic valve replacement (AVR) AKI or the need for early medical renal 
intervention; b) if the novel AKI biomarker NGAL is a predictor of post-AVR AKI or the 
need for early medical renal intervention; and c) if PWV is related to NGAL. 
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8.3 Materials and methods 
8.3.1 Patient population  
The patient population used in this study is described in detail in Chapter 3.  
 
8.3.2 Pulse wave velocity measurement protocol 
Detailed descriptions of measurement protocols, quality control, and reproducibility of PWV 
have been covered in the methodology section of Chapter 3.  
 
8.3.3 Clinical assessment 
Patient pre-operative renal history was recorded. Post-operative hourly urine output was 
recorded for the first 36–48 h, and for longer periods if the patient required further renal 
attention or intervention. Any extra use of diuretics or dopamine infusion for renal causes 
before a patient met the criteria of AKI was also recorded in our database. Fluid balance at the 
end of day zero and day one post-operatively, the duration of continuous intravenous fluid 
(IVF) infusion, and the need for any blood product post-operatively were also recorded for 
each patient.   
8.3.4 Serum creatinine and glomerular filtration rate  
Serum creatinine and GFR, the gold standard diagnostic tests, were measured prospectively 
from the collected blood samples and processed at our routine clinical high-standard 
laboratory, which was blind to the study parameters. The decision to use the routine clinical 
laboratory was made to accurately reflect a real clinical setting for identifying AKI patients. 
The GFR was calculated using the Modification of Diet in Renal Disease (MDRD) equation 
of GFR:  
186 x (Creat / 88.4)-1.154 x (Age)-0.203 x (0.742 if female) x (1.210 if black) 
where Creat represents serum creatinine levels. 
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8.3.5 Neutrophil gelatinase-associated lipocalin  
NGAL was measured pre-operatively, 3 h post-CPB, and on day one (18–24 h post-CPB) 
after AVR. NGAL levels were measured using a point-of-care, fluorescence-detected 
immunoassay test kit (Biosite Triage, Biosite Incorporated, San Diego, CA, USA currently 
Alere Triage MeterPro, Alere Ltd., Stockport, UK), which was previously described and 
validated against enzyme-linked immunosorbent assay (ELISA) [464, 465]. 
Ethylenediaminetetraacetic acid (EDTA)-containing tubes were used to collect 
the blood samples through venipuncture pre-operatively and through the central venous line 
post-operatively. Briefly, 250 µL of plasma was added to the disposal test strip that has a 
filter to separate cells and any other particles allowing only plasma to reach the reaction 
chamber that contains NGAL-specific monoclonal antibody conjugated to a fluorescent 
nanoparticle, NGAL antigen immobilized on a solid phase, and stabilizers. After the plasma 
forms a fluorescent antibody conjugate with the detection nanoparticles, it flows down the 
diagnostic lane via capillary action. NGAL present in the specimen prevents binding of the 
fluorescent detection particles to the solid phase immobilized in the detection zone, so that the 
analyte concentration is inversely proportional to the fluorescence-detected [465]. The test 
strip is then inserted into the Triage machine, which reports NGAL level. The entire 
measurement procedure takes approximately 15 minutes to complete. All NGAL 
measurements were performed within 30 minutes of sample collection after standard machine 
calibration with a standard calibrating strip. The triage assay has a detection range of 60 to 
1300 ng/ml with a coefficient of variation of 10% to 15%. All tests were performed by a 
single operator (EK) after proper training from the manufacturing company. The time-points 
for measuring NGAL levels were selected based on previously published studies [463, 465-
467]. 
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8.3.6 Acute kidney injury definition 
The primary outcome was the development of AKI, as defined by the RIFLE criteria [468]; 
the development of any stage of the RIFLE classification was considered AKI. RIFLE is the 
first consensus definition of acute renal failure that was developed by the Acute Dialysis 
Quality Initiative (ADQI) group in 2004 using serum creatinine, GFR, or urine output, 
whichever is worse. The RIFLE criteria consists of three graded levels of kidney dysfunction, 
including risk, injury, and failure, and two outcome measures, loss of function and end-stage 
renal disease (ESRD). Pre-operative serum creatinine and GFR levels were considered the 
baseline levels for calculating the percentage of increase or decrease. The RIFLE levels are as 
follows: A) risk: 1.5-fold increase in serum creatinine or 25% decrease in GFR from baseline 
level or urine output less than 0.5 ml/kg/hour for 6 h; B) injury: 2-fold increase in serum 
creatinine, or 50% decrease in GFR from baseline level, or urine output less than 0.5 
ml/kg/hour for 12 h; C) failure: 3-fold increase in the serum creatinine, or 70% decrease in 
GFR from baseline level, or urine output of less than 0.3 ml/kg/hour for 24 h, or anuria for 12 
h; D) loss: complete loss of kidney function for more than 4 weeks; and E) ESRD: complete 
loss of kidney function for more than 3 months. 
 
It is of note that GFR (ml/min/1.73 m2) is an fundamental parameter for measuring 
renal function, and it is used for staging CKD as follows [469]: stage 1, kidney damage with 
normal or relatively high GFR (≥90); stage 2, mild reduction in GFR (60–89); stage 3, 
moderate reduction in GFR (30–59); stage 4, severe reduction in GFR (15–29); and stage 5, 
established kidney failure (GFR <15), permanent renal replacement therapy (RRT), or ESRD.  
 
8.3.7 Need for early medical renal intervention  
In our institution it is common for clinicians in charge of immediate post-operative care to 
initiate preventive early medical intervention for potential cases of acute renal dysfunction 
based on their clinical judgment, rather than waiting for full AKI criteria to develop. Most of 
such clinical judgments are based on low urine output (less than 0.5 ml/kg/hour) for 3 h rather 
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than waiting for 6 h. Common early renal medical interventions in our institute include 
administering adequately hydrated patients with extra intravenous (IV) diuretics (repeated 
doses over 24–48 h) or low dose dopamine IV infusion (though controversial). Because it is 
ethically questionable to change these possibly beneficial practices, and to obtain best data 
reflecting the actual clinical practice and to keep the clinical staff blind to the study, we did 
not change this routine practice. However, we performed further analysis using the need for 
early medical renal intervention defined as extra IV diuretic or IV infusion of dopamine on 
adequately hydrated patient indicated by low urine output as a secondary outcome.  
 
8.3.8 Overview  
Ethical approval (11/H0709/3) and participant informed consent were obtained prior to 
undertaking this study. Patients undergoing AVR for moderate to severe AS between June 
2010 and August 2012 were eligible. Patients were excluded if they had: 1) aortic dissection; 
2) emergency cases; 3) thoracic aorta (more than just the root) or abdominal aortic aneurysm; 
4) Marfan’s syndrome; or 5) known case of chronic kidney disease. All patients were 
recruited and all data were recorded prospectively for this study.  
 
Carotid-femoral PWV was measured pre-operatively (before AVR). Markers being 
studied (serum creatinine, GFR, and NGAL) were measured from blood samples collected at 
three time-points: prior to surgery, 3h post-CPB, and 18–24h post-CPB. In addition, 
creatinine was measured daily until not indicated post-operatively to assess AKI development 
and/or progression.  
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8.3.9 Statistical analysis 
Statistical analysis was conducted using IBM SPSS 20.0 software package (IBM Corporation, 
Armonk, NY, USA). Patient characteristics and results are expressed as medians or means ± 
standard deviation for continuous variable and as frequencies for categorical variables. All 
tests were two-sided and considered significant at the 0.05 level. Test for normality was 
carried out on all the relevant variables.  
 
Comparative analyses between the two AKI groups (presence of AKI [AKI-Yes] and 
absence of AKI [AKI-No]) and the two early medical renal intervention groups (required 
intervention [Intervention-Yes] and did not require intervention [Intervention-No]) were 
carried out using independent samples t-tests or non-parametric equivalent (Mann–Whitney U 
test) for continuous variables, and Pearson Chi-square or Fisher’s exact for categorical 
variables. Correlation analysis between variables was conducted using Spearman’s rank-order 
correlation and point biserial correlation (for dichotomous variables). To assess the diagnostic 
utility of NGAL measurements for predicting primary and secondary outcomes (post-
operative AKI and the need for early medical renal intervention) compared to serum 
creatinine, conventional receiver operating characteristic (ROC) curves were produced and 
the area under the curve (AUC) was calculated for each test. A 3-hour post-CPB NGAL cut-
off point was selected based on best sensitivity and specificity values. The association 
between plasma NGAL level (3 h post-CPB) equal or greater than the selected cut-off point 
and the development of the primary and secondary outcomes were also tested using 
Contingency Table Analysis and Odds Ratios (ORs). We also explored the association of 
increasing levels of plasma NGAL (3 h post-CPB) with the development of primary and 
secondary outcomes by dividing the population into quartiles according to NGAL level and 
calculated the percentage of each outcome for each quartile. Finally, the predictive ability of 
plasma NGAL levels (3 h post-CPB) and the selected cut-off points for the primary and 
secondary outcomes were also assessed using logistic regression analysis in combination with 
other common predictors. 
 265 
8.4 Results 
8.4.1 Descriptive results 
Fifty-six patients were recruited for this study; three patients were excluded, two because 
NGAL level measurements at the three time-points were not completed, and one due to 
incidental pre-operative high serum creatinine levels of 183 µmol/L (GFR = 33 ml/min/1.73 
m2). Therefore, fifty-three patients were included in this study, including 37 (70%) males with 
a mean age of 71 ± 9 years, and none had a history of pre-operative renal disease (Table 8.1). 
No emergency cases were recruited and none of the included patients developed shock or 
sepsis or required intra-aortic balloon pump or intensive care admission. Sixteen patients 
(30%) developed AKI according to the RIFLE criteria, and 24 patients (45%) had early 
medical intervention (Intervention-Yes), indicated by low urine output for less than 6 h. There 
was no significant difference between AKI-Yes and AKI-No or between Intervention-Yes 
and Intervention-No groups with respect to age, gender, hemodynamic parameters, or main 
clinical and operative characteristics. Table 8.1 summarizes the demographic, clinical, and 
operative characteristics of the total population and for all groups.  
 
Parameter Total 
n = 53 
AKI-No 
n = 37 
AKI-Yes 
n = 16 
P-
value 
Intervention-
No 
n = 29 
Intervention-
Yes 
n = 24 
P-
value 
Male [n (%)] 37 (70%) 25 (67%) 12 (75%) 0.58 22 (76%) 15 (62%) 0.29 
Age (years) 71 ± 9 70 ± 9 73 ± 8 0.39 69 ± 8 73 ± 9 0.14 
White 
Caucasian [n 
(%)] 
52 
(98%) 
37 (100%) 15 (93%) 0.30 29 (100%) 23 (96%) 0.45 
SBP (mmHg) 138 ± 17 136 ± 17 143 ± 18 0.11 139 ± 16 136 ± 20 0.68 
DBP (mmHg) 76 ± 12 76 ± 12 77 ± 14 0.51 79 ± 10 79 ± 13 0.14 
MAP (mmHg) 97 ± 12 96 ± 12 99 ± 12 0.12 99 ± 11 94 ± 13 0.55 
PP (mmHg) 62 ± 15 60 ± 13 66 ± 18 0.23 61 ± 13 63 ± 17 0.81 
DM [n (%)] 8 (16%) 7 (19%) 1 (6%) 0.23 5 (17%) 3 (12%) 0.68 
Hypertensive 
[n (%)] 
36 
(68%) 
25 (68%) 11 (69%) 0.93 17 (59%) 19 (79%) 0.11 
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Dyslipidemia 
[n (%)] 
35 
(66%) 
25 (68%) 10 (63%) 0.72 17 (59%) 18 (75%) 0.21 
Smoking [n 
(%)] 
2 (4%) 1 (3%) 1 (6%) 0.25 0 (0.0%) 2 (8%) 0.16 
BMI (kg/m2) 
27.3 ± 
4.4 
26.6 ± 4.3 28.9 ± 4.4 0.08 27.0 ± 4.4 27.6 ± 4.5 0.56 
PVD (n [%]) 1 (2%) 0 (0.0%) 1 (6%) 0.30 0 (0.0%)  1 (4%) 0.45 
EF 60 ± 15 63 ± 14 55 ± 17 0.16 63 ± 13  57 ± 17 0.33 
AVA (cm2) 
0.74 ± 
0.22 
0.71 ± 0.21 0.80 ± 0.23 0.24 0.75 ± .22  0.73 ± 0.22 0.69 
AVPG 
(mmHg) 
81 ± 24 84 ± 25 73 ± 20 0.12 83 ± 28  78± 19 0.55 
AVMG 
(mmHg) 
47 ± 12 48 ± 12 44 ± 12 0.31 48 ± 12  47 ± 12 0.78 
PWV (m/s) 9.3 ± 2.3 9.1 ± 2.3 9.7 ± 2.1 0.34 8.9 ± 2.1 9.8 ± 2.4 0.13 
Logistic 
EuroScore 
5.5 ± 4.3 4.8 ± 3.5 6.9 ± 5.5 0.15 4.2 ± 2.2 6.9 ± 5.6 0.22 
Concomitant 
CABG [n (%)] 
15 (28%) 10 (27%) 5 (31%) 0.75 9 (30%) 9 (37%) 0.18 
Cross clamp 
time (minutes) 
68 ± 20 68 ± 18 67 ± 26 0.66 70 ± 19 65 ± 22 0.17 
CPB time 
(minutes) 
87 ± 23 86 ± 22 90 ± 28 0.66 88 ± 23 86 ± 25 0.47 
IVF duration 
(h) 
42 ± 17 42 ± 17 43 ± 17 0.41 38 ± 10  48 ± 22 0.04 
Fluid balance 
day 0 (ml) 
1987 ± 
658 
1854 ± 631 2328 ± 622 0.02 1948 ± 679 2037 ± 643 0.68 
Fluid balance 
day 1 (ml) 
1348 ± 
915 
1146 ± 854 1853 ± 893 0.02 1122 ± 808 1626 ± 978 0.05 
Post-operative 
blood products 
(n [%]) 
27 (53%) 18 (49%) 9 (56%) 0.51 11 (38%) 16 (66%) 0.03 
Hospital stay 
(days) 
6.7 ± 1.7 6.4 ± 1.5 7.3 ± 2.0 0.09 6.3 ± 1.5 7.3 ± 1.8 0.05 
Table 8. 1 Demographic and clinical characteristics. 
Values are shown as n (%) for categorical variables and means ± standard deviation for continuous variables; bold 
font indicates statistical significance. Abbreviations: AVA, aortic valve area; AVMG, aortic valve mean gradient; 
AVPG, aortic valve peak gradient; BMI, body mass index; CABG, coronary artery bypass graft; CPB, 
cardiopulmonary bypass; DBP, diastolic blood pressure; DM, diabetes mellitus; EF, ejection fraction; IVF, 
intravenous fluid; MAP, mean arterial blood pressure; PP, pulse pressure; PVD, peripheral vascular disease; PWV, 
pulse wave velocity; SBP, systolic blood pressure. 
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8.4.2 Pulse wave velocity, acute kidney injury, and early medical renal intervention  
There was no significant deference in PWV (m/s) between AKI-No and AKI-Yes groups (9.1 
± 2.3 vs. 9.7 ± 2.1, respectively) or between Intervention-No and Intervention-Yes groups 
(8.9 ± 2.1 vs. 9.8 ± 2.4, respectively). Bivariate correlation revealed no association between 
PWV and AKI development (r = 0.12, P = 0.13) or between PWV and early intervention (r = 
0.18, P = 0.18).  
It is important to note that 89% of patients had stage 1 and 2 CKD, 11% had stage 3, 
and no patient had stage 4 or 5. There was a trend of increasing PWV (m/s) across the CKD 
stages: 8.7 ± 1.7 for stage 1, 9.2 ± 2.4 for stage 2, and 10.8 ± 2.2 for stage 3 (P = 0.18; 
ANOVA). There was no correlation between PWV and renal function; the correlation 
coefficient between PWV and serum creatinine was 0.18 (not significant) and 0.268 (not 
significant) between PWV and GFR.  
 
8.4.3 Neutrophil gelatinase-associated lipocalin and acute kidney injury  
Sixteen patients (30%) developed AKI according to RIFLE criteria, 12 (75%) of which 
developed the “risk” aspect of RIFLE, while four (25%) patients achieved the “injury” aspect 
of RIFLE criteria, and none progressed to the “failure” stage or required renal replacement 
therapy. The mean time to AKI development was 34.2 ± 21 h post-operatively (range, 8–93 
h), and there was a clinically significant difference in BMI and the length of hospital stay 
(Table 8.1). Table 8.2 summarizes the levels of markers assessed for both AKI groups and 
over the three time-points; pre-operatively there was no difference in these markers between 
groups. At early post-operative stages (3 h post-CPB), among creatinine, GFR, and NGAL, 
only NGAL (ng/ml) differed significantly (113 ± 51 vs. 167 ± 66, AKI-No vs. AKI-Yes, 
respectively, P < 0.001; Table 8.2 and Figure 8.1). Mean early post-operative (3 h post-CPB) 
levels of the traditional diagnostic markers (creatinine and GFR) were lower than baseline 
pre-operative levels. As the difference in the traditional diagnostic markers (creatinine and 
GFR) from the baseline level started to be statistically significant at the time-point 3 (after 18 
h post-CPB), the mean level of NGAL for AKI-Yes group became nearly normal.  
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Marker Total 
n = 53 
AKI-No 
n = 37 
AKI-Yes 
n = 16 
P-
value 
Intervention
-No 
n = 29 
Intervention
-Yes 
n = 24 
P-
value 
Creatinine (µmol/L) 
Pre-operative 80 ± 14 79 ± 14 82 ± 12 0.25 76 ± 11 85 ± 14 0.02 
3 h post-CPB 71 ± 15  68 ± 13 77 ± 19 0.12 69 ± 13 73 ± 18 0.44 
18 h post-CPB 87 ± 35 74 ± 17 116 ± 45 <0.001 73 ± 16 103 ± 43 <0.01 
GFR (ml/min/1.73 m2) 
Pre-operative 80 ± 17 80 ± 19 77 ± 13 0.55 86 ± 16 72 ± 15 <0.01 
3 h post-CPB 94 ± 19 96 ± 19 88 ± 21  0.32 97 ± 18  89 ± 21 0.22 
18 h post-
CPB 
79 ± 26 88 ± 21 58 ± 24 <0.001 91 ± 19  65 ± 26 <0.001 
NGAL (ng/ml) 
Pre-operative 80 ± 35 83 ± 40  73 ± 20 0.55 83 ± 40 76 ± 25 0.96 
3 h post-CPB 129 ± 61 113 ± 51 167 ± 66 <0.001 100 ± 29  164 ± 70 <0.001 
18 h post-CPB 81 ± 38 74 ± 28 98 ± 53 0.02 71 ± 22 94 ± 49 0.01 
Table 8. 2 Levels of the renal function markers at different study time-points. 
Values are shown as mean ± standard deviation; bold font indicates significant values. Abbreviations: CPB, 
cardiopulmonary bypass; GFR, glomerular filtration rate (Modification of Diet in Renal Disease equation); NGAL, 
neutrophil gelatinase-associated lipocalin.  
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Figure 8. 1 Trend time of the NGAL and creatinine levels between AKI-No and AKI-Yes groups 
Squares indicate median values; bars represent the first and third quartiles (Q1–Q3). Abbreviations: CPB, 
cardiopulmonary bypass; NGAL, neutrophil gelatinase-associated lipocalin. 
 
The AUC-ROC curve of the 3-hour post-CPB NGAL measurements to predict AKI 
was much greater than for 3-hour post-CPB creatinine (0.83, 95% confidence interval [CI] 
0.70–0.95 vs. 0.65, 95%CI 0.47–0.82, respectively; Figure 8.2). The cut-off point of 150 
ng/ml for 3-hour post-CPB NGAL levels showed a sensitivity and specificity of 80.0 and 
88.9, respectively. Plasma NGAL level (3 h post-CPB) equal or greater than 150 ng/ml was 
significantly associated with AKI development (Phi-coefficient = 0.68, P < 0.001) with an 
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OR of 33.0 (95%CI 6.4–169.5). Dividing the population into quartiles according to 3-hour 
post-CPB NGAL level and calculating the percentage of AKI for each quartile revealed a 
proportional relationship between increasing NGAL level and the rate of AKI, moving from 
7.6% in quartile 1 to 69.2% in quartile 4 (Figure 8.3).  
 
 
 
Figure 8. 2 Receiver operator characteristic curve for 3 h post-CPB NGAL and creatinine for the diagnosis 
of AKI within the next 1–3 days. 
The area under the ROC for the NGAL was 0.83 (95%CI 0.70–0.95), indicating a good performance for the 
diagnosis of AKI, while for creatinine it was 0.65 (95%CI 0.47–0.82). Abbreviations: ROC, receiver operator 
characteristic; CPB, cardiopulmonary bypass; NGAL, neutrophil gelatinase-associated lipocalin; AKI, acute 
kidney injury; CI, confidence interval.  
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Figure 8. 3 Rate of AKI and need for early medical renal intervention per quartile for the 3 hour post-CPB 
NGAL level. 
There is a proportional relationship between increasing NGAL levels (ng/ml) and the rate of AKI and the need for 
early medical renal intervention. Abbreviations: CPB, cardiopulmonary bypass; NGAL, neutrophil gelatinase-
associated lipocalin; AKI, acute kidney injury; Q, quartile.  
 
 
8.4.4 Neutrophil gelatinase-associated lipocalin and the need for early medical renal 
intervention  
Twenty-four patients (45%) had early medical intervention (Intervention-Yes group), such as 
intravenous diuretic administration or renal dose dopamine infusion, in an attempt to prevent 
AKI, indicated by low urine output for less than 6 h. Such interventions were successful in 
nine patients (37.5%) who did not develop any RIFLE criteria; among the rest (62.5%), 4 and 
11 patients developed I (injury) and R (risk) RIFLE criteria for AKI, respectively. Those who 
progressed to AKI (15 patients) represent 94% of the total AKI patients (n = 16). Table 8.1 
summarizes the demographic, clinical, and operative characteristics of the Intervention-Yes 
and Intervention-No groups. There was no significant difference between these two groups 
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with respect age, gender, hemodynamic parameters, main medical condition history, or 
operative characteristics. Compared to the Intervention-No group, the Intervention-Yes group 
had a significantly longer duration of intravenous fluid administration (48 ± 22 h vs. 38 ± 10 
h, respectively; P = 0.04) and higher day one positive fluid balance post-operatively (1626 ± 
978 ml vs. 1122 ± 808 ml, respectively; P = 0.05; Table 8.1). There was also a significant 
difference in the number of patients who received post-operative blood products (any number 
of units of any product) in favor of Intervention-No group (11 [38%] vs. 16 [66%], 
respectively; P = 0.03). Pre-operatively, the Intervention-No group had significantly better 
creatinine (76 ± 11 vs. 85 ± 14 µmol/L, respectively; P = 0.02) and GFR levels (86 ± 16 vs 72 
± 15, P < 0.01) compared to the Intervention-Yes group (Table 8.2). The AUC-ROC curves 
of these pre-operative tests to predict the need for early medical renal intervention were 0.68 
(95%CI 0.53–0.82) for creatinine and 0.71 (95%CI 0.57–0.85) for GFR. Bivariate correlation 
analysis showed a significant correlation between early medical intervention and; creatinine 
and GFR pre-operative markers; the correlation coefficients were 0.31 (P < 0.05) and –0.37 
(P < 0.01), respectively.   
 
For post-operative analysis, as we are examining early medical intervention, 
therefore, only the early (3 hour post-CPB) time-point was appropriate for use. Among the 
markers listed in Table 8.2, only NGAL (ng/ml) was significantly higher in the Intervention-
Yes group compared to the Intervention-No group (164 ± 70 vs. 100 ± 29, P < 0.001). The 
AUC-ROC curve of 3-hour post-CPB NGAL levels to predict the need for early medical renal 
intervention was 0.84 (95%CI 0.72–0.96), while for creatinine it was 0.56 (95% CI 0.38–
0.73), and the NGAL cut-off point of 136 ng/ml had a sensitivity and specificity of 73.9 and 
89.3, respectively. Plasma NGAL level (3 h post-CPB) equal or greater than 136 ng/ml was 
associated with a need for early medical renal intervention (Phi-coefficient = 0.64, P < 0.001; 
OR = 23.6 [95% CI 5.1–107.5]). Quartiles of plasma NGAL levels (3 h post-CPB) were 
proportionally associated with the rate of need for early medical renal intervention moving 
from 15.4% in Q1 to 92.3% in Q4 (Figure 8.3).  
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8.4.5 Logistic regression analysis 
To identify potential predictors, bivariate correlation analysis was performed between the two 
outcomes and all available risk factors identified from previous studies (see Introduction); 
some of these factors were absent in our sample, such as previous cardiac surgery, critical 
pre-operative status, and recent myocardial infarction. Most variables, including age and 
gender, were not significantly correlated with AKI or the need for early intervention (Table 
8.3). However, in the subsequent multiple logistic regression analysis, in addition to any 
significantly correlated variable, we included age, gender, and pre-operative GFR (as a 
baseline renal function marker). 
 
The multiple logistic regression model for AKI (Table 8.4) was statistically 
significant (P = 0.03) and the Hosmer and Lemeshow goodness of fit test was not significant 
(P = 0.37). The model explained 25.9% (Nagelkerke R2) of the variance in AKI status and 
correctly classified 72.5% of cases. In this model the sensitivity was 26.7%, the specificity 
was 91.7%, and only 3-hour post-CPB NGAL was statistically significant. The model for 
early medical renal intervention was statistically significant (P < 0.001) and explained 73.4% 
(Nagelkerke R2) of the variance in the outcome and correctly classified 87.2% of cases, and 
the sensitivity and specificity were 85.7% and 88.5%, respectively. The 3-hour post-CPB 
NGAL level and pre-operative haemoglobin were the only statistically significant predictors 
(P < 0.01 and 0.03, respectively; (Table 8.4). 
 
Additional multiple logistic regression analyses were performed using 3-hour post-
CPB NGAL level as a dichotomous variable using cut-off values of >150 ng/ml for the 
prediction of AKI and >136 ng/ml for the prediction of early medical renal intervention 
(Table 8.5). The AKI prediction model became more powerful after converting NGAL from a 
continuous to dichotomous variable; the variance in AKI status explained by the model 
increased from 25.9% to 53.9%, and the sensitivity and specificity improved to 80% and 
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88.9%, respectively; only 3-hour post-CPB NGAL level was statistically significant. The 
model for early medical renal intervention, however, did not change dramatically, explaining 
68.9% of the variance in the outcome and correctly classifying 89.4% of cases with a 
sensitivity and specificity of 85.7% and 92.3%, respectively. Pre-operative haemoglobin lost 
its significance in this model leaving only the 3-hour post-CPB NGAL cut-off level (>136 
ng/ml) as a statistically significantly predictor of outcome (P < 0.01). 
 
8.4.6 Neutrophil gelatinase-associated lipocalin and pulse wave velocity 
Bivariate correlation revealed a poor association between PWV and pre-operative NGAL 
level (r = 0.25, P = 0.07) and no association with 3-hour post-CPB NGAL level (r = 0.16, P = 
0.25); however, there was a significant association between PWV and 18-hour post-CPB 
NGAL level (r = 0.30, P= 0.03). Simple linear regression showed no relationship between 
PWV and pre-operative NGAL level (Beta = 0.23, P = 0.1), 3-hour post-CPB NGAL level 
(Beta = 0.09, P = 0.51), or 18-hour post-CPB NGAL level (Beta = 0.11, P = 0.41). 
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 Variables AKI Early medical renal 
intervention 
Age 0.13 0.22 
Gender 0.07 –0.14 
Body mass index (BMI) 0.24 0.07 
Pulse pressure (PP) 0.17 0.08 
Mean arterial pressure (MAP) 0.13 –0.20 
Diabetes mellitus (DM) –0.17 –0.06 
Hypertension 0.01 0.22 
Asthma  –0.03 –0.11 
Peripheral vascular disease 0.21 0.15 
New York Heart Association class (NYHA) 0.01 0.07 
Haemoglobin (pre-operative) –0.8 –0.37** 
Creatinine (pre-operative) 0.12 0.32* 
Glomerular filtration rate (pre-operative) –0.11 –0.41** 
Logistic EuroScore 0.23 0.31* 
Aortic valve mean gradient (AVMG) –0.16 –0.02 
Ejection fraction (EF) –0.25 –0.19 
Cardiopulmonary bypass (CPB) time 0.09 –0.06 
Concomitant coronary artery bypass surgery 0.04 0.18 
Post-operative blood products 0.09 0.30* 
Any Inotrope 0.16 0.28* 
NGAL (3 h post-CPB) 0.41** 0.53** 
NGAL (3 h post-CPB) >150 ng/ml 0.67** 0.66** 
NGAL (3 h post-CPB) >136 ng/ml 0.53** 0.64** 
Table 8. 3 Correlation value (r) between AKI and need for early medical renal intervention and potential 
predictive variables. 
*Correlation is significant at the 0.05 level (2-tailed); **correlation is significant at the 0.01 level (2-tailed). 
Abbreviations: AKI, acute kidney injury. 
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Predictors AKI Early medical renal intervention 
 OR★ (95%CI) P-value OR★ (95%CI) P-value 
NGAL (3 h post-
CPB) 
1.02 1.00–1.03 0.01 1.07 1.02–1.12 <0.01 
Age 1.01 0.93–1.01 0.78 1.04 0.86–1.25 0.69 
Gender (male) 2.41 0.37–15.63 0.35 0.59 0.01–33.13 0.79 
GFR (pre-operative) 1.00 0.95–1.05 0.88 0.96 0.88–1.05 0.34 
Logistic EuroScore    0.79 0.45–1.39 0.43 
Haemoglobin (pre-
operative) 
   0.39 0.17–0.90 0.03 
Post-operative blood 
products 
   7.05 0.49–101.07 0.15 
Any inotrope    1.38 0.1–19.08 0.81 
Table 8. 4 Adjusted logistic analysis of plasma NGAL level (3 h post-CPB) for prediction of AKI and early 
medical renal intervention. 
★Adjusted for all other variables in that model; bold font indicates significant value. Abbreviations: GFR, 
glomerular filtration rate (Modification of Diet in Renal Disease equation); NGAL, neutrophil gelatinase-
associated lipocalin; CPB, cardiopulmonary bypass; CI, confidence interval; AKI, acute kidney injury; OR, odds 
ratio. 
 
Predictors AKI Early medical renal intervention 
 ORA (95%CI) P-value ORA (95%CI) P-value 
NGAL (3-hour post-
CPB) B cut-off 
40.76 6.01–276.38 <0.001 32.49 3.17–332.97 <0.01 
Age 1.00 0.89–1.11 0.99 0.95 0.79–1.14 0.63 
Gender (male) 1.79 0.22–17.78 0.58 3.7 0.12–107.37 0.44 
GFR (pre-operative) 1.01 0.95–1.08 0.61 0.94 0.85–1.03 0.16 
Logistic EuroScore    1.03 0.72–1.47 0.86 
Haemoglobin (pre-
operative) 
   0.49 0.26–1.04 0.06 
Post-operative blood 
products 
   3.35 0.39–31.7 0.26 
Any Inotrope    2.08 0.16–26.61 0.57 
Table 8. 5 Adjusted logistic analysis of plasma NGAL level (3 h post-CPB) cut-off values for the prediction 
of AKI and early medical renal intervention. 
AAdjusted for all other variables in that model, B >150 ng/ml for AKI and >136 ng/ml for early medical renal 
intervention; bold font indicates significant value. Abbreviations: GFR, glomerular filtration rate (Modification of 
Diet in Renal Disease equation); NGAL, neutrophil gelatinase-associated lipocalin; CPB, cardiopulmonary bypass; 
OR, odds ratio; CI, confidence interval. 
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8.5 Discussion 
Aortic PWV was not significantly different between any of the groups that we investigated, 
although PWV was higher in the AKI-Yes group, and there was approximately a 1 m/s 
different between Intervention-No and Intervention-Yes groups (8.9 ± 2.1 vs. 9.8 ± 2.4). The 
lack of statistical significance noted here could be due to the lack of original correlation 
between PWV and baseline renal function (GFR or serum creatinine) in our sample. Looking 
into our data in more detail, the mean pre-operative GFR was not particularly low (80 ± 17 
ml/min/1.73 m2) in our sample, meaning that the majority of the patients were within normal 
to mildly reduced GFR ranges (CKD stages 1 and 2) [469]. Unlike our sample, most of 
previous studies linking aortic stiffness to reduced renal function were conducted on patients 
with moderate to severe GFR reduction (40 to 65 ml/min/1.73 m2) [97, 449]. Wang et al. 
studied 102 patients from all five CKD stages and found a significant stepwise increase in 
PWV from stages 1 to 5 (from normal to ESRD) [470]. These results encouraged us to assess 
the relationship between PWV and AKI or need for early medical renal intervention based on 
the assumption that PWV is related to all stages of renal function. Our results showed a 
similar trend of increasing PWV (m/s) across CKD stages; e.g., stage of renal function 
assessed with GFR, but it was a non-significant trend. The absence of a significant 
relationship between PWV and renal function may be due to the lack of stage 4 and 5 CKD 
patients in our sample, which are the patient groups that made such relationships significant 
in other studies [97, 449, 471, 472]. Mourad et al. studied a much larger sample of 1,290 
hypertensive and normotensive subjects and divided them into tertiles of normalized 
creatinine clearance (renal function). Interestingly, despite significant differences between the 
three groups with respect to age, blood pressure, cardiovascular risk factors, and renal 
function, PWV did not differ significantly [471]. Furthermore, and in support of our results, 
mean PWV in the Mourad et al. study was similar to the mean PWV of our patients (around 
9.31 ± 2.26 m/s). Also similar to our results, Mourad et al. showed that PWV and normalized 
creatinine clearance were negatively and significantly associated (P < 0.0178) exclusively in 
the lower tertile [471]. This indicates that our results in regards to the absence of an 
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association between aortic stiffness and baseline renal function is likely legitimate. 
Furthermore, our results are in line with the results of a study by Hermans et al. who studied 
more than 700 subjects with stages 2–3 CKD and divided them into three GFR tertiles. They 
found that despite significant age, blood pressure, and cardiovascular risk factor differences, 
central arterial stiffness indices were not different, and therefore the authors concluded that 
GFR was not related to greater central arterial stiffness [472]. Moreover, while we were 
conducting our project, other groups began considering and assessing the relationship 
between aortic stiffness and renal function in generally healthy subjects. In more than 13,000 
subjects, Xie et al. found that PWV was significantly and inversely correlated with GFR (r = 
–0.161, P <$0.001); however, this correlation disappeared in multivariable regression analysis. 
In the same study, GFR was associated with PWV in men only when GFR was <60 
ml/min/1.73 m2, indicating that such a relationship is significant only in patients with greater 
than mild renal impairment [473]. 
 
Therefore, it is appropriate to conclude that although there was no correlation 
between PWV and AKI or need for early renal intervention in our study, our hypothesis 
should not be entirely rejected because our sample was not sufficiently diverse in terms of 
renal function; i.e., there were no CKD stage 4 or 5 patients in our sample. Future studies 
testing this hypothesis across all stages of baseline renal function will help formulate more 
concrete conclusions.   
 
 In regards to our second objective, 3-hour post-CPB NGAL levels correlated 
significantly with post-AVR AKI and the need for early medical renal intervention. Although 
pre-operative NGAL level was not different across any of the groups we studied, it was the 
earliest marker to diverge between different groups. While early post-operative levels of the 
standard markers (creatinine and GFR) were better than pre-operative levels giving the false 
clinical message of nonexistent kidney injury, the NGAL biomarker was significantly 
different between AKI-Yes and AKI-No, and between Intervention-Yes and Intervention-No 
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groups. In fact, the lack of trust in early creatinine and GFR for detecting AKI is reflected in 
routine clinical practice, as even when these markers fell within normal ranges, the caring 
clinicians in the post-operative intensive care initiated preventive early medical renal 
intervention in 24 (45%) patients based on low urine output. Such practice indicates clinician 
knowledge of the delay between kidney injury onset and abnormal creatinine or GFR levels, 
and thus their decision during this period was made based on the only other available 
predictor or indicator, which is currently exclusive to urine output. The significances of a 
need for an early AKI biomarker is therefore apparent, and having more than just low urine 
output at the disposal of the caring clinicians can optimize the decision-making process and 
perioperative treatment plans to minimize the risk of AKI following surgery. Mean NGAL 
levels for the AKI-Yes group at 18 h post-CPB returned to pre-operative levels, signifying 
recovery of most of these patients at the time when creatinine and GFR measurements start to 
register as abnormal. In fact, none of the AKI-Yes group progressed to the “failure” stage of 
RIFLE or required renal replacement therapy. The AUC-ROC curve of the 3-hour post-CPB 
NGAL level and creatinine to predict AKI confirmed the above conclusion (0.83, 95%CI 
0.70–0.95 vs. 0.65, 95%CI 0.47–0.82, respectively). In addition, early NGAL level was 
comparable to 18-hour post-CPB creatinine and GFR (0.86, 95%CI 0.75–0.97 and 0.85, 95% 
CI 0.72–0.97, respectively). The cut-off point of 150 ng/ml for the 3-hour post-CPB NGAL 
level has a sensitivity and specificity of 80.0 and 88.9, respectively, and it was significantly 
associated with the development of AKI (r = 0.68, P < 0.001). These results are comparable 
with Haase-Fielitz et al.’s [463] results in which 73 adult cardiac surgery patients were 
studied implementing the cut-off value of 150 ng/ml.  
 
The number of studies investigating the predictive value of plasma NGAL in cardiac 
patients is limited, and none of them explore its predictive value for the need for early 
medical renal intervention [454]. We believe assessing the need for early intervention is an 
important step forward that researchers should consider in future studies, because by 
depending solely on AKI outcome we are ignoring a key group of patients who receive 
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preventive intervention and do not developed AKI. Furthermore, and perhaps even more 
important, is that these “pre-treated” patients are considered part of the group to which 
patients with AKI are compared.  
 
The benefits of the aforementioned early intervention measures are still debated 
[435]; however, clinicians implement them on a daily basis. In our study, 45% of patients 
were administered early intervention based on low urine output for less than 6 h; 37% of this 
group did not progress to AKI, while the remaining progressed to AKI and represented 94% 
of the total patients in the AKI group. In another words, 94% of the AKI group was already 
flagged by clinician hours before they meet RIFLE criteria for AKI. Early in the post-
operative period, among the markers assessed (Table 8.2), only NGAL (ng/ml) was 
significantly higher in the Intervention-Yes group compared to the Intervention-No group 
(164 ± 70 vs. 100 ± 29, P < 0.001). The AUC-ROC curve of the 3-hour post-CPB NGAL 
level to predict the need for early medical renal intervention was as good as for predicting 
AKI (0.84, 95%CI 0.72–0.96). Furthermore, plasma NGAL level (3 h post-CPB) equal to or 
greater than 136 ng/ml was strongly associated with the need for early medical renal 
intervention (r = 0.64; P < 0.001). In addition, the rate of need for early intervention was 
92.3% in highest quartile of 3-hour post-CPB NGAL level (>158 ng/ml). Predictably, those 
who received intervention had significantly longer duration of intravenous fluid 
administration and higher day one positive fluid balance post-operatively due to the 
intervention itself.  
 
Receiving blood product post-operatively was significantly higher in the 
Intervention-Yes group, and this can be explained by the fact that both anemia and 
transfusion of stored blood are risk factors for AKI [435]. Though pre-operative creatinine 
and GFR were significantly correlated with early intervention, their utility from a clinical 
standpoint is limited because the values were so close, and both groups had what is 
considered normal serum creatinine (76 ± 11 vs. 85 ± 14 µmol/L, P =0.02) and were CKD 
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stage 2 for GFR (86 ± 16 vs. 72 ± 15 ml/min/1.73 m2, P < 0.01). Early post-operative NGAL 
level seems to be appropriate as an additional predictive tool than can help identify those who 
will most likely need some sort of renal intervention. 
 
In this chapter, we faced a challenging situation as the demographic, clinical, and 
operative characteristics between the two AKI groups were very comparable, including pre-
operative GFR and creatinine levels. This made subsequent analysis to identify AKI 
predictors difficult, despite the fact that 30% of our sample developed AKI, which is similar 
to the previously reported rates [192, 437]. Interestingly, Tuladhar et al. studied a similar 
sample size of 50 cardiac surgery patients and, similar to our findings, they failed to identify a 
significant difference between AKI groups with respect to demographic, clinical, or operative 
characteristics [466]. Though there were large differences in mean plasma NGAL levels 
between our results and the results from Tuladhar et al., which may be due to differences in 
the methods used to measure NGAL levels (they used sandwich ELISA), their AUC-ROC 
curve for plasma NGAL levels 2 h after surgery to detect AKI was comparable (0.85, 95%CI 
0.73–0.97) [466]. 
 
Although we report the statistical details of the logistic regression models in the 
results section (Tables 8.4 and 8.5), we are not suggesting risk-predicting models because of 
the relatively small, and considerably homogenous study sample that makes it insufficient to 
predict renal outcomes on the basis of preoperative criteria. However, such analysis may have 
been necessary in order to test the sustainability and the independent nature of the relationship 
between early post-operative NGAL level and outcomes. For instance, 3-hour post-CPB 
NGAL level was independently related to both AKI and early intervention outcomes as a 
continuous variable and using cut-off values.  
 
It is clear from our results and the results of others that NAGL is a potentially useful 
biomarker for predicting patients with a higher probability of developing AKI or a need for 
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early attention and intervention. Interestingly, recent research advocates the use of NGAL 
levels as a diagnostic and prognostic tool for cardiovascular disease and heart failure [474]; 
NGAL level was correlated with the development and severity of coronary artery disease. 
Additionally, in acute myocardial infarction patients, NGAL is correlated with mortality and 
cardiovascular outcomes, and in patients with heart failure, it is correlated with the severity of 
clinical and neurohormonal deterioration [474]. Our study adds to the previously published 
results and establishes that NGAL measurements early after CPB may be a useful additional 
predictive biomarker of AKI development. 
 
Finally, there was no significant association between PWV and NGAL levels, which 
is explained in view of the absence of an association between PWV and AKI in our sample, 
as previously discussed. A sample with more diverse baseline renal functioning may uncover 
a positive relationship between aortic stiffness and AKI and biomarkers, such as NGAL, in 
patients with poorer renal function. This is expect due to the damaging hemodynamic effect 
of aortic stiffness on renal function, which may only be expressed in those with limited 
kidney function reserve.   
 
Limitations 
The main limitation of this study is that most of our patients had either normal to mildly 
impaired renal function, which limited the results and the conclusions that could be drawn 
from this group of patients; potentially different findings may come from patients with 
moderate to severe renal impairment. Another limitation is the relatively small sample size, 
which was insufficient to predict renal outcomes on the basis of pre-operative criteria. 
However, the aim of this study was not to identify a list of predictors or to build another AKI 
risk model; rather, it was a preliminary study to test a novel hypothesis in regards to the 
relationship between aortic stiffness and AKI. 
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8.6 Conclusions and potential future implications  
In AVR patients with normal to mildly impaired renal function, aortic PWV was not 
correlated with post-operative AKI or plasma NGAL levels. However, early post-operative 
plasma NGAL level is the earliest predictive marker of post-operative AKI or the need for 
early medical renal intervention.  
 
An accurate prediction model for post-cardiac surgery AKI will enhance decision-
making, informed consent, and perioperative treatment strategies. A long list of predictors of 
AKI have been identified and used in different risk-prediction models, but no universal model 
has been agreed upon yet. Adding an arterial wall (aorto-renal) marker and kidney tissue 
injury-specific biomarker, such as aortic PWV and NGAL, respectively, to the current known 
predictors may enhance the prediction model moving forward.  
 
 Though aortic PWV was not correlated with post-operative AKI or plasma NGAL 
level in our sample, this should not discourage colleagues from further assessing the utility of 
this very interesting central arterial parameter. Further prospective studies with larger sample 
sizes that includes more confounding factors and diverse renal function are needed to 
determine the association between aortic stiffness, AKI, and NGAL level.  
 
The development of post-operative AKI significantly increases the risk of death and 
morbidity, thus detection of AKI for early management is crucial for improving outcomes in 
this population. The shortest possible interval between injury and treatment using current AKI 
diagnostic criteria is 6 h if urine output is monitored; elsewise, the delay is even longer. 
Interventions, such as adequate hydration, optimizing blood pressure, correction of anemia, 
dopamine infusion (controversial), diuretics, avoiding nephrotoxic medication, and urinary 
alkalinisation, can all be initiated immediately post-operatively if AKI is signified. This study 
offers further evidence that early post-operative NGAL level is very useful tool (at least as an 
adjuvant biomarker) for identifying patients likely to have or develop AKI.  
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The current era is very active with respect to AKI diagnosis and management, with 
exciting new results from clinical trials on preventive and treatment measures frequently 
being published. With this in mind, we would like to bring to the attention of our colleagues 
in charge of double-blind randomized clinical trials the importance of the “need for early 
medical renal intervention” group, and recommend that this cohort not be overlooked. As 
many blinded clinicians may initiate AKI treatment based on low urine output for less than 6 
h, the incidence of AKI and the predictive value of novel biomarkers may thus be 
underestimated.  # #
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9 Chapter 9  
The relationship between aortic stiffness, cardiac function, 
and myocardial strain in aortic valve replacement 
 
This chapter investigates the potential relationship between aortic stiffness measured by pulse 
wave velocity (PWV) and cardiac function and myocardial strain in aortic valve replacement 
(AVR).  
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9.1 Abstract 
Background: As cardiac function and myocardial strain is affected by cardiac afterload, and 
at the same time aortic stiffness contributes to this afterload, we hypothesize that aortic 
stiffness is related to cardiac functional outcome and to myocardial strain in aortic valve 
replacement (AVR).  
 
Objectives: The objectives of this study are to assess the relationship between aortic pulse 
wave velocity (PWV) and: 1) cardiac function assessed by New York Heart 
Association (NHYA) class and left ventricle (LV) function class; and 2) the myocardial strain 
biomarker B-type natriuretic protein (BNP). 
 
Methods: Patients undergoing AVR their aortic PWV, NYHA class, LV function, and 
plasma BNP assessed pre-operatively. BNP level was measure at 3 h post-cardiopulmonary 
bypass (CPB) and on day one (18–24 h post-CPB). NYHA class, leg edema, and LV function 
were collected at the follow-up visit (409 ± 159 days) post-operatively. We analysed PWV in 
two ways: 1) as a continuous variable by using the actual value; and 2) as a dichotomous 
variable (PWV-norm and PWV-high groups). 
 
Results: Fifty six patients (16 females) with a mean age of 71 ± 8.4 years were included, 50 
(89%) patients completed the follow-up, and no mortality or cerebrovascular event was 
recorded during the follow-up period. There was no significant difference between the two 
PWV groups with respect to age, gender, or classical hemodynamic measurements. Post-
operatively, there was an overall significant improvement in mean NHYA. There was also a 
significant difference in NYHA class between the two PWV groups in favor of the PWV-
norm group pre- and post-operatively. Multiple logistic regression analysis revealed a 
significant independent relationship between PWV cut-off and NYHA class pre- and post-
operatively (odds ratio [OR] = 8.3, 95% confidence interval [CI], 2.27–33.33 and OR = 
14.44, 95%CI, 1.49–139.31, respectively), and between PWV cut-off and post-operative leg 
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edema (OR = 11.77, 95%CI 1.26–109.77). PWV had no significant relationship with LV 
function class or BNP level. Pre-operative BNP level independently predicted pre-operative 
LV function (OR = 1.01, 95%CI, 1.00–1.02) and aortic valve area in AS (beta= –0.38, P = 
0.03). 
 
Conclusion: In AVR patients, PWV is independently related to pre- and post-operative 
NYHA class. Pre-operative BNP independently predicts pre-operative LV function and aortic 
valve area in AS. Pre-operative measurement of ventriculoarterial stiffening and 
neurohormonal predictors, such as PWV and BNP, is a clinical utility that can improve the 
management of cardiac surgery patients. 
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9.2 Introduction  
9.2.1 Aortic stiffness measured by pulse wave velocity 
Detailed background on aortic stiffness and PWV, and its predictive value are discussed in 
Chapter 1. 
 
9.2.2 Cardiac function assessment  
The topic of cardiac function assessment is too large and detailed to be covered in this 
introduction. However, cardiac function assessment is categorized into four headings that are 
pertinent to this thesis. 
  
9.2.2.1 Clinical assessment 
This is the oldest method used to assess heart function, which was used before any other 
technology became available. This includes the development of clinical symptoms of cardiac 
disease, such as dyspnea, orthopnea, palpitation, chest pain, and leg edema. It does not 
involve any technology, making it the cheapest and most practical method, yet it is also one 
of the most effective and predictive methods currently available. Clinical classification 
models based on clinical severity have been used to classify patients and monitor their 
progress since 1928 [475]. The New York Heart Association (NYHA) functional 
classification might be the most popular, validated, and predictive model that has ever been 
used in clinical practice [475, 476], and it has been proposed or used as a variable in other 
risk assessment models [477]. It correlates well with and predicts survival, quality of life 
(QoL), hospitalization, and other clinical outcomes in heart failure patients [476], severe AS 
patients [478], AVR patients [479, 480] and in transcatheter aortic valve implantation (TAVI) 
patients [481]. Thus, it’s no wonder that NYHA class has been incorporated into the 
European cardiac surgery operative risk scoring system EuroScore II [482] and in the 
American Society of Thoracic Surgeons’ (STS) risk scoring system when heart failure is 
 289 
present (http://riskcalc.sts.org/STSWebRiskCalc273/) [483]. NYHA functional classification 
consists of four classes from normal to severely symptomatic as follows: 
  
Class I: Patients have cardiac disease but without resulting limitations on physical 
activity. Ordinary physical activity does not cause undue fatigue, palpitation, 
dyspnea or anginal pain.  
Class II Patients have cardiac disease resulting in slight limitations on physical 
activity. Patients are comfortable at rest. Ordinary physical activity results in 
fatigue, palpitation, dyspnea, or anginal pain. 
Class III Patients have cardiac disease resulting in a marked limitation on physical 
activity. Patients are comfortable at rest. Less than ordinary physical activity 
causes fatigue, palpitation, dyspnea, or anginal pain. 
Class IV Patients have cardiac disease resulting in the inability to carry out any 
physical activity without discomfort. Symptoms of cardiac insufficiency or of 
anginal syndrome may be present even at rest. If any physical activity is 
undertaken, discomfort is increased. 
 
Unlike other methods of cardiac function assessment that are more objective, clinical 
assessment is subjective, making careful interpretation of the symptoms by the clinician 
applying it crucial [476, 484-486].  
 
9.2.2.2 Echocardiography assessment 
Echocardiography is the most popular first-line tool for objective assessment of cardiac 
function for the diagnosis of heart valve disease [184, 487]. The combination of different 
imaging technologies such M-mode, tissue Doppler imaging, real-time 3D echocardiography, 
and speckle tracking have enormously increased the anatomical, geometrical, and functional 
hemodynamic information obtained [487]. The recently available real-time 3D 
echocardiography has added more details to structural/anatomical images obtained routinely 
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by 2D echocardiography and has improved the accuracy of cardiac chamber volume 
measurements [487, 488]. Functional and hemodynamic data achieved using this method 
includes velocities, chambers volumes, pressure gradients, shortening fraction, and ejection 
fraction (EF). A literature search of any database will show that among the long list of 
parameters/measurements obtained by echocardiography, EF, or its dependent LV function 
class, are the most commonly used parameters for assessing and monitoring cardiac function 
status in clinical practice, clinical trials, and research settings [489]. 
 
 EF is the fraction of blood volume ejected from the ventricle with each heart beat and 
it is calculated as follows: EF = (EDV−ESV)/EDV [297]. LV function class is graded based 
on EF, according to the European cardiac surgery operative risk scoring system EuroScore II 
[482]: 
• Good  LV EF >50% 
• Moderate LV EF 31%–50% 
• Poor  LV EF 21%–30% 
• Very poor LV EF equal or <20% 
 
EF or LV function is a predictor of mortality in heart failure [490] and survival after 
cardiac surgery [491], including AVR [492] and the length of intensive care stay after cardiac 
surgery [493]. Similar to NYHA class, the predictive value of LV function or EF is reflected 
in its use in the above mentioned cardiac surgery operative risk scoring systems [482, 483].  
 
9.2.2.3 Imaging assessment with computed tomography and cardiac magnetic 
resonance imaging 
Advances in computed tomography (CT) technology provide another non-invasive method of 
assessing cardiac anatomy, function, and myocardial perfusion. It is particularly useful in 
assessing coronary anatomy (CT angiography) and ventricle volumes [494].  However, the 
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need for nephrotoxic contrast dye and exposure to radiation are the main disadvantages 
preventing it from being routinely used for functional assessment, and limits its use to mainly 
coronary assessment [494].   
 
Over the past 10–15 years, the clinical use of cardiac MRI (CMRI) has dramatically 
increased, particularly for the evaluation of structural data that are difficult to be visualized or 
assessed by echocardiography or angiography. It is the standard reference for ventricular 
mass and volume quantification [495]. In addition, myocardial perfusion and reversible 
ischemia can also be assessed using this method [496]. Because global cardiac function is 
commonly assessed by measuring EF, which can be achieved in a very practical, available, 
accurate, and cost-effective way using echocardiography, these advanced and expensive 
methods are preserved for other clinical indications. Such indications are usually related to 
morphological (anatomical/structural) deformities or anomalies, coronary artery disease, and 
regional myocardial dysfunction [489, 497, 498]. 
 
9.2.2.4 Biochemical assessment 
The importance of cardiac or myocardial biomarkers is derived from their cellular origin, as 
they reflect pathophysiological processes at the cellular level before any symptomatic, 
clinical, or echocardiographic indices become apparent. The availability of such biomarkers 
are essential for assessing and monitoring cardiovascular diseases and for predicting 
outcomes. Different cardiac biomarkers have been studied for decades, and a successful 
example is the discovery of cardiac troponins, which then became fundamental for the 
diagnosis of myocardial infarction [499, 500].  However, biomarkers of myocardial damage, 
such as troponins, are different from biomarkers of myocardial function and strain, such as 
natriuretic peptides [501]. The former are related to acute myocardial damage, thus they are 
clinically used for the diagnosis of acute insult conditions and are valid over a relatively short 
period of time, while the latter are related to regular myocardial function and their levels vary 
according to the level of myocardial strain.  
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Natriuretic peptides 
Natriuretic peptides (NPs) are myocardial strain biomarkers that are released from the heart in 
response to pressure and volume overload. Their main action is to protect the heart from this 
overload by acting on various tissues to induce vasodilation, natriuresis, and diuresis [502]. 
The half-life of B-type NPs (BNPs) are approximately 20 minutes, while that of N-terminal 
pro-brain natriuretic peptide (NT-proBNP) is 60–120 minutes, leading to higher circulating 
levels and slower variations compared to BNP [503]. Normal values of these proteins vary; 
however, generally in healthy young adults, 90% will have BNP <25 pg/ml and NT-pro BNP 
≤70 pg/ml [503]. BNP rises with age but it stays below 20 pg/ml provided there is no 
underlying ventricular dysfunction or structural heart problem [502]. It has been demonstrated 
that NPs have good diagnostic and prognostic potential; in patients with acute dyspnea, a cut-
off of 100pg/ml for BNP has been suggested for diagnosing acute congestive heart failure 
(CHF) [504], while NT-proBNP levels <300 pg/ml were optimal for ruling out acute CHF 
with a negative predictive value of 99% [505]. The aforementioned proteins are independent 
predictors of outcome in CHF [506], after myocardial infarction [507], and in primary 
pulmonary hypertension [508]. They are also correlated to post-cardiac surgery recovery 
course [509, 510] and cardiac dysfunction [511].  
 
In AS populations, NPs are related to the severity and/or functional status symptoms 
of AS disease, and increase progressively with worsening NYHA functional class [512-515]. 
In patients who undergo valve replacement, NP levels might predict survival and post-
operative LV function [186]. Nozohoor et al. [516] demonstrated that post-AVR BNP levels 
(day zero) of >82 pg/ml and BNP >133 pg/ml were significantly associated with a prolonged 
intensive care unit stay >48 h and prolonged ventilator support >48 h.  
 Based on similar results from the general population and different disease-population 
studies, NPs are now considered markers of increased cardiovascular risk [517-520].  
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9.2.3 Aortic stiffness, cardiac function, and myocardial strain 
As reported in Chapter 1, we could not identify any study that specifically investigates the 
relationship between non-invasive aortic PWV and AS or any type of aortic valve surgery. 
Similarly, we found no study assessing the relationship between any aortic stiffness indices 
and post aortic valve surgery outcome, including cardiac function. However, we were able to 
locate a few studies investigating the relationship between aortic stiffness and cardiac 
function, but only in other patient populations. For instance, in type I diabetes mellitus (DM) 
patients, aortic PWV was found to be independently associated with LV EF [521], and in 
Marfan syndrome patients, aortic PWV was strongly associated with reduced LV systolic 
function [522]. In coronary artery disease patients that lack classical risk factors, PWV was 
significantly inversely correlated with EF [523]. Furthermore, aortic arch PWV was 
significantly associated with EF (r = –0.38, P = 0.01, beta = –1.12) in hypertensive patients 
[524], and with LV systolic and diastolic function in non-ischemic dilated cardiomyopathy 
[161]. 
 With regards to the relationship between aortic stiffness and NPs, PWV is 
significantly associated with plasma BNP level, independent of age, in healthy subjects [525] 
and in hypertensive patients [526]. Similar results were found between PWV and NT-pro-
BNP in Asian (Chinese) general populations (beta = 0.116, P < 0.05) [527], in European 
general populations without prevalent cardiovascular disease [528], and in type II DM (beta = 
0.177, P = 0.014) [529].  Sakuragi et al. have proposed PWV as the cause of increased BNP 
in coronary artery disease patients after they found brachial-ankle PWV and EF to be 
independently correlated with BNP level [530]. 
 
9.2.4 Hypothesis and objectives 
As cardiac function and myocardial strain is affected by cardiac afterload, and at the same 
time, aortic stiffness contributes to this afterload [525], we hypothesize that aortic stiffness is 
related to cardiac function and perioperative myocardial strain in AVR for AS.  
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 Therefore, the objectives of this study are to assess the relationship between aortic 
PWV and: a) cardiac function assessed by NHYA class and LV function class, pre- and post-
operatively; and b) myocardial strain assessed with BNP pre-operatively and immediately 
post-operatively, need for post-operative inotropes, and the development of post-operative 
arrhythmia.    
 
9.3 Materials and methods 
9.3.1 Patient population  
The patient population has been described in Chapter 3, including the methodology for 
grouping patients into PWV-norm and PWV-high groups.  
 
9.3.2 Pulse wave velocity measurement protocol 
Detailed descriptions of the measurement protocol, quality control, and reproducibility of 
PWV have been covered in the methodology section of Chapter 3  
 
9.3.3 Clinical assessment (symptoms) 
Clinical history and cardiac symptoms, including the NYHA functional classification, were 
recorded. The same clinical data, in addition to leg edema, were recollected at the study-
specific follow-up visit.  
 
9.3.4 Echocardiography assessment 
Cardiac function at the organ level was assessed using LV function class derived from pre-
and post-operative echocardiography as described in the General methodology section in 
Chapter 3. LV function was classified into good (LV EF >50%), moderate (LV EF 31%–
50%), poor (LV EF 21%–30%), and very poor (LV EF equal or ≤20%) [482]. 
 
 295 
9.3.5 Biochemical assessment (B-type natriuretic protein biomarker) 
Myocardial strain was assessed by measuring BNP pre-operatively, 3 h post-CPB, and on day 
one (18–24 h post-CPB) after AVR. Ethylenediaminetetraacetic acid (EDTA)-containing 
tubes were used to collect blood samples through venipuncture pre-operatively and through 
the central venous line post-operatively. Immediate centrifugation and plasma separation 
were performed. BNP was measured using a chemiluminescent immunoassay kit (Biosite 
Triage, Biosite Incorporated, San Diego, CA, USA, currently called Alere Triage MeterPro, 
Alere Ltd, Stockport, UK). The accuracy and analytic sensitivity of the test, and stability 
characteristics of the system, have been previously validated and described [504, 531, 532].  
 
Next, 250 µL of plasma was added to the disposal test strip which has a filter to 
separate cells and any other particles allowing only plasma to reach the reaction chamber that 
contains fluorescent-tagged BNP antibodies. The plasma BNP and BNP antibodies form a 
reaction complex, which requires a 2-minute incubation period before it migrates through 
capillary action to a sector of immobilized antibody that binds the desired BNP-fluorescent 
antibody complex. The test strip is then inserted into the Triage machine that measures the 
BNP concentration by detecting the fluorescent BNP signal in the sample and quantifies the 
concentration using an internal calibration curve. The whole measurement procedure takes 
about 15 minutes to complete. All BNP measurements were performed within 30 minutes of 
sample collection and after standard machine calibration with a standard calibrating strip. All 
tests were performed by a single operator (EK) after proper training from a company 
representative. The time points for measuring the BNP levels were selected based on 
previously published studies [533-535]. 
 
9.3.6 Protocol overview 
Aortic PWV, NYHA class, LV function, and plasma BNP were all assessed pre-operatively. 
Patients then underwent the AVR operation. BNP level was re-measured 3 h post-CPB and on 
day one (18–24 h post-CPB). In addition, the need for post-operative inotropes for more than 
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6 h and the development of any cardiac arrhythmia were recorded. NYHA class, LV function, 
and the presence of leg edema were recorded at the study-specific follow-up visit (409 ± 159 
days) post-operatively. 
 
9.3.7 Statistical analysis 
Statistical analysis was conducted using IBM SPSS 20.0 software package (IBM Corp., 
Armonk, NY, USA). Patient characteristics and results are expressed as means ± standard 
deviation for continuous variable and as frequencies for categorical variables; P-values < 0.05 
were considered statistically significant. Test for normality was carried out on all variables 
being studied. For the purpose of the regression analysis, the non-normally distributed 
variables were transformed.  
 
PWV was analyzed as a continuous variable to verify our hypotheses and, in addition, 
PWV was also analyzed as a dichotomous variable (PWV-norm group vs. PWV-high group). 
Comparative analysis between any two groups was carried out using independent samples t-
test or non-parametric equivalent (Mann–Whitney U test) for continuous variables, and 
Pearson Chi-square or Fisher’s exact test for categorical variables. The association between 
any two variables was tested with bivariate correlation analysis of Spearman's rank-order 
correlation (both continuous), point biserial correlation (continuous vs. dichotomous), Phi test 
(both dichotomous variables), and Carmer V (both nominal other than 2 x 2). All variables 
with significant correlation, in addition to age and gender, were then included in two models 
of multiple regression (linear or logistic based on the dependent variable; enter method) 
analysis: 1) Model 1 including PWV as a continuous predictor; and 2) Model 2 including 
PWV cut-off as a dichotomous predictor. 
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9.4 Results 
9.4.1 Descriptive results 
The descriptive results are identical to those presented in Chapter 4 and in Table 4.1. There 
was no significant difference between the PWV-norm and PWV-high groups in terms of age, 
gender, classical hemodynamic measurements, or other clinical characteristics. Table 9.1 
summarizes some of these characteristics in addition to the cardiac parameters related to this 
study.   
 
 
Parameter Total 
n = 56 
PWV-norm 
n = 35 
PWV-high 
n = 21 
P-value 
Male 40 (71.4%) 27 (77.1%) 13 (61.9%) 0.36 
Age (years) 71 ± 8.4 70.2 ± 9 72 ± 8 0.43 
DM [n (%)] 8 (14.3%) 4 (11.4%) 4 (19.1%) 0.43 
BMI (kg/m2) 27.2 (4.2) 26.5 (4.3) 28.1 (4.1) 0.18 
MAP (mmHg) 97 ± 12 96 ± 13 98 ± 11 0.56 
Hypertension [n (%)] 38 (67.9%) 22 (62.9%) 16 (76.2%) 0.38 
Pre-operative     
Aortic valve area (cm2) 0.73 ± 0.2 0.74 ± 0.2 0.71 ± 0.2 0.67 
AVMG (mmHg) 48 ± 13 50 ± 13 46 ± 11 0.27 
AVPG (mmHg) 82 ± 24 86 ± 27 76 ± 19 0.13 
PWV (m/s) 9.3 ± 2.2 8.1 ± 1.5 11.3 ± 1.6 <0.001 
Ejection fraction  59 ± 15 58 ± 15 61 ± 16 0.56 
LVDDiam (cm) 4.79 ± 0.72 4.78 ± 0.75 4.82 ± 0.69 0.85 
LVSDiam (cm) 3.34 ± 0.83 3.25 ± 0.76 3.47 ± 0.94 0.37 
NYHA [n (%)]    <0.01 
Class I 16 (29%) 16 (46%) 0 (0%)  
Class II 30 (53%) 15 (43%) 15 (71%)  
Class III 10 (18%) 4 (11%) 6 (29%)  
 298 
LV function [n (%)]    0.97 
Good 41 (76%) 25 (76%) 16 (76%)  
Moderate 10 (18%) 6 (18%) 4 (19%)  
Poor 3 (6%) 3 (6%) 3 (5%)  
BNP pg/ml (pre-op.) 134 ± 183 88 ± 88 214 ± 264 0.09 
Operative 
Concomitant CABG [n (%)] 15 (26.8%) 10 (28.5%) 5 (23.8%) 0.76 
CPB time (minutes) 87 ± 23 87 ± 20 87 ± 27 0.95 
Immediate post-operative     
BNP pg/ml (3 h post-CPB) 112 ± 143 85 ± 81 158 ± 199 0.32 
BNP pg/ml (18 h post-CPB) 334 ± 179 288 ± 157 406 ± 191 0.02 
Inotropes [n (%)] 16 (29%) 8 (23%) 8 (40%) 0.22 
Arrhythmia [n (%)] 23 (41%) 16 (46%) 7 (33%) 0.41 
Post-operative (409 ± 159 days)     
NYHA (post-op.) [n (%)] 
n = 50 
   <0.001 
Class I 40 (80%) 29 (97%) 11 (55%)  
Class II 10 (20%) 1 (3%) 9 (45%)  
LV function (post-op.) [n (%)]    1.0 
Good 40 (87%) 23 (85%) 17 (89%)  
Moderate 6 (13%) 4 (15%) 2 (10%)  
Leg edema [n (%)] 7 (14%) 1 (3%) 6 (30%) 0.01 
Table 9. 1 Demographic and clinical characteristics. 
Values are shown as n (%) for categorical variables and means ± standard deviation for continuous variables. 
Abbreviations: DM, diabetes mellitus; BMI, body mass index; MAP, mean arterial blood pressure; AVMG, 
aortic valve mean gradient; AVPG, aortic valve peak gradient; CABG, coronary artery bypass graft surgery; 
CPB, cardiopulmonary bypass; PWV, pulse wave velocity; LVDDiam, left ventricular diastolic diameter; 
LVSDiam; left ventricular systolic diameter; NYHA; New York Heart Association.  
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9.4.2 Pulse wave velocity and New York Heart Association functional classification 
There was a significant difference in NYHA class between the two groups in favor of PWV-
norm pre- and post-operatively (Table 9.1). Figure 9.1 shows the distribution rate of PWV 
groups according to NYHA class. Pre-operatively, none of the PWV-high group was in 
NYHA I class compared to 46% of the PWV-norm group, while the percentage of PWV-high 
group patients in NYHA II & III was much higher than PWV-norm group patients. Post-
operatively, there was an overall significant improvement in mean NHYA (1.89 ± 0.67 vs. 
1.20 ± 0.40, P < 0.001). NYHA class significantly improved in both groups after AVR; mean 
NYHA (pre- vs. post-operative) was 1.66 ± 0.68 vs. 1.03 ± 0.18 (P < 0.001) for the PWV-
norm group, and 2.29 ± 0.46 vs. 1.45 ± 0.51 (P < 0.001) for the PWV-high group. However, 
the PWV-norm group continued to score significantly better than the PWV-high group post-
operatively (409 ± 159 days; P <0.001; Table 9.1 and Figure 9.1).  
 
Bivariate correlation demonstrated a significant association between NYHA class and 
PWV, and PWV cut-off in particular (Table 9.2; correlation coefficient ranged from 0.36 to 
0.51, except for between post-operative NYHA and PWV, where r = 0.20). A Chi-square test 
was used to identify an association between PWV groups (PWV cut-off) and NYHA class. 
There was a statistically significant association between PWV cut-off and NYHA pre-
operatively (X2= 13.76, P < 0.01) and post-operatively (X2= 13.02, P < 0.001). 
 
Multiple logistic regression adjusted for age, gender, and any other significantly 
correlated variable  (Table 9.3) confirms the above findings and that PWV value (continuous 
variable) was an independent predictor of pre-operative NYHA class (OR [95% CI] = 1.43 
[1.08–1.91], but not of post-operative NYHA. While PWV cut-off (dichotomous) was a 
stronger predictor than PWV value, compared to PWV-norm, the odds of a PWV-high group 
patient to be in a higher (worse) NYHA class was 8.3 pre-operatively and 14.44 post-
operatively (Table 9.3). 
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 Leg edema was assessed clinically at the follow-up visit and it was present in 
approximately 14% (7 cases), 85% of which were in the PWV-high group (P = 0.01). 
Bivariate (Table 9.2) and multiple logistic regression (Table 9.3) analyses revealed a 
significant independent relationship between PWV cut-off and post-operative leg edema (r = 
0.38, OR [95% CI] = 11.77 [1.26–109.77]).  
 
 
Figure 9. 1 Distribution rate of NYHA functional classification for PWV-norm and PWV-high groups pre- 
and post-operatively.  
Abbreviations: PWV, pulse wave velocity; NYHA, New York Heart Association.   
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  Age Gender 
(male) 
DM Hypertension MAP AVMG 
(pre–op) 
CPB time PWV value PWV cut–-
off 
Pre–operative          
LV function 0.18 –0.19 –0.11 –0.38** –0.26 –0.13 –0.04 –0.12 –0.03 
NYHA class 0.09 –0.05 0.18 –0.11 0.04 –0.14 –0.08 0.36** 0.50** 
BNP  0.27 –0.35* –0.19 –0.07 –0.30* 0.10 –0.00 0.21 0.34* 
Immediate post-
operative 
         
BNP (3 h post-
CPB) 
0.22 –0.34* –0.23 –0.13 –0.20 –0.14 –0.15 0.09 0.26 
BNP (18 h post-
CPB) 
0.24 –0.26 –0.29* –0.01 0.03 –0.09 –0.04 0.24 0.32* 
Inotropes 0.24 –0.24 –0.11 –0.15 –0.06 –0.08 –0.14 0.35* 0.18 
Arrhythmia 0.24 0.13 –0.14 0.11 –0.20 0.04 –0.07 0.06 –0.12 
Post–operative          
LV function 0.07 0.10 0.23 –0.12 –0.11 –0.1 –0.08 –0.14 –0.06 
NYHA class 0.03 –0.24 0.28* 0.15 –0.12 –0.15 0.15 0.20 0.51** 
Leg edema –0.02 –0.13 0.02 0.05 0.08 –0.21 0.03 0.07 0.38** 
Table 9. 2 Bivariate correlation between potential predictors and the cardiac function and myocardial strain parameters.  
Values are shown as correlation coefficients (r); *Correlation is significant at the 0.05 level (2-tailed); **Correlation is significant at the 0.01 level (2-tailed). Abbreviations: DM, diabetes 
mellitus; MAP, mean arterial blood pressure; AVMG, aortic valve mean gradient; CPB, cardiopulmonary bypass; PWV, pulse wave velocity; LV, left ventricle; NYHA; New York Heart 
Association (NYHA) Functional Classification; BNP, B-type Natriuretic peptides. 
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Predictors Pre-operative 
OR (95%CI) 
Post-operative 
OR (95%CI) 
 LV function NYHA class Inotropes Arrhythmia LV function NYHA class Leg edema 
Model 1        
PWV value 0.73  
(0.52–1.05) 
1.43* 
(1.08–1.91) 
1.33 
(0.94–1.88) 
0.94 
(0.71–1.26) 
0.76 
(0.46–1.23) 
1.20 
(0.76–1.91) 
1.09 
(0.71–1.67) 
Age 1.11* 
(1.01–1.23) 
0.97 
(0.91–1.04) 
1.03 
(0.94–1.12) 
1.07 
(0.99–1.16) 
1.05 
(0.93–1.19) 
0.93 
(0.81–1.07) 
0.97 
(0.86–1.09) 
Gender (male) 0.35 
(0.08–1.49) 
1.11 
(0.35–3.57) 
0.36 
(0.09–1.45) 
1.80 
(0.49–6.56) 
1.80 
(0.18–18.01) 
0.34 
(0.04–2.36) 
0.47 
(0.08–2.66) 
DM 
 
     5.01 
(0.72–34.51) 
 
Hypertension 0.20* 
(0.05–0.81) 
      
Model 2        
PWV cut-off 
(PWV-high) 
0.91 
(0.21–3.84) 
8.3** 
(2.27–33.33) 
1.78 
(0.49–6.43) 
0.55 
(0.16–1.84) 
0.81 
(0.12–5.41) 
14.44* 
(1.49–139.31) 
11.77* 
(1.26–109.77) 
Age 1.06 
(0.98–1.15) 
1.02 
(0.95–1.08) 
1.06 
(098–1.15) 
1.07* 
(1.0–1.15) 
1.03 
(0.91–1.15) 
0.97 
(0.84–1.10) 
0.97 
(0.86–1.09) 
Gender (male) 0.47 
(0.11–1.92) 
1.21 
(0.38–4.0) 
0.34 
(0.08–1.30) 
1.65 
(0.45–6.03) 
2.10 
(0.19–22.13) 
0.43 
(0.05–3.52) 
0.62 
(0.09–4.18) 
DM 
 
     4.45 
(0.47–41.66) 
 
Hypertension 
 
0.18 * 
(0.04–0.71) 
      
Table 9. 3 Multiple logistic regression (binary and ordinal) to identify predictors of cardiac function and strain. 
Values are shown as odd ratio (95% CI), bold values indicate statistically significant values; *is significant at the 0.05 level (2-tailed); **is significant at the 0.01 level (2-tailed); Model 1 
includes PWV value as a continuous predictor; Model 2 includes PWV cut-off as a dichotomous predictor. Abbreviations: LV, left ventricle; NYHA; New York Heart Association (NYHA) 
Functional Classification; PWV, pulse wave velocity; DM, diabetes mellitus; CI, confidence interval; OR, odds ratio. 
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9.4.3 Pulse wave velocity and left ventricle function  
There was no significant difference in LV function categories (good, moderate, and poor) 
between the two PWV groups pre- and post-operatively (Table 9.1). The LV function 
category “Poor” disappeared from both groups following AVR, and the overall post-operative 
improvement in LV function was nearly significant (P = 0.058), but not at the subgroup level 
(P = 0.25 for PWV-norm and P = 0.08 for PWV-high).  
 
 Further correlation (Table 9.2) and multiple logistic regression (Table 9.3) analyses 
confirm the absence of any relationship between PWV and LV function; however, age and 
hypertension were related to pre-operative LV function (OR [95%CI] = 1.11 [1.01–1.23] and 
0.18 [0.04–0.71], respectively). 
 
9.4.4 Pulse wave velocity and myocardial strain  
BNP level (pg/ml) was significantly different between PWV-norm and PWV-high groups 
only at the 18 h post-CPB time point (288 ± 157 vs. 406 ± 191, P =0.02; Table 9.1). 
Furthermore, PWV cut-off was significantly associated with pre-operative BNP and 18 h 
post-CPB BNP (correlation coefficient [r] was 0.34 and 0.32, respectively). There was no 
similar relationship between PWV value (continuous variable) and BNP level at any time 
point. Multiple regression analysis (Table 9.4) demonstrates that age and mean atrial pressure 
(MAP) were independently related to pre-operative BNP, which changed to gender for 3 h 
post-CPB BNP and to PWV cut-off and diabetes for 18 h post-CPB BNP.  
 
 Post-operatively and during operative hospital stay, the rate of need for inotropes (>6 
h) was higher in the PWV-high group (40% vs. 23%). Conversely, the rate of arrhythmia 
development was higher in the PWV-norm group (46% vs. 33%); however, neither outcome 
was significantly different between the two PWV groups (Table 9.1). Although there was a 
significant association between PWV value and need for inotropes (r = 0.35; Table 9.2), this 
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association disappeared in multiple logistic regression (OR [95%CI] = 1.33 [0.94–1.88]; 
Table 9.3). Age was the only variable related to arrhythmia; the odds of developing post-
operative arrhythmia was 1.07 (95% CI = 1.0–1.15) for each year increase in age. 
 
 
 
Predictors BNP (pre-op.) A BNP (3h post-CPB) A BNP (18h post-CPB) A 
Model 1    
PWV value 0.06 
(0.72) 
0.11 
(0.51) 
0.18 
(0.29) 
Age 0.26 
(0.11) 
0.29 
(0.09) 
0.01 
(0.95) 
Gender (male) –0.20 
(0.15) 
–0.38 
(0.0.1) 
–0.12 
(0.43) 
MAP –0.36 
(0.01) 
  
DM   –0.30 
(0.05) 
Model 2    
PWV cut-off 
(PWV-high) 
0.20 
(0.14) 
0.09 
(0.51) 
0.32 
(0.03) 
Age 0.27 
(0.05) 
0.21 
(0.14) 
0.06 
(0.65) 
Gender (male) –0.17 
(0.22) 
–0.34 
(0.02) 
–0.09 
(0.51) 
MAP –0.35 
(0.01) 
  
DM   –0.33 
(0.03) 
Table 9. 4 Multiple linear regression to identify predictors of the myocardial strain biomarker BNP. 
Values are shown as beta (P-value), bold values indicate statistical significance; ALog transformation. Model 1 
includes PWV value as a continuous predictor; Model 2 includes PWV cut-off as a dichotomous predictor. 
Abbreviations: DM, diabetes mellitus; MAP, mean arterial blood pressure; PWV, pulse wave velocity; BNP, B-
type natriuretic peptides. 
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 A separate analysis to examine the correlation between BNP and other clinical 
characteristics and outcomes after taking PWV out of the equation was also performed (Table 
9.5). Pre-operative BNP was significantly and negatively correlated with male gender, MAP, 
LV function, and AS (valve area). Three h post-CPB, BNP significantly and negatively 
correlated with male gender, MAP, LV function, need for inotropes, and hospital stay, while 
18 h post-CPB BNP was significantly and negatively correlated with only DM. Interestingly, 
all BNP levels significantly and negatively correlated with post-operative follow-up NYHA 
class.  
 
Two multiple regression (linear and logistic) analyses (analysis 1 included pre-
operative BNP while analysis 2 included the 3 hour post-operative BNP) adjusted for age, 
gender, and any other significantly correlated variable from Table 9.5 were performed to 
identify predictors that are independently related to the main clinical outcomes (Table 9.6).  
Most of the significant correlations listed above disappeared in multiple regression analyses. 
Nevertheless, pre-operative BNP independently predicted pre-operative LV function (OR 
[95% CI] = 1.01 [1.00–1.02]) and aortic valve area in AS (beta = –0.38).  
 306 
  BNP 
(Pre-operative) 
BNP 
(3 h post-CPB) 
BNP 
(18 h post-CPB) 
Age Gender 
(Male) 
DM Hypertension MAP 
Age 0.26 0.22 0.24 1.00     
Gender (Male) –0.35* –0.35* –0.27 0.01 1.00    
DM –0.19 –0.23 –0.29* –0.15 0.12 1.00   
Hypertension –0.07 –0.13 –0.01 0.09 0.07 0.27* 1.00  
MAP –0.30* –0.20 0.03 0.03 0.14 0.07 –0.04 1.00 
Pre-operative         
NYHA class 0.21 0.23 0.20 0.09 –0.04 0.18 –0.05 0.04 
LV function 0.70** 0.66** 0.26 0.20 –0.16 –0.11 –0.35** –0.26 
AVMG 0.09 –0.14 –0.08 –0.15 0.19 0.03 –0.01 –0.04 
Aortic valve area –0.33* –0.20 –0.28 –0.19 0.29* 0.02 0.33* 0.29 
Immediate post-operative         
CPB time 0.02 –0.15 0.04 –0.23 0.13 0.08 –0.15 0.05 
Inotrope 0.29 0.32* 0.19 0.24 –0.24 –0.11 –0.15 –0.06 
Arrhythmia 0.13 0.05 0.06 0.25 0.13 –0.14 0.11 –0.20 
Hospital Stay 0.26 0.44* 0.14 0.17 –0.25 –0.06 0.07 0.04 
Post-operative         
NYHA class 0.38* 0.34* 0.36* –0.01 –0.24 0.28* 0.15 –0.12 
LV function 0.24 0.30 –0.02 0.07 0.10 0.23 –0.12 –0.11 
Leg edema 0.18 0.12 0.21 –0.02 –0.13 0.02 0.05 0.09 
Table 9. 5 Bivariate correlation between BNP and clinical characteristics and outcomes. 
Values are shown as correlation coefficient (r); *Correlation is significant at the 0.05 level (2-tailed); **Correlation is significant at the 0.01 level (2-tailed). Abbreviations: BNP, B-type 
natriuretic peptides; DM, diabetes mellitus; MAP, mean arterial blood pressure; NYHA; New York Heart Association (NYHA); LV, left ventricle; AVMG, aortic valve mean gradient; 
CPB, cardiopulmonary bypass. 
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 Analysis 1 Analysis 2 
  BNP 
(Pre-op.) 
Age Gender 
(Male) 
DM Hyper-
tension 
BNP 
(3 h post-CPB) 
Age Gender 
(Male) 
DM Hyper-
tension 
Pre-operative           
LV function A 1.01** 
(1.00–1.02) 
0.94 
(0.83–1.07) 
1.35 
(0.14–12.9) 
  1.01** 
(1.00–1.02) 
0.96 
(0.87–1.06) 
2.04 
(0.26–15.38) 
  
Aortic valve area B –0.38 
(0.03) 
0.03 
(0.82) 
0.17 
(0.27) 
 0.15 
(0.29) 
–0.30 
(0.09) 
–0.06 
(0.63) 
0.12 
(0.46) 
 0.18 
(0.23) 
Immediate post-
operative 
          
Inotrope A 1.00 
(0.99–1.00) 
1.09 
(0.99–1.19) 
2.98 
(0.61–12.98) 
  1.00 
(0.99–1.00) 
1.07 
(0.98–1.16) 
0.20 
(0.04–1.06) 
  
Hospital Stay B 0.01 
(0.94) 
0.25 
(0.11) 
–0.20 
(0.20) 
  0.15 
(0.34) 
0.07 
(0.34) 
–0.26 
(0.10) 
  
Post-operative           
NYHA class A 1.00 
(0.99–1.01) 
0.94 
(0.82–1.08) 
0.68 
(0.06–6.89) 
3.44 
(0.39–30.3) 
 1.00 
(0.99–1.01) 
0.93 
(0.82–1.07) 
0.56 
(0.05–16.6) 
6.25 
(0.81–47.6) 
 
Table 9. 6 Multiple regression to identify predictors of main clinical characteristics and outcomes. 
Values are shown as odd ratio (95%CI) for the logistic regression (A) or as beta (P-value), for the linear regression (B); *is significant at the 0.05 level (2-tailed); **is significant at the 0.01 
level (2-tailed). Abbreviations: BNP, B-type Natriuretic peptides; DM, diabetes mellitus; NYHA; New York Heart Association (NYHA) Functional Classification; LV, left ventricle; CI, 
confidence interval. 
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9.5 Discussion 
NYHA functional class improved significantly in this study following AVR, which supports the 
findings of previous studies [536]. Our literature search found only two studies correlating PWV to 
NHYA, one in patients with dilated cardiomyopathy heart failure (r = 0.25, I = 0.02) [537] and one in 
patients with coronary artery disease (r = 0. 444, P < 0.001) [538]. Our results are consistent with the 
findings of the aforementioned studies in surgical AS patients pre- and post-AVR, and the range of 
correlation coefficients (r = 0.36 to 0.51) was also comparable. The published European normal PWV 
values were used to classify AS patients into two significantly different NYHA class groups pre-
operatively and to predict their NYHA post-operatively. Furthermore, PWV cut-off predicted the 
likelihood of having post-operative leg edema despite generally good LV function. One could argue 
that the differences in pre-operative NHYA class were due to AS pathology; however, our data shows 
no significant difference between groups with respect to degree of AS (pressure gradients or valve 
area) or EF.  
 
 Controversially, there was no relationship between PWV and LV function category. Though 
LV function is commonly employed in clinical studies, its independent use to reflect global cardiac 
function may not be sufficient due to its specific nature. The dissociation between LV function and 
clinical symptoms is best observed in patients with heart failure and normal LV EF (HFNEF), also 
known as diastolic heart failure, which is more common in elderly and hypertensive patients [539]. 
Unfortunately, we did not assess diastolic dysfunction parameters in our study, which may have 
altered the results to match the clinical assessment (NYHA) [540]. In addition, the EF of both PWV 
groups was comparable (58 ± 15 vs. 61 ± 16, P = 0.56), which categorizes most patients (e.g., about 
75% pre-operatively and more than 85% post-operatively) within the “Good” LV function class. 
Therefore, the relation between PWV and LV function would be more conclusive and reliable if our 
sample was more diverse in terms of LV function.  
 
LV function is an objective organ measure, while NYHA class is a more symptomatic global 
measure that can be affected by other, non-cardiac factors. The absence of a relationship between 
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PWV and LV function may be considered a drawback to this study, but the fact that the relationship 
between PWV and NYHA class was established even after eliminating a fundamental component of 
NYHA class (cardiac function) makes such findings more reliable and stable. In the previous chapter 
we demonstrated a relationship between PWV and other functional outcomes, such as QoL and 
cognitive function, while in this chapter we have added an additional supporting finding to this 
relationship e.g. the NYHA class.   
 
 Consistent with the absence of a relationship between PWV and LV in our sample, we could 
not identify a meaningful relationship between PWV and the myocardial strain biomarker BNP. 
Although there was significant positive correlation between PWV cut-off and BNP (pre-operative and 
18 h post-CPB), this association disappeared for the pre-operative BNP in the multiple regression 
analysis (Table 9.4). Only a few studies have identified a link between PWV and BNP in healthy 
populations, or hypertensive, diabetic, and coronary artery disease patients [525, 526, 530].  The lack 
of previously published data regarding PWV and BNP in AVR makes it difficult to conclude whether 
this negative finding is sample- or disease-related. Future studies should be undertaken to definitively 
answer this question. 
 
Focusing on the BNP biomarker, mean pre-operative BNP in our sample was 134 ± 183 
pg/ml, which is markedly higher than normal values. However, the range of pre-AVR BNP was very 
wide in our sample (11–942 pg/ml, while in another study it was 8–2018 pg/ml [n = 89]) [541], and 
the mean or median differences between various studies depend on sample size. While normal or low 
BNP levels may indicate an absence of myocardial strain, elevated levels indicate that further 
diagnostic tests are required [542, 543]. In AS populations, NPs are related to the severity of AS 
disease, LV function, and NYHA functional class [512-515]. Our results are consistent with the above 
findings, as higher BNP levels (pre-operative and 3 h post-CPB) were independently related to worse 
LV function and AS (aortic valve area), even after adjustment for age and gender, but not with NYHA 
class (Table 9.6).  
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In AVR, NP levels might predict survival and post-operative LV function [186, 544]. 
Nozohoor et al. [516] studied in AVR population and demonstrated that BNP levels were significantly 
associated with prolonged ventilator and prolonged intensive care unit stay; however, BNP levels 
were not found to be independent predictors of these outcomes in multivariate analysis. We found a 
similar predictive behavior; for example, in univariate analysis 3 h post-CPB BNP level was positively 
associated with the need for post-operative inotropes, hospital stay, and follow-up NYHA class, but it 
was not an independent predictor of these outcomes in multiple regression analysis.  
 
This is the first study reporting a positive relationship between aortic PWV and NYHA class 
in surgical patients. The predictive value of NYHA for survival, QoL, and other outcomes has been 
reported extensively [476, 478-481], reaffirming that identifying a predictor for this predictor is of 
clinical interest. This is because their use might be exchangeable, and if PWV was found to be 
correlated with other predictors, such blood pressure, renal function, and specific biomarkers, then 
there is valid opportunity for PWV to replace some, or to add to, current variables used in clinical 
predicting system/models, such as operative risk scoring systems. 
  
Limitations 
The main limitation of this study is our use of LV function, which is dependent on EF, to assess 
cardiac function, thus limiting our analysis to systolic function, which is usually normal in AS 
patients. Using other parameters such as E/A ratio, mitral valve velocities, myocardial tissue Doppler 
measurements, and other diastolic dysfunction indices might have provided more insight into a 
potential relationship between PWV and cardiac function, leading to a more robust conclusion. 
Another correctable limitation is that we did not analyze BNP as a dichotomous variable by using a 
cut-off value; this would have added more information to the predictive value of BNP. However, this 
is beyond the scope of this chapter and it can be address in a separate studies.  
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9.6 Conclusions and potential future implications  
In AVR patients, NYHA class significantly improved after surgery. Aortic stiffness measured by 
aortic PWV is independently related to pre- and post-operative NYHA, and to post-operative leg 
edema, but not to LV function or the myocardial strain biomarker BNP. Pre-operative BNP 
independently predicted pre-operative LV function and aortic valve area in AS. These are other 
positive findings that support the use of pre-operative measurement of PWV and myocardial strain 
biomarkers in cardiac surgery patients. 
 
Both PWV and BNP have extensive predictive value in many conditions, but not in cardiac 
surgery populations. Current management of cardiac surgery patients, including operation timing, 
which is still debatable and evolving, does not involve aortic stiffness or any myocardial biomarker. 
Preliminary data from ours and other studies should be used to develop future large multicenter 
project testing promising ventriculoarterial stiffening and neurohormonal predictors in cardiac surgery 
patients, which will eventually optimize prediction and management and improve surgical outcomes. 
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10 Chapter 10  
Closing points 
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10.1 Originality 
The core hypothesis of this study is that aortic stiffness as measured by pulse wave velocity (PWV) is 
related to global functional outcome and injury to the brain, kidney and heart in patients undergoing 
aortic valve replacement (AVR). Based on this hypothesis, the aim of this thesis was to answer the 
following original research questions as to whether there is a relationship between: 
 
1. PWV and aortic stenosis (AS) in patients undergoing AVR? 
2. PWV and quality of life (QoL) pre- and post-AVR? 
3. PWV and cognitive function pre- and post-AVR? 
4. PWV and serum levels of the brain injury biomarker, N-methyl-D-aspartate receptor antibody 
(NR2Ab), pre-AVR? 
5. NR2Ab and cognitive function or QoL? 
6. PWV and post-AVR acute kidney injury (AKI) or the need for early preventive medical renal 
intervention? 
7. PWV and the AKI biomarker, neutrophil gelatinase-associated lipocalin (NGAL)? 
8. PWV and cardiac function pre- and post-AVR? 
9. PWV and myocardial strain biomarker, B-type natriuretic peptide (BNP), in AVR? 
 
It also has the novelty of using gold standard applanation tonometry PWV for the measurement of 
aortic stiffness and the computerized Cambridge Neuropsychological Test Automated Battery 
(CANTAB) for the measurement of cognitive function in patients undergoing cardiac surgery.  
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10.2 Novel findings derived from this thesis 
1. There was no relationship between PWV and the severity of AS, in addition, AVR had no 
effect on PWV post-operatively. 
2. AS may attenuate the association between aortic stiffness and classical hemodynamic 
parameters, such as blood pressure. 
3. PWV was independently and negatively related to the QoL scores both pre- and post-AVR. 
4. PWV was independently and negatively correlated with cognitive function both pre- and post-
AVR. 
5. PWV was independently and positively correlated with the level of NR2Ab. 
6. The NR2Ab level was independently and negatively correlated with QoL pre- and post-AVR. 
7. There was no meaningful relationship between NR2Ab levels and cognitive function. 
8. PWV was not correlated with post-operative AKI, the need for early medical renal 
intervention or plasma NGAL levels in patients with normal to mildly impaired renal function. 
9. The early post-operative plasma NGAL level is the earliest predictive marker of a post-
operative need for early medical renal intervention. 
10. PWV was independently and positively correlated with NYHA class pre- and post-AVR, but 
not to LV function class or the myocardial strain biomarker, BNP. 
11. This study also demonstrates that the published European PWV reference values can be used 
to identify the group of patients with abnormal PWV values who are at a higher risk of the 
above positive findings. 
 
 
10.3 Confirmation of the findings of previously published results 
1. PWV increases with age. 
2. QoL improves significantly following AVR. 
3. AVR surgery may not be associated with a decline in cognitive function. 
4. Age is independently and negatively related to cognitive function. 
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5. Post-operative AF is a potential predictor of mid-term post-operative cognitive dysfunction 
following AVR. 
6. The incidence of post-AVR AKI is approximately 30%. 
7. The early post-operative plasma NGAL level is the earliest predictive marker of post-
operative AKI. 
8. NYHA class significantly improved after AVR. 
9. Age and mean atrial pressure (MAP) were independently and negatively related to pre-
operative BNP levels. 
10. Pre-operative BNP levels were significantly and negatively correlated with pre-operative LV 
function, AS (valve area), and post-operative NYHA class. 
11. Age was independently and positively correlated with post-operative arrhythmia. 
 
 
10.4 General conclusions and recommendations for future work 
Cardiac surgery has advanced significantly over the recent decades and the associated mortality and 
morbidity rates have continued to decrease. As a result, higher risk patients are increasingly offered 
surgical options. As the operative mortality rates of major cardiac surgeries continue to fall, research 
has focussed on other outcomes such as functional capacity.  
 
Identifying predictors of mortality and morbidities is an ongoing research process in the field of 
cardiac surgery. The long list of pre-, intra- and post-operative predictors that have been identified is 
more or less fixed and does not include arterial wall indices. Historically, the importance of assessing 
arterial wall function with pulse waveforms was recognized hundreds of years ago, but the concept 
was let down practically by the lack of suitable technology at that time. Thus, when the easily 
measured blood pressure became available by the development of the sphygmomanometer, arterial 
wall assessment was forgotten for many decades. Now, with the availability of novel technology, the 
assessment of arterial or aortic stiffness, which is more direct and reflective of the arterial wall 
functional status than the classical blood pressure measurement become central and necessary. The 
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concept of aortic stiffness in cardiac surgery field unfortunately does not exist, which examinations of 
any related textbook or enquires to cardiac surgeons about aortic stiffness can confirm. However, and 
as shown in Chapter 1, the predictive value of aortic stiffness and its association with CV risk factors 
and outcomes, or with other non-CV outcomes in healthy and diseased populations, has a large body 
of evidence. Therefore, the aim of this thesis was to explore this risk factor for the first time in cardiac 
surgery and to raise the attention of cardiac surgeons and researchers about this potential predictor. 
This thesis created preliminary results that will be explored in future work in this population.          
 
The findings from this thesis highlight the potential use of PWV as a predictor of outcomes in 
cardiac surgery, and particularly functional outcomes such as QoL and cognitive function, which both 
have practical limitations when assessed using classical tools. The negative results regarding AKI and 
myocardial strain do not undermine the fact the future work in this direction is worth pursuing.  
 
As this is the first such study in cardiac surgery, an enormous amount of work is needed to 
establish solid conclusions. Future longitudinal studies with larger sample sizes and diverse patient 
characteristics to adjust for potential confounders, such as hypertension, diabetes, dyslipidemia, and 
coronary disease, are required to determine the nature of the relationship between aortic PWV and 
different clinical outcomes. Larger sample sizes and longer follow up periods will also enable 
assessing the relationship between aortic PWV and mortality and between PWV and classical 
morbidities such as coronary events, hospitalizations and strokes. It is also recommended that future 
studies should include assessments of the inflammatory and metabolic profiles of blood samples and 
aortic wall tissue from the aortotomy site, as this will assist in our understanding of the 
pathophysiology of aortic stiffness. In fact, this project took in consideration this point and we have 
stored plasma sample pre- and post-operatively for all our patients, and by the time this report was 
written, another research colleague has planned for metabolic profile analysis. Based on this 
interesting finding in our cognitive function end-point data, we advise future studies should use a 
computer-based battery as it is a more accurate test that is less operator- and language-dependent. 
Such a battery would also allow more measurable outcomes to be captured, such as response time in 
milliseconds. Finally, we would encourage future studies to involve neurohormonal biomarkers, 
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particularly the natriuretic peptides. The current management of cardiac surgery patients, including 
operation timing and operative risk, does not involve either myocardial biomarkers or aortic stiffness 
levels, and both might be very helpful in clinical decision-making.   
 
Establishing the relationship between aortic PWV and post-cardiac surgery outcomes will 
enable the application of PWV measurements in routine clinical practice. This parameter may reform 
pre-operative assessments, allowing better predictions of outcome and improvements in both the pre-
operative consent process and risk stratification. 
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